IMIDAZO[1,5-a]QUINOXALINES

Abstract: Imidazo[1,5-a]quinoxalines (I) which do not contain an endocyclic carbonyl group are useful as anxiolytic and sedative/hypnotic agents.

Description: IMIDAZOπ ,5-alOUINOXALINES BACKGROUND OF THE INVENTION 1. Field of the Invention The compounds of the present invention are imidazo[l,5-a]quinoxalines (I) which are useful pharmaceutical agents. 2. Description of the Related Art Many commercially available anxiolytic agents are from the chemical group known as benzodiazepines. The benzodiazepines are characterized by a seven member ring attached to an aromatic ring. US Patent 4,774,245 discloses a group of non-benzodiazepine anxiolytic agents which possess a six member ring rather than a seven member ring attached to the aromatic ring (imidazo[l,5-a]quinoxalines). These compounds have an endocyclic carbonyl group. EP 344,943A discloses a group of imidazo[l,5-a]quinoxaline compounds, useful as anxiolytic and anticonvulsant agents, having an exocyclic carbonyl at the N 5 position attached to a methyl group and not attached directly to the N 5 nitrogen, and an endocyclic carbonyl at C . EP 347,094A discloses imidazo[l,5-a]quinoxaline-4,5-enes useful for treating CNS disorders with no substitution at N 5 . EP 320,136 discloses N 5 -isopropyl-imidazo[1.5-a]quinoxalines having an endocyclic carbonyl at C , useful as anxiolytic and anticonvulsant agents. EP 368,652A discloses N 5 -(t-butyl)-imidazo[l,5-a]quinoxalines having an endocyclic carbonyl at C 4 , useful as anxiolytic and anticonvulsant agents. EP 283.162A discloses imidazole ftised ring compounds of varing types including quinoxalines. The quinoxalines have an endocyclic carbonyl group and alkyl substitution at N 5 or 4,5-ene and were useful as anxiolytic and anticonvulsant agents. BE 878,028 and 881,631 disclose imidazo[l,2-a]quinoxaline-2-carboxylic acids, and derivatives, useful for treating allergic asthma and asthmatic bronchitis. US Patent 4,128,716 discloses 4-halo-4,5-ene-pyrazolo[l,5-a]quinoxaline-3-carboxylates useful as antiinflammatory agents. US Patents 4,774,245 and 4,795,749 (EP 220.845A) discloses N 5 -alkyl and cycloalkyl substituted imida_o[l,5-a]quinoxalines without an endocyclic carbonyl. The imidazo[l,5- a]quinoxalines (I) of the present invention have a -CO- or -CS- in the side chain attached to N 5 . US Patent 5,075,304 discloses imidazo[l,5-a]quinoxalin-4-ones with (substituted) methyl at N 5 useful as anticonvulsants, anxiolytics and hypnotics. The substituents includes alkoxy carbonyl. The imidazo[l,5-a]quinoxalines (LX) of the present invention do not have a -CO- or -CS- in the side chain attached to N 5 . SUMMARY OF INVENTION Disclosed is an imidazo[l,5-a]quinoxaline of formula (T) where R 3 is (C 3 - 1) -COOR3.! where R 3 is (1) -H, (2) C r C 9 alkyl, (3) C 3 -C 7 cycloalkyl, (4) -(CH2) n6 -O-R 3 _3 where _ $ is 2 thru 4 and R 3 . 3 is -H, C r C 4 alkyl or C 3 -C 7 cycloalkyl, (5) -(CH 2 ) n6 -NR3_ 4 R 3 _5 where R 3 ^ is -H, C r C 4 alkyl, C 3 -C 7 cycloalkyl or -φ, R3.5 is -H, C j -Cg alkyl or C3-C7 cycloalkyl and where R 3 _ 4 and R3.5 are taken together with the attached nitrogen atom to form a heterocyclic ring -N*-(CHR3. 8 ) nA -(CH 2 )_ 1 -R3^-(CH 2 ) n2 -(C*HR 3 . 9 ) nB - (C 3 - la) -N*-(CH 2 )_ 1 -(CHR 3 . 8 ) nA -R 3 ^-(CHR3. 9 ) nB -(C*H 2 ) n2 - (C 3 - lb) where R 3 _ 8 is -H or C C 3 alkyl, n A is 1 or 2, n j is 0 thru 2, n 2 is 0 thru 2, R 3 _ 9 is -H or C j -C 3 alkyl, n B is 1 or 2, where the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring, with the proviso that the ring not contain more than 8 atoms, and where R 3-6 is -O-, -S-, -CO- -CR 3 ^ 1 R 3 ^2 where 3 ^χ and Rn-62 are tne same or different and are -H or C j ^ alkyl, -NR 3 _ 7 where R 3 . 7 is -H, C r C 4 alkyl, C3-C7 cycloalkyl, -(CH^- - where n 7 is 0 thru 4 and φ is optionally substituted with 1, 2 or 3 R3.2 where R 3 . 2 is selected from the group consisting of -F, -Cl, -Br, -I, -CN, -NO 2 , -O-CO^.^ where R^^ is -H, C r C 4 alkyl or C3-C7 cycloalkyl, -(CH 2 )_3 0 -CF 3 where n 30 is 0 thru 3, -O-CF3, C r C 6 alkyl, C3-C7 cycloalkyl, -CH 2 -(C 3 -C 7 cycloalkyl), -CH 2 CH(CF 3 )CH 3 , -C(OH)(CH 2 OH)(CH 2 CH 3 ), -C(OH)(CH 2 OH)CH 3 , -C(CH 3 )(OH)(CH 2 OH), -CH(OH)(CH 2 OH), -CH(OH)(CH 3 ), -CH 2 CH 2 OH, -C(CH 3 ) 2 (CH 2 OH), -CH(CH 2 OH) 2 , -C(CH 2 -OH) 3 , -C(CH 3 ) 2 -OH, -C(CH 3 ) 2 -F, -NR 3 . 2b -CO-R 3 . 2c where R 3 . 2b is -H or C r C 4 alkyl, and where Rs.^ is -H, C r C 6 alkyl, -Φ, -CH 2 -. , -(CH 2 ) n8 -OR 3 . 2d where n 8 is 0 thru 3 and R 3 . 2d is -H or C r C 4 alkyl, -( CH 2)_2l "OH where n 2i κ 3 mru > -(CΑ_^) Ω 22'^ where n 22 k ° h™ 3 ^ where -φ is optionally substituted with -F, -Cl, -Br, -I or C j ^ alkyl, -(C__2. n8 -N(R3_2d)2 where n 8 and R 3 . 2d are as defined above and where the two 3 _2_ . s can De taken together with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4- morpholinyl, 1 -(4-methyl)piperazinyl , ~ S ~ K_-2d wnere ^3 -2d l& ^ defined above, -SC^-N R^^ where R 3 . 2e is -H or C r C 4 alkyl, -CO-N(R3_ 2e ) 2 whereR 3 . 2e is as defined aboveand where the two R 3 _2e' s can be taken together with the attached nitrogen atom to from a ring selected from the group consisting of 1-pyrrolidinyl, 1-pϊperidinyl, 1-piperazinyl, 4-morpholinyl, l-(4~ methyl)piperazinyl , "N 3 -2f* -i -2 g where R3 _ 2 f and R 3 _2 g are the same or different and are -H or C j -C alkyl and where R 3 _2f and R 3 _ 2g can be taken together with the attached nitrogen atom to form a ring, which may contain an additional heteroatom, selected from the group consisting of piperazine, morpholine, pyrrolidine or piperidine, with the proviso that when R 3 ^ is -O-, -S- or -NR 3 . 7 -, n j and n 2 are 1 or 2, (6) aryl, where aryl is -φ optionally substituted with one or two R 3 . 2 where (F-Aryl-I) R3.2 is as defined above, 1-naphthyl optionally substituted with one or two (F-Aryl-H) R 3 _2 where R 3 . 2 is as defined above, 2-naphthyl optionally substituted with one or two (F-Aryl-III) R 3 _2 where R 3 . 2 is as defined above, 2-pyridyl optionally substituted with one or two (F-Aryl-IV) R 3 . 2 where R 3 _ 2 is as defined above, 3-pyridyl optionally substituted with one or two (F-Aryl-V) R 3 . 2 where R 3 _ 2 is as defined above, 4-pyridyl optionally substituted with one or two (F-Aryl-VI) R 3 _ 2 where R 3 _ 2 is as defined above, 2-pyrimidinyl optionally substituted with one or (F-Aryl-VU) two R 3 . 2 where R 3 . 2 is as defined above, 4-pyrimidinyl optionally substituted with one or (F-Aryl-VHI) two R 3 . 2 where R 3 _ 2 is as defined above, 5-pyrimidinyl optionally substituted with one or two (F-Aryl-IX) -2 wnere -2 * s ^ defined above, 3-pyridazinyl optionally substituted with one or two (F-Aryl-X) R 3 . 2 where R 3 _ 2 is as defined above, 4-pryidaziπyl optionally substituted with one or two (F -Aryl-XI) R 3 . 2 where R 3 . 2 is as defined above, 3-pyrazinyl optionally substituted with one or two (F-Aryl-XII) R 3 . 2 where R3_ 2 is as defined above, 2-quinolyl optionally substituted with one or two (F-Aryl-XIII) R3_ 2 where R 3 . 2 is as defined above, 3-quinoIyl optionally substituted with one or two (F-Aryl-XIV) R 3 . 2 where R 3 . is as defined above, 4-quinolyl optionally substituted with one or two (F-Aryl-XV) R 3 . 2 where R 3 . 2 is as defined above, 1-isoquinolyl optionally substituted with one or (F-Aryl-XVI) two R 3 . 2 where R 3 _ 2 is as defined above, 3-isoquinolyl optionally substituted with one or (F-Aryl-XVII) two R 3 _2 where R 3 _ 2 is as defined above, 4-isoquinolyl optionally substituted with one (F -Aryl-XVIII) or two R 3 _ 2 where R 3 . 2 is as defined above, 2-quinazolinyl optionally substituted with one (F-Aryl-XIX) or two R 3 . 2 where R 3 . 2 is as defined above, 4-quinazolinyl optionally substituted with one or (F-Aryl-XX) two R 3 . 2 where R 3 . 2 is as defined above, 2-quinoxalinyl optionally substituted with one or (F-Aryl-XXI) two R 3 . 2 where R 3 . 2 is as defined above, 1-phthalazinyl optionally substituted with one (F-Aryl-XXII) or two R 3 _2 where R 3 . 2 is as defined above, 2-imidazolyl optionally substituted with one or (F-Aryl-XXHI) two R 3 . 2 and R 3 _ι_ where R 3 . 2 and R 3 _ι 2 are as defined above, 4-imidazolyl optionally substituted with one (F-Aryl-XXIV) or two R 3 . 2 where R 3 . 2 is as defined above and where R3_ι 2 is -H, C j -C 4 alkyl or -CHO, 3-isoxazolyl optionally substituted with one (F-Aryl-XXV) or two R 3 . 2 where R 3 . 2 is as defined above, 4-isoxazolyl optionally substituted with one (F-Aryl-XXVI) or two R 3 _ 2 where R 3 . 2 is as defined above, 5-isoxazolyl optionally substituted with one or (F-Aryl-XXVII) two R 3 . 2 where R 3 . 2 is as defined above, 3-pyrazolyl optionally substituted with one or (F-Aryl-XXVHI) two R 3 _ 2 where 3.12 nd -2 are ω defined above, 4-pyrazolyl optionally substituted with one or (F-Aryl-XXIX) two R 3 _ 2 where R3.12 an R3-2 are ^ defined above, 5-pyrazolyl optionally substituted with one or (F-Aryl-XXX) two R 3 .2 where R3. 1 2 and R 3 -2 are ^ defined above, 2-oxazolyl optionally substituted with one or (F-Aryl-XXXI) two R 3 _2 where R 3 . 2 is as defined above, 4-oxazolyl optionally substituted with one or (F-Aryl-XXXU) two R 3 _ 2 where R 3 . 2 is as defined above, 2-thiazolyl optionally substituted with one or (F-Aryl-XXXIH) two R 3 _ 2 where R 3 _ 2 is as defined above, 4-thiazolyl optionally substituted with one (F-Aryl-XXXIV) or two R 3 . 2 where R 3 . 2 is as defined above, 2-indolyl optionally substituted with one or two (F-Aryl-XXXV) R 3 . 2 where 3.12 and R 3 . 2 are as defined above, 3 -indolyl optionally substituted with one or (F-Aryl-XXXVI) two R3.2 where 3 _i2 n R3-2 are ^ defined above, 3-indazolyl optionally substituted with one or (F-Aryl-XXXVII) twp R 3 . 2 where R3.12 nd R3-2 are ^ defined above, 2-benzoxazolyl optionally substituted with (F-Aryl-XXXVIII) one or two R3.2 where R 3 . 2 is as defined above, 2-benzothiazolyl optionally substituted with (F-Aryl-XXXIX) one or two R 3 _ 2 where R3.2 is as defined above, 2-benzimidazolyl optionally substituted with one (F-Aryl-XL) or two R 3 _ 2 where R 3 _ 12 and R 3 . 2 are as defined above, 2-benzofuranyl optionally substituted with one or (F-Aryl-XLI) two R . 2 where R 3 . 2 is as defined above, 3-benzofuranyl optionally substituted with one (F-Aryl-XLH) or two R 3 _ 2 where R 3 . 2 is as defined above, 2-furanyI optionally substituted with one or two (F-Aryl-XLIH) R 3 _ 2 where R 3 . 2 is as defined above, 3-furanyl optionally substituted with one or two (F-Aryl-XLIV) R 3 _2 where R3.2 is as defined above, 2-thienyl optionally substituted with one or two (F-Aryl-XLV) R 3 . 2 where R 3 . 2 is as defined above, 3-thienyl optionally substituted with one or two (F-Aryl-XLVI) R 3 . 2 where 3 . 2 is as defined above, 2-pyrrolyl optionally substituted with one or (F-Aryl-XLVH) two R 3 _ 2 where R3.12 and R 3 . 2 are as defined above, 3-pyrrolyl optionally substituted with one (F-Aryl-XLVIII) or two R3.2 where R3. 1 2 and R 3 _ 2 are as defined above, l,2,4-oxadiazol-3-yl optionally substituted with (F -Aryl-XLIX) one R 3 . 2 where R 3 . 2 is as defined above, l,2,4-oxadiazol-5-yl optionally substituted with one (F-Aryl-L) R 3 . 2 where R 3 . 2 is as defined above, l,2,4-thiadiazol-3-yl optionally substituted with one (F-Aryl-LI) R 3 . 2 where R 3 . 2 is as defined above, l,2,4-thiadiazol-5-yl optionally substituted (F-Aryl-Lϋ) with one R 3 _ 2 where R 3 . 2 is as defined above, l,2,4-triazo!-3-yl optionally substituted with (F-Aryl-LIII) one or two R3_ 2 where R3.12 and R3.2 are as defined above, l,2,4-triazol-5-yl optionally substituted with one (F-Aryl-LIV) R3.2 where 3 _i2 and R 3 _ 2 are as defined above, l,2,3,4-tetrazol-5-yl substituted with R 3 . 12 where (F-Aryl-LV) R 3 _12 is as defined above, 5-oxazolyl optionally substituted with with one (F-Aryl-L VI) or two R3.2 where R3.2 is as defined above, 5-thiazolyl optionally substituted with with one (F-Aryl-LVII) or two R3.2 where R 3 _ 2 is as defined above, oxazolo[4,5-b]pyridin-2-yl optionally substituted (F-Aryl-LXXI) with one or two R 3 . 2 where R 3 . 2 is as defined above; imidazo[l,2-a]pyridin-2-yl optionally substituted (F-Aryl-LXXII) with one or two R 3 . 2 where R 3 . 2 is as defined above; (C 3 - 2) -CO-NR3.10R3.11 where R 3 .ι 0 and R 3 _n are the same or different and are Cι-C 4 alkyl, C 3 -C 7 cycloalkyl or -φ, (C 3 - 3) -CN, (C 3 - 4) aryl, where aryl is as defined above, (C 3 - 5) -C =C-R 3 .ι where R 3 _ι is as defined above, (C 3 - 6) -CO-R 3 _ι where R 3 _ι is as defined above, (C 3 - 7) -CS-R 3 _ where R 3 _ι is as defined above, (C 3 - 8) -CO-R 3 .ι 3 where R 3 . 3 is selected from the group consisting of 1-imidazolyl optionally substituted with one (F-Aryl-L VIII) or two R 3 _2 where R 3 . 2 is as defined above, 1-pyrrolyl optionally substituted with one (F-Aryl-LK) or two R 3 . 2 where R 3 . 2 is as defined above, 1-pyrazolyl optionally substituted with one (F-Aryl-LX) or two R 3 . 2 where R 3 . 2 is as defined above, 1,2,3-triazol-l-yl optionally substituted (F-Aryl-LXI) with one or two R 3 . 2 where R 3 . 2 is as defined above, 1,2,4-triazol-l-yl optionally substituted (F-Aryl-LXH) with one or two R 3 . 2 where R 3 . 2 is as defined above, 1-tetrazolyl optionally substituted with one (F-Aryl-LXIH) or two R 3 . 2 where R 3 . 2 is as defined above, 1-indolyl optionally substituted with one (F-Aryl-LXIV) or two R 3 _ 2 where R 3 . 2 is as defined above, 1 -indazolyl optionally substituted with one (F-Aryl-LXV) or two R 3 . 2 where R 3 . 2 is as defined above, 2 -isoindolyl optionally substituted with one (F-Aryl-LXVI) or two 3 _2 where R 3 . 2 is as defined above, 1-purinyl optionally substituted with one (F-Aryl-LXVϋ) or two R 3 _ 2 where R 3 . 2 is as defined above, 2-furanyl optionally substituted with one or two (F-Aryl-XLIIl) R3-2 where R 3 _ 2 is as defined above, 3-furanyl optionally substituted with one or two (F-Aryl-XLIV) R 3 _2 where R 3 . 2 is as defined above, 2-thienyl optionally substituted with one or two (F-Aryl-XLV) or two R 3 _2 where R 3 _ 2 is as defined above, 3-thienyl optionally substituted with one or two (F-Aryl-XLVI) R 3 . 2 where R 3 . 2 is as defined above, 2-oxazolyl optionally substituted with one or two (F-Aryl-XXXI) R 3 . 2 where R 3 . 2 is as defined above, 4-oxazolyl optionally substituted with one or two (F-Aryl-XXXπ) R 3 . 2 where R 3 . 2 is as defined above, 5-oxazolyl optionally substituted with one or two (F-Aryl-LVI) R 3 . 2 where R 3 . 2 is as defined above, 3-isoxazolyl optionally substituted with one or two (F-Aryl-XXV) -2 WQere R3-2 i s ^ defined above, 4-isoxazolyl optionally substituted with one or two (F-Aryl-XXVI) R 3 _ 2 where R 3 . 2 is as defined above, 5 -isoxazolyl optionally substituted with one or two (F-Aryl-XXVII) R 3 _2 where R 3 . 2 is as defined above, 2-thiazolyl optionally substituted with one or two (F-Aryl-XXXIII) R 3 . 2 where R 3 . 2 is as defined above, 4-thiazolyl optionally substituted with one or two (F-Aryl-XXXIV) R3-2 where R3-2 is as defined above, 5-thiazolyl optionally substituted with one or two (F-Aryl-LVII) R 3 . 2 where R 3 . 2 is as defined above, 3-isothiazolyl optionally substituted with one or F-Aryl-LVIII) two R 3 . 2 where R 3 . 2 is as defined above, 4-isothiazolyl optionally substituted with one or two (F-Aryl-LXIX) R 3 . 2 where R 3 . 2 is as defined above, 5-isothiazolyl optionally substituted with one or two (F-Aryl-LXX) R 3 . 2 where R 3 . 2 is as defined above; imidazo[l,2-a]pyridin-2-yl optionally substituted (F-Aryl-LXXII) with one or two R 3 . 2 where R 3 . 2 is as defined above; (C 3 - 9) -C*=N-C(R3_ 14 )2-[C(R 3 _ 1 5) 2 ] n 23-R*3_ 16 where the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring, where the 3 .i4's are the same or different and are -H or Cι-C 3 alkyl, where n 23 is 1 thru 3, where the 3 _i5's are the same or different and are -H or C ~C 3 alkyl, where R 3 . 16 is -O-, -S-, -C^-i^i"' " NR 3-12 where 3 -i 2 and R 3 . 14 are as defined above, (C 3 - 10) -CH(OH)R 3 _ι where R 3 _ι is as defined above, (C 3 - 11) -CH 2 -O-R 3 _ι where R 3 _ is as defined above, (C 3 -12) -CH 2 -NR 3 _4R 3 _5 where R 3- and R 3 . 5 are as defined above; (R 4 /R 5 /R 6 - 1) where R 4 is α-R 4 .ι:/3-R 4 . 2 where one of R _ι and R . 2 is -H and die other of R 4 _ι and R 4 . 2 is taken together with R 5 to form a ring of the formula (R 5 end)-CO-R 45 . r (CH 2 )_ 3 - (R 4 end) ^4 ^ - 1 ) where n 3 is 0 thru 3 and R 4 5_ι is -O-, -CO-, -S-, -CH=CH-, -C(R3-17 . 2" where the R 3 . 7's are the same or different and are -H or Cι-C alkyl, "NR45-2 where R 4 5_ 2 is -H, C r C 6 alkyl, -(CΗ.2)n9~ where rig is 0 thru 4 and -φ is optionally substituted with -F, -Cl, -Br, -I or C r C 4 alkyl, -(CH 2 ) nl0 -NR 4 5_3R 4 5_4 where n 10 is 2 thru 6, where R 5 . 3 is -H, C r C 4 alkyl, -φ and where R^^ is -H or C -C3 alkyl, and where Rg is -H, -F, -Cl, -Br, -I, -CN, -NO 2 , -O-CO-Rg.! where R^ is -H, C r C 4 alkyl or C 3 -C 7 cycloalkyl, -CF 3 , -O-CF 3 , C r C 6 alkyl, C 3 -C 7 cycloalkyl, -CH 2 CH 2 OH, -NRg^-CO-Rg^ where Rg_ 2 is -H or C ~C alkyl, and where Rg_ 3 is -H, C r C 6 alkyl, -φ optionally substituted with -F, -Cl, -Br, -I or C1-C4 alkyl, -CH 2 -. , -(CH 2 ) n24 -OR 6 _ 4 where n 24 is 0 thru 3 and R^ is C r C 4 alkyl, -(CH 2 )n25-OH where n25 is 2 thru 4, -(CH^- j ^-φ where n 2 6 is 0 thru 3, -(CH2)-j2 -N R 6 _ t ) 2 where n 2 and R^ are as defined above, "S-R β - here Rg_4 is as defined above, -SO 2 -N(R 6 _5) 2 where R 6 . 5 is -H or C^ j alkyl, -CO-N(Rg_5) 2 where R 6 _5 is as defined above, -CO 2 -Rg^ ) where R 6 _ 4 is as defined above, -N g^R _7 where Rg_g and R5.7 are the same or different and are -H or C1-C4 alkyl and where R^ and Rg_ can be taken together with the attached nitrogen atom to form a ring, which may contain an additional heteroatom, selected from the group consisting of piperazine, morpholine, pyrrolidine or piperidine; (R 4 /R 5 R 6 - 2) where R 5 and Rg are taken together to form a heterocyclic ring selected from the group consisting of (Rg end) -(CH 2 ) nl 3-R5 6 . 1 -(CH 2 ) nl4 -CO-(CH 2 ) nl5 (R 5 end) (R 4 /R 5 /R6 - 2a) where n 13 is 0 thru 3, n 14 is 0 thru 3, n 15 is 0 thru 2, R 56 _! is -O-, -S-, -CH 2 -, -CH=CH-, -C^ β ^^ where the Rs6-3's are the same or different and are C1-C3 alkyl, or -N 56_ 2 where R 56 _ 2 is -H, C r C 6 alkyl, C 3 -C 7 cycloalkyl, -(CH^-IT-OH where n is 2 thru 4, -(CH 2 )_ι 6 -ψ where n 6 is 0 thru 4 and -φ is optionally substituted with -F, -Cl, -Br, -I, Cι-C 4 alkyl, (Rg end) -R 56 . r CO-CO- (R 5 end) (R 4 /R 5 /R 6 - 2b) where R 56 _! is as defined above, where R is where R 4 . 3 and R 4 _4 are the same or different and are -H, -OH or C "C 4 alkyl, with the proviso that only one of R 4 . 3 and R 4-4 can be -OH at any one time; (R R 5 /R 6 - 3) where R 4 is C 3 -C 7 spirocycloalkyl or α-R 4 . 5 :j_'-R 4 ^ where R 4 . 5 and R^_g are the same or different and are -H or C ~C 4 alkyl, where R 5 is -(CH 2 ) I _ >9 -CO-H where n 29 is 0 thru 4, -(CH^n^-C Ci-Cg alkyl) where n 29 is as defined above, -(CH2),_ j9 -CO-(C3-C7 cycloalkyl) where n 29 is as defined above, -(CH2),_ j -CS-(Cι-C 6 alkyl) where n 29 is as defined above, where n 28 is 0 thru 3, where R5.1 is as defined for R 3 _ι with the proviso that R 3 _ and R 5 _ι may be the same or different, where R 5 ^ is -H, C r C 6 alkyl, -CH 2 -CH 2 -OH, -CH 2 -CH 2 -OCH 3 or -φ optionally substituted with 1 or 2 R 3 . 2 ' s where R 3 . 2 is as defined above, and where the n 29 's may be the same or different and are as defined above, -(CH2)- ώ9 -CO-(CH 2 ) n28 -NR 5 ^((CH 2 ) n29 -NR 5 . 1 R 5 . 5 )whereR 5 .5 is -H, C r C 6 alkyl, -CH 2 -CH 2 -OH, -CH 2 -CH 2 -OCH 3 , where n 28 , R5.1, and R 5 ^ are as defined above, where the n 29 's may be the same or different and are as defined above, and where R 5 _ and R5.5 are taken together with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, l-(4-methyl)piperazinyl, -(CH 2 ) n 2 9 -CS-(C3-C7 cycloalkyl) where n 9 is as defined above, -(CH2) n 2 9 -CO-aryl where aryl and n 29 are as defined above, -(CH2) j _) 9 -CS-aryl where aryl and n 29 are as defined above, -(CH 2 ) n29 -CO-O-R 5 .ι where R 5 _ι and n 29 is as defined above, -(CH^ j ^-CO -S-R 5 _ι where 5 _ι and n 29 are as defined above, -(CH 2 )_2 9 -CO-(CH 2 ) n 2 8 -NR5_ t R5.5wheren 28 ,n2 9 ,R 5 ^andR 5 .5 are as defined above and where R 5 _4 and R5.5 are taken together with the attached nitrogen atom to from a heterocyclic ring selected from the group consisting of -N*-(CHR 5 . 8 ) nA -(CH 2 ) Ill -R5^-(CH 2 ) n 2-(C*HR5. 9 ) nB - (C 5 - la) -N^-^Hi^ ^HR j .g -Rs^-^HR^-B-^^- (C 5 - lb) where R 3 . 8 is -H or C ] ^ alkyl, n A is 1 or 2, χ is 0 thru 2, n 2 is 0 thru 2, R 3 . 9 is -H or C1-C3 alkyl, n B is 1 or 2, where the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring, with the proviso that the ring not contain more than 8 atoms, and where R 5-6 is -O-, -S-, -CO-, *CR5-8 R 5-9 where R 5 . 8 and R 5 . 9 are the same or different and are -H or C -C alkyl, -NR5.7 where R5.7 is -H, C r C 6 alkyl, -(CH^-^-ø where nι 8 is 0 thru 4 and where -φ is optionally substituted with -F, -Cl, -Br, -I or C1-C3 alkyl, -(CH 2 ) n ι 9 -OH where n l9 is 2 thru 4, with the proviso that when R5_g is -O-, -S- or -NR5.7-, n and r^ are 1 or 2, -(CH 2 )- 29 -CO-CO-NR5_4R 5 _5 where R 5-4 , R5.5 and n 29 are as defined above, -(CH 2 ) n29 -CO-COOR5_ 8 where n 29 is as defined above and where R 5 . 8 is -H, C r C 4 alkyl, where n 20 is 1 thru 4, -φ optionally substituted with 1 or 2 -F, -Cl,-Br, -I or C C 3 alkyl, -(CH 2 ) n29 -CO-R5_i3 where n 29 is as defined above and where R 5 _ 13 is defined as being selected from the same group as 3 3 -(CH 2 ) n29 -C*=N-C(R5.ι 0 ) 2 -[C(R5.ιι) 2 ] Il2 7-R* 5 .i2 where the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring, where the Rs.io's are the same or different and are -H or C1-C3 alkyl, where n 2 7 is 1 thru 3, where the R5_n's are the same or different and are -H or C1-C3 alkyl, where R 5 _ι 2 is -O-, -S-, -C(R 5 _ 13 )2-, -NR5_ι 4 where R 5 _ι 3 and R 5 _ι 4 are -H or C1-C3 alkyl, and where Rg is as defined for ^ 4 /R 5 /Rg - 1) above; where W 6 is -N= or -CR β = where Rg is as defined above; where W 7 is -N= or -CR 7 = where R 7 is as defined for R 6 , the Rg R 7 , R 8 and Rg may be the same or different. where W 8 is -N= or -CR g = where R 8 is as defined for R 6 , the Rg R 7 , R 8 and R9 may be the same or different. where W 9 is -N= or -CR9= where R9 is as defined for R 6 , the Rg R 7 , R 8 and .^ may be the same or different. with the proviso that not more than two of W 6 , W 7 , Wg and W 9 can be -N= at any one time; and pharmaceutically acceptable salts thereof where such exist. Further disclosed are imidazo[l,5-a]quinoxalines (LX) selected from the group consisting of tert-butyl 7-fluoro-4,5-dihydro-4(R methyl-5-(2-pyridylmethyl)imidazo[l,5-a]quinoxaline-3- carboxylate, 7-fluoro-4,5-dihydro-4(R)-methyl-3-[5-(l-methylcyclopropyl)-l,2,4-oxadiazol-3-yl]-5-(2- pyridylmethyl)imidazo[l ,5-a]quinoxaline, cyclopropylmemyl__mirib-fluoro-4,5-dihydro-4(R)-methyl-5-(2-pyridylmethyl)imidazo[l,5- a]quinoxaline-3-carboxamide, 7-fluoro-4,5-dihydro-4(R)-methyl-3-[5-(2-methylcyclopropyl)-l,2,4-oxadiazol-3-yl]-5-(2- pyridylmethyl)imidazo[ 1 ,5-a]quinoxaline. DETAILED DESCRIPTION OF THE INVENTION The imidazo[l,5-a]quinoxalines (I), CHART A, of the present invention are named and numbered following the Chemical Abstracts ring system nomenclature system, see Ring Systems Handbook, Chemical Abstracts Service, Ring Systems File I, see RF 23543, 1988 Edition or according to Chemical Abstracts Science, Columbus, Ohio. The imidazo[l,5-a]quinoxalines (I) are produced by a number of processess depending on the variable substituents involved, particularly those at postions 3, 4, 5, 6, 7, 8 and 9. In all cases the process to produce the imidazo[l,5-a]quinoxalines (I) can be viewed as a two "sequence" process, as will be explained in more detail below. The first part is the transformation of an appropriately substituted aromatic heteroaromatic compound to the bicyclic amide "quinoxaline" (TV). The second part is the addition of the appropriately substituted imidazo group and the desired exocyclic carbonyl functionality. Because the imidazo[l,5-a_quinoxalines (I) are novel, the overall chemical process is novel. However, it is realized that each step is known to those skilled in the art. The combination of known process chemistry in a novel way produces the novel imidazo[l,5- ajquinoxalines. CHART B discloses one of the general processes for the transformation of diamino compounds (H) to the corresponding bicyclic amides (IV) by two different routes. The diamino compound (H) starting materials are known to those skilled in the art or can be readily prepared by methods known to those skilled in the art. In one route, the diamino compounds (H) are reacted with a haloester (__) in a solvent such as DMF, THF, acetonitrile, ethanol or toluene with a weak base such as carbonate, bicarbonate, Hunig's base or triethylamine to produce the corresponding bicyclic amides (TV). The second route disclosed in CHART B reacts the diamino compounds (II) with glyoxalic acid (CHO-COOH) (V) to produce the corresponding unsaturated bicyclic amides (VI). The unsaturated bicyclic amides (VI) are then reduced by known methods such as sodium borohydride in ethanol or sodium cyanoborohydride in methanol to the correspondmg bicyclic amide (TV). See also J. Med. Chem, 24, 93 (1981). The processes of CHART B are operable regardless of whether the W 6 , W 7 , W 8 and/or W 9 's are -CR # = or -N= and therefore is a very general process for preparation of the important intermediate bicyclic amide (IV). CHART C discloses another general process for the preparation of the bicyclic amide (IV). The process of CHART C is useful in two ways. First, when the desired substituent is already present in the aromatic heteromatic ring and second when it is desired to have a substituent which it is best not to carry thru the entire synthesis process but rather add later by displacing a halogen atom (Xla — * ■ xm). In this process the precursor to the desired bicyclic amide (IV) is cyclized to form the bond at the top of the quinoxaline ring. This process is particularly useful when it is desired that the substituent at W 6 , W 7 , W 8 and/or W 9 is other than -CH=; Rg, R 7 , R 8 and Rg are ≠ -H. When it is desired to func tionalize the substituent at Rg, R 7 , Rg or Rg the process of CHART C is a preferred process. The halo -nϊtro (VII) starting materials are known to those skilled in the art or can be readily prepared by methods known to those skilled in the art from known compounds by methods known to those skilled in the art. When two halo substituents are present they may be the same or different. The particular halo group (Xla) will vary depending on whether it is desired to retain it in the final product (IV) or displace it as will be discussed below. The halo-nitro compounds (VII) are reacted with an amino-alcohol (VKI) to produce the corresponding nitro-alcohol (IX), which is oxidized to the corresponding acid (X) by known methods such as Jones oxidation. The acid (X) is then converted to the corresponding nitro-ester (XI) by known methods such as an alkylhalide, a base such as DBU in DMF. CHART C also discloses that the nitro-esters (XI) can alternatively be prepared by reacting the halo-nitro compounds (VII) with an amino-ester (XII) to form the nitro-esters (XI) directly. The nitro -acid (X) can also be prepared directly by reaction of the halo-nitro compound (VII) with the amino-acid (XHa) to form the nitro-acid (X). Should it be desired to retain the halogen in the bicyclic amide (TV) and eventually in the imidazo[l,5-a]quinoxalines (I), then the halo -nitro-ester (Xla) is cyclized by reduction with hydrogen over palladium on carbon in ethanol, platinium on carbon in ethanol, TiCl 3 in methanol or with Raney nickel. Alternatively, if it is desired that R 7 or R9 be other than halogen, nucleophilic (R " ) displacement of the halo -nitro-ester (Xla) will give the corresponding aromatic nitro-ester (XE ) where the halogen has been replaced by the nucleophile (R 7 and g ≠ -H OT halogen). Thus the nitro-ester (Xffl) or (XI) can then be reduced and cyclized as described above to provide the bicyclic amide (TV). CHART D discloses a process to produce the bicyclic amides (IV) starting with the corresponding nitro-amines (XIV). The nitroamines (XIV) are reacted with the haloester (III) to form the corresponding nitroester (XI). The nitro group is reduced (palladium on carbon or TiCl 3 or Raney nickel) and the ester and newly formed amino group are cyclized directly to produce the bicyclic amides (IV). CHART E discloses a route to produce the key intermediate bicyclic amides (IV) when it is convenient to start with a nitromethyl compound (XVI). The methyl group is oxidized to an acid to produce the nitroacid (XVII) with an oxidizing agent such as potassium permanganate or sodium hypochlorite catalyzed by ruthenium tetroxide. The nitroacid (XVII) is then transformed to the corresponding amide (XVIII) with a reagent such as thionyl chloride followed by ammonium hydroxide (30% aquesous solution). The nitroamide (XVIII) is then subjected to a Hoffmann-type rearrangement (lead tetraacetate in absolute tert-butanol) to produce the rearrangement product (XIX), followed by alkylation with the haloester (III) to provide the alkylated rearrangement product (XX). The alkylated rearrangement product is then hydrogenated with palladium on carbon in methanol to give the amino alkylated rearrangement product (XXI) which is then cyclized to form the N-substituted bicyclic amide (XXII) by stirring in an alcohol, such as methanol with or without catalytic p-toluenesulfonic acid. EXAMPLES 19-23 disclose this transformation with W 6 = -CF=. This process is also applicable where Rg, R 7 , R g or R 9 is -Cl, -Br, -I, -CF 3 , -OCF 3 , C r C 3 alkoxy, C r C 3 thioalkyl, -CN, -NO2, -O-CH 2 -COOH. The N-substituted bicyclic amide can then be transformed to the bicyclic amide (IV) using hydrochloric acid in methanol or trifluoroacetic acid in methylene chloride, or can reacted directly to form the side chain at R 3 . Alternatively, the Hoffman rearrangement product (XIX) can be reacted with trifluoroacetic acid in methylene chloride to give a nitroamine (XIV). The nitroamine can be reduced with hydrogen and palladium on carbon to the diamino compound (II) and used following the process of CHART B, or used as such following the procedure of CHART D. CHART E also discloses an alternative process from the Hoffman rearrangement product (XIX) to the bicyclic amide (IV). In this alternative process the nitro group of the Hoffman rearrangement product (XIX) is reduced with hydrogen and palladium on carbon, with TIC1 3 or with Raney nickel to give the amine amide (XLV). The amine amide (XLV) is then acylated with the dihalo compound (XLVI) to give the diamide (XLVII). The protecting group of the diamide (XL VII) is removed with hydrogen chloride in methanol or with trifluoroacetic acid in methylene chloride to give die bromoamine (XL VIII), which is then heated in toluene in the presence of a base such as Hunig's base to give the bicyclic amide (TV). CHART F discloses an alternative way of producing the bicyclic amide (IV). Previous processes producing the bicyclic amide (IV) first formed an amine at the "bottom N" at N 5 and then cyclized it with the "top" nitrogen to form the cyclic amide. In CHART F the process is reversed, the amide is first formed at the "top" nitrogen and then cyclized with the N 5 nitrogen to form the desired bicyclic amide (IV). In this process one starts with the nitro-halo compound (XXEQ) and replaces the halogen with ammonia in ethanol to form the amino-nitro compounds (XXIV). Alternatively, one can start with the amino-nitro compounds (XXIV) which are reacted with a dihalocarbonyl compound (XXV) to form the acyclic amide (XXVI). The nitro group is reduced by known means and the "top" chain acyclic amide (XXVI) is then cyclized with the newly formed amino group to form the corresponding bicyclic amide (TV). CHART G discloses a preferred process when R 4 is -H:-H and when R 3 is phenyl (-φ) or substituted phenyl. The starting material is the nitro-halo compounds (XXVII) which are reacted with a substituted amine such as t-butylamine or veratrylamine to form the nitro protected-amine (XXVm). The nitro group is then reduced by known methods, such as TiCl 3 in aqueous methanol with a base such as sodium acetate or with Raney Nickel in ethanol to give the amino protected- amine (XXIX). This protected amine is then reacted with ethyl oxalyl chloride (XXX) in a solvent such as toluene and diisopropyled ylamine followed by heating to give the protected bicyclic amide (XXXI). The protected bicyclic amide (XXXI) has the imidazole ring added to form the protected tricyclic amide (XXXIV) as described below. The protecting group is removed with trifluoroacetic acid in methylene chloride to give the tricyclic amide (XXXV). The tricyclic amide (XXXV) is reduced using a reducing agent such as lithium aluminum hydride or aluminum hydride to give tricyclic amine (XXXVI) which is acylated (as described below) at N5 to give the imidazo[1 . 5- a]quinoxaline (I). The deprotection and reduction steps may also be carried out in reverse order. Alternatively, the amino protected-amine (XXIX) is reacted with dihalocarbonyl compound (XXV) and base such as Hunigs base to form the protected amide (XXXIA). The protecting group of the protected amide (XXXIA) is then removed by reacting with an agent such as trifluoroacetic acid in methylene chloride to form the bicyclic amide (IV). CHART H discloses two methods of transforming the bicyclic amide (TV) to the corresponding imida_o[l,5-a]quinoxaline Q). One method involves first adding the appropriate sidechain at N 5 to form the N-substituted bicyclic amide (XXXII) followed by the formation of the imidazole ring (appropriately substituted) to give the desired imidazo[l,5-a]quinoxaline (I). The other method involves reversing the steps, first forming the imidazole ring to give the N5- unsubstituted imidazole (XXXIII) followed by addition of the N 5 side chain. With either method there are two ways of adding the N 5 sidechain. One way is to react the bicyclic amide (TV) or N 5 - unsubstituted bicyclic amide (XXXIII) with R 5 -X (where X is a good leaving group) in a solvent system such as THF and Huing's base. Alternatively, the the bicyclic amide (IV) or the N 5 - unsubstituted imidazole (XXXIII) is contacted with phosgene (C1-CO-C1) in a THF/amine solvent system followed by reaction with the desired nucleophile to displace the chlorine. When R^ is - CH 3 :-CH 3 it is preferred to use the phosgene process. When R is -H:-H, then either method is useful. The imidazole ring is formed by known methods using known compounds, see J. Med. Chem., 32, 2282 (1989), US Patent 4,774,245, EP 344,943A, EP 347,094A, EP320,136, EP 368,652A and EP 283, 102A. A preferred process when R3 is COOR^, R4 is -H:H, and R 5 = - (QE_2) n 29_CO-(CH 2 ) n2 gNR3_ 4 R3_5. The starting material is the N 5 unsubstituted imidazole (XXXIII) which is reacted with an alpha halo-amide to afford compound (I). Also, the N5 unsubstituted imidazole (XXXIII) can be reacted with chloroacetyl chloride to yield the N5 alpha chloro amide, which can be reacted with primary or secondary amines to give (I). Chart I discloses a preferred process when R3 is -CH2-O-R3. or -CH 2 NR 3 _ j R3.5, R4 is -H:-H and R5 is -(CH 2 ) n 9 CO-(CH 2 )_ 2 gNR3_ 4 R3_5. The starting material is the N 5 unsuhstituted imidazole (XXXIII) where R 3 is an ester or an amide or acid chloride which is reduced with lithium borohydride to give (XXXVII). The R-3 alcohol is protected to give the protected hydroxy methyl (XXXVIIa). The N 5 sidechain is then added to the protected alcohol (XXXVIIa) to give the protected-R 5 (XXXVIU) which is then coverted to the unprotected-R 5 (XXXVIIIb). After removal of the protecting group, that compound was treated- with thionyl chloride followed by the addition of the sodium salt of an alcohol to give the imidazo[l,5-a]quinoxaline (I). Alternately, treatment of the intermediate chloro compound with an amine also leads to compound (I). The imidazo[l,5-a]quinoxalines (I) where R 4 and R5 are cyclized to form a heterocyclic ring (H^Λ^/Rg-l) are prepared according to the procedure of CHART J. The dihalonitro compound (VII), CHART C, is transformed to either the halo-nitro-acid (X) or the halo-nitro-ester (XI) as previously desribed. Then these compounds are transformed to the bicyclic amide (IV) as described above. The bicyclic amide (IV) then is transformed to the corresponding 4,5-cyclic amide (XXXIX) by different processes depending on whether R4 terminates in an ester or carboxylic acid, or an alcohol or amine. When R 4 is an ester or carboxylic acid the bicyclic amide (IV) is stirred in solvents such as toluene or methanol to effect ring closure. Heating and the addition of a catalyst such as p-toluenesulfonic acid or camphorsulfonic acid will speed completion of the cyclization. When R 4 terminates in an alcohol or a substituted amine, the bicyclic amide (IV) is stirred with or without heating with a carbonyl source such as carbonyldiimidazole or phosgene (the choice of heating or not heating will depend on the reactivity of the carbonyl source) in aprotic solvents such as THF, toluene and methylene chloride to obtain the 4,5-cyclic amide (XXXIX). The 4,5-cyclic amide (XXXIX) is then transformed to the corresponding imid___o[l,5- ajquinoxaline (I) by the standard procedures described above. CHART K discloses a process whereby imidazo[l,5-a]quinoxalines (I) can be transformed into other imidazo[l,5-a]quinoxalines (I) as is apparent to one skilled in the art. For example, one imidazo[l,5-a]quinoxaline (I) end product is where R 3 is an ester (I-ester), -COOR 3 _ι (C 3 - 1), such as -COO-(t-buty 1). That compound can readily be transformed into one where R 3 is an amide -CO-NR 3 _ R 3 _5 (C 3 - 2) by means known to those skilled in the art. Also, imidazo[l,5- a]quinolxaline (I) where R 3 is an ester can be transformed into the corresponding acid (I-acid) and subsequently to the acid chloride. Reaction of that acid chloride with aromatic systems, i.e. benzene, in the presence of a Lewis Acid such as aluminum chloride, gives R-3 aryl ketones. Furthermore, treatment of those ketones with hydride reagents afford the corresponding alcohols. The 1,2,3-triazol-l-yls (I-F-Aryl-LXI) are prepared as set forth in CHART L. The starting material is the imida_ol[l,5-a]quinoxalines (I) where R 3 is -COOR^ (C 3 -l) where R 3 _! is alkyl. This compound is treated with trifluoroacetic acid in a solvent such as methylene chloride to remove the alkyl group. The resulting carboxylic acid is treated with thionyl chloride followed by sodium azide to give an acyl azide. The azide is heated in a hydrocarbon solvent to effect a molecular rearrangement followed by trapping of the unstable intermediate with methanol to form a carbamate. The carbamate is then decomposed with a strong base such as hydroxide to give the amine (XLI). This amine (XLI) is treated with (sodium) nitrate in an acidic medium followed by treatment of sodium azide and finally treatment with water to give the azide (XLH). The azide (XLII) is contacted with acetylenes in organic solvents such as toluene to give the 1,2,3-triazol-l- yls (I-F-aryl-LXI). The isomeric l,2,3-triazol-4-yls (I-F-Aryl-LXXI/LXXII) are prepared as set forth in CHART M and begin with the same starting material as for the 1,2,3-triaazol-l-yIs (I-F-Aryl-LXI). The alkyl ester is converted to the olefin (XLIII) using standard reduction and Wittig olefination procedures. Treatment of the olefin (XLIII) with bromine followed by treatment of the dibromointermediate with strong base such as sodium amide gives the acetylene (_XL.IV). The acetylene (XLIV) is contacted with substituted azides under standard conditions to give a mixture of the isomeric l,2,3-triazo_4-yls -F-Aryl-LXXI/LXXH). CHART N discloses the process to prepare the 5,6-cyclic compounds (R^/ ζ fR β - 2). The _midazo[l,5-a]quinoxalines (I) where R 5 and R 6 are taken together to form a heterocyclic ring are prepared by several methods. For example when nι 4 and n^ are 0 and n^ is not 0, it is preferred to prepare the desired 5,6-cyclized compounds by the procedure of CHART N. The nitro compound (LI) which is readily available or may be prepared by conventional methods known to those skilled in the art, is the starting material. Reaction of the nitro compound (LI) with phosgene, triphosgene or l, -carbonyldiimidazole in a solvent such as THF between 0 and 100°, preferrably in the presence of a base such as triethylamine provides the cyclic amide (LU). Reduction of the nitro group of the cyclic amide (LU) by hydrogenation in ethanol or ethyl acetate in the presence of palladium on carbon gives the amino cyclic amide (LIU). Reaction of the amino cyclic amide (LHI) with chloroacetyl chloride in the presence of a base such as diisopropylethylamine and subsequent treatment of the acylated material with a base such as potassium t-butoxide in THF gives the bis-amide (LIV). The imidazo[l,5-a]quinoxalines (I) are then prepared by cyclization of the bis-amide (LIV) with an isocyanide reagent as described above, see CHARTS G and H. In the situations where R 5 contains a alkyl or alkenyl chain, the cyclic amide (LU) is prepared from the nitro amino ester (LV, which is known to those skilled in the art) by heating in an inert solvent such as THF or toluene. When n 3 and n^ are 0 and n 1 is 1 thru 3, the 5,6-cyclic-imidazo[l,5-a]quinoxalines (I) are preferrably prepared by the process set forth in CHART O. Reaction of the aromatic nitro amino compound (LVI) with ethyl bromoacetate (or a chain extended variant) and diisopropylethylamine at reflux provides a mixture. Exposure of the mixture to ethoxide in ethanol at reflux provides the desired cyclized amide (LVII). Following the procedures described above for CHART N, but using the cyclized amide (LVII) provides the corresponding intermediates and desired 5,6-cyclic-imidazo[l,5 -a]quinoxalines (I). When n^ and n 1 are 0 and n^ is not 0, similar processes are utilized. When the bicyclic amide (IV) or 4,5-cyclic amide (XXXIX) has R^ = -H:-CH 3 , there will be an asymmetric center and therefore two enantiomers, one "S" and the other "R", either of which can be (+/d) and the other (-/l). Both enantiomers (+) and (-) are useful in the same way as the optically impure (racemic, +) mixture. Hence, they may be utilized in the racemic form without separating them. However, if it is desired to utilize one of the enantiomers, two methods are available to produce optically pure forms. The racemic bicyclic amide (IV) or other racemic compounds produced from it can be resolved using methods known to those skilled in the art, see for example, Optical Resolution Procedures for Chemical Compounds, Vol 1,: Amines and Related Compounds, Paul Newman, Optical Resolution Information Center, Manhattan College, Riverdale, NY, 10471, 1978. For example, treatment of the above mentioned racemic mixture (IV) with an optically active acid such as (+)-tartaric acid or alternatively with (-)-tartaric acid would yield a mixture of diastereomeric salts, which can be separated most conviently by fractional crystallization to give a salt containing only one enantiomer of the racemic mixture. Other suitable optically active acids include, (-) di- benzoyltartaric acid, (+)-camphoric acid, (+)- and (-)-maIic acid and (+)-camphor-10-sulfonic acid. By reacting the diastereomeric salt with a base one obtains the desired enantiomer as the free amino compound. In addition, treatment of racemic (X) with an optically active amine such as methyl benzylamine and using fractional crystallization gives a salt containing only one enantiomer of the racemic mixture. By reacting the diastereomeric salt with an acid, one obtains the desired enantiomer as the free carboxylic acid. Alternatively (see chart C), either (+) or (-) amino-acid (Xlla) can be added to halo-nitro (VII) to give the acid (X). Catalytic hydrogenation of acid (X) leads directly to bicyclic amides (IV) which are optically pure. Thus, depending on the chirality of the starting amino acids [(+) or (-)] the corresponding enantiomerically pure compound of formula IV can be prepared. These optically pure compounds are then used in the same way as the racemic mixture. When used in this patent application the term imidazo[l,5 -a]quinoxalines (I) includes both enantiomers as well as optically impure forms thereof, the most common of which is a racemic mixture (+., dl). The imid___o[l,5-a]quinoxalines Q) are amines. Many do not form salts, some do. If salts can be made it is preferrable to make them because of their increased water solubility. When salts of the imid___o[l,5-a]quinoxal_nes (I) are made they are produced by reaction with acids of sufficient strength. Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free amines since they produce compounds which are more water soluble. The preferred pharmaceutically acceptable salts include salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH 3 -(CH 2 ) n -COOH where . n is 0 thru 4, HOOC^CH^n-COOH where n is as defined above. It is preferred that R 3 is -COOR 3 _ι, aryl or -CO-NR 3 ^R 3 . 5 . When R 3 is aryl it is preferred that it be l,2,4-oxadiazoI-3-yl, l,2,4-oxadiazol-5-yl or substituted phenyl. It is preferred that R 3 . 2 is C 2 -C 4 alkyl and C 3 -C 5 cycloalkyl. It is more preferred that R 3 . 2 is -F, t-butyl and cyclopropyl. R5 can be either free or cyclized with either R or Rg. It is preferred that R5 is not cyclized. It is preferred that n 28 and n 29 be 0. It is preferred that R 4 is α- ^i/S-R^ where R4.5 and R _6 are -H:-H or C alkyhC alkyl. It is preferred that R 5 is selected from the group consisting of -(CH 2 ) n29 -CO-(C 1 -C 6 alkyl), -(CH^^-CO-^H^g-NRs^. j , -(CH^-CO- aryl, -(CH 2 ) n29 -CO-R 3 . 13 . It is more preferred that R 5 is -(CH 2 ) ώ9 -CO-(CH 2 ) n2 g-NR5_ 4 R 5 _5, -(CH^-^-CO-aryl and -(CH2) n 29-CO-O-(C 1 -C 6 alkyl). It is preferred that W 6 , W 7 , W 8 and W 9 all be -CR X = where the R's are -H. It is also preferred that W 6 or W 7 be -CF=, -CC1= or -CCH 3 =. It is preferred that the imidazo[l,5-a]quinoxaline (I) be selected from the group consisting of the compounds of EXAMPLES 30, 31, 33, 34, 36, 38, 40, 42, 44, 45B, 47-87, 89-93, 100, 102, 104-244, 248-258 and 259-273, 275, 305-318, 320-362, 367-559 as well as the 4,5-cyclized compounds of EXAMPLES 281-285, 289, 290. and the 5,6-cyclized compounds of EXAMPLES 363-366. It is more preferred that the imidazo[l,5-a]quinoxaIine ( ) be selected from the group consisting of the compounds of EXAMPLES 30, 31, 33, 34, 36, 38, 40, 42, 44, 45B, 47-87, 89-93, 100, 102, 104- 244, 248-258 and 259-273, 275, 305-318, 320-362, 367-431 as well as the 4,5-cyclized compounds of EXAMPLES 281-285, 289, 290. and the 5,6-cyclized compounds of EXAMPLES 363-366. It is even more preferred that the imidazo[l,5-a]quinoxaline (I) be selected from the group consisting of the compounds of EXAMPLES 51, 113, 128, 136, 332-334, 336, 338, 361, 393, 402, 405, 407, 409, 411-413, 422-424 and 426. The i_nidazo[l,5-a]quinoxalines (I) of the present invention have relatively more anxiolytic and less sedative activity than other known anxiolytic compounds such as diazepam and therefore are useful as anxiolytic agents at lower doses and as sedatives at higher doses. The imidazo[l,5-a]quinoxalines (I) are active orally or parenterally. Orally the imidazo[l,5-a]quinoxalines (I) can be given in solid dosage forms as tablets or capsules, or can be given in liquid dosage forms such as elixirs, syrups or suspensions as is known to those skilled in die art. It is preferred that the imidazo[l,5-a]quinoxalines (I) be given in solid dosage form and that it be a tablet. For anxiolytic effect the imidazo[l,5-a]quinoxalines (I) should be give in amount of about 0.125 mg to about 100 mg/person, one to three times a day. Preferably, about 0.25 to about 50 mg/day in divided doses. For sedative/hypnotic effect the imidazo[l,5-a]quinoxalines (I) should be given in the amount of about 0.125 mg to about 500 mg/person, preferrably at bedtime or when sedation is needed. It is preferred the sedative/hypnotic dose be from about 0.25 mg to about 50 mg/person. The exact dosage and frequency of administration depends on the particular imidazo[l,5- a]qunioxaline (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the imidazo[l,5-a]quinoxalines (I) in the patient's blood and/or the patient's response to the particular condition being treated. The imidazo[l,5-a]quinoxalines (LX) of the present invention are useful in treating the same conditions in exactly the same way as are the imidazo[l,5-a]quinoxalines (I). DEFINITIONS AND CONVENTIONS The definitions and explanations below are for the terms as used throughout this entire document including both the specification and d e claims. I. CONVENTIONS FOR FORMULAS AND DEFINITIONS OF VARIABLES The chemical formulas representing various compounds or molecular fragments in the specification and claims may contain variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a numerical subscript, for example, "Zi" or "R j " where "i" is an integer. These variable substituents are either monovalent or bivalent, that is, they represent a group attached to the formula by one or two chemical bonds. For example, a group ∑ι would represent a bivalent variable if attached to the formula CH 3 -C(=Z )H. Groups Rj and Rj would represent monovalent variable substituents if attached to the formula CH3-CH 2 -C(R i )(Rj)-H. When chemical formulas are drawn in a linear fashion, such as those above, variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis. When two or more consecutive variable substituents are enclosed in parentheses, each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses. Thus, in the formula above, both Rj and R are bonded to the preceding carbon atom. Also, for any molecule with an established system of carbon atom numbering, such as steroids, these carbon atoms are designated as C j , where "i" is the integer corresponding to the carbon atom number. For example, Cg represents the 6 position or carbon atom number in the steroid nucleus as traditionally designated by those skilled in the art of steroid chemistry. Likewise the term "Rg" represents a variable substituent (either monovalent or bivalent) at the Cg position. Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain. The symbol "-" in general represents a bond between two atoms in the chain. Thus CH 3 - O-CH 2 -CH(R j )-CH 3 represents a 2-substituted-l-n_ethoxypro pane compound. In a similar fashion, the symbol " = " represents a double bond, e.g., CH 2 =C(R j )-O-CH 3 , and the symbol " »" represents a triple bond, e.g., HCsC-CH(R j )-CH 2 -CH 3 . Carbonyl groups are represented in either one of two ways: -CO- or -C(=O)-, with the former being preferred for simplicity. Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion. Thus, the compound 4-chloro-2-methylpyridine can be represented in linear fashion by N*=C(CH 3 )-CH=CC1-CH=C*H with the convention that the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring. Likewise, the cyclic molecular fragment, 4-(ethyl)-l-piperazinyl can be represented by -^-(CH^-N^H^-O^- C*H 2 . A rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound. For saturated compounds which have two substituents attached to a carbon atom which is part of a cyclic system, -C X^ζX^- the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial. However, the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other. In chemical structural formulas depicting such compounds, a substituent (X ) which is "below" another substituent Q will be identified as being in the alpha ( ) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -" or "...". The corresponding substituent attached "above" (X^ the other (X ) is identified as being in the beta ( β ) configuration and is indicated by an unbroken line attach¬ ment to the carbon atom. When a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable. For example, a variable R j attached to a carbon atom as - C(=R j )- might be bivalent and be defined as oxo or keto (thus forming a carbonyl group (-CO-) or as two separately attached monovalent variable substituents α-Rj . • and B-R j .^. When a bivalent variable, R j , is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form "α-R j .j:β-R j _ k " or some variant thereof. In such a case both c.-R j . j and β-R j __ are attached to die carbon atom to give -C(α-Rj_j)(β -R j _ k )-. For example, when the bivalent variable Rg, -C(=Rg)- is defined to consist of two monovalent variable substit- uents, the two monovalent variable substituents are α-R _ :fi-Rg_ 2 o. Rg_ 9 :β-Rg_ 10 , etc, giving -C(α-Rg_ι)(β-Rg. 2 )-, .... -C(α-Rg_ 9 )(β-Rg_ιo)-, etc. Likewise, for the bivalent variable Rn, - C(=Ru)-, two monovalent variable substituents are α-Rn_ι:β-Rn_2- For a ring substituent for which separate α and β orientations do not exist (e.g. due to the presence of a carbon carbon double bond in the ring), and for a substituent bonded to a carbon atom which is not part of a ring the above convention is still used, but the a and β designations are omitted. Just as a bivalent variable may be defined as two separate monovalent variable substituents, two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable. For example, in the formula -C (R j )H-C2(Rj)H- (Ci and C 2 define arbitrarily a first and second carbon atom, respectively) R j and R; may be defined to be taken together to form (1) a second bond between Ci and C 2 or (2) a bivalent group such as oxa (-O-) and the formula thereby describes an epoxide. When R j and R are taken together to form a more complex entity, such as the group -X-Y-, then the orientation of the entity is such that C in the above formula is bonded to X and C 2 is bonded to Y. Thus, by convention the designation "... R j and R j are taken together to form -CH 2 -CH2-O-CO- ..." means a lactone in which the carbonyl is bonded to C^. However, when designated "... Rj and R j are taken together to form -CO-O-CH 2 - CH 2 -the convention means a lactone in which the carbonyl is bonded to C j . The carbon atom content of variable substituents is indicated in one of two ways. The first method uses a prefix to the entire name of the variable such as "Cι-C 4 ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable. The prefix is separated from the variable by a space. For example, "Cι-C alkyl" represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given). Whenever this single prefix is given, the prefix indicates the entire carbon atom content of the variable being defined. Thus C 2 -C 4 alkoxycarbonyl describes a group CH 3 -(CH2) n - O-CO- where n is zero, one or two. By the second method the carbon atom content of only each portion of the definition is indicated separately by enclosing die "C j -C:" designation in parendieses and placing it immediately (no intervening space) before the portion of the definition being defined. By this optional convention (Cι-C 3 )alkoxycarbonyl has the same meaning as C 2 -C 4 alkoxycarbonyl because the "C j -C 3 " refers only to the carbon atom content of the alkoxy group. Similarly while both C 2 -C 6 alkoxyalkyl and (Cι-C 3 )alkoxy(Cι-C 3 )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms. When the claims contain a fairly complex (cyclic) substituent, at the end of die phrase naming/designating diat particular substituent will be a notation in (parentheses) which will correspond to the same name/designation in one of me CHARTS which will also set forth the chemical structural formula of that particular substituent. II. DEFINITIONS All temperatures are in degrees Centigrade. TLC refers to thin-layer chromatography. THF refers to tetrahydrofiiran. DMF refers to dimethylformamide. DBU refers to l,8-diazabicyclo[5.4.0]undec-7-ene. Saline refers to an aqueous saturated sodium chloride solution. IR refers to infrared spectroscopy. NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from tetramethylsilane. -φ refers to phenyl (C 6 H 5 ). MS refers to mass spectrometry expressed as m/e or mass/charge unit. [M + H] + refers to the positive ion of a parent plus a hydrogen atom. El refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment. Hunig's base refers to diisopropylethylamine. [αj jj 25 refers to the angle of rotation of plant polarized light (specific optical rotation) at 25° with the sodium D line (5893A). Ether refers to diethyl edier. Alcohol refers to ethyl alcohol. Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. Pharmaceutically acceptable anion salts include mesylate, chloride, sulfate, phosphate, nitrate, citrate, CH 3 -(CH 2 ) nI -COO "1 where n χ is 0 thru 4, "1 OOC-(CH 2 )n 1 -COO "1 where n is as defined above, "1 OOC-CH=CH-COO- 1 , φ-COO *1 . When solvent pairs are used, the ratios of solvents used are volume/volume (v/v). When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight volume (wt/v). EXAMPLES Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare me various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques. PREPARATION 1 5-(2,2-Dimethylpropyl)-3-N-formylaminomethyl- 1,2,4- oxadiazole A mixture of 2-formylaminoethanamidoxime (5.49 g, prepared from N-formylamino- acetonitrile and hydroxylamine), triethylamine (7.19 ml) and dichloromethane (50 ml) is stirred at 0°. To this mixture is added dropwise over 5-10 minutes, tert-butylacetyl chloride (7.16 ml). The reaction is stirred for 3 hr at 0° and then additional triethylamine and tert-butylacetyl chloride are added. The reaction is stirred for 3 hr and then the solvent is removed under reduced- pressure. Water (25 ml) is added to the residue and the mixture is heated at 100° for about 24 hr. After cooling, sodium chloride is added and die mixture is partitioned between dichloromethane, water, and saline. The organic phase is separated and dried over sodium sulfate and concentrated. The solid is then chromatographed on silica gel (300 ml) eluting with methanol/dichloromed ane (4/96). The appropriate fractions are pooled and concentrated to give the title compound, NMR (CDC13) 1.06, 2.79, 4.65, 6.40 and 8.32 δ. PREPARATION 2 5-(2,2-Dimethylpropyl)-3-isocyanomethyl-l,2,4-oxadiazole To 5-(2,2-dimemylpropyl)-3-N-formylaminome yl-l ,2,4-oxadiazole (PREPARATION 1 , 4.94 g), triethylamine (10.5 ml) and dichloromethane (50 ml) at 0° is added, dropwise, phosphorus oxychloride (3.84 g). After stirring for 1 hr at 0°, sodium carbonate (2.65 g) in water (35 ml) is added. The reaction is stirred for 50 min and then partitioned between dichloromethane and saline. The phases are separated, the organic phase is dried over sodium sulfate, concentrated, and the residue chromatographed on silica gel (300 ml) eluting with ethyl acetate/hexane (1/3). The appropriate fractions are pooled and concentrated to give the title compound, NMR (CDC1 3 ) δ 1.06, 2.83 and 4.75. PREPARATION 3 2-Chloro-N-(2-hydroxyphenyl)acetamide To a mixture of 8.90 g (81.5 mmol) of 2-aminophenol and 11.4 ml (81.5 mmol) of triethylamine in 250 ml of ethyl acetate cooled at 0 °C were added over several minutes 6.5 ml (81.5 mmol) of chloroacetyl chloride. The reaction mixture was stirred at 0 °C for 100 min and then washed with saline, aqueous sodium bicarbonate, and saline. The organic layers were dried over magnesium sulfate and concentrated. Dichloromethane was added to the residue and the resulted solid collected and dried to give die tide compound, mp 133-134°; NMR (CDC1 3 ) 4.27, 6.93, 7.02, 7.17, 7.25, 7.80 and 8.53 δ. PREPARATION 4 2-Chloro-N-(2-hydroxyphenyl)acetamide A mixture of 14.55 g (78.4 mmol) of 2-chloro-N-(2-hydroxyphenyl)acetamide (PREPARATION 3) and approximately 35 ml of a solution prepared by stirring overnight methane- sulfonic acid and phosphorous pentoxide in a 10:1 (wt/wt) ratio was heated with stirring at 100° for 2 hr and then poured onto ice. The aqueous mixture was extracted widi dichloromediane. The dichloromethane layers were washed with aq. sodium bicarbonate and the organic layers dried over sodium sulfate. After concentration, the crude product was chromatographed on silica gel (600 ml) eluting with dichloromethane, me appropriate fractions are pooled and concentrated to give die tide compound as a liquid, NMR (CDC1 3 ) 4.77, 7.40, 7.57, 7.75 δ. PREPARATION 5 2-(Azidomethy_)benzoxazole To a mixture of 8.34 g (49.8 mmol) of 2-chloro-N-(2-hydroxyphenyl)acetamide (PREPARATION 4) and 0.75 g (5 mmol) of sodium iodide in 25 ml of DMSO were added 3.56 g (5.47 mmol) of sodium azide. A moderate exotherm ensued. After stirring for 30 min the reaction was partitioned between ethyl ether and saline. The organic layers were dried over magnesium sulfate and concentrated. The crude product was chromatographed on silica gel (700 ml) eluting with ethyl acetate/hexane (5/95), die appropriate fractions are pooled and concentrated to give the tide compound, NMR (CDC1 3 ) 4.60, 7.39, 7.56, 7.76 δ. PREPARATION 6 2-(Aminomethyl)benzoxazole A mixture of 8.28 g (47.5 mmol) of 2-(azidomethyl)benzoxazole (PREPARATION 5) and 0.526 g of 10% Palladium on charcoal in absolute edianol (150 ml) is shaken under hydrogen at 36 psi for 40 min. The catalyst is then filtered off and the filtrate is concentrated. The crude product is chromatographed on silica gel (700 ml) eluting wi medianol/dichloromethane (2/98), the appropriate fractions are pooled and concentrated to give the product. Crystallization from ethyl ether/hexane gives die title compound, mp 46.5-47.5°; MS (m/z) at 148; NMR (CDCI 3 ) 1.70, 4.14, 7.33, 7.51, 7.70 δ. PREPARATION 7 2-(N-Formylaminomemyl)benzoxazole A mixture of 4.29 g (28.9 mmol) of 2-(aminomethyl)benzoxazole (PREPARATION 6) and 20 ml of ethyl formate is heated at 80° for 2 hr, after which the excess ethyl formate is removed under reduced pressure. The residue is chromatographed on silica gel (350 ml) eluting widi methanol/dichloromethane (2/98), the appropriate fractions are pooled and concentrated to give the product, which is crystallized from dichloromemane/hexane to give the title compound, mp 98-99 °; MS (m/z) at 176; IR 1655, 1621, 1519, 1241, 750 cm "1 ; NMR (CDC1 3 ) 4.81, 6.45, 7.36, 7.53, 7.70, 8.39 δ. PREPARATION 8 2-(Isocyanome__yl)ben_oxa_ole To 2.83 g (16.1 mmol) of 2-(N-formylaminomethyl)benzoxazole, 7.39 ml (53.0 mmol) of triediylamine, and 30 ml of dichloromethane stirred at 0° are added dropwise 2.71 g (17.7 mmol) of phosphorous oxychloride in 5 ml of dichloromediane. The reaction mixture is stirred at 0° for 45 min and then 2.81 g of sodium carbonate dissolved in 20 ml of water is added. The mixture is stirred for 30 min and then partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated and die crude product is chromatographed on silica gel (325 ml) eluting with ediyl acetate/hexane (10/90), die appropriate fractions are pooled and concentrated to give die tide compound, mp 57.0-57.5°; MS (m/z) at 158; IR 766, 2166, 987, 1167 and 1230 cm "1 ; NMR (CDC1 3 ) 4.94, 7.42, 7.58 and 7.76 δ. EXAMPLE 1 l,2,3,4-Tetrahydroquinoxalin-2-one (IV) A solution of ediyl bromoacetate (III, 13.3 ml) in THF (50 ml) is added over 2 hr to a stirred solution of 1,2-phenylenediamine (II, 10.0 g) and triediylamine (16.8 ml) in THF (22 ml) and methylene chloride (22 ml). The mixture is heated at 60° for 3 hr, and is concentrated. The resulting solids are suspended and shaken vigorously in hexane (250 ml) and water (150 ml). The hexane layer is decanted, and die process is repeated widi two additional 250 ml portions of hexane. The solids are filtered, dried and recrystallized from methylene chloride/hexane to give the desired product as a solid. The concentrated filtrate is purified by flash chromatography eluting with ethyl acetate/methylene chloride (25/75) to give additional title compound, mp 135-136°: NMR (CDC1 3 ) 8.30, 6.85-6.95, 6.65-6.80, 4.00 and 3.86 δ. EXAMPLE 2 l,2,3,4-Tetrahydro-3,3-dimethylquinoxalin-2-one (IV) A mixture of 1,2-phenylenediamine (II, 7.55 g), ediyl 2-bromoisobutyrate (III, 12.8 ml), diisopropylamine (15.5 ml) and DMF (30 ml) is heated at 110° for 5 hr, after which an additional ediyl bromoisobutyrate (III, 0.5 ml) and diiopropylediylamine (0.8 ml) is added. After heating for 2 more hours, the reaction is cooled and die DMF is removed in under reduced pressure. The residue is stored overnight in the freezer and then partitioned between ediyl acetate, water, and saline. The phases are separated and the organic phase is dried over magnesium sulfate, the organic phase is removed under reduced pressure. The residue is chromatographed eluting with ethyl acetate/dichloromethane (20/80). The product crystallizes out in the column. The product is recrystallized from dichloromediane/hexane to give the tide compound, mp 173-174°; NMR (CDC1 3 ) 1.41, 3.72, 6.67, 6.76, 6.87 and 8.50 δ. EXAMPLE 3 6-Chloro-l ,2-dihydroquinoxalin -2-one (VI) Following the procedure of J. Med. Chem., 24, 93 (1981), glyoxylic acid (29.4 ml) is added to a solution of 4-chloro-l,2-phenylenediamine (38.0 g) and methanol (1.87 L) at 15°. The solution is stirred for 24 hr at 20-25° and is concentrated. The residue is washed widi water (4 X 608 ml), isopropanol (145 ml), and dried under reduced pressure to give a solid. Two successive recrystallizations from hot (ca 90°) 2-methoxyethanol (1.491 and 0.927 1) gives the tide compound, NMR (DMSO-dg) 12.55, 8.22, 7.86, 7.62 and 7.32 δ. EXAMPLE 4 6-Chloro-l,2,3,4-tetrahydroquinoxalin-2-one (IV) Sodium borohydride (5.10 g) is added to a mixture of 6-chloro-l ,2-dihydroquinoxalin-2-one (5.60 g), and ethanol (200 ml). The resultant solution is stirred for 2.5 hr at 20-25°. The material is partitioned between water and ethyl acetate, the phases are separated, the organic phase is dried over magnesium sulfate and concentrated under reduced pressure to give a solid which is recrystallized from ethyl acetate/hexane to give die tide compound, mp 171-174°; IR (mineral oil) 2953, 2925, 1687, 1517, 1408, 1307 and 1299 cm -1 ; NMR (CDCl 3 -MeOD) 6.6-6.8 and 3.95 δ; MS (m/z) 182, 153. EXAMPLE 5 N-(5-Fluoro-2-nitrophenyl)glycine ethyl ester (XI) To a mixture of 2,4-difluoronitrobenzene (VII, 19.20 g), glycine ethyl ester hydrochloride (XII, 16.52 g), and acetonitrile (50 ml) is added diisopropylethylamine (42 ml). A mild exotherm ensues. The reaction is stirred (without cooling) for two hours. The acetonitrile is removed under reduced pressure and die residue is partitioned between dichloromethane and water. The organic layers are dried over sodium sulfate and concentrated to give the produce as a solid (single spot by TLC), mp 194-195°; NMR (CDC1 3 ) 1.33, 4.05, 4.30, 6.35, 6.45,- 8.26 and 8.56 δ. EXAMPLE 6 6-Fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (_V) A mixture of N-(5-f_uoro-2-nitrophenyl)glycine ethyl ester (XI, EXAMPLE 5, 28.60 g), palladium on carbon (10%, 1.01 g) and methanol (500 ml) is shaken under 45 psi of hydrogen on a Parr shaker. After 2 hr an additional 0.54 g of 10% palladium on carbon catalyst is added. The mixture is shaken for an hour at 42 psi and dien die catalyst is removed by filtration, p- Toluenesulfonic acid (0.314 g) is added to the filtrate. The solution is concentrated under reduced pressure to a volume of about 250 ml and dien stirred at 20-25°. The reaction is then further concentrated and dichloromediane is added. The solid that formed is collected and chromatographed on 800 ml of silica gel (column) eluting with dichloromethaπe/methanol (98/2). The appropriate fractions are pooled and concentrated and triturated wid a small amount of dichloromediane. The solid is collected, dried, and triturated a second time widi dichloromethane and redryed to give the tide compound, mp 176.0-177.5°; NMR (CDC1 3 ) 3.95, 3.99, 6.42, 6.63 and 8.33 δ. EXAMPLE 7 N-(5-Fluoro-2-nitrophenyl) -2-methylalanine methyl ester (XI) A mixture of 2,4-difluoronitrobenzene (VII, 9.69 g), 2-aminoisobutyric acid (XII, 9.42 g; note- 1.1 equivalents would be sufficient), potassium carbonate (21.04 g), acetonitrile (15 ml), and water (25 ml) is heated at 80° for 28 hr. The warm reaction mixture is poured into a separatory funnel and d e layers are allowed to separate. The lower layer is discarded and die upper layer is stripped of solvents under high vacuum and dien used as is in die next step. The crude product from above is stirred widi potassium carbonate (12.4 g) and DMF (50 ml) at 0°. Methyl iodide (15 ml) is added and d e reaction mixture is allowed to stir over the weekend widi slow warming to 20-25°. The DMF is then removed under reduced pressure and the residue is partitioned between ether, water, and aqueous sodium bicarbonate. The organic phase is dried over magnesium sulfate, concentrated, and die crude product is chromatographed on silica gel (600 ml) eluting with ethyl acetate/hexane (10/90) to give die tide compound, NMR (CDC1 3 ) 1.68, 3.76, 6.22, 6.41, 8.26 and 8.58 δ. EXAMPLE 8 6-Fluoro-l,2,3,4-tetrahydro-3,3-dimediylquinoxalin-2-one (IV) A mixture of N-(5-fluoro-2-nitrophenyl)-2-methylalanine methyl ester (XI, EXAMPLE 7, 11.2 g), palladium on carbon (10%, 0.63 g), and medianol (350 ml) is shaken under 44 psi of hydrogen pressure for 1.5 hr. Additional palladium on carbon (10%, 0.23 g) is added and die mixture is shaken at 36 psi for another 45 min. p-Toluenesulfonic acid (0.46 g) is added and die catalyst is filtered off. The filtrate is concentrated to about 150 ml and warmed at 80° for 75 min. The solvent is then removed under reduced pressure and the residue is chromatographed on silica gel (700 ml) eluting with dichloromethane/methanol (98/2). aaa a solid. The product is crystallized from memanol/dichloromethane/hexane to give the tide compound, mp 148.5-149.0°; NMR (CDC1 3) 1.42, 3.80, 6.40, 6.46, 6.66 and 8.35 δ. EXAMPLE 9 2-[N-(5-Chloro-2-nitrophenyl)]amino-2-methyl-l-propanol (IX) A solution of 2,4-dichloronitrobenzene (VII, 20.0 g) and 2 -amino-2-methyl-l-propanol (VIII, 80 ml) is stirred at 110° for 68 hr. After cooling to 20-25°, adding water, extracting widi me iylene chloride, separting die phases and drying d e organic phase over magnesium sulfate) gives the desired product sufficiently pure (> 90%) to be carried on without further purification. An analytical sample is prepared by recry stall ization from ethyl acetate/hexane to give die tide compound, mp 102-104°; IR (mineral oil) 3335, 2954, 2925, 1610, 1577, 1492, 1467, 1331, 1251, 1154 and 748 cm '1 ; NMR (CDC1 3 ) 8.55, 8.13, 7.09, 6.59, 3.71, 2.11 and 1.48 δ; MS (m/z) 244, 213 and 166. EXAMPLE 10 N-(5-Chloro-2-nitrophenyl)-2-medιylalanine(X) Jones reagent (2.67 M) is added in aliquots (40 ml, 20 ml, 20 ml, 20 ml and 10 ml) every 15 min to a solution of 2-[N-(5-Chloro-2-nitrophenyl)]amino-2-medιyl-l-propanol (IX,EXAMPLE 9, 26.9 g) and acetone (2.05 1) at 0° until die reaction is done as measured by TLC. Isopropanol (150 ml) is added and die mixture is allowed to warm to 20-25°. The mixture is filtered and die solids are washed wid acetone several times. The combined filtrates are concentrated and partitioned between ether (800 ml) and potassium hydroxide (10%, 3 x 100 ml). The basic layers are acidified (3 N hydrochloric acid) and extracted with methylene chloride (3 x 180 ml). The methylene chloride layers are dried over magnesium sulfate, filtered, and concentrated to provide the tide compound, mp 146-147°; IR (mineral oil) 3363, 2953, 2924, 2855, 1707, 1613, 1573, 1495, 1336, 1272, 1241 and 753 cm "1 ; NMR (CDC1 3 ) 8.48, 8.16, 6.68, 6.64 and 1.74 δ; MS (El, m/z) 258 and 213. EXAMPLE 11 N-(5-Chloro-2-nitrophenyl)-2-methylalanine methyl ester (XI) A mixture of N-(5-chloro-2-nitrophenyl)-2-me_hylalanine(X, EXAMPLE 10, 22.3 g, DMF (260 ml), potassium carbonate (35.6 g), and iodomethane (26.9 ml) is stirred at 20-25° for 16 hr. Aqueous workup (edier, water and saline washes, drying over magnesium sulfate) gaves the tide compound, mp 87-89°; IR (Nujol) 3349, 2954, 2925, 1737, 1606, 1489, 1330, 1263, 1230, 1149 and 752 cm" 1 ; NMR (CDC1 3 ) 8.48, 8.15, 6.65, 6.54, 3.77 and 1.69 δ; MS (El) 272 and 213 m/z. EXAMPLE 12 6-Chloro-3,3-dime_hyl-l,2,3,4-tetrahydroquinoxalin-2-one (_V) Aqueous titanium trichloride (20%, 260 ml) is added dropwise over 10 min to a mixture of N-(5-cUoro-2-nitrophenyl)-2-methylalanine methyl ester, (XI, EXAMPLE 11, 14.1 g), sodium acetate (240 g), medianol (504 ml) and water (156 ml). The mixture is stirred for 2.5 hr at 20- 25°. The material is partitioned between aqueous sodium bicarbonate and ediyl acetate, the phases are separated, die organic phase is dried over magnesium sulfate and concentrated under reduced pressure widi heat to give die tide compound, mp 166-170°; IR (mineral oil) 3311, 2964, 2954, 2925, 1658, 1614, 1505, 1404 and 1355 cm "1 ; NMR (CDC1 3 ) 8.67, 6.73, 6.6-6.7, 3.78 and 1.42 δ; MS (FAB) m z 210, 195 and 167. EXAMPLE 13 2-[N-(6-Chloro-2-nitrophenyl)]amino-2-methyl-l-propanol (IX) A solution of 2,3-dichloronitrobenzene (VII, 20.0 g) and 2-amino-2-methyl-l-propanol (VIII, 80 ml) is stirred at 110° for 50 hr. After cooling to 20-25°, it is diluted widi water, partitioned widi memylene chloride, die phases are separated, die organic phase is dryed over magnesium sulfate and concentration to give the tide compound. An analytical sample is prepared by flash chromatography eluting with ethyl acetate/hexane (1/3). The appropriate fractions are pooled and concentrated to give the title compound, IR (neat) 3370, 2971, 1593, 1532, 1484, 1473, 1449, 1349, 1255, 1053, 754 and 725 cm '1 ; NMR (CDCI 3 ) 7.75, 7.63, 7.12, 3.47 and 1.11 δ; MS (m/z) 244 and 213. EXAMPLE 14 N-(6-Chloro-2-nitrophenyl)-2-methylalanine (X) Jones reagent (2.67 M) is added in aliquots (30 ml, 15 ml, 10 ml, 5 ml) every 15 min to a solution of 2-[N-(6-Chloro-2-nitrophenyl)]amino-2-methyl-l-propanol (DC, EXAMPLE 13, 21.6 g) and acetone (1.65 I) at 0° until die reaction is done as measured by TLC analysis. After 1 hr total time, isopropanol (90 ml) is added and die mixture is allowed to warm to 20-25°. The mixture is filtered and die solids washed widi acetone several times. The combined filtrates are concentrated and partitioned between ether (1.0 1) and potassium hydroxide (10%, 3 X 100 ml). The basic layer is acidified (3 N hydrochloric acid) and extracted widi methylene chloride (3 X 200 ml). The memylene chloride phase is dried over magnesium sulfate, filtered, and concentrated to give die tide compound sufficient pure to be used in the next step without additional purification, mp 107-109°; IR (mineral oil) 3358, 2953, 2924, 1715, 1597, 1496, 1330, 1280, 1231, 1174, 1105 and 747 cm *1 ; NMR (CDC1 3 ) 8.00, 7.61, 7.06, 6.5-7.1 and 1.54 δ; MS (m/z) 258 and 213. EXAMPLE 15 N-(6-Chloro-2-nitrophenyl)-2-me_iylalanine methyl ester (XI) A mixture of N-(6-chloro-2-nitrophenyl)-2-methylalanine (X, EXAMPLE 14, 11.4 g), DMF (130 ml), potassium carbonate (18.2 g) and iodomethane (13.8 ml) is stirred at 20-25° for 16 hr, diluted with water, extracted several times with ether. The ether phases are combined and are washed widi water and saline, dried over magnesium sulfate and concentrated to give die title compound, IR (mineral oil) 3369, 2990, 2951, 1738, 1598, 1534, 1492, 1451, 1386, 1337, 1277, 1188, 1145, 1103 and 749 cm "1 ; NMR (CDC1 3 ) 7.97, 7.55, 6.94, 6.89, 3.78 and 1.53 δ; MS (m/z) 272 and 213. EXAMPLE 16 5-Chloro-3,3-dimethyl-l,2,3,4-tetrahydroquinoxalin-2-one (_V) Aqueous titanium trichloride (20%, 375 ml) is added dropwise over 15 min to a mixture of N-(6-chloro-2-nitrophenyl)-2-me ylalanine methyl ester (XI, EXAMPLE 15, 15.7 g), sodium acetate (268 g), methanol (339 ml) and water (174 ml) at 20-25°. After stirring for 3 hr at 20-25°, addition of 950 ml of aqueous sodium bicarbonate, extraction widi ediyl acetate several times, stirring widi magnesium sulfate and concentration gives die tide compound; mp 153-156°; IR (mineral oil) 3369, 2954, 2924, 2856, 1680, 1594, 1489, 1470, 1450, 1381, 1368, 1357, 1300 and 764 cm' 1 ; NMR (CDC1 3 ) 8.25, 6.98, 6.70, 6.6-6.7, 4.25 and 1.45 δ; MS (FAB) m/z 210 and 195. EXAMPLE 17 N-(6-Methyl-2-nitrophenyl)glycine ethyl ester (XV) A mixture of 2-me yl-6-nitroaniline (XIV, 2.00 g), ediyl bromoacetate (III, 3.5 ml) and diisopropylethylamine (3.5 ml) is heated at reflux (140°) for 8 hr. The resultant solution is allowed to cool to 20-25°. After dilution with aqueous sodium bicarbonate, extraction several times with ethyl acetate, drying widi magnesium sulfate and concentration the residue is resubmitted to the above reaction conditions for an additional 16 hr. After workup, purification by flash chromatography eluting with a gradient of hexane/ethyl acetate (10/1 — ► 5/1), pooling and concentrating the appropriate fractions, the title compound is obtained, mp 49-52°; IR (mineral oil) 3365, 2953, 2925, 1731, 1536, 1475, 1461, 1374, 1344, 1236, 1207, 1104 and 1022 cm' 1 ; NMR (CDC1 3 ) 7.88, 7.33, 6.8-7.0, 6.86, 4.17, 3.94, 2.39 and 1.23 δ. EXAMPLE 18 l,2,3,4-Tetrahydro-5-methylquinoxalin-2-one (IV) A mixture of N-(6-methyl-2-nitrophenyl)glycine ethyl ester (XV, EXAMPLE 17, 675 mg), ethanol (60.0 ml) and palladium on carbon (10%, 150 mg) is hydrogenated (48 psi) at 20-25° for 3.5 hr. The mixture is filtered, die residue washed with ethanol, and die combined filtrates are concentrated to give the title compound, mp 168-171°; IR (mineral oil) 3382, 2955, 2925, 1671, 1490, 1444, 1393, 1295 and 770 cm "1 ; NMR (CDC1 3 ) 8.68, 6.79, 6.6-6.75, 4.04, 3.76 and 2.17 δ; MS (m/z) 162 and 133. EXAMPLE 19 2-Fluoro-6-nitrobenzoic acid (XVII) Prepared from (XVI) by the methods of J. Org. Chem. (1986) 51, 2880 and references cited therein. EXAMPLE 20 2-Fluoro-6-nitrobenzamide (XVIII) A mixture of 2-fluoro-6-nitrobenzoic acid (XVII, 5.01 g) and thionyl chloride (20 ml) is stirred at reflux for 2 hr. After cooling, the excess thionyl chloride is removed under reduced pressure. The residue is stirred in memylene chloride (5 ml) and cooled in an ice bath. Ammonium hydroxide (30%) is added cautiously (exodierm!) until no acid chloride remained. The solid is collected, washed with water and a small amount of memylene chloride and dried to give the tide compound, mp 161-162°; NMR (CDC1 3 ) 6.0, 7.50, 7.59 and 7.98 δ. EXAMPLE 21 N-(tert-butyloxycarbonyl)-2-fluoro-6-nitroaniline (XIX) Lead tetraacetate (11.08 g, which had been under high vacuum for several hours to remove acetic acid) is added to a slurry of 2-fluoro-6-nitrobenzamide (XVIII, EXAMPLE 20, 4.29 g) in dry tert-butanol (50 ml, dried over activated 4A molecular sieves for 24 hr). After stirring at reflux for 1.5 hr the reaction is cooled and excess tert-butanol is removed under reduced pressure. Acetone is added to dissolve die product and die slurry is filtered dirough Celite. The filtrate is concentrated and die crude product is chromatographed on silica gel (350 ml) eluting wi ediyl acetate/hexane (5/95). The appropriate fractons are pooled and concentrated to give die tide compound which is recrystallized from ethyl edier and hexane, mp 100-101°; MS (m/z) at 256; NMR (CDC1 3 ) 1.51, 7.28, 7.42 and 7.83 δ. EXAMPLE 22 N-(tert-Butyloxycarbonyl)-N-(2-fIuoro-6-nitrophenyl)glycine ediyl ester (XX) Potassium tert-butoxide (1 M in THF, 8,67 ml) is added (dropwise over 5 min) to a solution of N-(tert-butyloxycarbonyl)-2-fluoro-6-nittoaniline(XIX, EXAMPLE21, 1.85 g) in THF (15 ml) cooled at 0°. After 20 min, ethyl bromoacetate (0.96 ml) is added dropwise over several minutes. The ice bath is removed and die reaction is stirred for 2 h, after which it is partitioned between ethyl acetate, aqueous sodium bicarbonate and saline. The phases are separated, die organic phase is dried over magnesium sulfate and concentrated to give d e tide compound, NMR (CDCI3) 1.26, 1.35, 1.50, 3.98, 4.10, 4.20, 4.42, 4.45, 7.42 and 7.39 δ. EXAMPLE 23 4-(tert-Butyloxycarbonyl)-5-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (XXπ) A mixture of 2.06 g of N-(tert-butyloxycarbonyl)-N-(2-fluoro-6-nitrophenyl)glycine ediyl ester (XX, EXAMPLE 22, 2.06 g) and palladium on carbon (10%, 0.19 g) in methanol (150 ml) is shaken under hydrogen on a Parr apparatus at 37 psi for 1 hr. The catalyst is then filtered off and p-toluenesulfonic acid 0.016 g) is added. The solution is stirred at 80° for 1 hr and ien at 20-25° overnight. The solvent is then removed under reduced pressure and the residue is chromatographed on silica gel (200 ml) eluting widi ediyl acetate/dichloromediane (5/95). The appropriate fractions are pooled and concentrated to give die tide compound, mp 155-156°; MS (m z) at 266; NMR (CDC1 3 ) 1.48, 6.70, 6.84, 7.12 and 8.61 δ. EXAMPLE 24 5-Fluoro-l,2,3,4-tetrahydroquinoxalin-2-one(IV) A__)lutionof4-(tert-butyloxy)_arbonyl-5-fluoro-l,2,3,4-tettahydroquinoxalin-2-one(XXII, EXAMPLE 23, 6.13 g) in 75 ml of methanol saturated with HCl(g) is stirred at 20-25° for 7.5 hr. The solvent is then removed under reduced pressure and aqueous sodium bicarbonate is added to the residue. The solid is collected and washed with a small amount of water and dien dichloromediane and dried to give die tide compound, mp 246-248°' NMR (CDC1 3 ) 4.04, 4.10, 6.54, 6.63-6.74 and 8.54 δ. EXAMPLE 25 N-tert-Butyl-6-chloro-2-nitroaniline (XXVHI) A mixture of 2,3-dichloronitrobenzene (92.5 g), re/ -butylamine (138 ml) and ethanol (50 ml) is heated in a bomb at 150° for 3 days. Dilution widi water, extraction widi ediylacetate several times, drying with sodium sulfate, and concentration gives the tide compound, IR (neat) 2970, 1532, 1484, 1447, 1366, 1348, 1192 and 755 cm -1 ; NMR (CDC1 3 ) 7.73, 7.61, 7.07, 4.77 and 1.22 δ; MS (m/z) 172, 154, 142, 126, 114, 99 and 90. EXAMPLE 26 2-tert-Butylamine-3-chloroaniline (XXIX) A solution of hydrazine monohydrate (115 ml) in ethanol (270 ml) is added dropwise with stirring over 30 min to a 0° mixture of N-tert-butyl-6-chloro-2-nitroaniline (XXVIII, EXAMPLE 25, 108 g), Raney nickel (27 g, finely divided, Aldrich 22,167-8, slurry in water at pH 10) and of ethanol (540 ML). The mixture is stirred for 90 min at 0°. Dilution with water, extraction with ethyl acetate several times, drying the organic layer with sodium sulfate and concentration gives the tide compound, NMR (CDC1 3 ) 6.82, 6.75, 6.60, 4.11, 3.02 and 1.26 δ. EXAMPLE 27 4-tert-Butyl-5-chloro-l ,2,3,4-tetrahydroquinoxalin-2-one (XXXI) Chloroacetyl chloride (XXX, 55.2 ml) is added dropwise widi stirring over 1 hr to a -78° solution of 2-tert-butylamine-3-chloroaniline (91.7 g) and diisopropylethylamine (241 ml) in THF (900 ml). The mixture is allowed to warm slowly, and is stirred at 20-25° for 18 hr. Concentration dilution widi sodium bicarbonate, extraction several times with methylene chloride, drying over sodium sulfate and concentration gives the uncyclized intermediate, NMR (CDC1 3 ) 9.74, 8.33, 7.05-7.2, 4.20, 3.07 and 1.24 δ. A solution of the intermediate and diisopropylethylamine (120 ml) in acetonitrile (1.5 1) is heated at reflux in die presence of sodium iodide (9.00 g) for 18 hr. Concentration, dilution with water, extraction several times with memylene chloride, drying widi sodium sulfate and concentration gives the product as an oily solid. Flash chromatography eluting widi acetone/methylene chloride (10/90), pooling die appropriate fractions, concentration, and trituration widi methylene chloride give die tide compound, mp 197.5-198.5°. The filtrate is concentrated, rechromatographed, and triturated widi methanol/ ether/hexane (5/30/65) to give additional tide compound, IR (mineral oil) 2924, 1677, 1461, 1376 and 1367 cm -1 ; NMR (CDC1 3 ) 8.05, 7.0- 7.15, 6.73, 3.72 and 1.27 δ; MS (m/z) 238, 223, 182, 153, 90 and 57. EXAMPLE 28 5-Chloro-l,2,3,4-tetrahydroquinoxalin-2-one (TV) A suspension of 4-tert-butyl-5-chloro-l,2,3,4-tetrahydroquinoxalin-2-one (XXXI, EXAMPLE 27, 32.1 g) in sulfuric acid (2 N, 500 ml) is stirred at 20-25° for 18 hr. The solids are filtered, washed with aqueous sodium bicarbonate, water and dried at 20-25° to give a 23:1 mixture of the amine and corresponding imine as determined by NMR. Sodium borohydride (1.84 g) is added in one portion to a 0° slurry of the amine/imine mixture (20.5 g) in ethanol (680 ml). The mixture is allowed to warm to 20-25° and is stirred for 2 hr at 20-25°. The ethanol is evaporated and die solids are triturated with water, filtered, washed with water and dried to give die tide compound, mp 191-193°; IR (mineral oil) 3407, 2924, 1690, 1503, 1426, 1387 and 771 cm '1 ; NMR (d 6 -DMSO) 10.47, 6.89, 6.70, 6.59, 5.84 and 3.80 δ; MS (m/z) 182 and 153. EXAMPLE 29 5-Fluoro-l,2,3,4-tetrahydro-4-[(pyrrolidino)carbonyl]quinoxalin-2-one (xxxπ) Diisopropylethylamine (1.26 ml) followed by phosgene (1.2 M, 6.0 ml) are added to 5- fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 24, 1.20 g) in THF (15 ml) at 0°. The ice bath is removed and the reaction is stirred for 2 hr, at which time additional diisopropylediylamine (0.2 ml) and phosgene (1.0 ml) are added. After 70 min, diisopropylethylamine (1.26 ml) and pyrrolidine (0.60 ml) are added. The reaction is stored in the freezer over the weekend and dien stirred at 20-25° for 8 hr. The reaction mixture is then partitioned between ethyl acetate and brine. The organic layers are dried over magnesium sulfate and concentrated. Chromatography on silica gel eluting wi ethyl acetate/dichloromethane (3/7), pooling and concentrating die appropriate fractions gives the product. Crystallization from ethyl acetate/ediyl ether/hexane gives the tide compound, mp 126-132°; NMR (CDC1 3 ) 1.85, 3.28, .27, 6.68, 6.82, 7.04 and 8.41 δ. EXAMPLE 30 tert-Butyl 6-Fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyI]imidazo[l,5- a]quinoxaline-3-carboxylate (I) Potassium tert-butoxide (1M, 3.8 ml) is added to 5-fluoro-l,2,3,4-tetrahydro-4- [(pyrroIidino)carbonyl]quinoxalin-2-one (XXXII, EXAMPLE 29, 0.908 g) at 0° in THF (20 ml). The mixture is stirred for 30 min and then diediylchlorophosphate (0.55 ml) is added. The reaction is stirred for 1 hr at 0°, then cooled at -78°. tert-butyl isocyanoacetate (0.58 g) is added, followed by potassium tert-butoxide (1 M, 4.14 ml). The reaction is stirred at -78° for 4 hr, then allowed to warm to 20-25° over 1 hr. The mixture is then partitioned between ethyl acetate, water, and saline. The organic layers are dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel (250 ml) eluting with a gradient of ediyl acetate/dichloromethane (20/80 to 40/60). The appropriate fractions are pooled, concentrated and crystallized from dichloromethane/hexane to give the tide compound; mp 213.5-214.5°; MS (m z) at 386; IR (mineral oil) 1689, 1677, 1217, 1363 and 1157 cm "1 ; NMR (CDC1 3 ) 1.63, 1.88, 3.36, 5.08, 7.08, 7.20, 7.33 and 8.00 δ. EXAMPLE 31 6-Fluoro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5- [(pyrroIidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) Following die general procedure of EXAMPLE 30 and making non-critical variations but using 5-fluoro-l,2,3,4-tetrahydro-4-[(pyrrolidino)carbonyl]quinoxalin-2-one (XXXII, EXAMPLE 29, 0.978 g) and 3-isocyanometiιyl-5-isopropyl-l ,2,4-oxadiazole (0.673 g) are converted to the tide compound, mp 169-170°; MS (m z) at 396; IR (mineral oil) 1657, 1495, 1216, 1614 and 785 cm " l ; NMR (CDC1 3 ) 1.47, 1.86, 3.30, 3.34, 5.13, 7.08, 7.22, 7.38 and 8.12 δ. EXAMPLE 32 6 - F l u o r o - l , 2 , 3 , 4 - t e t r a h y d r o - 3 , 3 - d i m e t h y l - 4 - [(pyrrolidino)carbonyl]quinoxalin-2-one (XXXII) Phosgene in toluene (1.2 M, 12.9 ml) is added to a mixture of 6-fluoro-l ,2,3,4-tetrahydro- 3,3-dimedιylquinoxalin-2-one (IV, EXAMPLE 8, 1.001 g) and diisopropylediylamine (0.94 ml), and THF (10 ml) at 0°. After 45 min the reaction is allowed to warm to 20-25°. After stirring for 3 hr, the reaction is again cooled to 0° and additional phosgene (4.2 ml) is added. The ice bath is removed and die reaction is stirred for 100 min, after which the excess phosgene and solvents are removed via a water aspirator. The mixture is then stirred with THF (10 ml) and of pyrrol idine (0.90 ml) are added. After stirring overnight; d e reaction is concentrated and the residue chromatographed on silica gel eluting with medianol/me ylene chloride (2/98). The appropriate fractions are pooled and concentrated to give die tide compound; MS (m/z) at 291; IR (mineral oil) 1681, 1660, 1396 and 1163 cm '1 ; NMR (CDC1 3 ) 1.4-2.0, 3.15, 3.6, 6.43, 6.65, 6.76 and 8.32 δ. EXAMPLE 33 7-Fluoro-4,5-dihydro-4,4-dimethyl-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) Following die general procedure for EXAMPLE 30 and making non-critical variation but starting with 6-fluoro- 1 ,2,3 ,4-tetrahydro-3 ,3-dimedιyl-4-[(pyιτolidino)carbonyl]quinoxalin-2-one (XXXII, EXAMPLE 32, 0.647 g) and 3-isocyanomethyl-5-isopropyl-l,2,4-oxadiazole (0.403 g) the title compound is obtained which is crystallized from methylene chloride/ethyl ether/hexane, mp 154.5-155.5°; MS (m/z) at 424; IR (mineral oil) 1527, 1657, 1414, 1172 and 1395 cm" 1 ; NMR (CDC1 3 ) 1.45, 1.7-2.0, 3.0, 3.3, 3.33, 3.58, 6.55, 6.74, 7.45 and 8.06 δ. EXAMPLE 34 ter t-Butyl 7-fluoro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate (I) Following the general procedure for EXAMPLE 30 and making non-critical variation but starting with 6-fluoro-l,2,3,4-tetrahydro-3,3-dimediyl-4-[(pyrrolidino)carbonyl]quinoxalin-2-one (XXXII, EXAMPLE 32, 0.750 g) and t-butyl isocyanoacetate (0.436 g) are converted to the tide compound. After crystallization from ethyl ether/hexane, mp 168.5-169.5°; MS (m/z) at 414; IR (mineral oil) 1713, 1668, 1520, 1181 and 1155 cm "1 ; NMR (CDC1 3 ) 1.63, 1.8, 1.92, 2.08, 2.95, 3.23, 3.58, 6.52, 6.71 and 7.92 δ. EXAMPLE 35 4-(tert-Butyloxycarbonyl)-l ,2,3 ,4-tetrahydroquinoxalin-2-one (XXXII) A mixture of l,2,3,4-tetrahydroquinoxalin-2-one (TV, EXAMPLE 1, 1.08 g), di-tert- butyldicarbonate (1.59 g), potassium carbonate (1.01 g) and THF (10 ml) is stirred at 60° overnight. Additional di-tert-butyldicarbonate (0.93 g) and water (1 ml) are then added, and the reaction is stirred at 65° for 5.5 hr. After a final addition of di-tert-butyldicarbonate (0.24 g) and stirring for two more hours, die reaction is cooled, die solvent is removed under reduced pressure, and the residue is partitioned between dichloromediane and water, followed by a saline wash. The crude product is chromatographed on silica gel eluting widi methanol/mediylene chloride (2/98). The appropropriate fractions are pooled and concentrated to give the tide compound which is recrystallization from ethyl acetate and hexane, mp 143-144°; NMR (CDC1 3 ) 1.54, 4.40, 6.88, 7.09, 7.63 and 8.58 δ. EXAMPLE 36 5-(tert-ButyloxycarbonyI)-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) Following the general procedure of EXAMPLES 30 and 40 and making non-critical variations but using 4-(tert-butyloxycarbonyl)-l,2,3,4-tetrahydro-quinoxalin -_-one (XXXII, EXAMPLE 35, 1.031 g) die title compound is obtained which is recrystallized from methanol/ediyl acetate/hexane, mp 203.5-204.5°; MS (m/z) at 379; IR (mineral oil) 1706, 1509, 1574, 1308 and 1214 cm "1 ; NMR (CDC1 3 ) 1.24, 1.37, 1.52, 2.28, 5.23, 7.29, 7.53, 7.76 and 8.10 δ. EXAMPLE 37 4-Benzoyl-l ,2,3,4-tetrahydroquinoxalin-2-one (XXXH) A mixture of l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 1, 0.593 g) and triethylamine (0.725 ml) in THF (5 ml) is cooled at 0°. To this is added benzoyl chloride (0.56 ml). After the addition is complete, the ice bath is removed and additional THF (5 ml) is added. The reaction is stirred for 30 min and dien partitioned between ethyl acetate, aq. sodium bicarbonate, and saline. The organic phases are separated and die organic phase is dried over magnesium sulfate and concentrated. The crude product is recrystallized from methanol/dichloromediane/hexaneto give the tide compound, mp 208.0-208.5°; MS (m z) at 252; IR (mineral oil) 1684, 1666, 1502, 757 and 1362 cm '1 ; NMR (CDC1 3 ) 4.58, 6.7, 6.79, 6.98, 7.10, 7.34 and 7.40 δ. EXAMPLE 38 5-Benzoyl-3-(5-cyclopropyl-l,2,4-oxadia_ol-3-yI)-4,5-dihydroimidazo[l,5- a]quinoxaline (1) Following die general procedure of EXAMPLE 40 and making non-critical variations but using 4-benzoyl-l ,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 16, 0.6703 g) and DMF (0.25 ml) after the addition of diethyl chlorophosphate, the tide compound is obtained, mp 198-199° (from methylene chloride-ethyl acetate-hexane); MS (m z) at 383; IR (mineral oil) 1663, 1506, 1574, 762 and 1481 cm -1 ; NMR (CDC1 3 ) 1.25, 2.25, 5.40, 7.05, 7.3-7.45, 7.59 and 8.20 δ. EXAMPLE 39 4-Acetyl-l,2,3,4-tetrahydroquinoxal_n-2-one (XXXH) Acetyl chloride (0.36 ml) is added to l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 1, 0.676 g) and triethylamine (0.76 ml) in THF (8 ml) at 0°. After stirring for 1 hr, the solvent is removed under reduced pressure and the residue is partitioned between dichloromediane and aq. sodium bicarbonate. The layers are separated, the organic phase is filtered through sodium sulfate and concentrated. The concentrate is crytallized from medianol/methylene chloride/hexane to give the tide compound, mp 164-165°; NMR (CDC1 3 ) 2.28, 4.54, 7.00, 7.11, 7.21 and 9.19 δ. EXAMPLE 40 5-Acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) Potassium tert-butoxide (1 M in THF, 2.92 ml) is added to 4-acetyl-l, 2,3,4- tetrahydroquinoxalin-2-one (XXXII, EXAMPLE 39, 0.5054 g) cooled at 0°. After the addition is complete the cooling bath is removed and die reaction is allowed to stir for 50 min, when it is again cooled in an ice/saline bath. Diethyl chlorophosphate (0.42 ml) is added. After 30 min, the ice/saline ba is removed. The reaction is stirred for an additional 15 min and then cooled at - 78°. 5-Cyclopropyl-3-isocyanome_hyl-l,2,4-oxadiazole (0.436 g) is added, followed by potassium tert-butoxide (1 M in THF, 2.92 ml). The reaction is stirred for 3 hr and dien partitioned between ether and water and saline. The phases are separated, d e organic phase is dried over magnesium sulfate, concentrated, and die residue chromatographed on silica gel (200 ml) eluting with ethyl acetate/methylene chloride (25/75). The appropriate fractions are pooled and concentrated to give the tide compound which is recrystallized from mediylene chloride/ethyl acetate/hexane, mp 187- 188°; MS (m/z) at 321; IR (mineral oil) 1576, 1654, 1505, 1387 and 1355 cm -1 ; NMR (CDCI 3 ) 1.26, 1.38, 2.3, 5.30, 7.37, 7.60 and 8.13 δ. EXAMPLE 41 4-(2-Furoyl)-l ,2,3,4-tetrahydroquinoxalin-2-one (XXXII) 2-Furoyl chloride (0.49 ml) is added to a solution of the l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 1, 710 mg), triethylamine (0.80 ml), and THF (20.0 ml) at 0°. The mixture is stirred for 1.5 hr at 0° and for 2 hr at 20-25°. The mixture was diluted widi aq. sodium bicarbonate and extracted widi ethyl acetate and chloroform several times. The organic phases are combined, dried widi magnesium sulfate, concentrated, and recrystallized from hot ethyl acetate to give the tide compound, mp 229-230°; IR (mineral oil) 2954, 2925, 1684, 1648, 1504, 1474, 1391, 1373 and 756 cm '1 ; NMR (CDC1 3 ) 8.53, 7.39, 7.1-7.25, 6.85-7.05, 6.45 and 4.59 δ; MS (m/z) 242 and 95. EXAMPLE 42 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-(2-furoyl)-4,5-dihydro- imidazo[l,5-a]quinoxaline (I) Following die general procedure of EXAMPLES 30 and 40 and making non-critical variations but using 4-(2- uroyl)-l,2,3,4-tetrahydroquinoxalin-2-one (XXXII, EXAMPLE 41, 593 mg) the tide compound is obtained, mp 190-191°; IR (mineral oil) 2954, 2925, 1657, 1578, 1511, 1481, 1384, 1366, 1312, 1021 and 760 cm "1 ; NMR (CDC1 3 ) 8.35, 7.66, 7.1-7.5, 7.02, 6.48, 5.43, 2.2-2.3 and 1.2-1.5 δ; MS (m/z) 373, 278, 210 and 95. EXAMPLE 43 4-(tert-Butyloxycarbonyl)-l,2,3,4-tetrahydro-5-methylquinoxalin-2-one (XXXII) A solution of di-tert butyl dicarbonate (1.37 g) and THF (2.0 ml) is added to a solution of 5-methyl-l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 18, 0.925 g) and THF (11.0 ml) at 0°. The solution is stirred at 0° for 15 min and after warming to 20-25° is heated at reflux for 3 days. More di-tert butyl dicarbonate (0.390 ml) is added after 2 days. After cooling to 20-25°, dilution with water, extraction widi mediylene chloride several times, drying with magnesium sulfate and purification by flash chromatography, eluting widi hexane/ethyl acetate (3.5/1), pooling the appropriate fractions and concentration, the tide compound is obtained, mp 175-177°; IR (mineral oil) 2953, 2925, 2855, 1721, 1693, 1481, 1386, 1364, 1232 and 1156 em' 1 ; NMR (CDC1 3 ) 7.10, 6.95, 6.80, 4.33, 2.29 and 1.48 δ; MS (m z) 262, 206, 162 and 133. EXAMPLE 44 5-(tert-Butyloxycarbonyl)-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5- dihydro-6-methylimidazo[l,5-a]quinoxaline (I) Following die general procedure of EXAMPLES 30 and 40 and making non-critical v__ciationsbutusing4-(tert-butyloxyca_:bonyl)-l,2,3,4-tetr__ιydro-5-methylquinoxalin-2-one(XXXII, EXAMPLE 43, 420 mg) the tide compound from which an analytical sample is prepared by re¬ crystallization from methylene chloride/hexane, mp 189-192°; IR (mineral oil) 2954, 2924, 1697, 1577, 1499, 1458, 1421, 1369, 1241, 1159 and 772 cm '1 ; NMR (CDCI3) 8.14, 7.39, 7.15-7.35, 5.14,, 2.38, 2.2-2.4, 1.41 and 1.1-1.5 δ; MS (m/z) 393, 293 and 224. EXAMPLE 45 7-ChIoro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yI)-4,5-dihydro-5- [(pyrtolidino)c_ibonyl]imid__ro[l,5-a]quinox_dine (_) Part A Following the general procedure of EXAMPLES 29 and 32 and making non-critical variations but starting with 6-chloro-l,2,3,4-tetrahydroquinoxalin-2- ne (TV, EXAMPLE 4), 6- chloro-l,2,3,4-tetrahydro-4-[φyrrolidino)carbonyl]quinoxalin-2-one is produced. Part B Following die general procedure of EXAMPLES 36, 38, 40, 42 and 44 and making non- critical variations butstartingwi_ι6-chloro-l,2,3,4-tetrahydro-4-[φyrroIidino)carbonyl]quinoxaIin- 2-one (XXXII, Part A) the title compound is obtained, mp 202-204°: IR (mineral oil) 2953, 2924, 2855, 1679, 1660, 1576, 1503, 1406, 1390 and 1202 cm -1 ; NMR (CDClg) 8.08, 7.46, 7.05-7.2, 5.02, 3.2-3.4, 2.2-2.35, 1.75-1.9 and 1.2-1.4 δ ; MS (m z) 410, 340, 312, 272 and 98. EXAMPLE 46 6-__Uoro^[(dimemylamino)carbonyl]-l,2,3,4-tetrahydroquinoxalin-2-one (XXXH) Part A Phosgene (12.5% solution in toluene, 28 ml) is added to a solution of 6-ch!oro-l ,2,3,4- tetrahydroquinoxalin-2-one (IV, EXAMPLE 4, 4.64 g), diisopropylethylamine (5.90 ml) and THF (100 ml) at 0°. The mixture is stirred for 1 hr at 0° and for 1 hr at 20-25°. Dilution with water, extraction with ethyl acetate, drying widi magnesium sulfate and concentration gives die carbamyl chloride of the starting material sufficiendy pure to be used without further purification. Part B Diisopropylediylamine (11.4 ml) is added to a mixture of the crude carbamyl chloride (6.56 g), dimethylamine hydrochloride (2.50 g), and THF (130 ml) at 0°. The mixture is stirred for 1 hr at 0° and for 3 days at 20-25°. Dilution with water, extraction with ethyl acetate several times, drying over magnesium sulfate, concentration, and trituration with hexane/ ether/ethyl acetate gives the product, mp 242-244°. The filtrate is concentrated and recrystallized from ethyl acetate to provide additional product, IR (mineral oil) 2953, 2923, 2855, 1677, 1654, 1502, 1392, 1376, 1205, 833 and 804 cm *1 ; NMR (CDC1 3 ) 8.99, 6.99, 6.93, 6.85, 4.14, and 2.89 δ; MS (m/z) 253 and 72. EXAMPLE 47 7-Chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethyl- amino)carbonyl]-4,5-dihydroimidazo[l,5-a]quinoxaline (I) Following die general procedure of EXAMPLE 44 and making non-critical variations but using 6-chloro-4-[(dimethylamino)carbonyI]- 1 ,2,3,4-tetrahydroquinoxalin-2-one (XXXII, EXAMPLE 46, 275 mg), the tide compound is obtained, mp 254.5-255.5°; IR (mineral oil) 2955, 2924, 2855, 1676, 1666, 1633, 1496, 1457, 1446, 1397, 1382, 1359, 1201 and 1194 cm "1 ; NMR (CDC1 3 ) 8.08, 7.47, 7.14, 7.08, 4.98, 2.89, 2.2-2.35 and 1.2-1.4 δ; MS (m z) 384, 312, 272 and 72. EXAMPLES 48 - 87 The process to produce d e imidazol[l,5-a]quinoxalines (I) can be thought of as involving three steps. Step 1 is formation of the bicyclic amide (TV), step 2 is the addition of die exocyclic carbonyl-R 5 substituent at N 5 , and step 3 is die formation of the imidazole ring widi addition of the desired substituent at C 3 . The imidazol[l,5-a]quinoxaline (I) molecule has four different types of variable substituents. These are, in the order of their incorporation during d e three steps discussed above are (1) W 5 , Wg, W 7 and W g which are incorporated by definition when die starting material is chosen, (2) the R substituent which is incorporated when die bicyclic amide (IV) is formed, (3) die exocyclic carbonyI-R5 group which is added after formation of the bicyclic amide (IV, which has N 5 = -NH-) and (4) d e addition of d e desired substituent at C 3 when die imidazole ring is formed. EXAMPLES 1, 2, (3 and 4), (5 and 6), (7 and 8), (9-12), (13-16), (17 and 18), (19-24) and (25-28) all exemplify step 1, formation of the bicyclic amide (IV) containing the desired W 5 , W 6 , W 7 and W 8 substituent (by starting with the appropriate starting material) and die desired R substituent. EXAMPLES 29, 32, 35, 37, 39, 41, 43, 45 and 46 all exemplify step 2, the addition ^ - of the exocyclic carbonyl with the attached desired R5 substituent. EXAMPLES 30, 31, 33, 34, 36, 38, 40, 42, 44, 45B and 47 exemplify step 3, the formation of the imidazole ring with the R 3 substituent. Following the general procedure of one or more of the above EXAMPLES (for each of steps 1, 2 and 3), making non-critical variations and starting widi die appropriate starting material containing the desired W 5 , W 6 , W 7 and Wg substituents, the compounds of the EXAMPLES below are formed: EXAMPLE 48 5-(tert-Butyloxy carbonyl)-7-chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl - 4,5-dihydroimidazo[l,5-a]quinoxaline (J) mp 218-220°; IR (mineral oil) 2954, 2926, 1710, 1570, 1507, 1370, 1343, 1222 and 1213 cm" 1 ; NMR (CDC1 3 ) 8.08, 7.82, 7.47, 7.2-7.3, 5.22, 2.25-2.35, 1.54 and 1.2-1.4 δ; MS (m/z) 413, 313, 244 and 229. EXAMPLE 49 7-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-(2-furoyl)-4,5- dihydroimidazo[l,5-a]quinoxaIine Q) mp dec 190°: IR (mineral oil) 2954, 2925, 2855, 1671, 1577, 1510, 1468, 1366 and 1304 cm" 1 ; NMR (300 MHz, CDCI 3 ) 8.33, 7.58, 7.46, 7.32, 7.25, 7.15, 6.55, 5.44, 2.2-2.35 and 1.15-1.4 δ; MS (m z) 407, 312 and 244. EXAMPLE 50 5-Benzoyl-7-chloro-3-(5-cyclopropyl-l,2.4-oxadiazol-3-yl)-4,5-dihydro- imidazo[l,5-a]quinoxaline (I) mp 228-229°: IR (mineral oil) 2954, 2924, 2855, 1672, 1576, 1510, 1363, 1337 and 1207 cm" 1 ; NMR (CDC1 3 ) 8.41, 7.61, 7.2-7.6, 7.15, 5.35, 2.1-2.3 and 1.1-1.3 δ; MS (m z) 417, 348, 312 and 105. EXAMPLE 51 5<t__t-Butyloxycarbonyl)-3-(5-cyclopropyl-l,2,4-oxadiazoI-3-yl)-6-fluoro- 4,5-dihydroimidazo[l,5-a]quinoxaline (I) mp 199-200°; MS (m z) at 397; IR (mineral oil) 1715, 1494, 1505, 1226 and 880 cm "1 ; NMR (CDCI3) 1.23, 1.36, 1.45, 2.27, 7.10, 7.32 and 8.12 δ. EXAMPLE 52 5-Acetyl-7-chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro- imidazo[l,5-a]quinoxaline (I) mp 191-192: IR (mineral oil) 2954, 2925, 2855, 1663, 1575, 1504, 1386, 1211, 948 and 903 cm" 1 ; NMR (CDCl 3 ) 8.10, 7.53, 7.0-8.0, 7.37, 5.28, 2.34, 2.2-2.45 and 1.15-1.45 δ; MS (m/z) 355, 312, 272, 244 and 229. EXAMPLE 53 7-Chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-prop- ionylimidazo[l,5-a]quinoxaline (I) mp 185-186°; IR (mineral oil) 2954, 2927, 2855, 1688, 1583, 1506, 1382, 1315, 1201, 1192, 1169, 948, 898 and 817 cm "1 ; NMR (CDC1 3 ) 8.09, 7.72, 7.52, 7.36, 5.27 , 2.62, 2.2-2.35, 1.1-1.4 and 1.19 δ ; MS m/z 370. EXAMPLE 54 tert-Butyl 7-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 194-196°; IR (mineral oil) 2954, 2925, 2855, 1725, 1661, 1507, 1406, 1383, 1370, 1153 and 1125 cm "1 ; NMR (CDC1 3 ) 7.97, 7.43, 7.15, 7.12, 4.99, 3.2-3.4, 1.8-1.9, and 1.62 δ; MS (m z) 402, 346, 248, 231 and 98. EXAMPLE 55 tert-Butyl 7-Chloro-5-[(dimemylamino)carbonyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 210-211.5°: IR (mineral oil) 2954, 2925, 2855, 1726, 1660, 1506, 1459, 1455, 1381, 1194, 1185, 1150 and 1126 cm "1 ; NMR (CDC1 3 ) 7.97, 7.44, 7.12, 7.08, 4.94, 2.89 and 1.62 δ; MS (m/z) 376, 320, 248 and 230. EXAMPLE 56 7-Chloro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)- carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 201-201.5°: IR (mineral oil) 2954, 2923, 2855, 1659, 1566, 1505, 1464, 1451, 1410, 1389, 1364, 1309, 1282, 1192 and 949 cm "1 ; NMR (CDC1 3 ) 8.09, 7.48, 7.1-7.2, 5.05, 3.2-3.4, 1.8-1.9 and 1.46 δ; MS (m/z) 412, 341, 314, 272 and 98. EXAMPLE 57 7-Chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4- oxadiazol-5-yl)imidazo[l,5-a]quinoxaline (I) mp 189-190.5°; IR (mineral oil) 3102, 2954, 2925, 2855, 1653, 1638, 1511, 1383, 1365 and 1198 cm "1 ; NMR (300 MHz, CDC1 3 ) 8.11, 7.50, 7.16, 7.10, 5.04, 3.05-3.25, 2.91 and 1.40 δ; MS (m/z) 386, 314, 271 and 230. EXAMPLE 58 7-Chloro-3-(5-ethyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrol- idino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 220-221.5°; IR (mineral oil) 2966, 2961, 2953, 2926, 1654, 1623, 1570, 1508, 1391, 1385, 1380 and 1367 cm "1 ; NMR (CDC1 3 ) 8.09, 7.47, 7.1-7.2, 5.05, 3.31, 2.97, 1.75-1.95 and 1.45 δ; MS (m/z) 398, 300, 272 and 98. EXAMPLE 59 7-Chloro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-l,2,4-oxadiazol-3-yl 4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 205-207.5°; IR (mineral oil) 3100, 2953, 2925, 2868, 2855, 1666, 1577, 1507, 1485, 1473, 1383, 1363, 1310, 1281, 1271, 1205, 1188 and 1177 cm "1 ; NMR (CDC1 3 ) 8.09, 7.48 , 7.14, 7.08, 5.01, 2.97, 2.90 and 1.45 δ; MS (m z) 372, 300, 272 and 72. EXAMPLE 60 te_t-Butyl7-Fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaline-3-carboxylate (I) mp 115-116; IR (mineral oil) 1689, 1652, 1365, 1396 and 1519 cm-1; MS (m/z) 386; NMR (CDC1 3 ) 1.62, 1.86, 3.33, 4.99, 6.88, 7.45 and 7.95 δ. EXAMPLE 61 7-Fluoro-4,5-dihydro-3-(5-isopropyl- 1 ,2,4-oxadiazol-3-yl)- 5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 211-212.5; IR 1511, 1410, 1664, 1565 and 1393 cm- 1 ; MS (m z) 396; NMR (CDC1 3 ) 1.46, 1.85, 3.32, 5.04, 6.91, 7.50 and 8.07 δ. EXAMPLE 62 7-Chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l ,2,4- oxadiazol-3-yl)imidazo[l ,5-a]quinoxaline (I) mp 145-146°: IR (mineral oil) 2953, 2925, 2855, 1662, 1563, 1508, 1503, 1458, 1380, 1187 and 821 cm "1 ; NMR (CDCI 3 ) 8.09, 7.48, 7.05-7.2, 5.01, 3.2-3.4, 2.90 and 1.46 δ; MS (m/z) 386, 314 and 272. EXAMPLE 63 tert-Butyl 6-chloro-4,5-dihydro-5-[(pyrroIidino)carbonyl]imidazo[l,5- a]quinoxaline-3-ca_Doxylate (1) mp 246-248°: IR (mineral oil) 2925, 1691, 1671, 1373, 1360, 1296, 1159 and 1080 cm -1 ; NMR (CDCI 3 ) 8.00, 7.46, 7.36, 7.21, 5.06, 3.35-3.45, 1.85-1.95 and 1.63 δ; MS (m z) 402, 346, 248, 231, 203 and 98. EXAMPLE 64 6-Chloro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5- [(pyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaIine (J mp 233.5-234.5°; IR (mineral oil) 2926, 1670, 1491, 1381 and 1187 cm "1 ; NMR (CDC1 3 ) 8.13, 7.50, 7.37, 7.26, 5.11, 3.2-3.4, 1.8-1.95 and 1.47 δ; MS (m z) 412, 377, 342, 314, 272 and 98. EXAMPLE 65 tert-Butyl 6-chloro-5-[(dimethyl____ino)carbonyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 227-228°; IR (mineral oil) 2925, 1694, 1681, 1381, 1374, 1370, 1154 and 1083 cm" 1 ; NMR (CDCI3) 8.00, 7.46, 7.37, 7.22, 5.00, 3.02 and 1.63 δ; MS (m/z) 376, 320, 303, 248, 231, 203 and 72. EXAMPLE 66 6-Chloro-3-(5-ethyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5- [φyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 245-246°: IR (mineral oil) 2924, 1668, 1493, 1381, 1182 and 787 cm "1 ; NMR (CDCI3) 8.13, 7.50, 7.37, 7.23, 5.11, 3.3-3.45, 2.98, 1.8-1.95 and 1.46 δ; MS (m/z) 398, 363, 328, 300, 272 and 98. EXAMPLE 67 6-Chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l ,2,4- oxadiazol-3-yl)imidazo[l,5-a]quinoxaline (I) mp 227.5-228.5°; IR (mineral oil) 2924, 1672, 1492, 1464, 1387, 1184 and 780 cm" 1 ; NMR (CDCI3) 8.13, 7.51, 7.37, 7.24, 5.06, 3.25-3.4, 3.00 and 1.47 δ; MS (m/z) 386, 341, 314, 298, 272 and 72. EXAMPLE 68 6-Chloro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (J mp 208-209°; IR (mineral oil) 2926, 1655, 1393, 1072 and 779 cm "1 ; NMR (CDC1 3 ) 8.15, 7.51, 7.41, 7.26, 5.15, 3.35-3.45, 3.1-3.25, 1.85-1.95 and 1.41 δ; MS (m/z) 412, 377, 342, 230 and 98. EXAMPLE 69 6-Chloro-5-[(dime_hylamino)carbonyl]-3-(5-«hyl-l,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 252-254°; IR (mineral oil) 2925, 1668, 1494, 1389, 1180 and 780 cm "1 ; NMR (CDC1 3 ) 8.12, 7.50, 7.38, 7.24, 5.05, 3.00, 2.99 and 1.46 δ; MS (m z) 372, 328, 300, 272 and 72. EXAMPLE 70 6-Chloro-5-[(dimediylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l ,2,4- oxadiazol-5-yl)imidazo[l ,5-a]quinoxaline (I) mp 197.5-198°; IR (mineral oil) 2925, 1678, 1492, 1466, 1385 and 780 cm "1 ; NMR (CDCI3) 8.15, 7.52, 7.41, 7.26, 5.09, 3.1-3.3, 3.02 and 1.41 δ; MS (m z) 386, 351, 342, 314, 230 and 72. EXAMPLE 71 7-C_loro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- 5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 207-208°; IR (mineral oil) 3118, 2954, 2925, 2855, 1653, 1588, 1518, 1416, 1187 and 945 cm "1 ; NMR (CDC1 3 ) 8.07, 7.41, 7.00, 6.80, 3.59, 2.8-3.4, 2.2-2.35, 1.5-2.2 and 1.15-1.45 δ; MS (m/z) 438, 423 and 98. EXAMPLE 72 7-Chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethyl- amino)carbonyI]-4,5-dihydro-4,4-dimetiιyIimidazo[ 1 ,5-a]quinoxaline (I) mp 162-165°, IR (mineral oil) 2953, 2924, 2855, 1675, 1570, 1511, 1474, 1379, 1325, 1196, 1187, 949 and 813 cm "1 ; NMR (CDC1 3 ) 8.08, 7.41, 7.00, 6.70, 3.08, 2.75, 2.2-2.35, 1.95, 1.69 and 1.15-1.45 δ; MS (m/z) 412 and 397. EXAMPLE 73 7-Chloro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 193-195°; IR (mineral oil) 2953, 2925, 2855, 1654, 1518 and 1410 cm" 1 ; NMR (CDCI3) 8.07, 7.42, 7.01, 6.80, 3.59, 2.8-3.4, 1.5-2.1 and 1.47 δ; MS (m/z) 440 and 425. EXAMPLE 74 7-Chloro-5-[(dimemylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4- oxadiazol-3-yl)-4,4-dimemylimidazo[ 1 ,5-a]quinoxaline (I) mp 120-121°; IR (mineral oil) 2953, 2925, 1659, 1567, 1519, 1513, 1384, 1333 and 1301 cm "1 ; NMR (CDC1 3 ) 8.08, 7.43, 7.03, 6.72, 3.2-3.4, 3.10, 2.78, 1.99, 1.72 and 1.47 δ; MS (El m/z) 414 and 399. EXAMPLE 75 tert-Butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbon- yl]imidazo[l ,5-a]quinoxaline-3-carboxylate (I) mp 168-169°; IR (mineral oil) 2973, 2953, 2925, 2855, 1711, 1661, 1513, 1411, 1383, 1367, 1288, 1180, 1147 and 970 cm "1 ; NMR (CDC1 3 ) 7.93, 7.37, 6.98, 6.78, 3.5-3.7, 2.8-3.4, 1.5-2.2 and 1.63 δ; MS (El m/z) 430, 415 and 244. EXAMPLE 76 tert-Butyl 7-chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-4,4- dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 168-169°; IR (mineral oil) 2954, 2925, 1725, 1718, 1672, 1511, 1277 and 1141 cm "1 ; NMR (CDC1 3 ) 7.94, 7.38, 6.99, 6.70, 3.10, 2.77, 2.06, 1.68 and 1.63 δ; MS (El m z) 404, 389, 244. EXAMPLE 77 7-ChIoro-5-[(dime_hylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4- oxadiazol-5-yl)-4,4-dimedιylimidazo[l,5-a]quinoxaline (I) mp 122-125°; IR (mineral oil) 2954, 2924, 2855, 1677, 1618, 1512, 1467, 1460, 1385 and 949 cm "1 ; NMR (CDC1 3 ) 8.10, 7.44, 7.04, 6.74, 3.0-3.25, 3.11, 2.80, 2.10, 1.74 and 1.40 δ; MS (El m z) 414 and 399. EXAMPLE 78 7-Chloro-3-(5-ethyl-l,2,4-oxadiazol-3-yI)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 223-224°; IR (mineral oil) 2953, 2925, 1654, 1577, 1517, 1410 and 1389 cm "1 ; NMR (CDCI3) 8.07, 7.42, 7.01, 6.81, 3.60, 3.00, 2.8-3.4, 1.4-2.2 and 1.46 δ; MS (El m z) 426 and 411. EXAMPLE 79 7-ChIoro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-l,2,4 ) xadiazol-3-yl>4.5- dihydro-4,4-dimedιylimidazo[l,5-a]quinoxaline (I) mp 175.5-177.5°; IR (mineral oil) 2953, 2925, 2855, 1668, 1568, 1514 and 1183 cm "1 ; NMR (CDCI3) 8.08, 7.43, 7.03, 6.72, 3.10, 3.00, 2.78, 1.99, 1.72 and 1.46 δ; MS (El m z) 400 and 385. EXAMPLE 80 tert-Butyl 6-chloro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate (I) IR (mineral oil) 2954, 2925, 2856, 1707, 1666, 1496, 1476, 1461, 1392, 1369, 1346, 1284, 1151 and 1050 cm "1 ; NMR (CDCI3) 8.02, 7.40, 7.30, 7.08, 3.3-3.7, 2.5-2.9, 1.92, 1.5-1.9 and 1.63 δ; MS (El m/z) 430, 259, 244 and 98. EXAMPLE 81 6 3ιlo_o4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [φyrrolidino)carbonyI]imidazo[l,5-a]quinoxaline (I) mp 147-148°; IR (mineral oil) 2954, 2924, 2856, 1657, 1645, 1494, 1462, 1398 and 1386 cm "1 ; NMR (CDC1 3 ) 8.12, 7.44, 7.31, 7.11, 3.2-3.6, 2.5-2.8, 1.89, 1.5-2.0 and 1.47 δ; MS (El m z 440, 425 and 98. EXAMPLE 82 6-Chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l ,2,4- oxadiazol-3-yl)-4,4-dime ylimidazo[l,5-a]quinoxaline (I) mp 171-172°; IR (mineral oil) 2960, 2925, 1660, 1496, 1467, 1375 and 1209 cm "1 ; NMR (CDCI3) 8.14, 7.45, 7.32, 7.13, 3.2-3.4, 2.79, 1.86 and 1.47 δ; MS (El m/z) 414 and 399. EXAMPLE 83 6-Chloro-3-(5-ethyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)c__:bonyl]imid___o[l,5-a]quinoxaline (I) mp 204-206°; IR (mineral oil) 2954, 2926, 2856, 1653, 1645, 1498, 1461, 1399 and 1394 cm "1 ; NMR (CDC1 3 ) 8.12, 7.44, 7.31, 7.11, 3.2-3.7, 3.00, 2.5-2.9, 1.89, 1.55-2.0 and 1.47 δ; MS (El m/z) 426, 411 and 98. EXAMPLE 84 6-CWoro-4,5-dihydro-3-(3 -isopropyl-1 ,2,4-oxadiazol-5-yI)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 175-176°; IR (mineral oil) 2953, 2925, 2855, 1660, 1648, 1497, 1462, 1401 and 1390 cm" 1 ; NMR (CDC1 3 ) 8.14, 7.45, 7.34, 7.13, 3.3-3.7, 3.1-3.25, 2.6-3.0, 1.95, 1.6-1.9 and 1.40 δ; MS (El m/z) 440, 425 and 98. EXAMPLE 85 tert-Butyl 6-chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-4,4- dimethylimidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) mp 155-158°; IR (mineral oil) 3113, 2953, 2923, 2855, 1710, 1668, 1541, 1502, 1488, 1478, 1466, 1453, 1375, 1368, 1349, 1331, 1296, 1287, 1206, 1193, 1168, 1161, 1147, 1133, 1057 and 774 cm" 1 ; NMR (CDC1 3 ) 7.98, 7.40, 7.30, 7.11, 2.82, 1.88 and 1.63 δ; MS (El m/z) 404, 389, 333, 259 and 244. EXAMPLE 86 6-Chloro-5-[(dimemylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l ,2,4- oxadiazol-5-yl)-4,4-dimethylimidazo[l,5-a]quinoxaline (I) mp 184.5-185.5°; IR (mineral oil) 2956, 2925, 2855, 1662, 1617, 1495, 1468, 1376, 1326, 1283, 1206 and 795 cm "1 ; NMR (CDC1 3 ) 8.13, 7.46, 7.34, 7.16, 3.1-3.3, 2.87, 1.91 and 1.40 δ; MS (El m/z) 414, 399 and 72. EXAMPLE 87 6-Chloro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-l ,2,4-oxadiazol-3-yl>4,5- dihydro-4,4-dimethylimidazo[l ,5-a]quinoxaline (I) mp 176-177.5°; IR (mineral oil) 2953, 2925, 2855, 1671, 1584, 1503, 1488, 1463, 1380 and 1182 cm "1 ; NMR (CDC1 3 ) 8.12, 7.45, 7.31, 7.13, 3.00, 2.79, 1.87 and 1.47 δ; MS (El m/z) 400, 385, 300 and 72. EXAMPLE 88 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- ajquinoxaline (XXXIII) A solution of die l,2,3,4-tetrahydroquinoxalin-2-one (IV, 5.51 g) and THF (55 ml) is cooled to -40°, and potassium tert-butoxide (1.0 M in THF, 34.8 ml) is added dropwise over 5 min. The mixture is allowed to warm to -20° over 1 hr. DMF (10 ml) and THF (40 ml) are added to die resultant solid, allowing die mixture to stir. The mixture is cooled to -50°, and diediyl chlorophosphate (5.02 ml) is added dropwise over 5 min. The mixture is allowed to warm to -20° over 1 hr. The mixture is cooled to -78°, and the oxadiazole isocyanide (5.70 g) is added. Potassium tert-butoxide (34.8 ml) is added dropwise over 15 min, me mixture is allowed to warm slowly to 20-25°, and is stirred for 3 days at 20-25°. The mixture is quenched with water, filtered, washed with water and dried to provide the desired material as a solid. Additional solids that precipitated from the filtrate are filtered, triturated widi ediyl acetate/hexane (20/80) and dried to give the tide compound, mp 243-245°; NMR (CDC1 3 ) 8.07, 7.42, 7.10, 6.8-6.9, 4.81, 4.08, 2.2-2.3 and 1.2-1.4 δ. EXAMPLE 89 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-propionyl- imidazo[l,5-a]quinoxaline (I) Amixtureof3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline (XXXIII, EXAMPLE 88, 0.442 g), propionic anhydride (2 ml) and THF (1 ml) is stirred at 80° for 6 hr. The solvent is dien removed under reduced pressure with heat and die residue is parti¬ tioned between ediyl acetate, aqueous sodium bicarbonate and saline. The phases are separated and the organic phase is dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel eluting widi ediyl acetate/dichloromediane (10/90). The appropriate fractions are pooled and concentrated to give a solid which is crystallized from dichloromethane and hexane to give die tide compound, mp 175-176°; MS (m z) at 335; IR (mineral oil) 1491, 1671, 1509, 1202 and 1422 cm "1 ; NMR (CDC1 3 ) 1.16, 1.24, 1.37, 2.28, 2.58, 5.30, 7.36, 7.60, and 8.12 δ. EXAMPLE 90 3-(5-CycIopropyl-l,2,4-oxadiazol-3-yl)-5-(ethoxyoxalyl)-4,5- dihydroimidazo[l,5-a]quinoxaline(I) Triediylamme (0.11 ml) and DMF (4 ml) are added to 3-(5-cyclopropyl-l,2,4-oxadiazol-3- yl)-4,5-dihydroimidazo[l,5a]quinoxaliπe (XXXIII, EXAMPLE 88, 0.20 g) in THF (6 ml). Ethyl oxalyl chloride (0.088 ml) is then added dropwise over about 5 min. The mixture is stirred for 1 hr, concentrated, and partitioned between dichloromediane and aqueous sodium bicarbonate. The phasesa are separated and the organic phase is dried over sodium sulfate and concentrated. The crude product is chromatographed on silica gel (90 ml) eluting widi ethyl acetate/cyclohexane (60/40). The appropriate fractions are pooled and concentrated to give die tide compound, mp 150-151°; MS (m/z) at 379; IR (mineral oil) 1745, 1659, 1516, 1422, 1501 cm "1 ; NMR (CDC1 3 ) 1.17, 1.28, 1.37, 4.20, 4.43, 5.20, 5.38, 7.31, 7.51, 7.63, 8.17 and 8.19 δ. EXAMPLE 91 5-[(2-Chloro)benzoyl]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4 . 5- dihydroimidazo[l,5-a]quinoxaline 0 . A slurry consisting of 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline (XXXDI, EXAMPLE 88, 0.492 g), 2-chlorobenzoyl chloride (0.268 ml), dimethyl- aminopyridine (0.0538 g), diisopropylethylamine (0.368 g), and THF (9 ml) is stirred at 20-25° for 1.5 hr. The mixture is then partitioned between ethyl acetate, aqueous sodium bicarbonate, and saline. The product is poorly soluble in both die organic and aqueous phases, filtration of the extraction solvents gives additional material. The crude product is dien triturated widi ediyl ether and dried to give the tide compound, mp 254-256°; MS (m/z) at 417, 419; IR (mineral oil) 1659, 1576, 1508, 765 and 1394; NMR (CDC1 3 ) 8.16 δ. EXAMPLE 92 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(mo holino)- carbonyl]imidazo[l,5-a]quinoxaline (I) To a slurry consisting of 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline (XXXIII, EXAMPLE 88, 0.499 g), diisopropylethylamine (0.81 ml) and THF (15 ml) is added phosgene (1.93 M in toluene, 1.20 ml). A slight exotherm ensues and die slurry becomes homogeneous. After 10 min, morpholine (0.20 ml) is added. The mixture is stirred for 2 hr and dien partitioned between ediyl acetate, water, and saline. The phases are separated and die organic phase is dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel (150 ml) eluting with methanol/dichloromethane (2/98). The appropriate fractions are pooled and concentrated to give the product. Recrystallization from dichloromethane and hexane gives the tide compound, mp 198.0-198.5°; MS (m/z) at 392; IR 1662, 1506, 1409, 1277, and 1579 cm "1 ; NMR (CDC1 3 ) 1.24, 1.36, 2.27, 3.33, 3.64, 5.02, 7.21, 7.27, 7.55 and 8.11 δ. EXAMPLE 93 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(3,5-dimethylpyrazolo)carbonyl]- 4,5-dihydroimidazo[ 1 ,5-a]quinoxaline (I) Following the general procedure of EXAMPLE 92 and making non-critical variations but startingwid3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimida2»[l,5-a]quinoxaline(XXXIII, EXAMPLE 88, 0.501 g) and 3,5-dimethylpyrazole (0.426 g) the title compound is obtained, mp 85-95° (decomp); MS (m z) at 401; IR (mineral oil) 1388, 1702, 1355, 1414, and 1420 cm" 1 ; NMR (CDC1 3 ) 1.24, 2.19, 2.21, 2.43, 5.41, 5.99, 7.22, 7.32, 7.59, and 8.15 δ. EXAMPLE 94 Ethyl 4,5-Dihydro-4,4-dimemylimidazo[l,5-a]quinoxaline-3-carboxylate (XXXm) Potassium tert-butoxide (1 M, 4.54 ml) is added to l,2,3,4-tetrahydro-3,3- dimedιylquinoxalin-2-one (IV, EXAMPLE 2, 0.762 g) in THF (4 ml) at ice/saline temperature. The reaction is stirred for 40 min, at which time diethyl chlorophosphate (0.656 ml) is added. After stirring at ice-saline temperature for 2 hr, ediyl isocyanoacetate (0.562 g) is added, followed by potassium t-butoxide (1 M, 4.97 ml). The reaction is stirred for 3.5 hr, allowing it to slowly warm to 20-25°. The reaction is then quenched with several drops of acetic acid and then partitioned between ethyl acetate, aqueous sodium bicarbonate and saline. The phases are separated and die organic phase is dried over magnesium sulfate, concentrated, and die resulting crude product chromatographed on silica gel (200 ml) eluting widi medianol/dichloromediane (2/98). The appropriate fractions are pooled and concentrated to give the tide compound, mp 145-149°; NMR (CDCI3) 1.44, 1.74, 3.79, 4.40, 6.77, 6.82, 7.10, and 7.39 δ. EXAMPLE 95 Ethyl 4,5-Dihydroimidazo[l,5-a]quinoxaline-3-carboxylate (XXXIII) Potassium tert-butoxide (1M in THF, 7.5 ml) is added to l,2,3,4-tetrahydroquinoxalin-2- one (IV, EXAMPLE 1, 1.01 g) in THF (10 ml) cooled to 0°. A slurry formed after the addition is complete. Additional THF (5 ml) is added. The ice bath is removed and the reaction is stirred for 30 min, when it is cooled at -78°. Diediylchlorophosphate (1.08 ml) is added and the dry ice/acetone badi is replaced widi an ice/water bath. The reaction is stirred for 1 hr, when it is again cooled at -78°. Ethyl isocyanoacetate (0.82 ml) is added, followed by potassium tert- butoxide (1M in THF, 7.5 ml) over 10 min. Ten minutes after the addition is complete, the dry ice badi is removed and d e reaction is allowed to slowly warm to 20-25°. When it has stirred for a total of 3 hr, aqueous ammonium chloride (about 1 ml) is added. The mixture is partitioned between a mixture of chloroform and dichloromediane and water. The phases are separated, the organic phase is filtered through sodium sulfate, concentrated, and die residue crystallized from medianol/dichloromethane/hexane to give the tide compound, mp 248-250°; MS (m z) at 243; NMR (CDC1 3 ) 1.42, 4.08, 4.39, 4.83, 6.80, 6.85, 7.11, 7.39 δ. EXAMPLE 96 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydroimidazo[l ,5- a]quinoxaline (XXXHI) Potassium tert-butoxide (1M in THF, 13.8 ml) is added to 7-fluoro-l,2,3,4-tetrahyd- roquinoxalin-2-one (TV, EXAMPLE 6, 2.186 g) in THF (5 ml) and DMF (2 ml) cooled to 0°. ' The ice bath is removed and stirring improves as the reaction warms. After 15 min, the reaction is cooled in an ice/saline ba and diediylchlorophosphate (2.00 ml) is added. After 25 min 5- cyclopropyl-3-isocyanomethyl-l,2,4-oxadiazole (2.16 g) is added, followed by potassium tert- butoxide (14.5 ml). After stirring for 80 min, about 75 ml of water and ice is added. The solid is collected and washed several times with water, followed by small aliquots of ether. The solid is dried in under reduced pressure with heat over the weekend and dien triturated with ether and with dichloromethane. The solid is collected and dried to give the tide compound, mp 263-265°; NMR (CDCI3) 1.25, 1.32, 2.26, 4.78, 6.55, 7.38 and 8.07 δ. EXAMPLE 97 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimethyIimidazo[l,5-a]quinoxaline (XXXIII) Following the general procedure of EXAMPLES 88 and 94-96 and making non-critical variations but starting widi l,2,3,4-tetrahydroquinoxalin-2-one (TV, EXAMPLE 2), the tide compound is obtained, mp 166-169°; MS (m/z) at 307; NMR (CDC1 3 ) 1.23, 1.37, 2.27, 3.78, 6.79, 6.85, 7.10, 7.41 and 8.09 δ. EXAMPLE 99 3-(3-Cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4-dimethyl v - imida_o[l,5-a]quinoxaline (XXXIII) Potassium tert-butoxide (1M in THF, 1.95 ml) is added to cyclopropylcarboxam.de oxime (0.195 g) in THF (7 ml) at 0°. After 10 min ethyl 4,5-dihydro ,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate (XXXIII, EXAMPLE 94, 0.503 g) is added. The ice bath is removed after stirring for 10 min and d e reaction is allowed to slowly warm to 20-25°. After 2 hr DMF (4 ml) is added. When the reaction had stirred for a total of 7 hr, the solvents are removed under reduced pressurre and die residue is partitioned between ethyl acetate and saline. The phases are separated, die organic phase is dried over magnesium sulfate and concentrated to give the tide compound; mp 175-179°; NMR (CDC1 3 ): 1.10, 1.76, 2.18, 3.83, 6.79, 6.85, 7.13, 7.42 and 8.10 δ. EXAMPLE 100 5-Acetyl-3-(3-cyclopropyl-l ,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline (I) Amixtureof3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4-dimedιylimidazo[l,5- a]quinoxaline (XXXIII, EXAMPLE 99, 0.19 g) and acetic anhydride (3 ml) is stirred at 100° for 3 days. Excess acetic anhydride is dien removed under reduced pressure and die residue is partitioned between dichloromethane and aqueous sodium bicarbonate. The phases are separated and die organic phase is filtered dirough sodium sulfate and concentrated. The crude product is chromatographed on silica gel (200 ml) eluting widi ethyl acetate/dichloromediane (20/80). The appropriate fractions are pooled and concentrated to give die title compound, mp 169-171 °; MS (m/z) at 349; IR (mineral oil) 1666, 1613, 1327, 1281 and 1504 cm "1 ; NMR (CDC1 3 ) 1.12, 1.94, 2.16, 2.18, 7.20, 7.33, 7.52 and 8.14 δ. EXAMPLE 101 3-(3-Cyclopropyl-l ,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[l,5- a . quinoxaline (XXXIII) Sodium hydride (60% in oil, 0.142 g) is washed diree times wi pentane. THF (30 ml) is added, followed by cyclopropylcarboxamide oxime (0.356 g). After 10 min, Ediyl 4,5- dihydroimidazo[l,5-a]quinoxaline-3-carboxylate (XXXIII, EXAMPLE 95, 0.786 g) is added, followed by additional THF (5 ml). After an hour, DMF (14 ml) is added. The reaction is stirred an additional 4 hr, after which die solvents are removed under reduced pressure. Water is added to die residue and the solid is collected, washed widi a small amount of edier, and dried under reduced pressure at 20-25° to give the title compound, mp 248-250°; NMR (CDC1 3 ) 1.07, 1.15, 1.93, 2.15, 4.83, 6.86, 7.14, 7.43 and 8.11 δ. EXAMPLE 102 5-Acetyl-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) A mixture of 3-(3-cyclopropyl- 1 ,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline (XXXiπ, EXAMPLE 101, 0.201 g) and acetic anhydride (3 ml) in THF (0.7 ml) is heated at 80° for 45 min. The reaction mixture is men cooled, concentrated, and partitioned between dichloromethane and aqueous sodium bicarbonate. The organic phase is separated and filtered dirough sodium sulfate and concentrated. The crude product is crystallized from dichloromethane and hexane to give the tide compound, which is dien recrystallized from ediyl ether/ethyl acetate/- hexane, mp 202.0-202.5°; MS (m/z) at 321; IR (mineral oil) 1674, 1639, 1501, 1358 and 1401 cm -1 ; NMR (CDC1 3 ) 1.15, 2.18, 2.29, 5.32, 7.41, 7.62 and 8.15 δ. EXAMPLE 103 3-(5-Cy clopropyl- 1 ,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[ 1 ,5- a]quinoxaline (XXXIII) Amixtureof5-(tert-butyloxycarbonyl)-3-(5-cyclopropyl- 1 ,2,4-oxadiazol-3-yl)-6-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline (I, EXAMPLE 51 , 3.39 g) and 50 ml of methanol saturated widi HCl(g) is stirred at 20-25° overnight. The solvent is then removed under reduced pressure and die residue is partitioned between dichloromediane and aqueous sodium bicarbonate. The organic phase is separated and dried over sodium sulfate and taken to dryness to give the title compound, NMR (CDC1 3 ) 1.23, 1.35, 2.26, 4.32, 4.86, 6.80, 6.95, 7.22 and 8.06 δ. EXAMPLE 104 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-6- fluoro-4,5-dihydroimid_zo[l,5-a]quinoxaline (I) To 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[ l,5-a]quinoxaline (XXXm, EXAMPLE 103, 0.520 g) in THF (15 ml) is added diisopropylethylamine (0.305 ml) followed by phosgene (1.2 M in toluene, 2.19 ml). After stirring for 3 hr, dimemylamine hydrochloride (0.285 g) is added, followed by diisopropylediylamine (0.91 ml). The reaction is stirred for 3 hr, after which several ml of aqueous sodium bicarbonate is added. The reaction is concentrated under reduced pressue and die residue partitioned between dichloromediane, aqueous sodium bicarbonate and saline. The phases are separated, die organic phase is dried over sodium sulfate and concentrated. The solid is chromatographed on silica gel (150 ml) eluting widi metha- nol/dichloromethane (2/98). The appropriate fractions are pooled and concentrated to give a solid, which is recrystallized from dichloromediane and hexane to give die tide compound, mp 194-195°; MS m z at 368; IR (mineral oil) 1657, 1502, 1391, 786 and 1224 cm "1 ; NMR (CDC1 3 ) 1.25, 1.36, 2.25, 2.94, 5.05, 7.08, 7.21, 7.37, 8.11 δ. EXAMPLE 105 3-(5-CyclopropyI-l ,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) To 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[l,5-a]quinoxaline (XXXπi, EXAMPLE 103, 0.418 g) in THF (15 ml) is added diisopropylethylamine (0.245 ml) followed by phosgene (1.2 M in toluene, 1.76 ml). The reaction is stirred for 3 hr, after which pyrrolidine (0.23 ml) and diisopropylediylamine (0.25 ml) are added. The reaction is stirred for 1 hr, then treated widi several ml of water and concentrated. The residue is partitioned between dichloromediane, aqueous sodium bicarbonate, and saline. The phases are separated, the organic phase is dried over sodium sulfate and concentrated. The crude product is chromatographed on silica gel (150 ml) eluting with memanol/dichloromethane (2/98). The appropriate fractions are pooled and concentrated to give the product which is recrystallized from dichloromediane and hexane to give the tide compound, mp 220.5-221.5°; MS m/z at 394; IR (mineral oil) 1500, 1392, 1662, 1221, 793 and 1613 cm "1 ; NMR (CDCl 3 ), 1.35, 1.86, 2.26, 3.33, 5.10, 7.08, 7.21, 7.37 and 8.11 δ. EXAMPLE 106 5-Acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5- d_hydroimidazo[l,5-a]quinoxaline Q A solution of 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimid___o[l,5- a]quinoxaIine (XXXHI, EXAMPLE 103, 0.504 g), dimethylaminopyridine (0.03 g) and acetic anhydride (12 ml) is stirred at 100° for 1 hr. After cooling, excess acetic anhydride is removed under reduced pressure and die residue is partitioned between dichloromethane and aqueous sodium bicarbonate. The phases are separated and the organic phase is dried over sodium sulfate and concentrated. Chromatography on silica gel (320 ml) eluting with methanol/dichloromethane (2/98) gives a poor separation of the product from the imine byproduct. The imine impurity is success¬ fully removed by taking up the mixture in dichloromediane and allowing die imine to precipitate out. The filtrate is collected, concentrated and die product crystallized from dichloromediane and hexane to give die title compound, mp 208.5-210.0°; MS m/z at 339; IR (mineral oil) 1671, 1503, 1254, 879 and 1204 cm "1 ; NMR (CDC1 3 ) 1.28, 2.38, 2.13, 2.29, 7.16, 7.41 and 8.13 δ. EXAMPLE 107 5-Benzoyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-di- hydroimidazo[l,5-a]quinoxaline (I) To 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[l ,5-a]quinoxaline (XXXIII, EXAMPLE 103, 0.438 g), diisopropylediylamine (0.26 ml), and dimemylaminopyridine (0.018 g) in THF (20 ml) is added benzoyl chloride (0.19 ml). After stirring for 5 hr, additional benzoyl chloride (0.20 ml) is added. The reaction is stirred at 20-25° for 2 hr, then stored over the weekend in die freezer. It is then stirred again at 20-25° for 24 hr, after which the THF solvent is removed under reduced pressure and replaced widi dichloromediane. After stirring for a final 7 hr, the reaction is partitioned between dichloromethane and aqueous sodium bicarbonate. The phases are separated and the organic phase is filtered through sodium sulfate, concentrated, and the crude product chromatographed on silica gel (300 ml) eluting with ediyl acetate/dichloro¬ methane (20/80). The appropriate fractions are pooled and concentrated to give die producet which is recrystallized from dichloromediane and hexane to give die tide compound, mp 234.5-235.5°; MS m/z at 401; IR (mineral oil) 1660, 1502, 1366, 786 and 1247 cm "1 ; NMR (CDC1 3) 1.21, 2.20, 5.32, 6.98, 7.3-7.5 and 8.19 δ. EXAMPLES 108-148 There are a number of processes to produce die imidazo[l,5-a]quinoxalines (I). One process to produce die imidazol[l,5-a]quinoxalines (I) can be diought of as involving diree steps. Step 1 is formation of the bicyclic amide (IV), step 2 is die formation of the imidazole ring with addition of die desired substituent at C 3 and step 3 is the addition of the R5 substituent at N 5 . It should be noted that steps 2 and 3 are reversed from EXAMPLES 48-87. The imidazol[l,5-a]quinoxaline (I) molecule has four different types of variable substituents. These are, in die order of their incorporation during die three steps discussed above are (1) W 5 , Wg, W 7 and Wg which are incorporated by definition when die starting material is chosen, (2) the R 4 substituent which is incorporated when die bicyclic amide (TV) is formed, (3) die addition of the desired substituent at C3 when the imidazole ring is formed and (4) die R 5 group which is added after formation of the bicyclic amide (TV, which has N 5 = -NH-). EXAMPLES 1, 2, (3 and 4), (5 and 6), (7 and 8), (9-12), (13-16), (17 and 18), (19-24) and (25- 28) all exemplify step 1, formation of the bicyclic amide (TV) containing the desired W 5 , Wg, W 7 and Wg substituent (by starting with the appropriate starting material) and the desired R 4 substituent. EXAMPLES 88-107 exemplify step 2, the formation of the imidazole ring with the R 3 substituent and step 3 the addition of die R5 group. Following the general procedure of one or more of the above EXAMPLES (for each of steps 1, 2 and 3), making non-critical variations and starting widi the appropriate starting material containing the desired W 5 , Wg, W ? and Wg substituents, the compounds of the EXAMPLES below are formed: EXAMPLE 108 5-Acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 180.5-182.5°; MS (m/z) at 339; IR (mineral oil) 1512, 1577, 1669, 1221 and 1622 cm" H NMR (CDCI3) 1.25, 2.36, 2.28, 2.35, 5.28, 7.09, 7.26, 7.58 and 8.08 δ. EXAMPLE 109 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-7- fluoro-4,5-dihydroimidazo[l,5-a]quinoxaline (I) mp 227-228.5°; MS (m/z) at 368; IR (mineral oil) 1670, 1204, 1575, 1514 and 1364 cm "1 ; NMR (CDCI3) 1.23, 1.32, 2.27, 2.89, 4.98, 6.85, 7.50 and 8.06 δ. EXAMPLE 110 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5- [(pyrroIidino)carbonyl]imidazo[l,5-a]quinoxaline ® mp 203-204°; MS m/z at 394; IR (mineral oil) 1406, 1582, 1414, 1510, 1365, 1662 cm" 1 ; NMR (CDCI3) 1.23, 1.35, 1.85, 2.25, 3.32, 5.02, 6.88, 7.50 and 8.06 δ. EXAMPLE 111 5-Benzoyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yI)-7-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline Q) mp 190-193°; MS m z at 401; IR (mineral oil) 1367, 1672, 1515, 1499, 1577 cm "1 ; NMR (CDCl 3 ) 1.24, 2.20, 5.35, 6.89, 7.00, 7.35-7.60 and 8.14 δ. EXAMPLE 112 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l- imidazo)carbonyl]imidazo[l,5-a]quinoxaline 0. mp 263-265°; MS m/z at 391; IR (mineral oil) 1699, 1394, 1514, 1224, 1406 cm -1 ; NMR (CDC1 3 ) 1.26, 1.33, 2.28, 5.36, 6.73, 7.08, 7.62, 7.83 and 8.17 δ. EXAMPLE 113 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yI)-7-fluoro-4,5-dihydro-5- [(morpholino)carbonyI]imidazo[l,5-a]quinoxaline (I) mp 224-225°; MS m/z at 410; IR (mineral oil) 1662, 1504, 1423, 1578, 1280 cm" 1 ; NMR (CDC1 3 ) 1.25, 1.36, 2.28, 3.37, 3.67, 5.01, 6.92, 7.02, 7.53 and 8.07 δ. EXAMPLE 114 5-Acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline (I) mp 162-163°; MS m z at 349; NMR (CDC1 3 ) 1.26, 1.35, 1.90, 2.15, 2.27, 1.17, 7.32, 7.51 and 8.12 δ. EXAMPLE 115 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl>4,5-dihydro-5-[(me_hoxy)carbonyl]- 4,4-dime ylimidazo[l,5-a]quinoxaIine (I) mp 183-184°; MS: m/z at 365; IR (mineral oil) 1725, 1296, 1569, 1256, 1515 cm-1; NMR (CDC1 3 ) 1.25, 1.36, 1.88, 2.28, 3.68, 7.28, 7.36, 7.48 and 8.09 δ. EXAMPLE 116 3-(5-Cyclopropyl- l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5- [(isopropyloxy)carbonyl]-4,4-dimethylimidazo[ 1 ,5-a]quinoxaline (I) mp 172.5-173.0°; MS m/z at 393; IR (mineral oil) 1716, 1252, 1288, 1510, 1291 cm" 1 ; NMR (CDCI3) 1.23, 1.25, 1.35, 2.28, 4.98, 7.25, 7.38, 7.47 and 8.09 δ. EXAMPLE 117 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethoxy)oxalyl]-4,5-dihydro-4,4- dimedιyIimidazo[l,5-a]quinoxaIine (I) mp 157-158°; MS m/z at 407; IR (mineral oil) 1672, 1576, 1517, 1198, 1743 and 1748 cm "1 ; NMR (CDC1 3 ) 1.08, 1.27, 1.34, 1.98, 2.29, 4.09, 7.22, 7.25, 7.39, 7.55 and 8.16 δ. EXAMPLE 118 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(phenoxy)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 172.5-174.5°; MS m/z at 427; IR (mineral oil) 1744, 1186, 1580, 1336 and 1514 cm" 1 ; NMR (CDCI3) 1.25, 1.36, 1.95, 2.28, 7.08, 7.21, 7.32, 7.51, 7.58 and 8.15 δ. EXAMPLE 119 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)oxalyl]imidazo[l,5-a]quinoxaline (I) mp 189.5-190.5°; MS m z at 432; IR (mineral oil) 1644, 1651, 1573, 1674 and 1516 cm" 1 ; NMR (CDCI3) 1.28, 1.36, 1.75, 1.96, 2.28, 3.16, 3.29, 7.30, 7.40, 7.45, 7.53 and 8.14 δ. EXAMPLE 120 6-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5- [(pyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaIine (I) mp 243-244.5°: IR (mineral oil) 2924, 1651, 1497, 1407, 1395, 1380 and 781 cm" 1 ; NMR (CDCI3) 8.11, 7.50, 7.36, 7.22, 5.08, 3.25-3.45, 2.2-2.35, 1.8-1.95 and 1.2-1.4 δ; MS (m z) 410, 375, 340, 312, 272 and 98. EXAMPLE 121 6-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimetiιylamino)- carbonyl]-4,5-dihydroimidazo[l ,5-a]quinoxaline (I) mp 226-228°; IR (mineral oil) 2924, 1661, 1600, 1495, 1389 and 1167 cm "1 ; NMR (CDCI3) 8.12, 7.50, 7.38, 7.2-7.3, 5.02, 3.00, 2.2-2.3 and 1.2-1.4 δ; MS (m/z) 384, 340, 312, 272 and 72. EXAMPLE 122 6-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5- [(methanethio)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 212.5-213.5°; IR (mineral oil) 2925, 1656, 1594, 1492, 1412, 1344 and 1152 cm" 1 ; NMR (CDCI3) 8.13, 7.35-7.55, 6.1-6.5, 4.0-4.5, 2.33, 2.2-2.4 and 1.2-1.4 δ; MS (m/z) 387, 340, 312, 272, 244, 229 and 69. EXAMPLE 123 3-(5-Cyclopropyl- l ,2 ,4-oxadiazol-3-yl)-4,5-dihydro-5- (trifluoroac etyI)imidazo[ 1 ,5-a]quϊnoxaline (I) mp 175-177°; IR (mineral oil) 2954, 2925, 1707, 1604, 1512, 1498, 1459, 1432, 1424, 1419, 1283, 1218, 1211, 1205, 1194, 1163, 1154, 1087 and 768 cm "1 ; NMR (CDC1 3 ) 8.16 , 7.88, 7.63, 7.35- 7.55, 5.38, 2.2-2.4 and 1.2-1.4 δ; MS (m/z) 375, 306, 278 and 210. EXAMPLE 124 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-imidazo- lyl)carbonyl]imidazo[l,5-a]quinoxaline ([) mp 148-150°; IR (mineral oil) 3121, 3110, 2954, 2926, 2855, 1704, 1577, 1509, 1502, 1406, 1390, 1334, 1287, 1246 and 746 cm "1 ; NMR (CDCl 3 ) 8.26, 8.20, 7.65, 7.38, 7.1-7.3, 6.91, 5.34, 2.1-2.3 and 1.15-1.35 δ; MS (m/z) 373, 306, 277, 238, 210 and 195. EXAMPLE 125 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2- pyridylcarbonyl)imidazo[ 1 ,5-a]quinoxaIine (I) mp 239-240°; IR (mineral oil) 2954, 2925, 2855, 1660, 1590, 1513, 1499, 1448, 1411, 1376, 1290, 1153, 906, 773 and 765 cm "1 ; NMR (CDC1 3 ) 8.56, 8.21, 7.83, 7.73, 7.60, 7.0-7.5, 5.45, 2.0-2.3 and 1.15-1.35; MS (m z) 384, 278 and 210. EXAMPLE 126 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2-pyrrolyl)- carbonyl]imidazo[l,5-a]quinoxaline (I) IR (mineral oil) 3120, 2954, 2925, 2855, 1643, 1579, 1509, 1401, 1359, 1294, 1037 and 767 cm" 1 ; NMR (CDC1 3 ) 9.49, 8.15, 7.59, 7.2-7.4, 6.95, 6.30, 6.17, 5.49, 2.2-2.35 and 1.15-1.4 δ ; MS (m z) 372, 279, 210 and 195. EXAMPLE 127 5-[(Anilino)carbonyl]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 211-212.5°; IR (mineral oil) 2926, 2854, 1686, 1535, 1501, 1427, 1211 and 745 cm" 1 ; NMR (CDC1 3 ) 8.13, 7.55-7.7, 7.2-7.45, 7.0-7.15, 5.30, 2.1-2.35 and 1.2-1.4 δ; MS (m z) 398, 279, 238, 210, 195 and 119. EXAMPLE 128 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 196- 197°; IR (mineral oil) 2925, 2855, 1664, 1573, 1500, 1275, 1202 and 756 cm "1 ; NMR (CDC1 3 ) 8.11, 7.54, 7.2-7.3, 7.05-7.2, 4.99, 2.85, 2.2-2.3 and 1.2-1.4 δ; MS (m/z), 350, 306, 278, 263, 238, 210, 195 and 72. EXAMPLE 129 3-(5-Cyciopropyl-l,2,4-oxadiazoi-3-yI)-4,5-dihydro-5-[(methyl- __mino)carbonyl]imid___o[l,5-a]quinoxaIine (I) mp 214-215°; IR (mineral oil) 3374, 3100, 2925, 2855, 1655, 1575, 1503 and 767 cm "1 ; l H NMR (CDCI3) 8.10, 7.5-7.65, 7.2-7.4, 5.26, 5.06, 2.75-2.90, 2.2-2.3 and 1.15-1.4 δ; MS (m z) 336, 279, 238, 210, 195 and 69. EXAMPLE 130 5-[(2-Chlorophenylamino)carbonyl]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl 4,5-dihydroimidazo[l ,5-a]quinoxaline (I) mp 209-210°: IR (mineral oil) 3247, 2925, 2854, 1687, 1571, 1508, 1213 and 763 cm "1 ; NMR (CDC1 3 ) 8.28, 8.21, 7.65-7.8, 7.4- 7.5, 7.2-7.35, 7.00, 5.37, 2.2- 2.35 and 1.2-1.4 δ; MS (m/z) 432, 279, 238, 210, 195 and 153. EXAMPLE 131 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(isopropyl- amino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 210-211°; IR (mineral oil) 3268, 2924, 2855, 1682, 1672, 1580, 1505, 1334 and 750 cm "1 ; NMR (CDC1 3 ) 8.11, 7.5-7.65, 7.2-7.4, 5.23, 4.87, 3.95^.10, 2.2-2.35, 1.0-1.4 and 1.14 δ; MS (m/z) 364, 279, 238, 210 and 195. EXAMPLE 132 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dietiιylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 173-174°: IR (mineral oil) 3101, 2925, 2855, 1645, 1579, 1511, 1287 and 753 cm" 1 ; NMR (CDCI3) 8.11, 7.53, 7.1-7.3, 4.95, 3.26, 2.2-2.3, 1.2-1.4 and 1.13 δ; MS (m/z) 378, 306, 278, 238, 100 and 72. EXAMPLE 133 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 181.5-182.5°: IR (mineral oil) 3007, 2925, 2855, 1648, 1513, 1501, 1409, 1204, 760, 756 cm "1 ; NMR (CDC1 3 ) 8.10, 7.54, 7.1-7.3, 5.04, 3.28, 2.2-2.3, 1.75-1.9 and 1.2-1.4 δ; MS (m/z) 376, 306, 278 and 238. EXAMPLE 134 5-[(Benzenethio)carbonyl]-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 222.5-223.5°: IR (mineral oil) 2925, 2855, 1673, 1592, 1500, 1362, 1206, 751 cm "1 ; NMR (CDCI3) 8.16, 7.92, 7.61, 7.3-7.55, 5.38, 2.2-2.35 and 1.2-1.4 δ; MS (m/z) 415, 306, 278, 238 and 210. EXAMPLE 135 3-(5-Cyclopropyl-l ,2,4-oxadi___ol-3-yl)-5-[(ethanethio)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 169-170°: IR (mineral oil) 2925, 2855, 1657, 1579, 1491, 1207, 1177 and 765 cm "1 ; NMR (CDCI3) 8.12, 7.86, 7.58, 7.3-7.45, 5.33, 2.94, 2.2-2.35, 1.1-1.45, 1.29 δ; MS (m z) 367, 306, 278, 238 and 195. EXAMPLE 136 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 189-190°: IR (mineral oil) 2924, 2855, 1672, 1576, 1506, 1218 and 762 cm "1 ; NMR (CDCI3) 8.11, 7.5-7.65, 7.2-7.4, 5.25, 5.04, 3.25-3.4, 2.2-2.3, 1.2-1.4 and 1.12 δ; MS (m/z) 350, 279, 238, 210 and 195. EXAMPLE 137 5-(Carbamoyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro- imidazo[l,5-a]quinoxaline (I) mp 114-115°; IR (mineral oil) 2924, 2855, 1695, 1579, 1513, 1387 and 759 cm *1 ; NMR (CDC1 3 ) 8.16, 7.6-7.7, 7.2-7.45, 5.34, 5.24, 2.2-2.35 and 1.2-1.4 δ; MS (m z) 322, 279, 238, 210 and 195. EXAMPLE 138 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(methane- thio)carbonyl]imidazo[l,5-a]quinoxaline 0) mp 176-177°: IR (mineral oil) 2925, 2855, 1660, 1497, 1422, 1357, 1206 and 761 cm "1 ; NMR (CDC1 3 ) 8.12, 7.85, 7.58, 7.3-7.45, 5.34, 2.36, 2.25-2.4 and 1.2-1.4 δ; MS (m z) 353, 306, 278, 210 and 195. EXAMPLE 139 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imid___o[l,5-a]quinoxaline (I) mp 200.5-201.5°: IR (mineral oil) 3104, 2925, 2855, 1674, 1573, 1507, 1402 and 749 cm "1 ; NMR (CDC1 3 ) 8.09, 7.48, 7.19, 7.04, 6.82, 3.55, 2.75-3.3, 2.2-2.35, 1.45-2.15 and 1.2-1.4 δ; MS (m z) 404 and 389. EXAMPLE 140 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydro-4,4-dimedιylimidazo[l,5-a]quinoxaline () mp 160-161°: IR (mineral oil) 3111, 2925, 2855, 1646, 1568, 1479, 1313 and 747 cm "1 ; NMR (CDCI3) 8.10, 7.49, 7.20, 7.05, 6.73, 3.07, 2.72, 2.2-2.35, 1.99, 1.70 and 1.15-1.45 δ; MS (m z) 378, 363 and 295. EXAMPLE 141 5-[(Benzenetiιio)carbonyl]-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5- dihydro-4,4-dimethylimidazo[l ,5-a]quinoxaline (I) mp 171-172°: IR (mineral oil) 3098, 2925, 2855, 1695, 1590, 1510 and 1190 cm "1 ; NMR (CDCI3) 8.12, 7.72, 7.25-7.55, 2.2-2.3, 1.86 and 1.2-1.4 δ; MS (m/z) 443, 334 and 266. EXAMPLE 142 5-(Carbamoyl)-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimethylirnidazo[l,5-a]quinoxaline (I) mp 168-169°: IR (mineral oil) 3347, 2924, 2855, 1711, 1696, 1577, 1510 and 749 cm" NMR (CDCI3) 8.06, 7.48, 7.37, 7.2-7.3, 7.16, 5.15, 2.2- 2.35, 1.89 and 1.2-1.4 δ; MS (m/z) 335, 307, 292, 224 and 209. EXAMPLE 143 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(diethylamino)carbonyI]-4,5- dihydro-4,4-dimethylimidazo[l ,5-a]quinoxaline (I) mp 148-149°: IR (mineral oil) 2925, 2855, 1671, 1572, 1508, 1302, 1264 and 749 cm "1 ; NMR (CDC1 3 ) 8.10, 7.49, 7.18, 7.03, 6.84, 3.3-3.7, 3.0- 3.3, 2.2-2.35, 1.98, 1.59, 1.1-1.4 and 0.89 δ; MS (m/z) 406, 391. EXAMPLE 144 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(medιylamino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 126-127°: IR (mineral oil) 2925, 2855, 1678, 1577, 1518, 1288 and 753 cm" 1 ; NMR (300 MHz, (CDC1 3 ) 7.92, 7.42, 7.15-7.3, 6.95-7.1, 5.70, 2.91, 2.2-2.3, 1.84 and 1.2-1.4 δ; MS (m z) 364, 349, 292 and 224. EXAMPLE 145 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethylamino)carbonyl]-4,5- dihydro-4,4-dimedιylimidazo[ 1 ,5-a]quinoxaline (I) mp 194-195°: IR (mineral oil) 2925, 2855, 1677, 1577, 1279, 1263 and 755 cm "1 ; NMR (CDC1 3 ) 7.98, 7.44, 7.21, 7.05, 5.63, 3.3-3.45, 2.2-2.3, 1.85, 1.1-1.4 and 1.19 δ; MS (m/z) 378, 363, 292 and 224. EXAMPLE 146 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(methane- thio)carbonyl]-4,4-dimethylimidazo[l ,5-a]quinoxaline (I) mp 163-164°: IR (mineral oil) 2924, 2855, 1687, 1573, 1507, 1290, 1195, 763 and 731 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.4- 7.65, 7.25-7.35, 2.2-2.35, 2.17, 1.86 and 1.2-1.4 δ; MS (m/z) 381, 366, 338 and 266. EXAMPLE 147 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(ethanethio)carbonyl]-4,5- dihydro-4,4-dimedιylimidazo[l,5-a]quinoxaline (I) mp 121-122°: IR (mineral oil) 2924, 2855, 1683, 1578, 1508, 1194 and 764 cm "1 ; NMR (CDC1 3 ) 8.12, 7.58, 7.45-7.55, 7.42, 7.2-7.35, 2.73, 2.2- 2.35, 1.86, 1.1-1.4 and 1.18 δ; MS (m/z) 395, 380, 352, 320 and 266. EXAMPLE 148 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-5-formyl-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline (I) mp 117.5- 118.5°: IR (mineral oil) 2925, 2855, 1672, 1571, 1512, 1352, 1298 and 760 cm" 1 ; NMR (CDC1 3 ) 8.76, 8.12, 7.87, 7.5-7.6, 7.3-7.45, 2.25-2.35, 1.93 and 1.2-1.45 δ; MS (m/z) 335, 320, 292, 252 and 224. EXAMPLE 149 3-(5-CyclopentyI- l , 2 ,4-oxad iazol-3-yl)-4, 5-dihydro-5- [(pyπOlidino)carbonyl]imidazo[ 1 ,5-a]quinoxaIine (I) mp 185-8°; NMR (CDC1 3 ) 8.03, 7.45, 7.1-6.9, 4.8, 3.2, 3.09, 1.92, 1.81 and 1.6-1.4 δ. EXAMPLE 150 4,5-Dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-4,4-dimethyl-5-[(pyrro- lidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 180-3°; NMR (CDC1 3 ) 8.12, 7.50, 7.22, 7.05, 6.83, 3.60, 3.18, 3.10, 1.90, 1.77, 1.41 and 1.39 δ. EXAMPLE 151 7-Chloro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazoI-5-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 210-3°; NMR (CDC1 3 ) 8.10, 7.44, 7.02, 6.81, 3.61, 3.18, 3.10, 2.00, 1.94, 1.83, 1.41, 1.38 δ. EXAMPLE 152 tert-Butyl 4,5-dihydro-4(S)-memyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 178-9°; NMR (CDC1 3 ) 7.85, 7.38, 7.2-6.9, 5.72, 3.04, 2.91, 1.62, 1.49, 1.39 and 1.15 δ. EXAMPLE 153 tert-ButyW ,5-dihydro-4(RS)-methyl-5-[(pyrroIidino)carbonyl]imidazo[ 1 ,5- a]quinoxaline-3-carboxylate (I) mp 177-9°; NMR (CDC1 3 ) 7.98, 7.51, 7.3-7.1, 5.94, 3.26, 3.14, 1.85, 1.72, 1.63 and 1.37 δ. EXAMPLE 154 tert-Butyl 4,5-dihydro-4(S)-methyl-7-methyl-5-[(pyrrolidino)- carbonyI]imidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 223-4°; NMR (CDC1 3 ) 7.94, 7.37, 6.99, 6.95, 5.92, 3.25, 3.14, 2.37, 1.86, 1.70, 1.63 and 1.36 δ. EXAMPLE 155 4,5-Dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yI)-4(S)-methyl-5- [φyrrolidino)carbonyI]imidazo[l,5-a]quinoxaline (I) mp 158-61°; NMR (CDC1 3 ) 8.11, 7.41, 7.06, 6.86, 6.79, 5.36, 4.79, 3.28, 1.46, 1.43 and 1.29 δ. EXAMPLE 156 4,5-Dihydro-3-(3-isoρropyl-l,2,4-oxadiazol-5-yl)-4(S)-methyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 149-55°; NMR (CDC1 3 ) 8.11, 7.56, 7.3-7.1, 6.05, 3.27, 3.17, 3.15, 1.86, 1.76, 1.45 and 1.40 δ. EXAMPLE 157 tert-Butyl 4,5-Dihydro-5-[2-(morpholino)acetyl]imidazo[l,5-a]quinoxaline (0 mp 182-4°; NMR (CDCI 3 ) 8.01, 7.84, 7.55, 7.34, 5.33, 3.78, 2.17 and 1.64 δ. EXAMPLE 158 tert-Butyl 4,5-Dihydro-7-methyl-5-[2-(morphoIino)ace_yl]imidazo[l,5- a . quinoxaline (I) mp 153-5°; NMR (CDC1 3 ) 8.00, 7.46, 7.28, 3.52, 3.17, 2.37, 1.93 and 1.62 δ. EXAMPLE 159 4,5-Dihydro-3-(3-isopropyl-l,2,4 )x_dia_»l-5-yl>5-[(pyrrolidiικ))carbonyl]- 4-(spirocyclopentyl)imidazo[l ,5-a]quinoxaline (I) mp 134-6°; NMR (CDC1 3 ) 8.11, 7.50, 7.19, 7.04, 6.86, 3.29, 3.28, 2.29, 1.95, 1.80 and 1.46 δ. EXAMPLE 160 7-CMoro^,5-dihy<ko-3-(3-iMpropyl-l,2,4-oxadiazol-5-yl)-5-[(ipyrroIidino)- carbonyl]imidazo[I,5-a]quinoxaline (I) mp 193-6°; NMR (CDC1 3 ) 8.11, 7.49, 7.18, 5.08, 3.33, 3.17, 1.86 and 1.39 δ. EXAMPLE 161 7-Fluoro-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-5-[φyrrolidino)- carbonyI]imidazo[l,5-a]quinoxaline (I) mp 202-5°; NMR (CDC1 3 ) 8.10, 7.53, 6.92, 5.08, 3.34, 3.17, 1.86 and 1.39 δ. EXAMPLE 162 tert-Butyl 4, 5-Dihydro-5-[(pyrrolidino)carbonyl]-4- (spirocyclopentyl)imidazo[l ,5-a]quinoxaline (I) mp 165-7°; NMR (CDC1 3 ) 7.97, 7.47, 7.18, 7.04, 6.84, 2.25, 2.01 and 1.84 δ. EXAMPLE 163 tert-Butyl 4,5-dihydro-5-[2-(pyrrolidino)acetyl]imidazotl,5-a]quinoxaline (I) mp 178-9°; NMR (CDC1 3 ) 8.01, 7.84, 7.56, 7.35, 5.32, 2.60, 2.18, 1.76 and 1.64 δ. EXAMPLE 164 7-Fluoro-4,5-dihydro-4(S)-methyl-N-pyrrolidino-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxamide (I) mp 211-14°; NMR (CDC1 3 ) 7.88, 7.48, 6.97, 6.86, 6.06, 4.12, 4.01, 3.64, 3.33, 3.18, 1.98, 1.88, 1.74 and 1.44 δ. EXAMPLE 165 tert-Butyl 4,5-Dihydro-4,4-dimethyl-5-[2-(pyπOlidino)acetyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 235-40°. EXAMPLE 166 4,5-Dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)carbonyl]- 4-(spirocyclo-pentyl)imidazo[ 1 ,5-a]quinoxaline (I) mp 133-5°; NMR (CDC1 3 ) 8.13, 7.51, 7.23, 7.08, 6.88, 3.18, 2.44, 2.32, 2.00, 1.96, 1.83 and 1.39 δ. EXAMLE 167 7-Fluoro-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4(S)-methyl-5- ' [(pyrrolidino)carbonyl]-imidazo[l,5-a]quinoxaline (I) mp 191-3°; NMR (CDC1 3 ) 8.07, 7.53, 6.98, 6.91, 6.01, 3.31, 3.20, 3.19, 1.89, 1.76, 1.47 and 1.40 δ. EXAMPLE 168 7-Fluoro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4(S)-methyl-5- [(pyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 212-4°; NMR (CDC1 3 ) 8.05, 7.52, 6.96, 6.87, 5.97, 3.32, 3.18, 1.88, 1.74, 1.46 and 1.43 δ. EXAMPLE 169 tert-Butyl 7-fluoro-4,5-dihydro-4(S)-methyl-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxylate (I) mp 188-90°; NMR (CDC1 3 ) 7.93, 7.47, 6.94, 6.87, 5.91, 3.30, 3.18, 1.90, 1.76, 1.62 and 1.39 δ. EXAMPLE 170 tert-Butytt,5-D_hydro-4(S)-isobutyl-5-[(pyrroIidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 204-8°; NMR (CDC1 3 ) 7.97, 7.51, 7.3-7.17, 6.01, 3.16, 3.05, 1.82, 1.70, 1.63, 1.60, 1.47, 1.32, 0.99 and 0.89 δ. EXAMPLE 171 tert-Butyl 4(S)-Ethyl-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline3-carboxylate (I) mp 163-6°; NMR (CDCI 3 ) 7.99, 7.50, 7.27, 7.16, 5.87, 3.20, 3.08, 1.83, 1.72, 1.63 and 0.93 δ. EXAMPLE 172 4(S)-Ethyl-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5- [(pyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 150-3°; NMR (CDC1 3 ) 8.10, 7.54, 7.27, 7.18, 5.93, 3.28, 3.18, 3.08, 1.81, 1.66, 1.46 and 0.92 δ. EXAMPLE 173 4(S)-Ethyl-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-5- [φyrroIidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 188-91°; NMR (CDC1 3 ) 8.12, 7.56, 7.30, 7.19, 5.94, 3.24, 3.18, 3.08, 1.90, 1.66, 1.40 and 0.92 δ. The product of EXAMPLES 174-181 is an amide, R 3 is -CO-NR 3 _ 4 R 3 . 5 which is produced by transformation from die corresponding ester, R 3 is -COO-R 3 _ι: EXAMPLE 174 N-tert-Butylamino-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[ 1 ,5- a]quinoxaline-3-carboxamide (I) mp 185-6°; NMR (CDC1 3 ) 7.89, 7.47, 7.2-7.0, 6.98, 5.08, 3.30, 1.81 and 1.48 δ. EXAMPLE 175 N-tert-Butylamino-6-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaIine-3-carboxamide (I) mp 233-6°; NMR (CDC1 3 ) 7.89, 7.30, 7.18, 7.05, 7.00, 5.13, 3.48, 1.92 and 1.48 δ. EXAMPLE 176 N - t e r t - B u t y l a m i n o - 6 - c h l o r o - 4 , 5 - d i h y d r o - 5 - [φy_τolidino)carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxamide (I) mp 291-4°; NMR (CDC1 3 ) 7.89, 7.42, 7.34, 7.19, 6.99, 5.05, 3.54, 1.93 and 1.47 δ. EXAMPLE 177 7-Chloro-4,5-dihydro-N-mo_pholino-5-[φyrrolidino)carbonyl]imidazo[l ,5- a]quinoxaline-3-carboxamide (I) mp 275-7°; NMR (CDC1 3 ) 7.93, 7.46, 7.36, 7.21, 5.04, 4.40, 3.78, 3.54 and 1.93 δ. EXAMPLE 178 N-tert-Butylamino-7-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline-3-carboxamide Q mp 116-9°; NMR (CDC1 3 ) 7.71, 7.26, 7.02, 6.93, 4.93, 3.20, 1.72 and 1.34 δ. EXAMPLE 179 7-Chloro-N-cyclohexylamino-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaIine-3-carboxamide (I) mp 213-5°; NMR (CDC1 3 ) 8.05, 7.56, 7.34, 7.25, 7.12, 5.24, 4.10, 3.51, 2.14, 2.02, 1.90-1.78 and 1.60-1.30 δ. EXAMPLE 180 N-.ert-Butylamino-6-chloro-4,5-dihydro-5-(2-pyrrolidino-2- oxoethyl)imidazo[l,5-a]quinoxaline-3-carboxamide (I) mp 200-2°; NMR (CDC1 3 ) 7.92, 7.35, 7.23, 7.04, 4.63, 3.82, 3.28, 1.88, 1.68 and 1.53 δ. EXAMPLE 181 N-tert-Butylamino-7-chloro-4,5-dihydro-5-(2-pyrrolidino-2-oxoeti_yl)- imidazofl ,5-a]quinoxaline-3-carboxamide Q mp 131-43°; NMR (CDC1 3 ) 7.93, 7.30, 6.79, 6.54, 4.87, 4.01, 3.53, 3.47, 2.06, 1.91 and 1.60 δ. The product of EXAMPLE 181A is an alcohol, R 3 is -CH 2 OH produced by transformation from the corresponding ester, R 3 is -COO-R3..1: EXAMPLE 181A 4,5-Dihydro-3-(hydroxymeΛyI)-5-[φyrrolidino)carbonyl]imidazo-[l,5- ajquinoxaline (I) 4,5-Dihydro-5-[(pyrrolidino)carbonyI]imidazo[l,5- a]quinoxaline-3-methanol (I) mp 214-5°; NMR (CDC1 3 ) 8.00, 7.47, 7.3-7.1, 4.73, 4.67, 3.26 and 1.81 δ. Following the general procedure of EXAMPLES 48-87 and die EXAMPLES referenced dierein and making non-critical variations the following compounds are produced: EXAMPLE 182 3-(2-Benzoxazolyl)-7-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo- [l,5-a]quinoxaline (I) mp 256.5-257.5°; MS m/z at 403; IR (mineral oil) 1513, 1660, 1637, 1395 and 1412 cm" 1 ; NMR (CDC1 3 ) 1.86, 3.35, 5.22, 6.86-6.96, 7.34, 7.53, 7.60, 7.74 and 8.11 δ. EXAMPLE 183 tert-Butyl 4,5-dihydro-5-[(moφholmo)c__i ) onyl]imidazo[l,5-a]qu_noxalin-3- carboxylate (I) mp 205-206°; MS m/z at 384; IR (mineral oil) 1685, 1653, 1506, 1113 and 1151 cm" 1 ; • NMR (CDCI3) 1.64, 3.33, 3.64, 4.99, 7.18, 7.28, 7.52 and 8.01 δ. EXAMPLE 184 4,5-Dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(morpholino). carbonyl]imidazo[l,5-a]quinoxaline (I) mp 207-208°; MS m/z at 394; IR (mineral oil) 1668, 1277, 1505, 1566 and 1423 cm" 1 ; NMR (CDC1 3 ) 1.47, 3.30, 3.34, 3.64, 5.04, 7.20, 7.28, 7.56 and 8.13 δ. EXAMPLE 185 tert-Butyl 5-[(di-n-propylamino)carbonyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 130.131°; MS m/z at 398; IR (mineral oil) 1718, 1152, 1660, 1504 and 1283 cm" 1 ; NMR (CDC1 3 ) 0.82, 1.56, 1.62, 3.15, 4.91, 7.10-7.24, 7.50 and 8.01 δ. EXAMPLE 186 5-[(Di-n-propylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4- oxadiazol-3-yl)imidazo[ 1 ,5-a]quinoxaline (I) mp 149-152°; MS m/z at 408; IR (mineral oil) 1645, 1510, 751, 1427 and 1574 cm" 1 ; NMR (CDC1 3 ) 0.81, 1.46, 1.55, 3.15, 3.29, 4.98, 7.12-7.26, 7.54 and 8.12 δ. EXAMPLE 187 7-Fluoro-4,5-dihydro-3-phenyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline (I) mp 194.5-196.5°; MS m/z at 362; NMR (CDC1 3 ) 1.82, 3.29, 4.91, 6.82-6.90, 7.30, 7.42- 7.50, 7.66 and 8.04 δ. EXAMPLE 188 tert-Buty5-(tert-butyloxycarbonyl)-4,5-dihydroimidazo[l,5-a]quinoxaline- 3-carboxylate (I) mp 178-180°; MS m z at 371; IR (mineral oil) 1711, 1367, 1154, 1509 and 1300 cm" 1 ; NMR (CDC1 3 ) 1.54, 1.64, 5.17, 7.23-7.33, 7.50, 7.76 and 8.01 δ. EXAMPLE 189 tert-Butyl 5-acetyl-4,5-dihydroimid___o[l ,5-a]quinoxaline-3-carboxylate (I) mp 150-152°; MS m/z at 313; IR (mineral oil) 1691, 1669, 1502, 1154 and 1489 cm" 1 ; NMR (CDC1 3 ) 1.64, 2.28, 5.27, 7.37, 7.56 and 8.03 δ. EXAMPLE 190 3-(2-Benzoxazolyl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline (I) mp 213-214°; MS m/z at 385; IR (mineral oil) 1666, 1242, 1510, 747 and 1408 cm "1 ; NMR (CDC1 3 ) 1.82, 3.31, 5.23, 7.15-7.37, 7.59, 7.74 and 8.15 δ. EXAMPLE 191 3-(2-Benzoxazolyl 7-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo- [l,5-a]quinoxaline (I) mp 256.5-257.5°; MS m z at 403; IR (mineral oil) 1513, 1660, 1637, 1395, 1412 and cm " l ; NMR (CDC1 3 ) 1.86, 3.35, 5.22, 6.86-6.96, 7.34, 7.53, 7.60, 7.74 and 8.11 δ. EXAMPLE 192 7-Fluoro-3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-[(pyrrol- idino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 225-226.5°; MS m/z at 408; IR (mineral oil) cm "1 ; NMR (CDC1 3 ) 1.63, 1.79, 1.91, 2.9-3.4, 3.56, 6.54, 6.75, 7.10, 7.41-7.47 and 7.96 δ. EXAMPLE 193 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5- [φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 241-242°; MS m/z at 410; NMR (CDC1 3 ) 1.50, 1.85, 3.32, 5.04, 6.88, 6.93, 7.50 and 8.07 δ. EXAMPLE 194 3-(5-tert-Butyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(morpholino)- carbonyl]imidazo[l,5-a]quinoxaline Q) mp 203-204.5°; NMR (CDC1 3 ) 1.51, 3.33, 3.64, 5.04, 7.20, 7.29, 7.56 and 8.13 δ. EXAMPLE 195 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 179-180°; NMR (CDC1 3 ) 1.51, 1.7-2.1, 2.98, 3.23, 3.58, 6.55, 6.74, 7.45 and 8.06 δ. EXAMPLE 196 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihyd_o-5- [(py_τolidino)carbonyl]imid___o[l,5-a]quinoxaline (I) mp 200-202°; NMR (CDCl 3 ) 1.50, 1.86, 3.35, 5.14, 7.07, 7.22, 7.37 and 8.12 δ. EXAMPLE 197 5-[(Dimethylamino)carbonyl]-3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 179°: IR (mineral oil) 3090, 2951, 2924, 2855, 1654, 1563, 1505, 1403, 1387 and 1357 cm "1 ; NMR (CDCl 3 ) 8.12, 7.55, 7.2-7.35, 7.05-7.2, 5.02, 2.97, 2.86 and 1.45; MS (m z) 338, 266, 238, 210, 195, 72 and 43. EXAMPLE 198 5-[(Dimethylamino)carbonyl]-3-(5-edιyl-l ,2,4-oxadiazoI-3-yl)-4,5-dihydro- 4,4-dimedιylimidazo[l,5-a]quinoxaline (I) mp 201-202°: IR (mineral oil) 3119, 2953, 2925, 2855, 1658, 1517, 1496, 1399, 1317, 1281 and 1186 cm "1 ; NMR (CDC1 3 ) 8.12, 7.50, 7.1-7.25, 7.06, 6.74, 3.07, 3.00, 2.73, 2.00, 1.72 and 1.47; MS (m/z) 366, 351, 295, 266 and 72. EXAMPLE 199 3-(5-Ethyl-l,2,4-oxadiazol-3-ylH,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 196.5-197°: IR (mineral oil) 3106, 2951, 2925, 2871, 2855, 1656, 1585, 1511, 1499, 1409, 1314, 1184 and 750 cm "1 ; NMR (CDC1 3 ) 8.11, 7.49, 7.1-7.25, 7.04, 6.82, 3.4-3.7, 2.8- 3.3, 2.99, 1.6-2.1 and 1.46 δ ; MS (m/z) 392, 378, 377, 266, 98 and 55. EXAMPLE 200 3-(5-Ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline (I) mp 190.5-191°: IR (mineral oil) 2957, 2926, 2883, 2866, 2856, 1647, 1572, 1509, 1410, 1400 and 771 cm "1 ; NMR (CDC1 3 ) 8.12, 7.54, 7.1-7.3, 5.07, 3.28, 2.97, 1.7-1.9 and 1.45 δ; MS (El, m/z) 364, 293, 266, 238, 210, 98 and 55. EXAMPLE 201 4,5-Dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(piperidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 190-191°: IR (mineral oil) 3095, 2953, 2925, 2856, 1644, 1571, 1508, 1430, 1355 and 1279 cm "1 ; NMR (CDC1 3 ) 8.12, 7.54, 7.1-7.3, 5.01, 3.15-3.4, 1.4-1.7 and 1.46 δ; MS (m/z) 392, 307, 280, 238, 210, 112, 69 and 40. EXAMPLE 202 tert-Butyl,5-dihydro-5-[(piperidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate (I) mp 167°: IR (mineral oil) 3098, 2947, 2924, 2856, 1697, 1669, 1510, 1426, 1377, 1301, 1288, 1262 and 1151 cm "1 ; NMR (CDC1 3 ) 8.00, 7.49, 7.1-7.3, 4.95, 3.2-3.3, 1.45-1.7 and 1.63 δ; MS (m/z) 382, 326, 214, 197, 112, 69 and 40. EXAMPLE 203 4,5-Dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-5-[(piperidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 173.5-174.5°: IR (mineral oil) 3116, 2952, 2941, 2925, 2858, 1646, 1640, 1506, 1451 and 1420 cm" 1 ; NMR (CDC1 3 ) 8.14, 7.56, 7.1-7.35, 5.05, 3.2-3.35, 3.05-3.3, 1.4-1.7 and 1.40 δ; MS (m/z) 392, 280, 196, 112, 69 and 40. EXAMPLE 204 3-(5-Ethyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(piperidino)carbonyl]- imidazo[l,5-a]quinoxaline (I) mp 191-191.5°: IR (mineral oil) 2944, 2924, 2854, 1646, 1571, 1505, 1424, 1273, 1211 and 756 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.54, 7.1-7.3, 5.02, 3.15-3.35, 2.97, 1.4-1.7 and 1.46 δ; MS (m/z) 378, 266, 238, 210, 112, 69 and 40. EXAMPLE 205 tert-Butyl 4,5-dihydro-4,4-dimedιyl-5-[(piperidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 176-177°: IR (mineral oil) 2926, 2856, 1720, 1654, 1514, 1367 and 1144 cm" 1 ; NMR (CDC1 3 ) 7.98, 7.44, 7.18, 6.95-7.05, 6.77, 3.8-4.2, 3.1-3.5, 2.8-3.1, 2.08, 1.2-1.8 and 1.63 δ; MS (m/z) 410, 395, 210 and 112. EXAMPLE 206 4,5-Dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [φiperidino)carbonyl]imidazo[l,5-a]quinoxaIine (I) mp 190-191°: IR (mineral oil) 2926, 2854, 1654, 1512, 1429, 1317 and 1267 cm "1 ; NMR (CDC1 3 ) 8.12, 7.50, 7.1-7.25, 6.95-7.1, 6.79, 3.8-4.1, 3.1-3.4, 2.8-3.1, 1.2-2.1, 1.48 δ; MS (m/z) 420, 405, 113, 112 and 69. EXAMPLE 207 tert-Butyl 5-[(dimethylamino)carbonyl]-4,5-dihydro-7-methylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 164-165°: IR (mineral oil) 3113, 2925, 1684, 1656, 1521, 1491, 1353 and 1158 cm "1 ; NMR (CDCI3) 7.96, 7.38, 6.95, 6.89, 4.93, 2.86, 2.37 and 1.62 δ; MS (m/z) 356, 300, 228, 211, 210, 183 and 72. EXAMPLE 208 5-[(Dime_iylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3- yl)-7-methylimidazo[l,5-a]quinoxaline (_) mp 175-176°: IR (mineral oil) 3100, 2925, 2855, 1654, 1566, 1515, 1492, 1355, 1284 and 1192 cm "1 ; NMR (CDC1 3 ) 8.08, 7.42, 6.96, 6.90, 4.99, 3.2-3.35, 2.86, 2.38 and 1.45 δ; MS (m z) 366, 294, 278, 252, 224, 209 and 72. EXAMPLE 209 tert-Butyl 4,5-dihydro-7-mediyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- ajquinoxaline -3-carboxylate (I) mp 207.5-208°: IR (mineral oil) 2954, 2925, 2869, 2856, 1692, 1641, 1518, 1410, 1394 and 1374 cm "1 ; NMR (CDC1 3 ) 7.96, 7.37, 4.98, 3.2-3.4, 2.37, 1.75-1.9 and 1.62 δ; MS (mz) 382, 326, 309, 228, 211, 210, 98 and 55. EXAMPLE 210 4,5-Dihydro-3-(5-isopropyl-l,2,4-oxadia_»l-3-ylH-me yl-5-[φyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 231-231.5°: IR (mineral oil) 2955, 2925, 2873, 2855, 1653, 1566, 1412 and 1392 cm " l ; NMR (CDCI3) 8.08, 7.42, 6.85-7.05, 5.03, 3.1-3.4, 2.38, 1.7-1.9 and 1.46 δ; MS (m/z) 392, 321, 294, 252, 224, 209, 98 and 55. EXAMPLE 211 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 219-220°: NMR (CDC1 3 ) 8.12, 7.55, 7.05-7.35, 5.01, 2.86 and 1.50 δ. EXAMPLE 212 3-(5-tert-Butyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydro-4,4-dimedιylimidazo[l,5-a]quinoxaline (I) mp 160.5-162: NMR (CDC1 3 ) 8.12, 7.51, 7.15-7.25, 7.06, 6.74, 3.08, 2.73, 2.00, 1.72 and 1.51 δ. EXAMPLE 213 tert-Butyl 4,5-dihydro-4,4-dimedιyl-5-[φyrrolidino)carbonyl]imidazo[l ,5- a]quinoxaline-3-carboxylate (J mp 124-125°: IR (mineral oil) 2925, 1712, 1663, 1512, 1408, 1283 and 1155 cm "1 ; NMR (CDC1 3 ) 7.97, 7.44, 7.1-7.25, 7.01, 6.80, 3.5-3.65, 2.8-3.35, 1.6-2.3 and 1.63 δ; MS (m z) 396, 381, 210 and 98. EXAMPLE 214 tert-Butyl 5-[(dimemylamino)carbonyl]-4,5-dihydro-4,4-dimemylimidazo- [l,5-a]quinoxaline-3-carboxylate (I) mp 162-163°: IR (mineral oil) 2925, 1712, 1670, 1662, 1510, 1489, 1386, 1269, 1186 and 1153 cm" 1 ; NMR (CDC1 3 ) 7.98, 7.45, 7.19, 7.03, 6.72, 3.08, 2.72, 2.08, 1.68 and 1.63 δ; MS (m z) 370, 355, 210 and 72 δ. EXAMPLE 215 4,5-Dihydro-3-(5-isopropyI-l,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 130-132°: IR (mineral oil) 2925, 1665, 1566, 1403, 1308, 1288 and 752 cm "1 ; NMR (CDC1 3 ) 8.11, 7.50, 7.20, 7.04, 6.83, 3.5-3.7, 3.25-3.4, 2.8-3.3, 1.6-2.1 and 1.47 δ; MS (m/z) 406, 391 and 98. EXAMPLE 216 5-[(Dimethylamino)carbonyl]-4,5-dihydro-3-(5-i_opropyl-l,2,4-oxadiazol-3- yl)-4,4-dimethylimidazo[l,5-a]quinoxaline (I) mp 171-172°: IR (mineral oil) 2925, 1664, 1512, 1185 and 768 cm "1 ; NMR (CDC1 3 ) 8.12, 7.51, 7.15-7.25, 7.06, 6.74, 3.2-3.4, 3.07, 2.73, 2.00, 1.72 and 1.48 δ; MS (m/z) 380, 365 and 72. EXAMPLE 217 tert-Butyl4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline- 3-carboxylate (I) mp 127-128°: IR (mineral oil) 2925, 1731, 1643, 1506, 1408, 1375 and 1149 cm" 1 ; NMR (CDCI3) 8.00, 7.50, 7.1-7.3, 5.00, 3.2-3.35, 1.75-1.9 and 1.63 δ; MS (m/z) 368, 312, 214, 197 and 98. EXAMPLE 218 tert-Butyl 5-[(dimethylamino)carbonyl]-4,5-dihydroimidazo[l,5-a]- quinoxaline-3-carboxylate (1) mp 184-186°: IR (mineral oil) 2925, 1691, 1680, 1509, 1379, 1153 and 774 cm "1 ; NMR (CDCI3) 8.00, 7.51, 7.2-7.35, 7.05-7.2, 4.96, 2.85 and 1.63 δ; MS (m/z) 342, 286, 269, 214, 196, 169 and 72. EXAMPLE 219 5-[(Dime_ιylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3- yl)imidazo[l,5-a]quinoxaline (I) mp 190-191°: IR (mineral oil) 2925, 1651, 1565, 1508, 1387, 1380, 1356, 1187 and 747 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.55, 7.25-7.35, 7.05-7.2, 5.02, 3.2-3.4, 2.86 and 1.46 δ; MS (m/z) 352, 280, 264, 238, 210, 195 and 72. EXAMPLE 220 4,5-Dihydr^4,4-dimrthyl-5-[φyrrolidino)carbonyl]-3-(p-tolyl)imidazo[l ,5- a]quinoxaline (I) mp 215-216°C: IR (mineral oil) 2926, 1650, 1522, 1505, 1407 and 745 cm "1 ; NMR (CDCI3) 8.02, 7.49, 7.37, 7.1-7.25, 7.0-7.1, 6.80, 3.5-3.7, 2.9-3.3, 2.40, 1.6-1.95 and 1.66 δ; MS (m/z) 386, 371 and 98. EXAMPLE 221 5-[ imedιylamino)caιt .nyl]-4,5-dihydro-4,4-dimedιyl-3-(p-tolyI)imidazo- [l,5-a]quinoxaIine (I) mp 248-249°: IR (mineral oil) 2925, 1665, 1660, 1505, 1277, 1187, 1180 and 750 cm "1 ; NMR (CDCl 3 ) 8.02, 7.50, 7.37, 7.1-7.25, 7.05, 6.71, 3.04, 2.74, 2.40 and 1.65 δ; MS (m/z) 360, 345, 316 and 72. EXAMPLE 222 3-(4-Fluorophenyl)-4,5-dihydro-4,4-dimediyl-5-[(pyrrolidino)carbonyI]- imidazo[l,5 -a]quinoxaline d) mp 232-233°: IR (mineral oil) 2925, 1648, 1501, 1407, 1215 and 748 cm "1 ; NMR (CDCI3) 8.02, 7.4-7.55, 7.0-7.2, 6.81, 3.5-3.65, 2.9-3.3, 1.6-1.95 and 1.64 δ; MS (m/z) 390, 375, 320 and 98. EXAMPLE 223 5-[(Dimethylamino)carbonyI]-3-(4-fluorophenyl)-4,5-dihydro-4,4- dimemylimidazo[l,5-a]quinoxaline (I) mp 248-249°: IR (mineral oil) 2925, 1653, 1516, 1503, 1274, 1219 and 752 cm "1 ; NMR (CDCI3) 8.02, 7.4-7.55, 7.0-7.25, 6.72, 3.05, 2.74 and 1.64 δ; MS (m/z) 364, 349, 320 and 72. EXAMPLE 224 4,5-Dihydro-3-phenyI-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (1) mp 205-207°: IR (mineral oil) 2954, 2925, 2855, 1644, 1511, 1401, 1392, 1190, 763, 754, 701 and 697 cm "1 ; NMR (CDC1 3 ) 8.09, 7.68, 7.53, 7.44, 7.1-7.35, 4.93, 3.25 and 1.65- 1.85 δ; MS (m z) 344, 246. EXAMPLE 225 4,5-Dihydro-3-(5-isopropyl-l,2,4 )xadia_ol-3-yl)-5-[φyrtolidino)carbonyl]- imidazo[l,5-a]quinoxaline (J) mp 195-196°: IR (mineral oil) 2954, 2924, 2855, 1644, 1572, 1509, 1407, 1394 and 1360 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.54, 7.1-7.35, 5.06, 3.2-3.4, 1.7-1.9 and 1.46 δ; MS (m z) 378, 307, 280, 238 and 98. EXAMPLE 226 5-[(Dimemylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5- yl)ϊmidazo[l,5-a]quinoxaline (I) mp 186-187.5°: IR (mineral oil) 3104, 2954, 2925, 2855, 1655, 1652, 1625, 1561, 1505, 1486, 1466, 1458, 1389, 1349, 1276, 1259, 1171 and 750 cm "1 ; NMR (CDCI 3 ) 8.14, 7.56, 7.05- 7.35, 5.05, 3.05-3.25, 2.87 and 1.40 δ; MS (m z) 352, 280, 196 and 72. EXAMPLE 227 5-[(Dimemylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4-ox_di___oI-5- yl)-4,4-dimethylimidazo[l,5-a]quinoxaline (I) mp 172-173° IR (mineral oil) 2961, 2953, 2925, 1668, 1626, 1510, 1388, 1384, 1291, 1281, 1269, 1188 and 768 cm "1 ; NMR (CDC1 3 ) 8.13, 7.51, 7.2-7.3, 7.07, 6.75, 3.0-3.3, 3.09, 2.75, 2.11, 1.74 and 1.40 δ; MS (m/z) 380, 365 and 72. EXAMPLE 228 5-[(DimethyIamino)carbonyl]-4,5-dihydro-4,4-dimethyl-3- phenylimidazo[l,5-a]quinoxaline (I) mp 224-225.5°: IR (mineral oil) 2954, 2924, 2855, 1650, 1518, 1497, 1383, 1274 and 778 cm" 1 ; NMR (CDC1 3 ) 8.04, 7.25-7.6, 7.18, 7.06, 6.72, 3.04, 2.74 and 1.66 δ; MS (m/z) 346, 331, 302 and 72. EXAMPLE 229 6-Chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-4,4-dimethyl-3- phenylimidazo[l,5-a]quinoxaline (I) mp 194-195°: IR (mineral oil) 2953, 2925, 2855, 1652, 1502, 1380, 785, 775 and 706 cm" 1 ; NMR (CDC1 3 ) 8.04, 7.2-7.5, 7.13, 2.78 and 1.65 δ; MS (m/z) 380, 365, 336 and 72. EXAMPLE 230 7-Chloro-4,5-dihydro-4,4-dimetiiyl-3-phenyl-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline (I) mp 218.5-219°: IR (mineral oil) 2951, 2925, 2869, 2855, 1662, 1508, 1401, 1388, 1324 and 955 cm "1 ; NMR (CDC1 3 ) 7.99, 7.3-7.5, 7.01, 6.79, 3.4-3.6, 2.8-3.4, 1.65-2.0 and 1.65 δ; MS (m/z) 406, 391 and 98. EXAMPLE 231 7-Chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-4,4-dimedιyl-3-phe- nylimidazo[l,5-a]quinoxaline (I) mp 172-174°: IR (mineral oil) 2951, 2924, 2855, 1650, 1517, 1479, 1380, 1279 and 775 cm "1 ; NMR (CDC1 3 ) 8.00, 7.3-7.5, 7.03, 6.70, 3.07, 2.79, 1.68 and 1.62 δ; MS (m z) 380, 365 and 72. EXAMPLE 232 tert-Butyl 4,5-dihydro-6-methyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 233-234°: IR (mineral oil) 2967, 2953, 2924, 2872, 2855, 1689, 1666, 1510, 1374, 1359, 1299, 1213, 1158 and 1131 cm "1 ; NMR (CDC1 3 ) 8.01, 7.3-7.4, 7.1-7.25, 5.09, 3.1-3.25, 2.21, 1.7-1.9 and, 1.63 δ; MS (m/z) 382, 326, 228, 211 and 98. EXAMPLE 233 4,5-Dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl _i-methyl-5-[(pyrrolid_no carbonyl]imidazo[l,5-a]quinoxaline (I) mp 220-222°: IR (mineral oil) 2970, 2953, 2924, 2873, 1654, 1505, 1493, 1471, 1402, 1382 and 1371 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.41, 7.1-7.3, 5.16, 3.2-3.4, 3.0-3.2, 2.23, 1.7-1.85 and 1.46 δ; MS (m/z) 392, 321, 294, 252, 98 and 55. EXAMPLE 234 tert-Butyl 5-[(dimethylamino)carbonyl]-4,5-dihydro-6-methylimidazo[ 1 ,5- a]quinoxaline-3-carboxylate (I) mp 214-216°: IR (mineral oil) 2953, 2925, 2855, 1692, 1674, 1508, 1380, 1370, 1354, 1301, 1210, 1162 and 1153 cm "1 ; NMR (CDC1 3 ) 8.00, 7.3-7.4, 7.1-7.3, 5.02, 2.90, 2.20 and 1.63 δ; MS (m z) 356, 300, 228, 211 and 72. EXAMPLE 235 5-[(Dimethylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3- yl)-6-methylimidazo[ 1 ,5-a]quinoxaline (I) mp 188-189°: IR (mineral oil) 2952, 2924, 2855, 1668, 1498, 1494, 1471, 1380 and 1186 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.42, 7.1-7.3, 5.07, 3.2-3.4, 2.88, 2.22 and 1.47 δ; MS (m/z) 366, 294, 278, 252 and 72. EXAMPLE 236 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[φyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline (I) mp 226-227.5°: IR (mineral oil) 2925, 1642, 1557, 1508, 1411, 1396, 1360 and 748 cm "1 ; NMR (CDC1 3 ) 8.11, 7.54, 7.1-7.3, 5.05, 3.28, 1.7-1.9 and 1.50 δ; MS (m/z) 392, 294, 264, 238, 210, 195, 98 and 55. EXAMPLE 237 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 172-173.5°: ER (mineral oil) 2925, 1660, 1516, 1404, 1315 and 1183 cm" 1 ; NMR (CDCI3) 8.11, 7.49, 7.19, 7.04, 6.83, 3.5-3.7, 2.8-3.3, 1.6-2.1 and 1.51 δ; MS (m/z) 420, 405, 98 and 55. EXAMPLE 238 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-7-chloro-4,5-dihydro-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 235-236°: NMR (CDC1 3 ) 8.09, 7.47, 7.1-7.2, 5.04, 3.2-3.4, 1.8-1.95 and 1.50 δ. EXAMPLE 239 3-(5-tert-Butyl-l,2,4-oxadiarol-3-yl 7-cWoi_ 5-[(dimediylamino)carbonyl]- 4,5-dihydroimidazo[l,5-a]quinoxaIine (I) mp 191-192.5°: NMR (CDC1 3 ) 8.09, 7.48, 7.14, 7.09, 5.00, 2.90 and 1.49 δ. EXAMPLE 240 3-(5-tert-Butyl-l,2,4-oxadia_»l-3-yl)-7-c_doro-5-[(dimedιylamino)carbonyl]- 4,5-dihydro-4,4-dimethylimidazo[l ,5-a]quinoxaline (I) mp 112-113°: NMR (CDC1 3 ) 8.08, 7.43, 7.02, 6.72, 3.10, 2.78, 1.98, 1.72 and 1.51 δ. EXAMPLE 241 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,5-dihydro-4,4-dimethyl-5- [φyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaIine (Q mp 185-187°: NMR (CDC1 3 ) 8.11, 7.44, 7.31, 7.11, 3.3-3.6, 2.5-2.8, 1.89, 1.6-1.9 and 1.51 δ. EXAMPLE 242 3-(5-tert-Butyl-l,2,4 )xadiazol-3-yl 6-chloro-5-[(dimethyIamino)carto 4,5-dihydro-4,4-dimemylimidazo[l,5-a]quinoxaline ( mp 147-148.5°: NMR (CDC1 3 ) 8.12, 7.45, 7.32, 7.13, 2.79, 1.86 and 1.51 δ. EXAMPLE 243 3-(5-te_t-Butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,5-dihydro-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline (I) mp 246-247°: NMR (CDC1 3 ) 8.13, 7.50, 7.37, 7.23, 5.12, 3.25-3.45, 1.75-1.95 and 1.50 δ. EXAMPLE 244 3-(5-tert-Butyl-l,2,4-oxadiazol-3-yl)-6-chloro-5-[(dimethyl_mi_K))_art onyl]- 4,5-dihydroimidazo[l ,5-a]quinoxaline (I) mp 214-215°: NMR (CDC1 3 ) 8.12, 7.51, 7.38, 7.24, 5.06, 3.01 and 1.51 δ. EXAMPLE 245 5-tert-Butyl-3-(4-fluorophenylH,5-dihydroimidazo[l,5-a]quinoxaIin-4-one (XXXIV) Potassium tert-butoxide (1.0 M in THF, 24.1 ml) is added to a mixture of l-(tert-butyl)- tetrahydroquinoxalin-2,3-dione (XXXI, 5.00 g) and THF (54.0 ml) at - 20°. The mixture is allowed to warm to 0° over 30 min. After cooling to -40°, diethyl chlorophosphate (3.53 ml) is added and die solution is allowed to warm to 20-25° over 40 min. After cooling to -78°, a solution of 4-fluorobenzyl isocyanide (3.62 g) and THF (5.0 ml) is added. Potassium tert-butoxide (24.1 ml) is then added dropwise over several min. The mixture is stirred at - 78° for 30 min and is allowed to warm slowly to 20-25° over 2 hr. Aqueous workup (ethyl acetate, magnesium sulfate) and purification by flash chromatography eluting with ethyl acetate/hexane (1/2), pooling die appropriate fractions and concentration gives the title compound, mp 135-137°; IR (mineral oil) 2953, 2925, 2855, 1668, 1498, 1299 and 751 cm "1 ; NMR (CDC1 3 ) 8.31, 8.22, 7.63, 7.55, 7.05- 7.35 and 1.76 δ; MS (m/z) 335, 279. EXAMPLE 246 3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxalin-4-one (XXXV) Trifluoroacetic acid (50.0 ml) is added to a solution of 5-tert-butyl-3-(4-fluorophenyl)-4,5- dihydroimidazo[l,5-a]quinoxalin-4-one (XXXIV, EXAMPLE 245, 4.01'g) and methylene chloride (50.0 ml) at 0°. The solution is stirred for 1 hr at 0° and is concentrated. The residue is triturated widi water, filtered, washed widi water (2 X 100 ml), ether (2 X 100 ml), and dried under reduced pressure to give the title compound, mp > 300°; IR (mineral oil) 2955, 2922, 2868, 2855, 1667, 1499, 1377 and 1366 cm "1 ; NMR (dg-DMSO) 11.45, 9.16, 8.3-8.45, 8.21 and 7.2-7.45 δ; MS (El, m z) 279, 251 and 223. EXAMPLE 247 3-(4-FluorophenyI)-4,5-dihydroimidazo[l ,5-a]quinoxaline (XXXVI) Aluminum hydride (0.6 M in THF, 80 ml) is added to 3-(4-fluorophenyl)-4,5- dihydroimidazo[l ,5-a]quinoxalin-4-one (XXXV, EXAMPLE 246, 3.21 g) and die resulting solution is heated at reflux for 36 hr. After 24 hr, lithium aluminum hydride (600 mg) is added as starting material is still present. After cooling to 20-25°, methanol (12.1 ml) and sodium hydroxide (6N, 50.0 ml) are added successively and the resultant solution stirred for 30 min at 20-25°. Aqueous workup (ediyl acetate, magnesium sulfate) and purification by flash chromatography eluting wim hexane/ediyl acetatge (2/1), pooling the appropriate fractions and concentration gives the tide compound, IR (mineral oil) 3381, 2924, 1511, 1492, 1290, 1231, 838 and 741 cm" 1 ; NMR (CDC1 3 ) 8.04, 7.58, 7.42, 7.0-7.2, 6.8-6.95, 4.66 and 4.07 δ; MS (m z) 265, 264, 237, 144 and 118. EXAMPLE 248 3-(4-Fluorophenyl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline (I) Triphosgene (427 mg) is added to a mixture of 3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5- a]quinoxaline (XXXVI, EXAMPLE 247, 702 mg), methylene chloride (27.0 ml) and diisopropylethylamine (0.53 ml) at 0°. The resultant solution is stirred for 1 hr at 0° and for 2 hr at 20-25°. The mixture is cooled to 0° and pyrrolidine (0.85 ml) is added. The mixture is maintained at 0° for 1 hr and is allowed to warm to 20-25°. After stirring for 16 hr, basic workup using sodium bicarbonate, mediylene chloride and magnesium sulfate and purification by flash chromatography eluting with ediyl acetate/hexane (1/1), pooling die appropriate fractions and concentration gives die product. Recrystallization from hot ethyl acetate-hexane give the tide compound, mp 217-218°; IR (mineral oil) 2925, 1641, 1506, 1414 and 753 cm "1 ; NMR (CDC1 3 ) 8.07, 7.64, 7.53, 7.05-7.3, 4.89, 3.25 and 1.7-1.85 δ; MS (m/z) 362, 264, 98 and 55. Following die general procedure of EXAMPLES 245-248 and making non-critical variations but using various starting materials the products of EXAMPLES 249 thru 252 are obtained: EXAMPLE 249 5-[(Pimemylamino)carbonyl]-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5- a . quinoxaline CD mp 192-193.5°; IR (mineral oil) 2925, 1648, 1504, 1485, 1384, 1364, 1213 and 1205 cm " x ; NMR (CDC1 3 ) 8.07, 7.55-7.7, 7.54, 7.05-7.3, 4.84 and 2.83 δ; MS (m/z) 336, 264 and 72. EXAMPLE 250 5-[(Dimethylamino)carbonyl]-4,5-dihydro-3-phenylimidazo[l,5- a]quinoxaline (I) mp 225-226°: IR (mineral oil) 2954, 2924, 2855, 1657, 1506, 1498, 1388, 1199, 752 and 702 cm "1 ; NMR (CDCl 3 ) 8.09, 7.67, 7.54, 7.44, 7.05-7.35, 4.88 and 2.83 δ; MS (m/z) 318, 246 and 72. EXAMPLE 251 4,5-Dihydro-3-phenyl-5-[(piperidino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 177-180°: IR (mineral oil) 2953, 2930, 2853, 1651, 1410, 1213, 744 and 698 cm "1 ; NMR (CDCI3) 8.12, 7.68, 7.54, 7.45, 7.1-7.4, 4.88, 3.15-3.35 and 1.4-1.65 δ; MS (m z) 358, 246, 112 and 69. EXAMPLE 252 4,5-Dihydro-5-[(pyrrolidino)carbonyl]-3-φ-tolyl)imidazo[l,5-a]quinoxaline CO mp 238.5-239.5°: NMR (CDC1 3 ) 8.07, 7.45-7.65, 7.05-7.3, 4.91, 3.25, 2.39 and 1.65- 1.85 δ. Following the general procedure of EXAMPLES 48-87 and the EXAMPLES referenced therein and making non-critical variations die following compounds are produced: EXAMPLE 253 5-Benzoyl-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline (I) mp 232-233°. EXAMPLE 254 3-(3-Cyclopropyl-l ,2,4-oxadiazoI-5-yl)-4,5-dihydro-5- propionylimidazo[l ,5-α]quinoxaline (I) mp 197-198°. EXAMPLE 255 3-(3-Cyclopropyl- l ,2,4-oxadiazol-5-yl)-4,5-dihydro-5- (phenoxycarbonyl)imidazo[l,5-a]quinoxaline (I) mp 212-213°. EXAMPLE 256 3-(3-Cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5- (ethoxycarbonyl)imidazo[l,5-a]quinoxaline (I) mp 204-205°. EXAMPLE 257 3-(3-Cyclopropyl-l,2,4-oxadiazol-5-yl)-5-[(diethylamino)carbonyl]-4,5- dihydroimidazo[l,2-a]quinoxaline (I) mp 165-166°. EXAMPLE 258 3-(3-Cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(2- furoyl)imidazo[l,5-a] quinoxaline (I) mp 197-198°. EXAMPLE259 tert-Butylamino 7-fluoro-4,5-dihydro-4,4-dimethyl-5- [(pyrτolidino)carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxamide (I) mp 196-197°. EXAMPLE 260 4,5-Dihydro-3-[5-[l-(2-methylpropyl)]-l,2,4-oxadiazol-3-yl]-5- [(py_τolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 138^0°. EXAMPLE 261 tert-Butylamino 7-Fluoro-4,5-dihydro-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxamide(I) mp 243-244°. EXAMPLE 262 4,5-Dihydro-5-[(pyrrolidino)carbonyl]-3-[5-(3,3,3-trifluoropropyl)-l,2,4- oxadiazol-3-yl]imidazo[l ,5-a]quinoxaline (I) mp 193-4°. EXAMPLE 263 tert-Butyl 6-fluoro-4,5-dihydro-5-(p-tolylsulfonyl)imidazo[l,5- a]quinoxaline-3-carboxylate mp 153-5°. EXAMPLE 264 7-Fluoro-4,5-dihydro-3-[5-(2-methylpropyl)-l ,2,4-oxadiazol-3-yl]-5- [(pyrrolidino)carbonyI]imidazo[ 1 ,5-a]quinoxaline (I) mp 198-9°. EXAMPLE 265 7-Fluoro-4,5-dihydro-3-[5-(2-methyl-3,3,3-trifluoropropyl)-l,2,4- oxadiazol-3-yl]-5-[(pyπOlidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 183-4°. EXAMPLE 266 4,5-Dihydro-3-[5-(2-methyl-3,3,3-trifluoropropyl)-l ,2,4-oxadiazol-3-yl]-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline(I) mp 142-4°. EXAMPLE 267 4,5-Dihydro-3-[5-(2-me_hyl-3,3,3-trifluoropropyl)-l,2,4-oxadiazol-3-yl]-5- [(morpholino)carbonylmethyl]imidazo[l ,5-a]quinoxaline (I) mp 167-71°. EXAMPLE 268 3-[5-(Cyclopentyl)-l,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-4(R)-me_ιyl- 5-[(morpholino)carbonylmethyl]imidazo[l ,5-a]quinoxaline (I) mp 174-5°. EXAMPLE 269 7-Fluoro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazoI-3-yl)-4(R)-mediyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 211-2°. EXAMPLE 270 3-(5-Cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R>medιyl-5- [2-(morpholino)acetyl]imidazo[l,5-a]quinoxaline (I) mp 212-3°. EXAMPLE 271 3-(5-Cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R me_ιyl-5- [(piperidino)carbonylmedιyl]imidazo[l,5-a]quinoxaline (I) mp 185-6°. EXAMPLE 272 te rt- B u ty l 7 -flu o ro -4 , 5-dihydr o -4 (R) -m ethy l -5 - [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 188-9°. EXAMPLE 273 3-(5-Cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro^.,5-dihydro-40R)-medιyl-5- [2-(pyrroIidino)acetyl]imidazo[l,5-a]quinoxaline (I) mp 146-7°. EXAMPLE 274 tert-Butyl 7-fluo ro -4, 5-d ihydro-4(R)-methyl-5-(2- pyridylmethyl)imidazo[l,5-a]quinoxaline-3-carboxylate (LX) mp 152-3°. EXAMPLE 275 3-(5-Cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4 l>medιyl-5- [(pyrrolidino)carbonylmethyl]imidazo[l ,5-a]quinoxaline (I) mp 241-2°. EXAMPLE 276 7-Fluoro-4,5-dihydro-4(R)-meti_yl-3-[5-(l-methylcyclopropyI)-l,2,4- oxadiazol-3-yl]-5-(2-pyridylmedιyl)imidazo[l,5-a]quinoxaline (LX) mp 147-8°. EXAMPLE 277 Cyclopropylmethylamino 7-Fluoro-4,5-dihydro-4(R)-methyl-5-(2- pyridylmethyl)imidazo[l ,5-a]quinoxaline-3-carboxamide (LX) mp 145-6°. EXAMPLE 278 7-Fluoro-4,5-dihydro-4(R)-meti_yl-3-[5-(2-methylcyclopropyl)-l,2,4- oxadiazol-3-yl]-5-(2-pyridylmethyl)imidazo[l,5-a]quinoxaline (LX) mp 97-8°. EXAMPLES 279-290 disclose the process to prepare the compounds of the present invention where R 4 and R 5 are cyclized to form a heterocyclic ring (I-R 4 /R 5 /Rg-1), via the 4,5- cyclic amide (XXXIX) intermediate, see CHART J. EXAMPLE 279 N-(2-Nitrophenyl)-DL-glutamic acid dimediyl ester (XI) A mixture of l-fluoro-2-nitrobenzene (VII, 4.80 g), DL-glutamic acid hydrate (Xlla, 5.62 g), potassium carbonate (8.00 g), edianol (50 ml) and water (10 ml) is heated at 105° for 24 hr. The reaction mixture is then stripped of solvents and die residue stirred in DMF with methyl iodide (4 ml). After about a week, the DMF is removed and die residue is partitioned between dichloromediane and water. Silica gel chromatography (500 ml) using ethyl acetate/hexane (30/70) gives the tide compound, NMR (CDC1 3 ) 2.28, 2.51, 3.69, 3.79, 4.40, 6.73, 6.80, 7.45, 8.20 and 8.33 δ. EXAMPLE 280 3,3a Dihydropyrrolo[l,2-a]quinoxaline-l,4(2H, 5H)-dione (TV) To N-(2-nitrophenyl)-DL-glutamic acid dimethyl ester (XI, EXAMPLE 279, 5.09 g) in medianol (150 ml) is added p-toluenesulfonic acid (0.158 g) and pallacium on carbon (10%, 0.495 g). The mixture is shaken under hydrogen at 37 psi for 2 hr; the mixture is then filtered and die filtrate is concentrated to about 70 ml. Additional p-toluenesulfonic acid (0.15 g) is added, and the solution is heated at 60° for 1 hr. After cooling, the solid is collected, washed widi medianol, and dried to give the tide compound, mp 231-232°; NMR (CDC1 3 ) 2.65, 4.41, 6.93, 7.14, 8.10 and 8.55 δ. EXAMPLE 281 l-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-12, 12a-dihydroimidazo[l,5- a]pyrrolo[2, l-c]quinoxalin-10(l lH)-one (I) 3,3a Dihydropyrrolo[ 1 ,2-a]quinoxaline-l ,4(2H, 5H)-dione (IV, EXAMPLE 280, 0.520 g) is stirred in DMF (6.5 ml) and cooled at 0°. To this is added potassium tert-butoxide in THF (1M, 2.70 ml). After 10 min the ice badi is removed. Ten minutes later an additional DMF (6 ml) is added. After 30 min had elapsed, the reaction mixture is cooled in an ice/metiianol badi and diediylchlorophosphate (0.39 ml) is added. The reaction is stirred for 10 minutes, after which the ice/ medianol badi is removed. After a total of 45 minutes, the reaction is cooled at -78° and 5- cyclopropyl-3-isocyanomedιyl-l,2,4-oxadiazole (0.403 g) is added, followed by potassium tert- butoxide in THF (1M, 2.70 ml) dropwise over 10 minutes. The reaction is stirred at -78° for 1.5 hr, after which the cooling badi is removed. The reaction is allowed to warm to 20-25° over about 30 min. Water is added and the reaction mixture is partitioned between ethyl acetate and water, followed widi a saline wash. The organic layers are dried over magnesium sulfate and concentrated. The residue is chromatographed on silica gel (200 ml) eluting widi ediyl acetate/hexane 75/25, the appropriate fractions are pooled and concentrated to give die tide compound, which is recrystallized from dichloromethane/ethyl acetate/hexane, mp 180-183° (decomp); MS (m/z) at 333; IR (mineral oil) 1701, 1574, 1509, 1477 and 766 cm "1 ; NMR (CDC1 3 ) 1.26, 1.36, 2.27, 2.60, 2.78, 3.38, 5.30, 7.29, 7.35, 7.57, 8.17 and 8.38 δ. EXAMPLE 282 (S)-l-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazo[l,5- a]pyrrolo[2, l-c]quinoxalin-10(l lH)-one CD Following the general procedure of EXAMPLES 279, 280 and 281 and making non-critical variations but using N-(2-nitrophenyl)-L-glutamic acid diethyl ester, the tide compound is obtained, mp 181.5-183° (decomp); MS (m z) at 333; IR (mineral oil) 1708, 1511, 761, 1204, 1403 cm "1 ; NMR (CDC1 3 ) 1.28, 1.38, 2.25, 2.6, 2.78, 3.36, 5.30, 7.28, 7.36, 7.55, 8.18, 8.38 δ; [α] D = - 197° (0.98, CH 2 C_2). EXAMPLE 283 (R)-l-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazo[l,5- a]pyrrolo[2, l-c]quinoxalin-10(l lH)-one (T) Following me general procedure of EXAMPLES 279, 280 and 281 and making non-critical variations but using N-(2-nitrophenyl)-D-glutamic acid diethyl ester, die tide compound is obtained,mp 181.5-183° (decomp); MS (m/z) at 333; IR (mineral oil) 1707, 1511, 1499, 761, 1403 cm" 1 ; NMR (CDC1 3 ) 1.27, 1.38, 2.27, 2.58, 2.77, 3.37, 5.30, 7.30, 7.36, 7.57, 8.17, 8.36 δ; [α] D = + 154° (0.98, CH 2 C1 2 ). EXAMPLE 284 (S)-l-(Benzoxazol-2-yl)-12, 12a-dihydroimidazo[l,5-a]pyrrolo[2, 1- a]quinoxalin-10(llH)-one (I) Following the general procedure of EXAMPLE 30 and making non-critical variations but starting widi (S)-3,3a-dihydropyrrolo[l,2-a]quinoxaline-l,4(2H,5H)-dione (intermediate formed in EXAMPLE 282, 0.638 g) and 2-(isocyanome_ιyl)benzoxazole (0.599 g), the tide compound is obtained, which after crystallization from methanol/dichloromethane/hexane, mp 270-273°; MS (m z) at 342; IR (mineral oil) 1705, 1510, 1271, 1690, 747, 1630 cm "1 ; NMR (CDC1 3 ) 2.37-2.48, 2.57-2.66, 2.76-2.89, 3.62-3.72, 5.45, 7.30-7.42, 7.60, 7.64, 7.75, 8.22, 8.40 δ. EXAMPLE 285 tert-Butyl (S)-12,12a-dihydroimidazo[l,5-a]pyrrolo[2,l-c]quinoxaline-l- carboxylate (I) Following the general procedure of EXAMPLE 30 and making non-critical variations but starting with (S)-3,3a-dihydropyrrolo[l ,2-a]quinoxaline-l,4(2H,5H)-dione (intermediate formed in EXAMPLE 282, 0.638 g) and tert-butyl isocyanoacetate (0.621 g), the tide compound is obtained, mp 202-207° (decomp); MS (m/z) at 325; IR (mineral oil) 1719, 1363, 1700, 1507, 1161, 1293 cm" 1 ; NMR (CDC1 3 ) 1.64, 2.25-2.40, 2.55-2.81, 3.31-3.41, 5.26, 7.23-7.29, 7.33, 7.52, 8.06, 8.34 δ; [α] D = -248° (0.96, methanol). EXAMPLE 286 N-(2-Nitrophenyl)-DL-serine methyl ester (XI) To 15.66 g of l-fluoro-2-nitrobenzene (VID, 16.87 g of potassium carbonate, 100 ml of 95% ethanol, and 40 ml of water are added 11.66 g of DL-serine. The reaction is stirred at 90° overnight and dien cooled. The solvents are removed under vacuum and the residue is azeotroped with toluene to remove residual water. The resulting solid is washed widi edier and toluene to remove unreacted l-fluoro-2-nitrobenzene. The solid is then stirred for 18 hr at 20-25° in 80 ml of DMF widi 15.34 g of potassium carbonate and 24 ml of iodomediane. Excess iodomethane and DMF are then removed under vacuum and die residue is partitioned between a mixture of methylene chloride, chloroform and water. The organic layers are dried over sodium sulfate and concentrated. Ethyl ether and hexane are added to die residue and die solid is collected and dried to give the title compound, mp 138-140°; NMR (CDC1 3 ) 2.15, 3.83, 4.10, 4.41, 6.73-6.81, 7.46, 8.22, 8.60 δ. EXAMPLE 287 3-Hydroxymedιyl-l,2,3,4-tetrahydroquinoxalin-2-one (IV) A mixture of N-(2-nitrophenyl)-DL-serine methyl ester (XL, EXAMPLE 286, 0.506 g, 4.30 g), palladium on carbon (10%, 506 g) and 150 ml of methanol is shaken under hydrogen at 40 psi for 3.5 hr. The catalyst is then removed by filtration and the filtrate is concentrated under reduced pressure. The residue is then chromatographed on silica gel (400 ml) using eluting widi medianol/mediylene chloride (6/94), die appropriate fractions are pooled and concentrated to give the title compound, NMR (CDC1 3 ) 2.70, 3.90, 4.00-4.18, 6.75, 6.92, 8.23. δ. EXAMPLE 288 3,3a,-Dihydro-lH-oxazolo[3,4-a]quinoxaline-l,4(5H)-dione (IV) To 3-hydroxymethyl-l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 286, 1.35 g), 1.00 g of carbonyldiimidazole, and 30 ml of THF are added 1.64 ml of triethylamine. The reaction is stirred at 20-25° for 6 hr, then at 80° for 18 hr, at which time an additional 0.11 g of carbonyldiimidazole are added. Heating is continued for another 6 hr, at which time the reaction mixture is cooled and die solvent is removed under reduced pressure. The residue is partitioned between methylene chloride and water, die organic layers are dried over sodium sulfate and concentrated. The residue is crystallized from medianol/dichloromethane to give the tide compound, mp 230-231°; MS (m/z) at 204; NMR (CDC1 3 ) 4.60, 4.78, 6.93, 7.19, 7.82 and 8.48 δ. EXAMPLE 289 12-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-l , 12b-dihydroimidazo[5, 1- a]oxazolo[4,3-c]quinoxalin-3(3H)-one (I) Following me general procedure of EXAMPLE 30 and making non-critical variations but starting with 3,3a,-dihydro-lH-oxazolo[3,4-a]quinoxaline-l,4(5H)-dione (IV, EXAMPLE 288, 0.485 g) and 0.425 g of 5-cyclopropyl-3-isocyanomethyl-l,2,4-oxadiazoIe, the title compound is obtained, mp 228-230°; MS (m/z) at 335; IR (mineral oil) 1749, 1570, 1511, 1213, 761 cm "1 ; NMR (CDC1 3 ) 1.27-1.40, 2.30, 4.63, 5.35, 5.57, 7.30, 7.40, 7.60, 8.19, 8.23 δ. EXAMPLE 290 (S)-l-[5-(l , l-Dimethylethyl)-l ,2,4-oxadiazol-3-yl]-12, 12a- dihydroimidazo[ 1 ,5-a]pyrrolo[2, 1 -c]quinoxaline (I) Following the general procedure of EXAMPLE 30 and making non-critical variations but starting wim 3,3a,-dihydro-lH-oxazolo[3,4-a]quinoxaline-l,4(5H)-dione (IV, EXAMPLE 288, 1.002 g) and 0.982 g of 5-(l,l-dimethyl)ethyl-3-isocyanomedιyl-l,2,4-oxadiazole, die tide compound is obtained, mp 253-257°; MS (m/z) at 349; IR (mineral oil) 1699, 1558, 1515, 755, 1300, 1573 cm" 1 ; NMR (CDC1 3 ) 1.52, 2.20-2.35, 2.55-2.64, 2.71-2.84, 3.34-3.44, 5.32, 7.28, 7.37, 7.58, 8.19, 8.37 δ; [α] D = -381° (0.89, CH 2 Cl2). EXAMPLE 291 4-Benzoyl-l ,2,3,4-tetrahydroquinoxalin-2-one (IV) To l,2,3,4-tetrahydroquinoxalm-2-one (TV, EXAMPLE 1, 4.425 g), 5.4 ml of triethylamine, and 40 ml of THF cooled at 0° are added dropwise over several minutes 4.2 ml of benzoyl chloride. After stirring for 35 min the ice badi is removed and after stirring an additional 25 min the reaction mixture is partitioned between ediyl acetate and aq. sodium bicarbonate and saline. The organic layers are dried over magnesium sulfate and concentrated. The product is crystallized from medianol/dichloromediane/hexane to give the tide compound, mp 208-209°; NMR (CDC1 3 ) 4.60, 6.75, 6.93, 7.10, 7.32, 7.42, 8.44 δ. EXAMPLE 292 4-Benzoyl-6-fluoro-l,2,3,4-tetrahydroquinoxaIin-2-one (_V) To 6-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (TV, EXAMPLE 6, 2.65 g), 2.9 ml of triethylamine, and 20 ml of THF at 0 °C are added dropwise over several minutes 2.22 ml of benzoyl chloride. The reaction mixture is stirred for 35 min at 0°, at which time the ice bath is removed. After stirring an additional 25 min, the reaction mixture is partitioned between ethyl acetate and aq. sodium bicarbonate and saline. The organic layers are dried over magnesium sulfate and concentrated. The product is crystallized from methanol/dichloromediane/hexane to give the tide compoud, mp 226-227°; NMR (CDC1 3 ) 4.55, 6.54, 6.80-6.92, 7.35-7.49, 8.54 δ. EXAMPLE 293 4-(2-Chlorobe___oyl)-l,2,3,4-tetrahydroquinoxaIin-2-one (IV) To l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 1, 2.11 g), 2.58 ml of triethylamine, and 40 ml of THF at 0° are added 2.16 ml of 2-chlorobenzoyl chloride. After 15 min e ice badi is removed and the reaction is stirred for 20 min. Ether is added to die reaction mixture and die solid collected. TLC showed bodi solid and filtrate to contain product, so they are recombined and partitioned between dichloromediane and aq. sodium bicarbonate. The organic layers are filtered dirough sodium sulfate and concentrated. Edier is added to die crude product and die edier layer decanted from die crystalline product to give, after drying the tide compound, mp 222.5-224°; NMR (CDC1 3 ) 4.18, 4.48, 4.98, 6.50, 6.70, 7.2-7.5, 8.55 δ. EXAMPLE 294 4-Medιoxycarbonyl-l ,2,3,4-tetrahydroquinoxalin -2-one (TV) To 2.99 g of l,2,3,4-tetrahydroquinoxalin-2-one (TV) in 30 ml of methyl tert-butyl edier are added 2.18 ml of mediyl chloroformate. After stirring for 1 hr, 4.9 ml of diisopropylediylamine are added. The reaction is stirred an additional 30 min and then concentrated under reduced pressure. The residue is partitioned between dichloromethane and aq. sodium bicarbonate and die organic layers dried over sodium sulfate and concentrated. The crude product is crystallized from dichloromethane/hexane/ethyl ether to give the title compound, NMR (CDCI3) 3.84, 4.45, 6.87, 7.11, 7.65, 8.27 δ. EXAMPLE 295 3,3-Dimethyl-6-fluoro-4-methoxycarbonyl-l,2,3,4-tetrahydroquinoxal_n-2- one (TV) To 3,3-dimethyl-6-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 8, 5.14 g), 4.84 ml of diisopropylethylamine, and 30 ml of THF at 0° are added 66 ml of 1.2 M phosgene in toluene. After 25 min the ice badi is removed and die reaction is allowed to warm slowly to 20-25° with stirring over 2.5 hr. The reaction mixture is stored overnight in the refrigerator and die next morning concentrated and partitioned between dichloromediane, water, and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. Ether and hexane are added to die crude product and the solid is collected. To 1.55 g of this material in 10 ml of medianol are added 1.3 g of sodium me oxide in methanol (25% by weight). After stirring for 1 hr the solvent is removed under reduced pressure and die residue is partitioned between dichloromediane and saline. The organic layers are dried over sodium sulfate and concentrated and the crude product chromatographed on silica gel (250 ml) eluting with ethyl acetate/methylene chloride (10/90), die appropriate fractions are pooled and concentrated to give die title compound which after crystallization from memylene chloride/hexane, mp 166-168.5°; NMR (CDC1 3 ) 1.63, 3.77, 6.75-6.88, 7.00, 8.38 δ. EXAMPLE 296 3,3-Dimethyl-4-[(l-methyl)ethyl]oxycarbonyl-l,2,3,4-tetrahydroquinoxalin- 2-one (TV) To 2.28 g of 4-chlorocarbonyl-3,3-dimethyl-l,2,3,4-tetrahydroquinoxalin-2-one (prepared by die mediod of Example 32 but using 3,3-dimethyl-l,2,3,4-tetrahydroquinoxalin-2-one rather than 6-fluoro-3,3-dimethyl-l ,2,3,4-tetrahydroquinoxalin -2-one) in 25 ml of 2-propanol (die starting material is not all in solution) are added 0.694 g of lidiium isopropoxide. After about 1.5 hr the reaction mixture became homogeneous and then again heterogeneous as die product precipitated out. After a total of 2 hr the solvent is removed under reduced pressure and die residue is partitioned between dichloromediane and saline. The organic layers are dried over sodium sulfate and die filtrate is concentrated. Ether is added and die resulting solid is collected to give die title compound, NMR (CDC1 3 ) 1.28, 1.63, 5.01, 6.80, 6.98-7.11, 7.27, 7.96 δ. EXAMPLE 297 5-Fluoro-4-methoxycarbonyl-l,2,3,4-tetrahydroquinoxalin-2-one (IV) To 5-fluoro-l ,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 24, 0.883 g) and 1.39 ml of diisopropylediylamine in 10 ml of THF are added 0.62 ml (7.97 mmol) of methyl chloroformate. The reaction mixture is stirred for 3 hr, when several mis of aqueous sodium bicarbonate are added to quench die unreacted mediyl chloroformate. The mixture is then partitioned between ediyl acetate and aqueous sodium bicarbonate and saline. The organic layers are dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel (120 ml) eluting with ediyl acetate/methylene chloride (20/80), die appropriate fractions are pooled and concentrated to give die tide compound which after crystallization from dichloromethane/hexane, mp 170.5-172°; NMR (CDC1 3 ) 3.83, 6.71, 6.87, 7.13-7.21, 8.72.δ. EXAMPLE 298 4-[(Morpholino)carbonyl]-l ,2,3,4-tetrahydroquinoxalin-2-one (IV) A mixture of 4.79 g of l,2,3,4-tetrahydroquinoxalin-2-one (IV, EXAMPLE 1) and 45 ml of THF is stirred at 0°. To this is added 6.66 ml of diisopropylediylamine, followed by 32.4 ml 1.2 M phosgene in toluene. After starring at 0° for 1.3 hr, an additional 6.76 ml of diisopropylediylamine is added, followed by 3.4 ml of morpholine. The reaction is stirred for 30 minutes and then die ice bath is removed and the reaction is allowed to warm to 20-25° over 2 hr, at which time water is added and die mixture is partitioned between ethyl acetate and saline. The organic layers are dried over magnesium sulfate and concentrated under reduced pressure. The crude product is crystallized from ethyl acetate to give die tide compound, mp 179.5-180.5°; MS (m/z) at 261; IR (mineral oil) 1679, 1664, 1390, 1402, 761 cm" 1 ; NMR (CDC1 3 ) 3.32, 3.64, 4.20, 6.94, 7.06, 7.14, 8.90 δ. EXAMPLE 299 N-(5-Fluoro-2-nitrophenyl)-2-methylalanine (II) A mixture of 32.62 g of 2,4-difluoronitrobenzene, 24.2 g of 2-aminoisobutyric acid, 15.2 g of potassium carbonate, 100 ml of acetonitrile, and 100 ml of water is heated at 80° for 2 days (until TLC shows little or no starting material). The reaction is then cooled and acetonitrile is removed under reduced pressure. The pH is adjusted to 5 widi 4 N hydrochloric acid and die mixture is extracted widi chloroform (3 x 300 ml). The organic layers are dried over sodium sulfate and concentrated. The material is used in the next step without further purification. EXAMPLE 300 3,3-DimeΛyl-6-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (_V) N-(5-Fluoro-2-nitrophenyl)-2-methylalanineis taken up in approximately 1 L of ethanol and divided into two lots for reduction. The reductions are done with 1.7-1.9 g of palladium on carbon (10%) under hydrogen at initial pressures of 41 and 43 psi. After 4 hr the reaction is judged complete and the catalyst is filtered off. The filtrates are combined after concentration (with heating) to about 100 ml, then further concentrated. The crude product is chromatographed on silica gel (900 ml) eluting with ethyl acetate/dichloromethane (20/80), die appropriate fractions are pooled and concentrated to give the tide compound which is crystallized from medianol/dichloromethane/hexane, mp 146-148°. EXAMPLE 301 3,3-Dimethyl-6-fluoro-4-[(pyrrolidino)carbonyl]-l ,2,3,4- tetrahydroquinoxalin-2-one (IV) To amixtureof3,3-dimethyl-6-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one(IV, EXAMPLE 300, 1.001 g) and 0.94 ml of diisopropylethylamine, and 10 ml of THF at 0 ° are added 12.9 ml of 1.2 M phosgene in toluene. After 45 min the reaction is allowed to warm to 20-25°. After stirring for 3 hr, the reaction is again cooled to 0° and additional 4.2 ml of phosgene are added. The ice bath is removed and the reaction is stirred for 100 min, after which the excess phosgene and solvents are removed via a water aspirator. The mixture is then stirred with 10 ml of THF and 0.90 ml of pyrrolidine are added. After stirring overnight, the reaction is concentrated and die residue chromatographed on silica gel using 2% methanol-98% dichloromethane. Recrystallization from dichloromethane/hexane gives the product; mp 199-200°; MS (m z) at 291; IR (mineral oil) 1681, 1660, 1396, 1163 cm" 1 ; NMR (CDC1 3 ) δ 1.4-2.0, 3.15, 3.6, 6.43, 6.65, 6.76, 8.32. EXAMPLE 302 5-Fluoro-4-[(pyrrolidino)carbonyl]-l ,2,3,4-tetrahydroquinoxaIin-2-onf V) To 1.20 g of 5-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (EXAMPLE 24), 1.26 ml of diisopropylediylamine, and 15 ml of THF at 0° is added 6.0 ml of 1.2 M phosgene in toluene. The ice bath is removed and the reaction is stirred for 2 h, at which time an additional 0.2 ml of diisopropylethylamine and 1.0 ml of phosgene solution are added. After an hour, 1.26 ml of diisopropylethylamine and 0.60 ml of pyrrolidine are added and die reaction is stored in d e freezer over die weekend. The reaction is then partitioned between ethyl acetate and aq. sodium bicarbonate and saline. The organic layers are dried over magnesium sulfate and concentrated and die crude product is chromatographed on silica gel (250 ml) using ethyl acetate/dichloromethane (30/70) to give 1.47 g of product. Recrystallization from ethyl acetate/ethyl ether/hexane gives product in two crops; mp 186.5-187.5°; MS (m z) at 263; IR (mineral oil) 1692, 1658, 1407, 1604, 1623 cm "1 ; NMR (CDC1 3 ) 1.85, 3.28, 4.27, 6.68, 6.82, 7.04, 8.41 δ. EXAMPLE 303 4-[[4-(tert-Butyloxycarbonyl)piperazino]carbonyl]-l , 2,3,4- tetrahydroquinoxalin-2-one (IV) To l,2,3,4-tetrahydroquinoxalin-2-one (TV, EXAMPLE 1, 2.13 g), 2.75 ml of diisopropylediylamine, and 20 ml of THF cooled at 0° are added 13.2 ml of 1.2 M phosgene in toluene. The reaction is stirred at 0° for 1.5 hr and then allowed to warm to 20-25°, at which time 2.75 ml of diisopropylediylamine and 2.94 g of tert-butyl 1-piperazinecarboxylate are added. The reaction is stirred for an additional 1.5 hr and d en partitioned between a mixture of dichloromethane and chloroform and aq. sodium bicarbonate and saline. The organic layers are dried over sodium sulfate and concentrated. The addition of dichloromethane and ethyl edier gives a crystalline solid which is collected and washed widi ether to give d e title compound after drying, mp 166-167°; MS (m z) at 360; IR (mineral oil) 1685, 1646, 1698, 1419, 1499 cm "1 ; Y U NMR (CDC1 3 ) δ 1.44, 3.28, 3.40, 4.20, 6.92, 7.01-7.08, 7.11, 8.76. EXAMPLE 304 3,3-Dimemyl-4-[(mo holinyl)carbonyl]-l,2,3,4-tetrahydroquinoxalin-2-one (IV) To2.70gof4-(chlorocarbonyl)-3,3-dimediyl-l,2,3,4-tetrahydroquinoxalin-2-one(prepared from 3,3-dimemyl-l,2,3,4-tetrahydroquinoxalin-2-one (EXAMPLE 2) and phosgene) in 30 ml of dichloromediane are added 1.97 g of morpholine. After stirring for 30 min, die reaction mixture is partitioned between dichloromediane and saline. The organic layers are dried over sodium sulfate, concentrated, and crystallized from dichloromethane/hexane to give the title compound, mp 190.5-193°; MS (m/z) at 289; IR (mineral oil) 1683, 1661, 1409, 1238, 1121, 1506 cm" 1 ; NMR (CDC1 3 ) δ 1.3-1.9, 3.0-4.1, 6.70, 6.84, 6.95-7.03, 8.31. EXAMPLES 305-322 Following the general procedure of EXAMPLS 30, 31, 33, 34, 36, 38, 40, 42, 44, 45B and 47 and making non-critical variations but starting with die bicyclic amides (TV) of EXAMPLES of 23, 35, 291-298 and 301-304, the imidazo[l,5-a]quinoxalines (D of the following EXAMPLES are obtained: EXAMPLE 305 5-Benzoyl-4,5-dihydro-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3- yl]imida_o[l,5-a]quinoxaline (I) mp 201-202°; MS (m z) at 399; IR (mineral oil) 1497, 1659, 1670, 1240, 1392, 1604 cm " , NMR (CDC1 3 ) 1.46, 5.42, 7.08, 7.25-7.46, 7.60, 8.21 δ. EXAMPLE 306 5-BenzoyM,5-dihydro-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3-yl]-7- fluoroimidazo[l,5 -ajquinoxaliπe (I) mp 187-190°; MS (m/z) at 417; IR (mineral oil) 1366, 1499, 1674, 1668, 1239, 1514 cra " l ; NMR (CDCI3) 1.44, 5.39, 6.95, 7.02, 7.36-7.51, 7.57, 8.16 δ. EXAMPLE 307 tert-Butyl 5-benzoyl-4,5-dihydroimidazo[l,5-a]quinoxaline-3-carboxylate 0) mp 218.5-219.5°; MS (m/z) at 375; IR (mineral oil) 1713, 1509, 1141, 1157, 1339, 1242 cm "1 ; NMR (CDCI3) 1.56, 5.33, 7.08, 7.23-7.48, 7.56 and 8.10 δ. EXAMPLE 308 tert-Butyl 5-benzoyl-4,5-dihydro-7-fluoroimidazo[l,5-a]quinoxaliπe-3- carboxylate (I) mp 204-205.5°; MS (m/z) at 393; IR (mineral oil) 1726, 1151, 1665, 1233, 1240, 1513 cm" 1 ; NMR (CDCI 3 ) 1.53, 5.29, 6.93, 7.00, 7.38-7.56, 8.05 δ. EXAMPLE 309 tert-Butyl 5-(2-chlorobenzoyl)-4,5-dihydro-7-fluoroimidazo[l,5- a]quinoxaline-3-carboxylate (J.) mp 199-200.5°; MS (m z) at 409; IR (mineral oil) 1659, 1700, 1143, 1295, 1509, 1493 cm "1 ; NMR (CDC1 3 ) 8.06 δ. EXAMPLE 310 tert-Butyl 4,5-dihydro-6-fluoro-5-[(tert-butyloxy)carbonyl]imidazo[l,5- a]quinoxalin-3-carboxylate (I) mp 184-186°; MS (m/z) at 389; IR (mineral oil) 1698, 1367, 1256, 1711, 1151, 1500 cm" l ; NMR (CDCI3) 1.47, 1.64, 7.10, 7.31, 8.02 δ. EXAMPLE 311 5-[(tert-Butyloxy)carbonyl]-4,5-dihydro-3-[(l,l-dimethyl)ethyl-l,2,4- oxadiazol-3-yl]imidazo[l,5-a]quinoxaline (1) mp 188-190.5°; MS (m/z) at 395; IR (mineral oil) 1708, 1508, 1366, 1306, 1161, 752 cm " NMR (CDCI3) 1.51, 1.52, 5.26, 7.24-7.34, 7.54, 7.79, 8.12 δ. EXAMPLE 312 5-[(tert-Butyloxy)carbonyl]-4,5-dihydro-3-[(l,l-dimethyl)ethyl-l,2,4- oxadiazol-3-yl]-6-fluoroimidazo[l ,5-a]quinoxaline CD mp 170-171°; MS (m z) at 413; IR (mineral oil) 1709, 1498, 1259, 1162, 1483, 1280 cm" x ; NMR (CDC1 3 ) 1.46, 1.51, 7.11, 7.31-7.38, 8.14 δ. EXAMPLE313 4,5-Dihydro-5-methoxycarbonyl-3-(benzoxazol-2-yl)imidazo[l,5- a]quinoxaline (I) mp 201-203.5°; MS (m/z) at 346; IR (mineral oil) 1511, 1719, 1243, 750, 1638, 1448 cm" l ; NMR (CDC1 3 ) 3.86, 5.46, 7.30-7.40, 7.56-7.64, 7.77-7.80, 8.16 δ. EXAMPLE314 tert-Butyl 4,5-dihydro-4,4-dimethyl-7-fluoro-5- methoxycarbonylimidazo[l ,5-a]quinoxalin-3-carboxylate (I) mp 164-165°; MS (m/z) at 375; IR (mineral oil) 1727, 1527, 1294, 1262, 1289, 1151, 1142, 1333 cm" 1 ; NMR (CDC1 3 ) 1.62, 1.92, 3.74, 6.96, 7.07, 7.39, 7.92 δ. EXAMPLE 315 tert-Butyl 4,5-dihydro-4,4-dimethyl-5-[(l- methyl)edιoxycarbonylimidazotl,5-a]quinoxalin-3-carboxylate (I) mp 179-180.5°; MS (mz) at 385; IR (mineral oil) 1244, 1722, 1292, 1297, 1144, 755, 1108, 1706 cm "1 ; NMR (CDC1 3 ) 1.25, 1.62, 1.92, 4.97, 7.20-7.24, 7.34, 7.40 and 7.96 δ. EXAMPLE 316 tert-Butyl 4,5-dihydro-6-fluoro-5-methoxycarbonylimidazo[l,5- a]quinoxalin-3-carboxylate (I) mp 174-175°; MS (m/z) at 347; IR (mineral oil) 1717, 1709, 1142, 1496, 1504, 1279 cm" l ; NMR (CDC1 3 ) 1.64, 3.81, 7.13, 7.33, 8.02 δ. EXAMPLE 317 4,5-Dihydro-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3-yl]-5- [(moφholino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 203.0-204.5°; MS (m/z) at 408; IR (mineral oil) 1647, 1424, 1510, 1557, 1281 cm "1 ; NMR (CDC1 3 ) 1.51, 3.33, 3.64, 5.04, 7.20, 7.29, 7.56, 8.13 δ. EXAMPLE 318 4,5-Dihydro^,4-dimethyl-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3-yl]- 7-fluoro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline(I) mp 179-180°; MS (mz) at 438; IR (mineral oil) 1681, 1521, 1172, 1285, 1560 cm "1 ; NMR (CDC1 3 ) 1.51, 1.7-2.1, 2.9-3.4, 3.58, 6.55, 6.74, 7.45, 8.06 δ. EXAMPLE 320 5-[[4-(tert-Butyloxycarbonyl)piperazino]carbonyl]-4,5-dihydro-3-[5-[(l,l- dimethyl)edιyl]-l,2,4-oxadiazol-3-yl]imidazo[l,5-a]quinoxaline(I) mp 147-151° (softening), 176-178°; MS (mz) at 507; IR (mineral oil) 1700, 1670, 1692, 1416, 1403 cm "1 ; NMR (CDC1 3 ) 1.44, 1.50, 3.29, 3.40, 5.04, 7.17-7.29, 7.56, 8.13 δ. EXAMPLE 321 tert-Butyl 5-[[4-(tert-butyloxycarbonyl)piperazino]carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 140-145°; MS (m/z) at 483; IR (mineral oil) 1696, 1687, 1657, 1424, 1435 cm "1 ; NMR (CDC1 3 ) 1.44, 1.63, 3.29, 3.41, 5.00, 7.15-7.30, 7.52, 8.01 δ. EXAMPLE 322 tert-Butyl4,5-dihydro-4,4-dimedιyl-5-[(moφholino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 181-182°; MS (m/z) at 419; IR (mineral oil) 1668, 1274, 1239, 1112, 1699, 756 cm" 1 ; NMR (CDC1 3 ) 1.63, 1.7-2.2, 2.9-4.1, 6.78, 7.06, 7.21, 7.46, 7.98 δ. EXAMPLE 323 4,5-Dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylic acid (I) Totert-butyI4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaIine-3-carboxylate (I, EXAMPLE 217, 2.97 g) are added 20 ml of a solution of trifluoroacetic acid and dichloromethane (1/1). After stirring for 3.5 hr an additional 2 ml of the trifluoroacetic acid/dichloromediane solution are added, followed an hour later by another 2 ml and 30 min later with a final 2 ml of die trifluoroacetic acid/ dichloromediane solution. The reaction is stirred 2 additional hours and dien concentrated under reduced pressure. Dichloromediane is added to the residue and the mixture is again concentrated to give die tide compound, which is crystallized from methanol/dichloromethane, mp 197-200°; MS (m/z) at 312; NMR (DMSO-d6) 1.72, 3.15, 4.86, 7.18-7.22, 7.33, 7.90, 8.70 δ. EXAMPLE 324 Phenyl4,5-Dihydro-5-[φyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline-3- carboxylate (I) To a mixture of 4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylic acid (I, EXAMPLE 323, 0.543 g), 0.245 g of phenol, 0.48 ml of triethylamine, and 6 ml of dichloromethane are added 0.42 ml of diethyl cyanophosphonate. After stirring for 1 hr an additional 0.11 g of phenol are added. When die reaction had stirred anodier 2.5 hr an additional 0.11 g of phenol and 0.26 ml of diethyl cyanophosphonate are added. The reaction is stored overnight in the refrigerator and then stirred widi 1 ml of aqueous sodium bicarbonate for about 30 min. The mature is then partitioned between dichloromediane and aqueous sodium bicarbonate. The organic layers are dried over sodium sulfate, concentrated, and die residue chromatographed on silica gel (300 ml) eluting with medianol/memylene chloride (2/98), the appropriate fractions are pooled and concentrated to give die tide compound, which is crystallized from dichloromethane/hexane, mp 196.5-199°; MS (m/z) at 388; IR (mineral oil) 1648, 1199, 1723, 1502, 1410 cm "1 ; X H NMR (CDC1 3 ) 1.81, 3.31, 5.09, 7.15-7.33, 7.42, 7.55, 8.11 δ, EXAMPLE 325 N-(Cyanomethyl)-4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxamide (I) To a mixture of 4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylic acid (I, EXAMPLE 323, 0.203 g), 0.060 g of aminoacetonitrile hydrochloride, and 3 ml of dichloromethane are added 0.23 ml of triethylamine and 0.15 ml of ethyl cyanophosphonate. A slight exotherm ensued. After about 45 min a precipitate formed and an additional 5 ml of dichloromethane are added. When the reaction had stirred for a total of 70 min it is partitioned between dichloromediane and aqueous sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The crude product is chromatographed on silica gel (125 ml) eluting with methanol/methylene chloride (2/98), die appropriate fractions are pooled and concentrated to give die tide compound, mp 241-242.5°; MS (m/z) at 350; IR (mineral oil) 1641, 1506, 1658, 1409, 1417, 2237 (weak) cm "1 ; NMR (CDC1 3 ) 1.83, 3.31, 4.36, 5.06, 7.12-7.30, 7.40, 7.49, 7.94 δ. EXAMPLE 326 4,5-Dihydro-3-(oxazolin-2-yl)-5-[(pyrrolidino)carbonyl]imidazo[l ,5- a . quinoxaline (I) To a mixture of 4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylic acid (I, EXAMPLE 322, 1.03 g) and 25 ml of dichloromethane cooled at 0° in an ice badi are added 1.15 ml of triediylamine and 0.650 ml) of ediyl cyanophosphonate, followed immediately by 0.811 g of 2-bromoethylamine hydrobromide. The ice bath is dien removed and the reaction is stirred for 40 min. Aqueous sodium bicarbonate is then added. The mixture is stirred for 10 min and then partitioned widi dichloromethane. The organic layers are dried over sodium sulfate and concentrated. The resulting mixture is stirred in 20 ml of THF and 3.3 ml of 1M potassium tert-butoxide is added dropwise over 2-3 min and die reaction is stirred an additional 10 min, at which time the reaction mixture is partitioned between ethyl acetate, water, and saline. The organic layers are dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel (300 ml) eluting with methanol/methylene chloride (4/96), die appropriate fractions are pooled and concentrated to give die tide compound, mp 217-220°; MS (m/z) at 337; IR (mineral oil) 1651, 1512, 1416, 1357, 1396 cm "1 ; NMR (CDC1 3 ) 1.81, 3.27, 4.05, 4.42, 4.99, 7.11-7.18, 7.26, 7.51, 8.03 δ. EXAMPLES 327-330 Following the general procedure of EXAMPLES 89-93, 100, 102, 104-107, 149-173 and making non-critical variations, the tide compoudns are obtained EXAMPLE 327 4,5-Dihydro-3-(hydroxymed yl)imidazo[ 1 ,5-a]quinoxaline (I) mp 190-2° EXAMPLE 328 4,5-Dihydro-3-(benzoylmemyl)-5-(benzoyl)imida_o[l,5-a]quinoxaline (I) EXAMPLE 329 4,5-Dihydro-3-(benzoylmedιyI)-5-(pyrrolidinyl)carbonyl]imidazo[l,5- ajquinoxaline (I) mp 161° EXAMPLE 330 4,5-Dihydro-3-(isopropyloxymemyl)-5-(pyrrolidinyl)carbonyl]imidazo[l ,5- ajquinoxaline (I) mp 104-105° EXAMPLES 331-332 Following the general procedure of EXAMPLES 48-87 (and die EXAMPLES referenced therein) and making non-critical variations, the title compounds are obtained: EXAMPLE 331 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-medιyl- 5[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline (I) mp 242-3° EXAMPLE 332 7-Fluoro-4,5-dihydro-4(R)-methyl-3-[5-(l-methylcyclopropyl-l,2,4- oxadiazol-3-yl)-5[(pyrroIidino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 243-5° EXAMPLE 333 3-[3-Cyclopropyl-l,2,4-oxadiazol-5-yl]-7-fluoro-4,5-dihydro-4- (moφholinocarbonyl)imid azo[ 1 ,5-a]quinoxaline (I) Following me general procedure of EXAMPLE 30 and making noncritical variations but using 6-fluoro-l,2,3,4-tetrahydroquinoxaIin-2-one (TV, EXAMPLE 6, 1.023 g) and 5- isocyanome__yl-3-cyclopropyl-l,2,4-oxadiazole (0.616 g) are converted to die tide compound, mp 240.5-242°; MS (m/z) 410; IR (mineral oil) 1662, 1422, 1509, 1178, 1638 cm "1 ; NMR (CDC1 3 ) 1.09, 1.17, 2.15, 3.39, 3.68, 5.03, 6.94, 7.03, 7.53, 8.08 δ. EXAMPLE 334 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-(morpholinocarbonyl)- imidazo[l,5-a]quinoxaline (I) Following the general procedure of EXAMPLE 323 and making noncritical variations 1.45 g of tert-butyl 4,5-dihydro-5-(moφholinylcarbonyl)imidazo[l,5-a]quinoxaline-3-carboxylate (I, EXAMPLE 183) is converted to 0.91 g of 4,5-dihydro-5-(moφholinocarbonyl)__αidazo[l,5- a]quinoxaline-3-carboxylic acid, mp 267-267.5°; MS m/z 328; IR 1662, 1219, 1428, 1112, 1269 cm-1; NMR (DMSO-d6) 3.2, 3.5, 4.87, 7.20-7.25, 7.33, 7.91, 8.58 δ. A mixture of 0.88 g of 4,5-dihydro-5-(moφholinocarbonyl)imidazo[l,5-a]quinoxaline-3- carboxylic acid and excess thionyl chloride is stirred at reflux for 1 hr. Excess thionyl chloride is dien removed under reduced pressure. Dichloromethane is added to die residue and dien removed under reduced pressure to remove residual diionyl chloride. The residue is dien added as a dichloromethane slurry to an ice-cooled solution of 30% ammonium hydroxide. After the addition die ice badi is removed and die reaction is stirred at 20-25° for 2.5 hr. The mixture is then partitioned between dichloromediane, water, and saline. The organic layers are dried over sodium sulfate and concentrated to give product, which after crystallization from methanol/dichloromethane/hexanegives0.52gof4,5-dihydro-5-(moφholinocarbonyl)imidazo[l,5- a]quinoxaline-3-carboxamide; mp 220-221°; MS (m/z) 327; IR (mineral oil) 1680, 1668, 1417, 1509, 1223 cm "1 ; NMR (CDC1 3 ) δ 3.36, 3.65, 5.07, 5.43, 6.94, 7.18, 7.24-7.32, 7.95. To0.40gof4,5-dihydro-5-(moφholinocarbonyl)imidazo[l,5-a]quinoxaline-3-carboxamide in 5 ml of THF is added 0.74 g of 2,4-bis(4-memoxyphenyl)-l,3-diathia-2,4-diphosphetane-2,4- disulfide. The mixture is stirred at reflux for 2 hr, then cooled and added direcdy to a silica gel column. Elution with a gradient of 100% dichloromethane to methanol/dichloromethane (8/92) gave product fractions which are combined, concentrated, and rechromatographed using medianol/dichloromediane (5/95) to give 0.293 g of 4,5-dihydro-5-(moφholinocarbonyl)imidazo- [l,5-a]quinoxaline-3-thiocarboxamide; NMR (CDCI3) δ 3.38, 3.68, 5.36, 7.12-1.30, 7.50, 7.94, 8.45. A mixture of 0.29 g of 4,5-dihydro-5-(moφholinocarbonyl)imidazo[l,5-a]quinoxaline-3- thiocarboxamide and 0.165 g of 1-bromomethyl cyclopropyl ketone in 10 ml of ethanol is stirred at 20-25° for 1 day and then at 80° for 5.5 hr, after which it stirred at 20-25° for an additional 20 hr. The mixture is then concentrated under reduced pressure and chromatographed on silica gel eluting wi methanol/dichloromediane (2/98). The product fractions are combined and rechromatogaphed using ethyl acetate/dichloromethane (25/75) to give a solid. Crystallization from dichloromethane/hexane gives e title compound; mp 193-194°; MS (m/z) 407; IR (mineral oil) 1511, 1669, 1115, 1392, 1227 cm "1 ; NMR (CDC1 3 ) 0.98, 2.09, 3.35, 3.66, 5.09, 6.79, 7.19, 7.28, 7.53, 8.01 δ. EXAMPLE 335 3-(Benzoxazol-2-yl)-4,5-dihydro-5-(morphoIinocarbonyl)imidazo[l,5- ajquinoxaline (I) Following die general procedure of EXAMPLE 30 and making noncritical variations but starting with die appropriate starting materials die tide compound is obtained, mp 288-290°; MS (m/z) 419; IR (mineral oil) 1671, 1519, 1270, 1636, 747 cm "1 ; NMR (CDC1 3 ) 3.41, 3.68, 5.21, 6.94, 7.05, 7.36, 7.55, 7.62, 7.75, 8.11 δ. EXAMPLE 336 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5- (moφholinylcarbonyl)imidazo[ 1 ,5-a]quinoxaline (I) Following the general procedure of EXAMPLE 104 and making noncritical variations but starting with die appropriate starting materials die title compound is obtained, mp 198.5-201 °; MS (m z) 410; IR (mineral oil) 1235, 1419, 1501, 1660, 1213 cm "1 ; NMR (CDC1 3 ) 1.27, 1,35, 2.27, 3.43, 3.73, 5.07, 7.09, 7.24, 7.38, 8.12 δ. EXAMPLE 337 3-tert-Butyl 5-methyl-7-fluoro-4,5-dihydroimidazo[l,5-a]quinoxaline- 3,5(4H)-dicarboxylate (I) To a mixture of 1.97 g of 6-fluoro-l,2,3,4-tetrahydroquinoxalin-2-one (EXAMPLE 6), 3.1 ml of diisopropylediylamine, and 11 ml of THF is added 1.4 ml of methyl chloroformate. The reaction is cooled with cool tap water as an exotherm ensued. After 35 min, the mixture is partitioned between ethyl acetate, aq. sodium bicarbonate, and saline. The organic layers are dried over magnesium sulfate, concentrated, and die crude product is crystallized from dichloromethane/medianol/ediyl acetate to give 2.06 g of methyl 6-fluoro-l,2,3,4-tetrahydro-4- (methoxycarbonyl)quinoxaline-2-one; mp 206.5-207.5°; NMR (CDC1 3 ) 3.86, 4.43, 6.84, 7.48, 8.67 δ. Following die general procedure of EXAMPLE 30 and making noncritical variations mediyl 6-fluoro-l,2,3,4-tetrahydro-4-(methoxycarbonyl)quinoxaline-2-one is converted to die tide compound; mp 130.5-132°; MS (m/z) 347; NMR (CDC1 3 ) 1.66, 3.87, 5.26, 7.01, 7.49, 7.62, 7.98 δ. EXAMPLE 338 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl)- moφholinocarbonyl]-7-fluoro-4,5-dihydroimidazo[l,5-a]quinoxaline (I) Following the general procedure of EXAMPLE 104 and making noncritical variations but starting with die appropriate starting materials the tide compound is obtained, mp 143-146°; MS (m/z) 438; IR (mineral oil) 1515, 1665, 1409, 1575, 1363 cm "1 ; NMR (CDC1 3 ) 1.1-1.4, 2.27, 2.8-5.4, 6.93, 7.24, 7.52, 8.08 δ. EXAMPLES 339-352 Following the general procedure of EXAMPLE 30 and making non-critical variations but starting with the appropriate starting materials, the tide componds are obtained: EXAMPLE 339 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5- (pyrτolidinoca_:bonyl)imidazo[l,5-a]quinoxaline (_) mp 231-233°; MS (m/z) at 406, 336, 308, 278, 98; IR (mineral oil) 1695, 1505, 1499, . 1493, 1473, 1402, 1385, 1186 cm "1 ; NMR (CDC1 3 ) 8.12, 7.4-7.45, 7.15-7.3, 5.14, 3.15, 2.23, 1.7-1.85, 1.50 δ. EXAMPLE 340 3-(5-tert-butyl - l ,2,4-oxadiazol-3 -yl)-4,5-dihydro-5- (piperidinocarbonyl)in_dazo[l,5-a]quinoxaIine (I) mp 209-211°; MS (m/z) at 406, 294, 112; IR (mineral oil) 3098, 1645, 1558, 1516, 1431, 1286, 1274, 745 cm" 1 ; NMR (CDCU,) δ 8.12, 7.55, 7.1-7.3, 5.01, 3.2-.35, 1.45-1.7, 1.50. EXAMPLE 341 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yI)-5-(3-fluorobenzoyl)-4,5- dihydroimidazo[l,5-a]quinoxaline (D mp 164-165°; MS (m/z) at 417, 360, 294, 123, 95; IR (mineral oil) 1660, 1498, 1408, 1376, 748; NMR (CDC1 3 ) δ 8.21, 7.62, 7.25-7.4, 7.0-7.25, 5.40, 1.46. EXAMPLE 342 Methyl 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline-5-carboxylate (I) mp 154-155°; MS (m/z) at 353, 294,268, 209, 195; IR (mineral oil) 1711, 1514, 1503, 1471, 1442, 1402, 1372, 1303, 1293, 1257, 1221, 765, 756 cm "1 ; NMR (CDCl 3 ) δ 8.13, 7.7- 7.85, 7.5-7.6, 7.2-7.4, 5.30, 3.84, 1.52. EXAMPLE 343 Methyl 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-7-chloro-4,5- dihydroimidazo[l,5-a]quinoxaline-5-carboxylate (D mp 175-176.5°; MS (m/z) at 387, 328, 302, 243, 229; IR (mineral oil) 3094, 1719, 1559, 1511, 1449, 1441, 1379, 1365, 1344, 1305, 1288, 1251, 1218, 1203, 819 cm "1 ; NMR (CDC1 3 ) 8.10, 7.86, 7.49, 7.207.3, 5.30, 3.86, 1.51 δ. EXAMPLE 344 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-5-benzoyl-4,5-dihydroimidazo[l,5- ajquinoxaline (D mp 202.5-204°; MS (m/z) at 433, 376, 105, 77; IR (mineral oil) 1661, 1364, 1237, 812 cm" 1 ; NMR (CDC1 3 ) δ 8.17, 7.35-7.6, 7.15-7.3, 5.38, 1.43. EXAMPLE 345 Methyl 3-(5-tert-butyl- l ,2,4-oxadiazol-3-yl)-7-chloro-4,4- dimethylimidazo[l ,5-a]quinoxaline-5-carboxylate (I) mp 63-67°; MS (m/z) at 415, 400, 316, 257; IR (mineral oil) 1724, 1511, 1443, 1331, 1282, 1253, 1248, 1184 cm "1 ; NMR (CDC1 3 ) δ 8.08, 7.42, 7.37, 7.26, 3.72, 1.51. EXAMPLE 346 3-(5-tert-butyl-l,2,4-oxadiazoI-3-yl)-7-chloro-4,4-dimethyl-5-(4- moφholinylcarbonyl)imidazo[ 1 ,5-a]quinoxaline (I) mp 219-220°; MS (m/z) at 470, 455, 114; IR (mineral oil) 1650, 1519, 1512, 1416, 1243, 1122 cm "1 ; NMR (CDC1 3 ) δ 8.09, 7.44, 7.05, 6.80, 3.0-4.1, 1.6-2.1, 1.51. EXAMPLE 347 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,4-dimethyl-5-(4- moφholinylcarbonyl)imidazo[l,5-a]quinoxaIine (I) mp 132-136°; MS (m/z) at 470, 455, 114; IR (mineral oil) 1652, 1498, 1414, 1272, 1230 1117 cm "1 ; NMR (CDC1 3 ) δ 8.13, 7.46, 7.33, 7.17, 3.4-3.6, 3.28, 1.87, 1.51. EXAMPLE 348 3 - (3 -tert-butyl - 1 , 2 , 4-ox ad iazol -5-yl ) -4 , 5-dih yd ro -5- (pyrrolidinocarbonyl)imidazo[l,5-a]quinoxaline (I) mp 207.5-208.5°; MS (m z) at 350, 308, 293, 267, 252, 212; IR (mineral oil) 2961, 1925, 1657, 1508, 1466, 1392, 1343, 1307, 1304; NMR (CDC1 3 ) δ 8.06, 7.52, 7.1-7.3, 6.53, 5.04, 3.2- 3.4, 1.75-1.85, 1.38. EXAMPLE 349 3-(5-tert-butyl- l ,2 ,4-oxad iazol-3-yl)-4,5-dihydro-5-(4- nitro ber__oyl)iπ_idazo[ 1 ,5-a]quinoxaline (I) mp 243-245°; MS (m/z) at 444, 387, 294, 150; IR (mineral oil) 1662, 1551, 1528, 1508, 1344, 1278, 767 cm "1 ; NMR (CDC1 3 ) δ 8.24, 8.20, 7.65, 7.59, 7.0-7.2, 5.42, 1.45. EXAMPLE 350 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yl)-5-(4-fluorobenzoyl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 182-183°; MS (m/z) at 417, 360, 294, 123; IR (mineral oil) 1657, 1505, 1240, 1191, 1154, 752; NMR (CDC1 3 ) δ 8.21, 7.61, 7.4-7.5, 7.25-7.35, 6.95-7.15, 5.41, 1.47. EXAMPLE 351 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yl)-5-(3-chlorobenzoyI)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 209-211°; MS (m/z) at 433, 376, 294, 139; IR (mineral oil) 1670, 1500, 1343, 1243 cm "1 ; NMR (CDC1 3 ) δ 8.22, 7.2-7.35, 7.05-7.2, 5.39, 1.46. EXAMPLE 352 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yl)-5-(2-fluorobenzoyl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 213.5-214.5°; MS (m z) at 417, 360, 294, 123; IR (mineral oil) 1660, 1512, 1501, 1493, 1398, 1285, 1210, 766 cm "1 ; NMR (CDC1 3 ) δ 8.19, 7.60, 6.7-7.55, 5.0-5.7, 1.44. EXAMPLE 353 4,5-Dihydro-5-dimemyl___ιino-_ 4-me_hylphenyl)imidazo[l,5-a]quinoxaIine (I) Following the general procedure of EXAMPLE 248 and making noncritical variations but starting widi the appropriate starting materials the title compound is obtained, mp 204-205°; IR (mineral oil) 2925, 1653, 1507, 1393, 1271, 752 cm "1 ; NMR (CDC1 3 ) δ 8.07, 7.5-7.6, 7.05-7.3, 4.86, 2.82, 2.39; MS (m/z) at 332, 260, 72. EXAMPLE 354 3-(4-Fluorophenyl)-4,5-dihydro-5-(4-moφholinocarbonyl)imidazo[l ,5- a]quinoxaline (D Following the general procedure of EXAMPLE 248 and making noncritical variations but starting with the appropriate starting materials the title compound is obtained, mp 193-194°; MS (m/z) at 378, 264, 114; IR (mineral oil) 1660, 1506, 1423, 1272, 1265, 755 cm "1 ; NMR (CDC1 3 ) δ 8.08, 7.55-7.7, 7.55, 7.1-7.3; 4.87, 3.55-3.65, 3.2-3.35. EXAMPLE 355 3-(4-FluorophenyI)-5-(3-fluorobenzoyI)-4,5-dihydroimidazo[l,5- a]quinoxaline (I) Following die general procedure of EXAMPLE 107 and making noncritical variations but starting with the appropriate starting materials the tide compound is obtained, mp 176-177°; MS (m/z) at 387, 264, 123, 95; IR (mineral oil) 1663, 1588, 1507, 1445, 1369, 1345, 1283, 1274, 1210, 844, 750 cm "1 ; NMR (CDC1 3 ) δ 8.18, 7.55-7.75, 7.0-7.35, 7.01, 6.75-6.9, 5.25. EXAMPLE 356 Methyl 3-(4-Fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxaIine-5- carboxylate Q) Following the general procedure of EXAMPLE 250 and making noncritical variations but starting with die appropriate starting materials the tide compound is obtained, mp 156-160°; MS (m/z) at 323, 308, 264, 236; IR (mineral oil) 1709, 1505, 1438, 1368, 1223 cm "1 ; NMR (CDC1 3 ) δ 8.07, 7.6-7.8, 7.65, 7.5-7.6, 7.25-7.35, 7.16, 5.11, 3.81. EXAMPLE 357 5-(tert-Butylaminocarbonyl)-3-(4-fluorophenyl)-4,5-dihydroimidazo[l ,5- ajquinoxaline Q Following the general procedure of EXAMPLE 250 and making noncritical variations but starting with die appropriate starting materials the tide compound is obtained, mp 241-243.5°; MS (m/z) at 364, 264; IR (mineral oil) 1673, 1532, 1506, 1223, 749 cm "1 ; NMR (CDCl 3 ) δ 8.08, 7.55-7.75, 7.45-7.55, 7.25-7.35, 7.13, 5.07, 4.99, 1.33. EXAMPLE 358 3-(4-Fluorophenyl)-4,5-dihydro-5-(4-trifluoromethylbenzoyl)imidazo[l ,5- ajquinoxaline (I) Following me general procedure of EXAMPLE 107 and making noncritical variations but starting widi die appropriate starting materials the tide compound is obtained, mp 211-212°; MS (m z) at 437, 264, 173, 145; IR (mineral oil) 1673, 1505, 1397, 1329, 1172, 1149, 1112, 837, 759; NMR (CDC1 3 ) δ 8.20, 7.4-7.75, 7.2-7.35, 7.16, 7.01, 6.65-6.85, 5.27. EXAMPLE 359 5-(Aminocarbonyl)-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) Following the general procedure of EXAMPLE 248 and making noncritical variations but starting widi the appropriate starting materials me title compound is obtained, mp 222-223°; IR (mineral oil) 3120, 1673, 1506, 1415, 1405, 1227 cm "1 ; MS (m z) at 308, 264; NMR (CDC1 3 ) δ 8.13, 7.55-7.7, 7.3-7.45, 7.15, 5.33, 5.11. EXAMPLE 360 5-(Ethylaminocarbonyl)-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) Following die general procedure of EXAMPLE 248 and making noncritical variations but starting widi die appropriate starting materials the tide compound is obtained, mp 196-200°; IR (mineral oil) 1670, 1550, 1507, 1225, 759; NMR (CDC1 3 ) δ 8.08, 7.5-7.75, 7.25-7.4, 7.13, 5.12, 4.95-5.1, 3.2-3.35, 1.12; MS (m/z) at 336, 264. EXAMPLE 361 Isopropyl 3-(4-Fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxaIine-5- carboxylate (I) Following die general procedure of EXAMPLE 248 and making noncritical variations but starting with the appropriate starting materials the title compound is obtained, mp 160-160.5°; MS (m/z) at 351, 308, 264, 236; IR (mineral oil) 1701, 1506, 1403, 1284, 1225, 753; NMR (CDCy δ 8.07, 7.5-7.75, 7.2-7.35, 7.15, 5.10, 4.9-5.1, 1.29. EXAMPLE 362 3-(4-Fluorophenyl)-5-(4-fluorobenzoyl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) Following die general procedure of EXAMPLE 107 and making noncritical variations but starting wim the appropriate starting materials the title compound is obtained, mp 230-231°; IR (mineral oil) 1647, 1600, 1506, 1367, 1232, 1222, 846, 753 cm "1 ; MS (m/z) at 387, 264, 123, 95; NMR (CDC1 3 ) δ 8.17, 7.55-7.75, 7.35-7.45, 7.1-7.3, 6.9, 7.05, 6.78, 5.25. EXAMPLE 363 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b-hexahydro-7H- imidazo[5, l-f]-7-oxa-4a, 10b-diazaphenalen-5-one (I) A mixture of 2-amino-3-nitrophenol (LVI, 1.00 g, 6.49 mmol), diisopropylethylamine (1.60 ml, 9.19 mmol), and ediyl bromoacetate (2.00 ml, 18.0 mmol) is heated at reflux for 5.5 hr. The resultant solution is allowed to cool to 20-25°. Aqueous workup (chloroform and magnesium sulfate) and purification by flash chromatography, eluting widi hexane/ediyl acetate (3/1), pooling and concentration of die appropriate fractions gives a mixture. The crude material was combined widi edianol (75 ml) and a solution of sodium emoxide (20.0 ml of ethanol and 69 mg of sodium). The mixture is heated at reflux for 72 hr. Potassium carbonate (57.0 mg, 0.41 mmol) is added after 24 hr. After cooling to 20-25°, concentration, and aqueous workup (chloroform and magnesium sulfate) die cyclized amide (LVII) is obtained and is recrystallized from ethyl acetate/hexane, mp 82-85°; IR (mineral oil) 3293, 2954, 2925, 2855, 1731, 1538, 1532, 1490, 1344, 1302, 1249, 1180, 735 cm "1 ; NMR (300 MHz, CDC1 3 ) 10.07, 7.94, 7.32, 7.09, 4.71; MS (El) m/e 194. A mixture of die cyclized amide (LVII, 533 mg, 2.75 mmol), 10% Palladium on carbon (175 mg), and edianol (75 ml) is hydrogenated (48 psi) at 20-25° for 16 hr. The mixture is filtered, the residue washed with edianol several times, and the combined filtrates concentrated to provide an amino cyclic amide, mp 213-215°; IR (mineral oύ ' ) 3448, 3350, 3217, 2954, 2925, 1698, 1687, 1650, 1614, 1451, 1412, 723 cm "1 ; NMR (300 MHz, CDC1 3 ) 6.80, 6.44, 4.54; MS (El) m/e 164, 135. Chloroacetyl chloride (0.28 ml, 3.5 mmol) was added to a partial solution of the amino cyclic amide (514 mg, 3.13 mmol), THF (40.0 ml), and diisopropylediylamine (1.36 ml, 7.81 mmol) at 0°. The mature is stirred for 1 hr at 0° and for 16 hr at 20-25°. Basic workup (ediyl acetate, sodium bicarbonate and magnesium sulfate) gives a 1/1 mixture of the intermediate chloride and bis-amide sufficientiy pure to be carried on crude. Spectral features for the chloride are NMR (300 MHz, dg-acetone) 6.8-7.1, 4.54 and 4.35. Potassium tert-butoxide (7.14 ml, 7.14 mmol, 1.0 M in THF) is added to a mixture of the intermediate chloride and bis-amide (1.70 g, ca 8.6 mmol), and THF (120 ml) at 0°. The mixture is stirred for 1 hr at 0° and for 16 hr at 20-25°. Aqueous workup (ethyl acetate, magnesium sulfate) and trituration of the residue several times with ethyl acetate provides die bis-amide, homogeneous by TLC analysis, mp 285-287°; IR (mineral oil) 2953, 2924, 1691, 1674, 1616, 1506, 1400, 1390, 1240 cm "1 ; NMR (300 MHz, dg-acetone) 9.77, 6.95, 6.71, 6.66, 4.66 and 4.43; MS (El) m/e 204, 175 and 147. Potassium tert-butoxide (2.50 ml, 2.50 mmol, 1.0 M in THF) is added to a mixture of me bis-amide (467 mg, 2.29 mmol), THF (4.0 ml), and DMF (4.0 ml) at 0°. The mixture is allowed to warm to 20-25° and is stirred for 30 min. After cooling to -20°, diediyl chlorophosphate (0.430 ml, 2.98 mmol) was added and die mixture is allowed to warm to 20-25°. The resultant solution is stirred at 20-25° for 40 min and was dien cooled to -78°. A solution of the isocyanide (372 mg, 2.49 mmol) and THF (0.80 ml) is added. Potassium tert-butoxide (2.50 ml, 2.50 mmol) is then added dropwise over several minutes to form a mixture. This misture is stirred at -78° for 30 min, and was allowed to warm to 20-25° over 1.5 hr. After stirring for an additional 3 hr at 20-25°, die reaction is quenched with aqueous ammonium chloride. Aqueous workup (ethyl acetate and then chloroform and magnesium sulfate) and purification by flash chromatography, eluting with chloroform acetone (10/1), pooling and concentrating die appropriate fractions gives the tide compound which is purified by recrystallization from methanol/ether, mp 267-268°; IR (mineral oil) 2954, 2924, 2855, 1689, 1519, 1507, 1424, 1415, 1402, 1207 cm "1 ; NMR (300 MHz, CDC1 3 ) 8.24, 7.28, 7.12, 6.95, 5.40, 4.71, 2.15-2.35, 1.2-1.4. EXAMPLE 364 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b-hexahydro-7H- imidazo[5, l-f]-6-oxa-4a, 10b-diazaphenalen-5-one (D A solution of 2-chloro-3-nitrobenzoic acid (5.00 g, 24.8 mmol), ammonium hydroxide (25.0 ml) and copper (1) chloride (50 mg) is heated in a bomb at 125° for 20 hr and is then allowed to cool to 20-25°. The solid residue is dissolved in water and the solution acidified widi 3 N hydrochloric acid. The resultant mixture is filtered, washed, and dried to provide the 2-amino- 3-nitrobenzoic acid, mp 201-203; IR (mineral oil) 3478, 3345, 2954, 2925, 2855, 1692, 1677, 1571, 1559, 1520, 1512, 1442, 1271, 1259, 1130 cm "1 ; NMR (300 MHz, CDCl 3 -MeOD) 8.38, 8.30, 6.66; MS (El) m e 182, 164. Borane-mediyl sulfide complex (1.20 ml, 12.0 mmol, 10.0 M) is added to a mixture of the 2-amino-3 -nitrobenzoic acid (1.05 g, 5.76 mmol), and THF (17.4 ml). The mixture is stirred for 3 hr at 20-25° and 16 hr at reflux. After cooling to 20-25°, the mixture is quenched with 10% hydrochloric acid. Basic workup (methylene chloride, sodium bicarbonate and magnesium sulfate) gives the 2-amino-3-nitrobenzyl alcohol (LI), mp 100-101°; IR (mineral oil) 3488, 3466, 3365, 3346, 2953, 2925, 1641, 1515, 1428, 1250, 1015, 745 cm "1 ; NMR (300 MHz, CDC1 3 ) 8.13, 7.30, 6.85, 6.65), 4.78; MS (El) m/e 168, 150. A solution of me 2-amino-3-nitrobenzyl alcohol (LI, 1.70 g, 10.1 mmol), THF (86.0 ml) and l, -carbonyldiimidazole (1.81 g, 11.2 mmol) is heated at reflux for 48 hr. After cooling to 20-25°, aqueous workup (methylene chloride and magnesium sulfate) provides the cyclic amide (LII) as a solid. Recrystallization from ethyl acetate/hexane (2 lots) gives die cyclic amide (LU), mp 181-182.5°; IR (mineral oil) 3314, 2925, 1779, 1765, 1619, 1530, 1466, 1351, 1243, 1228, 1061, 765, 736 cm "1 ; NMR (300 MHz, CDC1 3 ) 9.68, 8.22, 7.46, 7.19, 5.37; MS (JET) m/e 194, 150. A mixture of the cyclic amide (LII, 195 mg, 1.00 mmol), ethanol (20.0 ml), and 10% Palladium on carbon is hydrogenated (44 psi) at 20-25°. The mixture is filtered, die residue washed wid ethanol, medianol, and memylene chloride and d e combined filtrates concentrated to provide the amino cyclic amide (LIII), mp 198-200; IR (mineral oil) 3465, 2953, 2925, 1713, 1697, 1633, 1414, 1289, 1048 cm "1 ; NMR (300 MHz, CDC1 3 ) 9.13, 6.89, 6.72, 6.57, 5.29; MS (El) m e 164, 120, 105, 93. Chloroacetyl chloride (0.39 ml, 4.9 mmol) is added to a solution of he amino cyclic amide (LIII, 708 mg, 4.31 mmol), diisopropylethylamine (1.71 ml, 9.82 mmol), and THF (50.0 ml) at 0°. The mixture is stirred at 0° for 1 hr and 16 hr at 20-25°. The mixture is filtered and the solids washed several times with water and ethyl acetate to give the chloride intermediate. Aqueous workup (ethyl acetate, magnesium sulfate) of the filtrate provides additional intermediate chloride, mp 255-257; IR (mineral oil) 2954, 2924, 2855, 1715, 1704, 1679, 1555, 1475, 1459, 1267, 1062, 780 cm "1 ; NMR (300 MHz, dg-DMSO) 9.69, 7.27, 7.10, 7.02, 5.29, 4.29; MS (El) m/e 240, 191, 147. Potassium tert-butoxide (3.50 ml, 3.50 mmol, 1.0 M in THF) is added to a mixture of the intermediate chloride (822 mg, 3.42 mmol) and THF (70.0 ml) at 0°. The mixture is stirred for 1 hr at 0° and 16 hr at 20-25°. The mixture is men quenched widi aqueous ammonium chloride. Aqueous workup (ediyl acetate, magnesium sulfate) and trituration of die resultant solid with edier provides the bis-amide (LIV), mp 255-256°; IR (mineral oil) 2954, 2924, 1705, 1630, 1504, 1410, 1271 cm "1 ; NMR (300 MHz, dg-acetone) 9.80, 7.05, 6.98, 6.92, 5.32, 4.48; MS (El) m/e 204, 160, 131. Potassium tert-butoxide (2.30 ml, 2.30 mmol, 1.0 M in THF) is added to a mixture of the bis-amide (LIV, 425 mg, 2.08 mmol), THF (2.10 ml), and DMF (1.30 ml) at 0°. The resultant mixture is allowed to warm to 20-25° and is stirred for 30 min. After cooling to -20°, diediyl chlorophosphate (0.39 ml, 2.7 mmol) is added and die mixture allowed to warm to 20-25°. THF (4.0 ml) and DMF (1.0 ml) are added to die mixture to form a solution which is stirred at 20-25° for 45 min. After cooling to -78° a solution of the isocyanide (339 mg, 2.27 mmol) and THF (0.80 ml) is added followed by dropwise addition of potassium tert-butoxide (2.30 ml, 2.30 mmol) over 5 min. The mixture is stirred at -78° for 30 min and is allowed to warm to 20-25° over 2 hr. After stirring at 20-25° for an additional 2 hr die mixture is quenched with aqueous ammonium chloride. Aqueous workup (ethyl acetate, magnesium sulfate) and purification by flash chromatography eluting with ethyl acetate gives the tide compound. An analytical sample is prepared by recrystallization from ediyl acetate, mp 235-237°; ER (mineral oil) 2954, 2924, 2855, 1710, 1574, 1510, 1456, 1419, 1399, 1377, 1293, 1201, 725 cm "1 ; NMR (300 MHz, CDC 8.32, 7.58, 7.22, 7.09, 5.48, 5.34, 2.2-2.4, 1.2-1.4; MS (El) m e 335, 291, 266, 222, 207; Anal. Calcd for C 1 7H 13 N 5 O3-(C 4 H 8 O 2 ) 1/ 2-CH 2 O) 1 4 : C, 59.45; H, 4.60; N, 18.24; found: C, 59.54; H, 4.22; N, 18.49. EXAMPLE 365 3-(5-Cycloproρyl-l,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b _ιexahydro-7H-6- (l-methylethyl)imidazo[5, l-f]-4a,6, 10b-triazaphenalen-5-one (I) A solution of methanesulfonyl chloride (69.0 mg, 0.602 mmol) and THF (0.50 ml) is added to a solution of 2-amino-3-nitrobenzyl alcohol (100 mg, 0.595 mmol), diisopropylethylamine (0.12 ml, 0.69 mmol), and THF (4.0 ml) at 0°. After 2.5 hr at 0°, isopropylamine (0.51 ml, 6.0 mmol) is added. The solution is stirred for an additional hour at 0° and is allowed to warm to 20- 25°. After 24.hr, basic workup (ediyl acetate, saodium bicarbonate and magnesium sulfate) and purification by flash chromatography eluting with hexane/ediyl acetate (2/1), pooling and concentrating the appropriate fractions gives nitro compound (LI), IR (neat) 3451, 3230, 2966, 1622, 1576, 1518, 1453, 1440, 1355, 1333, 1257, 743 cm '1 ; NMR (300 MHz, CDC1 3 ) 8.07, 7.72, 7.23, 6.57, 3.90, 2.7-2.9, 1.12; MS (El) m e 209, 192, 162, 151. A solution of the nitro compound (LI, 780 mg, 3.73 mmol), toluene (33.0 ml), and 1,1'- carbonyldiimidazole (CDI, 589 mg, 3.63 mmol) is heated at reflux for 6 days. After 2 days additional CDI (300 mg, 1.85 mmol) is added. After coolingto 20-25°, concentration and aqueous workup (methylene chloride and magnesium sulfate) gives a solid which is a mixture of the desired product and starting material. Resubmission of the crude to die above reaction conditions (1.19 g of CDI, 6 days at reflux) provides (after workup as described above) cyclic amide (LII) as a solid, homogeneous by TLC analysis, IR (mineral oil) 3400, 2962, 2925, 1693, 1683, 1620, 1593, 1530, 1471, 1454, 1342, 1265, 1204 cm "1 ; NMR (300 MHz, CDC1 3 ) 9.33, 8.14, 7.39, 7.02, 4.7- 4.9, 4.38, 1.24; MS (El) m/e 235, 220, 192, 177. A mixture of die cyclic amide (LII, 842 mg, 3.58 mmol), ethanol (66.0 ml) and 10% palladium on carbon (132 mg) is hydrogenated (38 psi) at 20-25° for 16 hr. The mixture is filtered, and the residue washed with edianol, chloroform and medianol successively. The combined filtrates are concentrated to provide amino cyclic amide (LIII), mp 148-150°; IR (mineral oil) 3370, 2954, 2925, 2855, 1676, 1631, 1506, 1455, 1447, 1295 cm "1 ; MS (El) m/e 205, 190, 162, 147, 120. Chloroacetyl chloride (0.29 ml, 3.6 mmol) is added to a solution of amino cyhclic amide (LIII, 660 mg, 3.21 mmol), THF (37.0 ml), and diisopropylethylamine (1.28 ml, 7.35 mmol) at 0°. The solution is allowed to stir for 1 hr at 0° and for 16 hr at 20-25°. Aqueous workup (ethyl acetate, magnesium sulfate) of die mixture provides a solid which is purified by flash chromatography eluting with ethyl acetate/hexane (2/1) to give die chloro intermediate, mp 173- 174°; IR (mineral oil) 3329, 2954, 2925, 2855, 1702, 1663, 1552, 1472, 1459, 1453, 754 cm *1 ; MS (El) m/e 281, 266, 223, 147. Potassium tert-butoxide (2.35 ml, 2.35 mmol, 1.0 M in THF) is added to a solution of the chloro intermediate (644 mg, 2.29 mmol) and THF (47.0 ml) at 0°. The solution is stirred for 1 hr at 0° and for 16 hr at 20-25°. After quenching with aqueous ammonium chloride, aqueous workup (ethyl acetate, magnesium sulfate), and trituration of the residue widi ediyl acetate/edier provides the bis-amide (LIV), mp 244-247°; IR (mineral oil) 2954, 2924, 2855, 1681, 1637, 1617, 1505, 1447, 1409, 786 cm" 1 ; MS (El) m/e 245, 230, 202, 160, 131. Potassium tert-butoxide (1.80 ml, 1.80 mmol, 1.0 M in THF) is added to a solution of the bis-amide (LIV, 400 mg, 1.63 mmol), THF (2.50 ml), and DMF (0.33 ml) at 0°. The mixture is allowed to warm to 20-25° and is stirred for 30 min. After cooling to -20°, diethyl chlorophosphate (0.31 ml, 2.15 mmol) is added and mixture is allowed to warm to 20-25°. After stirring for 45 min at 20-25°, the resultant solution is cooled to -78°. A solution of die isocyanide (266 mg, 1.78 mmol) and THF (0.60 ml) is added followed by the addition of potassium tert- butoxide (1.80 ml, 1.80 mmol) dropwise over several min. The mixture is stirred for 1.5 hr at - 78°, and is allowed to warm to 20-25° over 1.5 hr. After stirring at 20-25° for 1.5 hr the mixture is quenched widi aqueous ammonium chloride. Aqueous workup (ethyl acetate and dien chloroform, magnesium sulfate), purification by flash chromatography eluting with ethyl acetate, pooling and concentration of the appropriate fractions, and trituration of the isolated material widi ether gives the tide compound, mp 191-193°; IR (mineral oil) 2955, 2927, 2855, 1652, 1572, 1511, 1466, 1458, 1446, 1396, 1384, 1378, 1294, 1215, 1035 cm "1 ; NMR (300 MHz, CDC1 3 ) 8.10, 7.43, 6.95-7.10, 5.43, 4.7-4.85, 4.35, 2.2-2.35, 1.1-1.4, 1.24; MS (El) m/e 376, 307, 222, 207; Anal. Calcd for C, 62.65; H, 5.00; N, 21.92, found: C, 62.55; H, 5.42; N, 21.70. EXAMPLE 366 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yI)-3a,4,4a,5,6, 10b-hexahydro-7H-6- methylimidazo[5,l-f]-4a,6,10b-tri___aphenalen-5-one (I) Methanesulfonyl chloride (0.36 ml, 4.7 mmol) is added to a solution of die 2 -amino-3- nitrobanzyl alcohol (783 mg, 4.66 mmol), THF (31.0 ml), and diisopropylediylamine (0.94 ml, 5.4 mmol) at 0°. The mixture is stirred at 0° for 4 hr. Aqueous memylamine (40%, 4.0 ml, 46 mmol) is added and die misture stirred for an additional hour at 0° and for 24 hr at 20-25. Acidic workup (ether, methylene chloride, magnesium sulfate) provides the nitro compound (LI), homogeneous by TLC analysis, IR (neat) 3449, 2847, 1621, 1575, 1516, 1451, 1350, 1331, 1254, 743 cm" 1 ; NMR (300 MHz, CDC1 3 ) 8.08, 7.67, 7.23, 6.58, 3.87, 2.42, 1.2-1.5; MS (ED m/e 181, 164, 134, 105. A solution of the nitro compound (LI, 1.74 g, 9.60 mmol), THF (75.0 ml), and CDI (2.33 g, 14.4 mmol) is heated at reflux for 6 days. After 3 days additional CDI (1.16 g, 7.15 mmol) is added. After cooling to 20-25°, the mixture is diluted with ediyl acetate and die organic layer is washed widi water, 5% hydrochloric acid, sodium bicarbonate, and saline. The organic layer is dried (magnesium sulfate), filtered and concentrated. Recrystallization of the residue from ethyl acetate/hexane gives the cyclic amide (LU), mp 155-157°. The filtrate is concentrated and purified by flash chromatography (ethyl acetate) to provide an additional product, IR (mineral oil) 3396, 2954, 2925, 2855, 1700, 1620, 1591, 1529, 1483, 1464, 1339, 1271, 1233, 1216, 753, 747 caf 1 ; MS (ED m/e 207, 160. A mixture of the cyclic amide (LII, 1.38 g, 6.66 mmol), 10% palladium on carbon (250 mg), and edianol (132 ml) is hydrogenated (50 psi) at 20-25° in a Parr flask. After 16 hr, the mixture is filtered and die remaining solids washed widi edianol, chloroform and methanol. The combined filtrates are concentrated. Trituration (edier) of die crude provides die amino cyclic amide (LIU), mp 229-231°; IR (mineral oil) 3298, 2953, 2925, 2855, 1677, 1515, 1443, 1406, 1299, 1278 cm "1 . Chloroacetyl chloride (0.54 ml, 6.8 mmol) is added to a mixture of die cyclic amide (LIII, 1.07 g, 6.04 mmol), THF (70 ml), and diisopropylethylamine (2.40 ml, 13.8 mmol) at 0°. The solution is stirred for 1 hr at 0° and for 16 hr at 20-25°. Aqueous workup (ethyl acetate, magnesium sulfate) and trituration with ediyl acetate gives the chloro intermediate, mp 197-199°. The filtrate is concentrated and die residue purified by flash chromatography eluting widi ediyl acetate to provide additional chloro intermediate, IR (mineral oil) 3256, 2954, 2925, 2855, 1701, 1648, 1527, 1458, 1270 cm "1 ; MS (El) m e 253, 204, 176, 147. Potassium tert-butoxide (4.8 ml, 4.8 mmol, 1.0 M in THF) is added to a mixture of the chloro intermediate (1.19 g, 4.69 mmol) and THF (96 ml) at 0°. The mixture is stirred for 1 hr at 0°, 16 hr at 20-25°, and is then quenched widi aqueous ammonium chloride. Aqueous workup (ethyl acetate, chloroform/methanol, magnesium sulfate) and trituration of the residue widi ediyl acetate gives the bis-amide (LIV), mp 238-241°. The filtrate is concentrated and after trituration widi ethyl acetate provides additional bis-amide (LIV), IR (mineral oil) 3359, 2954, 2925, 1693, 1649, 1505, 1448, 1268 cm "1 ; NMR (300 MHz, CDCl 3 -MeOD) 6.94, 6.76, 4.52, 4.46, 3.04. Potassium tert-butoxide (1.90 ml, 1.90 mmol, 1.0 M in THF ) is added to a mixture of the bis-amide (LIV, 380 mg, 1.75 mmol), and DMF (8.0 ml) at 0°. The mixture is allowed to warm to 20-25° and is stirred for 30 min. After cooling to 0°, diethyl chlorophosphate (0.29 ml, 2.0 mmol) is added and mixture is allowed to warm to 20-25°. After stirring for 30 min at 20-25° the resultant solution is cooled to -40°. A solution of the isocyanide (286 mg, 1.92 mmol) and THF (1.0 ml) is added followed by die addition of potassium tert-butoxide (1.90 ml, 1.90 mmol) dropwise over several min. The mixture is stirred for 30 min at -30°, and is then allowed to warm to 20-25°. After stirring at 20-25° for 3 hr the mixture is quenched with aqueous ammonium chloride. Aqueous workup (ethyl acetate, magnesium sulfate), and purification by flash chromatography eluting widi ethyl acetate gives die title compound. An analytical sample is prepared by recrystallization from ediyl acetate, mp 215-217°; IR (mineral oil) 2954, 2925, 2855, 1659, 1583, 1517, 1501, 1478, 1444, 1410, 1270, 891, 783 cm "1 ; NMR (300 MHz, CDC1 3 ) 8.10, 7.43, 7.05, 6.97, 5.39, 4.49, 3.08, 2.2-2.35, 1.2-1.4; MS (FAB) m/e 349 [M+H] + , 348, 281, 162; Anal. Calcd for Ci8H 16 Ngθ2: C, 62.06; H, 4.63; N, 24.13, found: C, 61.87; H, 4.55; N, 24.17. EXAMPLES 367-393 Following the general procedure of EXAMPLES 48-87 (R 5 dien R 3 ) and making non- critical variations but starting with d e appropriate starting materials, die compounds of EXAMPLES 367 thru 393 are obtained: EXAMPLE 367 3-(5-tert-Butyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 231-233°: IR (mineral oil) 1659, 1505, 1499, 1493, 1473, 1402, 1385, 1186 cm" 1 ; NMR (CDC1 3 ) 8.12, 7.4-7.45, 7.15-7.3, 5.14, 3.15, 2.23, 1.7-1.85, 1.50; MS (El) m e 406, 336, 308, 278, 98. EXAMPLE 368 tert-Butyl 7-chloro-4,5-dihydro-5-[(methoxy)carbonyl]-4,4- dimediylimidazof 1 ,5-a]quinoxaline-3-carboxylate (I) mp 162.5-164.5°: IR (mineral oil) 1716, 1690, 1512, 1326, 1282, 1240, 1159, 1144 cm" 1 ; NMR (CDC1 3 ) 7.93, 7.3-7.4, 7.22, 3.74, 1.92, 1.62; MS (El) m/e 391, 376, 320, 276, 244. EXAMPLE 369 tert-Butyl 5-benzoyl-7-chloro-4,5-dihydroimidazo[l,5-a]quinoxaline-3- carboxylate (I) mp 244-244.5°: IR (mineral oil) 1724, 1660, 1505, 1381, 1370, 1362, 1330, 1236, 1153, 1141, 729 cm "1 ; NMR (CDCl 3 ) 8.06, 7.35-7.55, 7.15-7.3, 5.28, 1.52; MS (Eϊ) m/e 409, 353, 336, 248, 231, 105. EXAMPLE 370 tert-Butyl 7-chloro-4,5-dihydro-5-[(methoxy)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 176-177°: IR (mineral oil) 1725, 1717, 1700, 1513, 1433, 1377, 1370, 1338, 1299, 1226, 1158, 1131, 1063 cm "1 ; NMR (CDC1 3 ) 7.98, 7.85, 7.45, 7.2-7.3, 5.25, 3.87, 1.64; MS (El) m/e 363, 307, 289, 261, 248, 230. EXAMPLE 371 tert-Butyl 4,5-dihydro-5-[(4-trifluoromethyl)benzoyI]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 233-234°: IR (mineral oil) 1694, 1672, 1517, 1324, 1298, 1169, 1141, 965, 756 cm "1 ; NMR (CDC1 3 ) 8.11, 7.5-7.7, 7.2-7.4, 6.9-7.2, 5.32, 1.56; MS (El) m e 443, 387, 370; 214, 196, 173, 145. EXAMPLE 372 tert-Butyl 5-[(4-dimethyIamino)benzoyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 152-153°: IR (mineral oil) 1696, 1650, 1604, 1593, 1505, 1365, 1352, 1341, 1298, 1288, 1191, 1160, 758 cm "1 ; NMR (CDC1 3 ) 8.09, 7.54, 7.34, 7.15-7.25, 6.95-7.15, 6.53, 5.32, 3.00, 1.60; MS (El) m/e 418, 345, 148. EXAMPLE 373 tert-Buty5-benzoyl-4,5-dihydro-4,4-dimethylimidazo[l ,5-a]quinoxaline-3- carboxylate CD mp 198-200°: IR Cmineral oil) 1714, 1675, 1513, 1367, 1332, 1304, 1284, 1262, 1153, 1141, 1032, 764, 717 cm "1 ; NMR (CDCI 3 ) 8.08, 7.55, 7.35-7.5, 7.2-7.35, 7.06, 6.88, 6.61, 2.06, 1.65; MS (El) m e 403, 388, 210, 105. EXAMPLE 374 tert-Buty_4,5-dihydro-5-[(isopropoxy)carbonyl]imidazo[l,5-a]quinoxaline- 3-carboxylate () mp 201-202°: IR (mineral oil) 1708, 1694, 1511, 1380, 1294, 1119 cm "1 ; NMR (CDC1 3 ) 8.01, 7.79, 7.52, 7.2-7.4, 5.22, 5.0-5.15, 1.64, 1.33; MS (El) m/e 357, 301, 283, 241, 214, 196, 169. EXAMPLE 375 tert -B u ty l 7 -chl o ro -4 , 5 -d ih yd ro -4 , 4-d im eth y l -5 - [(moφholino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 193-194°: IR (mineral oil) 1704, 1647, 1529, 1515, 1420, 1288, 1271, 1241, 1148, 1125, 969 cm "1 ; NMR (CDCl 3 ) 7.94, 7.39, 7.02, 6.78, 3.0-4.1, 1.5-2.2, 1.63; MS (El) m/e 446, 431, 244, 114. EXAMPLE 376 tert-Butyl 4,5-dihydro-5-[(methoxy)carbonyl]-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 212-212.5°: IR (mineral oil) 3103, 1724, 1707, 1518, 1333, 1295, 1292, 1258, 1156, 1145, 760 cm" 1 ; NMR (CDC1 3 ) 7.96, 7.2-7.5, 3.70, 1.92, 1.63; MS (El) m/e 357, 342, 286, 242, 210. EXAMPLE 377 tert-Butyl 5-[(tert-butyloxy)carbonyl]-7-chloro-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 157-158°: IR (mineral oil) 1731, 1727, 1706, 1517, 1372, 1366, 1294, 1286, 1244, 1156, 1145, 971 cm "1 ; NMR (CDC1 3 ) 7.92, 7.3-7.4, 7.14, 1.92, 1.62, 1.50; MS (El) m/e 433, 377, 362, 318, 306, 277, 262, 244. EXAMPLE 378 3-(3-tert-Butyl-5-isoxazolyl)-4,5-dihydro-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 207.5-208.5°: IR (mineral oil) 2961, 2925, 1657, 1508, 1466, 1392, 1343, 1307, 1304, 745 cm "1 ; NMR (CDC1 3 ) 8.06, 7.52, 7.1-7.3, 6.53, 5.04, 3.2-3.4, 1.75-1.85, 1.38; MS (ED m/e 350, 308, 293, 267, 252, 212. EXAMPLE 379 tert-Butyl 6-chloro-4,5-dihydro-5-[(methoxy)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 203-204°: IR (mineral oil) 1717, 1705, 1492, 1441, 1214, 1135 cm" 1 ; 2 H NMR (CDCI3) 8.02, 7.4-7.5, 7.3-7.4, 6.05-6.35, 4.0-4.4, 3.78, 1.64; MS (El) m/e 363, 307, 289, 248, 230. EXAMPLE 380 tert-Butyl 5-benzoyl-7-chloro-4,5-dihydro-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 195.5-196.5°: IR (mineral oil) 1709, 1680, 1510, 1286, 1279, 1248, 1154, 968 cm" 1 ; NMR (CDCI3) 8.04, 7.5-7.6, 7.4-7.5, 7.25-7.4, 7.02, 6.59, 2.05, 1.64; MS (El) m/e 437, 422, 259, 244, 105. EXAMPLE 381 tert-Butyl 5-[(3-fluoro)benzoyl]-4,5-dihydro-4,4-dimedιylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 214-215.5°: IR (mineral oil) 1706, 1672, 1518, 1440, 1295, 1291, 1268, 1144, 752 cm "1 ; NMR (CDC1 3 ) 8.08, 7.45, 7.15-7.35, 7.05-7.15, 6.92, 6.62, 2.05, 1.65; MS (El) me 421, 406, 210, 123. EXAMPLE 382 tert-Butyl 5-[(3-fluoro)benzoyl]-7-chloro-4,5-dihydro-4,4- dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 187-187.5°: IR (mineral oil) 1713, 1684, 1511, 1480, 1444, 1324, 1285, 1282, 1261, 1153, 1141, 968 cm" 1 ; NMR (CDC1 3 ) 8.04, 7.39, 7.25-7.35, 7.10-7.25, 7.07, 6.59, 2.04, 1.64; MS (El) m/e 455, 440, 244, 123. EXAMPLE383 tert-Butyl 6-chloro-4,5-dihydro-4,4-dimethyl-5- [(moφholino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate (I) mp effr 73-76°: IR (mineral oil) 1707, 1670, 1496, 1476, 1412, 1367, 1290, 1274, 1248, 1229, 1160, 1151, 1117, 1051 cm "1 ; NMR (CDCU,) 7.99, 7.40, 7.32, 7.14, 3.45-3.6, 3.30, 1.89, 1.63; MS (El) m/e 446, 431, 244, 114. EXAMPLE 384 tert-Butyl 6-chloro-4,5-dihydro-5-[(methoxy)carbonyl]-4,4- dimethylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 108-109°: IR (mineral oil) 1752, 1710, 1503, 1439, 1330, 1285, 1257, 1229, 1146, 1050, 783 cm "1 ; NMR (CDC1 3 ) 7.95, 7.25-7.45, 3.60, 1.89, 1.63; MS (El) m/e 391, 376, 320, 302, 244. EXAMPLE 385 tert-Butyl 7-chloro-4,5-dihydro-5-[(isopropoxy)carbonyl]-4,4- dimediylimidazofl ,5-a]quinoxaline-3-carboxylate Q.) mp 126-127°: IR (mineral oil) 1722, 1708, 1517, 1291, 1242, 1144, 1111, 971 cm "1 ; X H NMR (CDC1 3 ) 7.93, 7.3-7.4, 7.17, 4.9-5.1, 1.93, 1.63, 1.29; MS (Eϊ) m/e 419, 404, 262, 244. EXAMPLE 386 tert-ButyF-Chloro-5-[(4-dimethylamino)benzoyl]-4,5-dihydroimidazo[l ,5- ajquinoxaline -3-carboxylate (I) mp 135-137° EXAMPLE 387 tert-Butyl 7-chIoro-4,5-dihydro-4,4-dimethyl-5-[(3 ,5- dimethylmoφholino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxyIate(I) mp 187.5-188° EXAMPLE 388 7-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5- [(moφholino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 209-210° EXAMPLE 389 7-Chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5- [(moφhoIino)carbonyl]imidazo[l ,5-a]quinoxaIine (D mp 244-246° EXAMPLE 390 7-Chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (D mp 189-191° EXAMPLE 391 7-Chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-(3,5- dimethyl)moφhoIino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 139-145° EXAMPLE 392 7-Chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyllimidazo[l,5-a]quinoxaline (D mp 187-189° EXAMPLE 393 7-Chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5- [(isopropoxy)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 204-205° EXAMPLES 394^23 Following the general procedure of EXAMPLES 108-148 (R 3 then R 5 ) and making non- critical variations but starting with die appropriate starting materials, die compounds of EXAMPLES 394 thru 423 are obtained: EXAMPLE 394 tert-Butyl5-[(ethylamino)carbonyl]-4,5-dihydroimidazo[l ,5-a]quinoxaline- 3-carboxylate (I) mp 193-194°: IR (mineral oil) 2926, 1726, 1662, 1508, 1381, 1367, 1282, 1149 cm "1 ; l H NMR (CDC1 3 ) 8.01, 7.5-7.65, 7.25-7.4, 5.22, 5.0-5.1, 3.25-3.4, 1.64, 1.15; MS (Eϊ) m e 342, 286, 269, 214, 196, 169. EXAMPLE 395 tert-Butyl 5-[(tert-butylamino)carbonyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 194-195°: IR (mineral oil) 2925, 1699, 1678, 1505, 1281, 1133 cm "1 ; l H NMR (CDC1 3 ) 8.02, 7.5-7.6, 7.25-7.4, 5.14, 4.94, 1.64, 1.36; MS (El) m/e 370, 314, 297; 214, 197, 169. EXAMPLE 396 tert-Buty_f-carbamoyl-4,5-dihydro-4,4-dimethylimidazo[ 1 ,5-a]quinoxaline- 3-carboxylate (I) mp 172-173°: IR (mineral oil) 3429, 2954, 2925, 1702, 1691, 1516, 1300, 1286, 1163, 1149 cm "1 ; l H NMR (CDC1 3 ) 7.78, 7.3-7.4, 7.2-7.3, 7.05-7.15, 5.44, 1.91, 1.62; MS (Eϊ) m e 342, 327, 299, 284, 271, 228, 184. EXAMPLE 397 tert-Butyl 5-[(tert-butylamino)carbonyl]-4,5-dihydro-4,4- dimemylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 189-191 °): IR (mineral oil) 2925, 1703, 1686, 1541, 1509, 1365, 1361, 1280, 1268, 1155, 973, 744 cm "1 ; l H NMR (CDC1 3 ) 7.85, 7.37, 7.15-7.25, 6.95-7.1, 5.68, 1.87, 1.62, 1.42; MS (El) m/e 398, 383, 325, 299, 284, 228, 210, 184. EXAMPLE 398 tert-Butyl 5-[(ethylamino)carbonyl]-4,5-dihydro-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 198-199°): IR (mineral oil) 2953, 2926, 1708, 1681, 1544, 1311, 1283, 1262, 1157, 974, 748 cm "1 ; l NMR (CDC1 3 ) 7.80, 7.36, 7.15-7.25, 6.95-7.1, 5.75-5.85, 3.3-3.45, 1.88, 1.62, 1.21; MS (El) m/e 370, 355, 297, 284, 228, 210, 184. EXAMPLE 399 tert-Butyl 5-carbamoyl-7-chloro-4,5-dihydro-4,4-dimetiiylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 229-231°: IR (mineral oil) 3433, 1719, 1602, 1538, 1516, 1513, 1356, 1333, 1325, 1278, 1183, 1150, 1050, 972, 799 cm "1 ; J H NMR (CDC1 3 ) 7.84, 7.25-7.35, 7.05, 5.72, 1.91, 1.61; MS (El) m/e 376, 361, 305, 262, 218. EXAMPLE 400 tert-Butyl 7-chloro-5-[(ethylamino)carbonyl]-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline-3-carboxylate (I) mp 228-230°: IR (mineral oil) 1712, 1680, 1515, 1288, 1260, 972 cm "1 ; l H NMR (CDCI3) 7.84, 7.32, 6.95-7.05, 5.6-5.75, 3.3-3.5, 1.88, 1.62, 1.24; MS (El) m/e 404, 389, 318, 262, 244, 218. EXAMPLE 401 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2-(4- moφholinyl)e_ιylamino)carbonyl]imidazo[l,5-a]quinoxaline(D mp 188-189° EXAMPLE 402 3-(5-cycIopropyl-l,2,4-oxadiazol-3-yl)-5-[(2- (die_hylamino)ediylamino)carbonyl]-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline (I) mp 155-156° EXAMPLE 403 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2- (methoxy)ethylamino)carbonyl]imidazo[l,5-a]quinoxaline(I) mp 166.5-167.5° EXAMPLE 404 3-(5-cyclopropyI-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) mp 201.5-202.5° EXAMPLE 405 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2- medιoxyethoxy)carbonyl]imid___o[l ,5-a]quinoxaline (I) mp 119-120° EXAMPLE 406 7-chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(ediylamino)carbonyl]- 4,5-dihydroimidazo[l,5-a]quinoxaline (I) mp 248.5-250° EXAMPLE 407 5-(carbamoyl)-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline (I) mp 228-229° EXAMPLE 408 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5- [(isopropoxy)carbonyl]-7-me_ιylimidazo[l,5-a]quinoxaline(D mp 191.5-192° EXAMPLE 409 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5- [(moφholino)c_jbonyI]imidazo[l,5-a]quinoxaline(_) mp 227-228° EXAMPLE 410 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]-7-methylimidazo[l ,5-a]quinoxaline (D mp 237-238° EXAMPLE 411 5-(carbamoyl)-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7- medιylimidazo[l,5-a]quinoxaline (I) mp 205-207° EXAMPLE412 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,4,5- trimethyI)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 189.5-190.5° EXAMPLE 413 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[((2- dimethylamino)edιoxy)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 165.5-167° EXAMPLE 414 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-5-[(ethylamino)carbonyl]-4,5- dihydro-7-medιyl imidazo [ 1 ,5-a] quinoxal ine (I) mp 240-241° EXAMPLE 415 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 191.5-192° EXAMPLE 416 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 223-224° EXAMPLE 417 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5- [(moφholino)carbonyl]imidazo[l ,5-a]quinoxaline (I) mp 265-265.5° EXAMPLE 418 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) mp 192-193° EXAMPLE 419 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) 25728-EJJ-149A mp 231-234° EXAMPLE 420 5-[(2-fluoro)benzoyl]-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5- ajquinoxaline (I) mp 185-189° EXAMPLE 421 3-(4-fluorophenyl)-4,5-dihydro-5-[(3-trifluoromethyl)benzoyl]imidazo[l,5- a]quinoxaline (I) mp 176-178° EXAMPLE 422 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5- [(moφholino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 180-181.5° EXAMPLE 423 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5- [(moφholino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) mp 142-144° EXAMPLES 424-430 Following die general procedure of EXAMPLE 30 and making non-critical variations but starting with the appropriate starting materials, the compounds of EXAMPLES 424 thru 430 are obtained: EXAMPLE 424 3-(5-Cyclopropyl-l ,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[bis-(2- methoxyethyl)aminocarbonyl]imidazo[l,5-a]quinoxaline (D U-96502 (25813-RET-89) mp 124.5-125.0°; MS (m/z) 456; IR (mineral oil) 1673, 1203, 1517, 1417, 1498 cm "1 ; NMR (CDCI 3 ) δ 1.24, 1.34, 2.25, 3.29, 3.48, 4.94, 6.84, 7.32, 7.47, 8.05. EXAMPLE 425 tert-Butyl 7-fluoro-4,4-dimethyl-5-(moφhoIino)carbonylimidazo[l,5- a]quinoxaline-3-carboxylate (I) mp 167-191°; MS (m/z) 430; IR (mineral oil) 1652, 1705, 1531, 1124, 1524 cm "1 ; NMR (CDC1 3 ) δ 1.63, 1.70, 2.08, 3.1-4.1, 6.51, 6.75, 7.42, 7.93. EXAMPLE 426 tert-Butyl 7-fluoro-5-[bis(2-methoxyethyl)aminocarbonyl]-4,4- dimethylimidazo[l ,5-a]quinoxaline-3-carboxylate (I) U-96504 (25813-RET-94) mp 144-145°; MS (m/z) 476; IR (mineral oil) 1707, 1282, 1153, 1658, 1666 cm "1 ; NMR (CDC1 3 ) δ 1.63, 1.67, 2.09, 3.16, 3.43, 3.2-3.4, 3.61, 3.72, 4.1, 6.73, 6.88, 7.38, 7.92. EXAMPLE 427 tert-Butyl 7-fluoro-4,5-dihydro-5-(isopropyloxycarbonyl)imidazo[l,5- a]quinoxaline-3-carboxylate (D mp 182-183°; MS (m/z) 375; IR (mineral oil) 1710, 1519, 1302, 1696, 1227 cm "1 ; NMR (CDC1 3 ) δ 1.35, 1.64, 5.08, 5.22, 6.99, 7.48, 7.61, 7.97. EXAMPLE 428 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5- (isopropyloxycarbonyl)imϊdazo[l,5-a]quinoxaline (D U-96545 (25813-RET-79) mp 203.5-205°; MS (m/z) 383; IR (mineral oil) 1710, 1512, 1234, 1640, 1254 cm "1 ; NMR (CDCI3) δ 1.09, 1.16, 1.35, 2.18, 5.07, 5.30, 7.03, 7.52, 7.63, 8.08. EXAMPLE 429 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5- (piperazinylcarbonyl)imidazo[l,5-a]quinoxaline hydrochloride (T) U-96546A (25813-RET-87B) mp 216-220°; MS (m/z) 409; IR (mineral oil) 1421, 1671, 1660, 1199, 1477 cm" 1 ; NMR (CDCI3) δ 1.25, 1.35, 1.45, 2.26, 3.33, 3.42, 5.01, 6.91, 6.99, 7.52, 8.07. EXAMPLE 430 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5- φiperazinylcarbonyl)imidazo[l,5-a]quinoxaline hydrochloride CD U-96547A (25813-RET-91) mp 240-248°; MS (mz) 409; IR (mineral oil) 1663, 1425, 1420, 1583, 1247 cm "1 ; NMR (CDC1 3 ) δ 1.18, 1.30, 2.44, 3.09, 3.55, 5.08, 7.28, 7.39, 7.85, 8.76, 9.30. EXAMPLE 431 t-Butyl 7-fluoro-4,5-dihydro-5-(morpholinocarbonyl)inidazo[l,5- a]quinoxaline-4-carboxylate (I) Following the general procedure of EXAMPLES 48-87 (R 5 then R 3 ) and making non- critical variations but starting widi die appropriate starting material, the title compound is obtained, mp 195.5-196.5°. EXAMPLES 432-560 Following the general procedure of EXAMPLES 48-87 (R 5 then R 3 ) or of EXAMPLES 108-148 (R3 then R 5 ) and making non-critical variations but starting widi the appropriate starting materials, me compounds of EXAMPLES 432 thru 560 are obtained: EXAMPLE 432 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl] imidazo [ 1 ,5-a] quinoxal ine (I) EXAMPLE 433 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 434 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 435 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 436 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 437 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 438 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- me_ιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 439 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxal ine (I) EXAMPLE 440 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-a] quinoxal ine (I) EXAMPLE 441 7-chloro-3-(4- fluorophenyl) -4, 5-dihydro-5-[(l- (4- medιyl)piperazino)carbonyl]imidazo[l ,5-a] quinoxal ine (I) EXAMPLE 442 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxal ine (I) EXAMPLE 443 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 444 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 445 7-chloro-3-(4-cyclopropylthiazol-2-yI)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(D EXAMPLE 446 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 447 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(D EXAMPLE 448 3-(4-cyclopropylthiazol-2-yI)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 449 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (D EXAMPLE 450 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 451 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-_-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaIine (D EXAMPLE 452 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yI)-4,5-dihydro-7-medιyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline(I) EXAMPLE 453 3-(5-cyclopropyl- l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l -(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(D EXAMPLE 454 3-(5-cyclopropyi-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(D EXAMPLE 455 3-(5-cycIopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,4,5- trime_ιyl)piper_zino)c_ιbonyI]imidazo[l,5-a]quinoxaline(_) EXAMPLE 456 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxalineOD EXAMPLE 457 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline Q EXAMPLE 458 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 459 7-fluoro-3-(4-fluorophenyl)-4, 5-dihydro-5-[(l -(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (D EXAMPLE 460 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 461 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 462 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 463 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 464 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 465 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 466 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 467 3-(3-cycloρropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 468 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 469 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(3,5- dimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline (I) EXAMPLE 470 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,5- dimemyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline(D EXAMPLE 471 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimedιyDpiperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 472 3-(5-cyclopropyI-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- dimemyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 473 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (D EXAMPLE 474 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 475 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5- dimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 476 3 -(4-fluoropheny l)-4,5-dihy dro-7 -methyl -5-[(l -(3,5- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 477 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,5- d imedιyl)piperazino)carbonyl] imidazo[ 1 ,5-a]qu inoxal ine (I) EXAMPLE 478 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 479 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 480 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- dimetiιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 481 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 482 3-(3-cyclopropyl-l,2,4-oxadiazoI-5-yl)-4,5-dihydro-5-[(l-(2,4,6- trimetiιyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline (I) EXAMPLE 483 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(2,4,6- trime_ιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 484 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piper___ino)carbonyl]imidazo[l,5-a]quinoxaline (D EXAMPLE 485 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trime_hyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 486 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(2,4,6- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 487 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,4,6- trime_iyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline © EXAMPLE 488 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,4,6- trimemyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 0) EXAMPLE 489 3-(5-cyclopropyl-l,2,4-oxadi_zol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline CD EXAMPLE 490 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (D EXAMPLE 491 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-medιyl-5-[(l-(2,4,6- trime_ιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 492 3 - (4 -fl u o r o p h en y l ) - 4 , 5 - d i h y d ro - 5 - [ ( l - (2 , 4 , 6 - trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (D EXAMPLE 493 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l -(2,4,6- trime_ιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (D EXAMPLE 494 7-fluoro-3-(4-f luoroρhenyl)-4,5-dihydro-5-[(l -(2,4,6- trime_ιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline CD EXAMPLE 495 3 -(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[( l -(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (D EXAMPLE 496 3-(4-cycloρropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 497 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piper___ino)carbonyl]imidazo[l ,5-a]quinoxaline (J_) EXAMPLE 498 3-(4-cyclopropylthiazoI-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyDpiperaz ino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 499 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 500 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l -(2,4,6- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 501 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yI)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 502 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a] quinoxal ine (I) EXAMPLE 503 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 504 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dimediyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 505 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (I) EXAMPLE 506 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,6- dimediyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 507 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 508 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 509 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dime yl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaIine (I) EXAMPLE 510 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 511 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,6- dimetiιyI)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 512 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 513 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline (I) EXAMPLE 514 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline(I) EXAMPLE 515 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 516 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (I) EXAMPLE 517 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline (D EXAMPLE 518 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline (D EXAMPLE 519 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l ,5-a]quinoxaline (D EXAMPLE 520 tert-butyl 4, 5-dihydro-4 , 4-dimethyl-5- [( l -(3 , 4, 5- trimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline-3-carboxylate(D EXAMPLE 521 tert-butyl 7-chIoro-4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trime_iyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 522 tert-butyl 7-fluoro-4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl] imidazo [ 1 ,5-a] quinoxal ine-3-carboxylate (I) EXAMPLE 523 tert-butyl 6-fluoro-4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 524 tert-butyl 4,5-dihydro-7-methyl-4,4-dimethyl-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaIine-3-carboxylate(D EXAMPLE 525 tert-butyl 5-[(l-(3,5-dimetiιyl)pϊperazino)carbonyl]-4,5-dihydro-4,4- dimethylimidazo[l ,5-a]quinoxaline-3-carboxylate (D EXAMPLE 526 tert-butyl 7-chloro-5-[(l-(3,5-dimediyl)piperazino)carbonyl]-4,5-dihydro- 4,4-dimethylimidazo[l ,5-a]quinoxaline-3-carboxylate (D EXAMPLE 527 tert-butyl 5-[(l-(3,5-dimedιyI)piperazino)carbonyl]-7-fluoro-4,5-dihydro- 4,4-dimethylimidazo[l,5-a]quinoxaline-3-carboxylate (D EXAMPLE 528 tert-butyl 5-[(l -(3 ,5-dimethyl)piperazino)carbonyl]-6-fluoro-4,5-dihydro- 4,4-dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (D EXAMPLE 529 tert-butyl 5-[(l-(3 ,5-dimethyl)piperazino)carbonyl]-4,5-dihydro-7-methyl- 4,4-dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (D EXAMPLE 530 tert-bu tyl 4 , 5-d ih ydro-4 , -dim ethyl -5-[( l -(2 , 4, 6- trime_iyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 531 tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(l-(2,4,6- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 532 tert-butyl 7-fluoro-4,5-dihydro-4,4-dimethyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 533 tert-butyl 6-fluoro-4,5-dihydro-4,4-dimethyl-5-[(l-(2,4,6- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 534 tert-butyl 4,5-dihydro-7-methyl-4,4-dimethyI-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 535 tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5-dihydro-4,4- dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 536 tert-butyl 7-chloro-5-[(l-(2,6-dimedιyl)piperazino)carbonyl]-4,5-dihydro- 4,4-dimethylimidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 537 tert-butyl 5-[(l-(2,6-dimediyl)piperazino)carbonyl]-7-fluoro-4,5-dihydro- 4,4-dimethylimidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 538 tert-butyl 5-[(l-(2,6-dimediyl)piperazino)carbonyl]-6-fluoro-4,5-dihydro- 4,4-dime_hylimidazo[l ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 539 tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5-dihydro-7-medιyl- 4,4-dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 540 tert-butyl 4 , 5 -d ih yd ro-5- [ ( l -(3 , 4 , 5 - trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 541 tert-butyl 7-chloro-4,5-dihydro-5-[(l -(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 542 tert-butyl 7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 543 tert-butyl 6-fluoro-4, 5-dihydro-5-[(l -(3,4,5- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 544 tert-butyl 4,5-dihydro-7-methyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 545 tert-but^-[(l-(3,5-dimediyl)piperazino)carbonyl]-4,5-dihydroimid___o[l,5- a]quinoxaline-3-carboxylate (I) EXAMPLE 546 tert-butyl 7-chloro-5-[(l-(3,5-dimethyl)piperazino)carbonyl]-4,5- dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 547 tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-7-fluoro-4,5- dihydroimidazo[l ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 548 tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-6-fluoro-4,5- dihydro imidazo! 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 549 tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-4,5-dihydro-7- methylimidazo[l ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 550 tert-butyl 4 ,5 -dihydro-5 - [ ( l -(2 , 4 , 6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 551 tert-butyl 7-chloro-4,5-dihydro-5-[(l -(2,4,6- trimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 552 tert-butyl 7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaIine-3-carboxylate(I) EXAMPLE 553 tert-butyl 6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trime_iyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 554 tert-butyl 4,5-dihydro-7-methyl-5-[(l-(2,4,6- trimethyI)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 555 tert-but^-[(l-(2,6-dime_hyl)pipera__ino)carbonyl]-4,5-dihydroimidazo[l,5- a] quinoxal ine-3-carboxylate (I) EXAMPLE 556 tert-butyl 7-chloro-5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5- dihydroimidazofl ,5-a]quinoxaline-3-carboxylate (I) EXAMPLE 557 tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-7-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 558 tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-6-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline-3-carboxylate(I) EXAMPLE 559 tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5-dihydro-7- memylimidazo[l,5-a]quinoxali_e-3-carboxylate(I) CHART A 15 / \ ^ (R 4 /R 5 /Rg-2a) (CH 2 )n l3 (CH 2 )n 15 CO 56-1 \ / 20 CCH 2 14 30 35 CHART A - Continued 20 35 CHART A - Continued 10 15 25 30 35 CHART A - Continued 30 (F-Aryl-XX) CHART A - Continued 15 25 < . (F-Aryl-XXV) *3-2 30 . (F-Aryl-XXVI) <3-2 CHART A - Continued (F-Aryl-XXVIII) ^3-2 _f^ ) 20 3-2 *-=- (F-Aryl-XXXI) N^N) *3-2* 25 (F-Aryl-XXXU) _ ^S 30 (F-Aryl-XXXIII) 35 (F-Aryl-XXXIV) CHART A - Continued (F-Aryl-XXXV) *3-12 (F-Aryl-XXXVI) 3-12 (F-Aryl-XXXVH) *3-12 (F-Aryl-XXXVm) (F-Aryl-XXXIX) 30 3-2 CHART A - Continued 10 (F-Aryl-XLIII) 20 (F-Aryl-XLV) *3-12 30 . -N. (F-Aryl-XLVII) fr l 3-2 '3-12 35 (F-Aryl-XLVIII) R 3 . 2 CHART A - Continued CHART A - Continued l 3-2 (F-Aryl-LVI) & 10 (F-Aryl-LVIII) 35 CHART A - Continued (F-Aryl-LXIII) 10 15 20 (F-Aryl-LXVII) 25 ^ 3-2 > (F-Aryl-LXVIII) 30 35 ^ . _-_ U (F-Ar l- XX) CHART A - Continued 10 15 (F-Aryl-LXXII) CHART B CHART C CHART C - Continued (XD CHART D 25 CHART E (XVIII) Hoffmann rearrangement CO-O Bu Br-C (R^-COOR (HO CHART E - Continued ϊ CHART E - Continued UT) Br-C(R 4 )-C0-Bτ 15 (XLVI) 20 (XLVII) 25 (XLVIΠ) (IV) CHART F 10 20 (XXVII) (XXVffl) * .. Protecting Protecting Protecting (IV) CHARTG -Continued 15 (XXXVI) (I) CHART H CHART I (xxxπi) (xxxvπ) Protected (XXXVHa) (xxxvπi) (xxxvmb) ( ?) CHART J (VII) 15 (XXXLX) standard 25 procedures CHART K (I-ester) 25 CHART L 25 35 CHART M (XLffl) (I-F-Aryl-LXXI) α-F-Aryl-LXXH) CHART N 30 CHART N - Continued 15 25 standard cyclization 30 Ci) CHART O • 56-1 (LVI) 10 15 25 By procedure of CHART N 1) nitro reduction 30 2) cyclization (I)

Claims: CLAIMS 1. An imidazo[l,5-a]quinoxali_e of formula ( ) where R 3 is (C 3 - 1) -COOR3.! where R 3Λ is (1) -H, (2) C r C 9 alkyl, (3) C3-C7 cycloalkyl, (4) -(CH2) n 6-O-R 3 _3 where r^ is 2 thru 4 and R 3 . 3 is -H, C r C 4 alkyl or C 3 -C 7 cycloalkyl, (5) is -H, C r C 4 alkyl, C3-C7 cycloalkyl or -φ, R3.5 is -H, C j -Cg alkyl or C3-C7 cycloalkyl and where R 3 _ 4 and R 3 . 5 are taken together widi the attached nitrogen atom to form a heterocyclic ring -N*-(CHR3. 8 )- A -(CH 2 ). 1 -R3^-(CH 2 ) n2 -(C*HR3. 9 ) nB - (C 3 - la) -N*-CCH 2 ) nl -(CHR3.8) nA -R3^-(CHR 3 . 9 ) nB -(C*H 2 ) Il2 - (C 3 - lb) where R 3 . g is -H or ^-€3 alkyl, n A is 1 or 2, n j is 0 thru 2, n 2 is 0 thru 2, R3.9 is -H or C1-C3 alkyl, n B is 1 or 2, where the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring, with the proviso that die ring not contain more dian 8 atoms, and where R 3 _6 is -O-, -S-, -CO- -CR3_£ 1 R3_62 where R3_$ι and R3_6 2 are me same or different and are -H or C j ^ alkyl, -NR3.7 where R3.7 is -H, C r C 4 alkyl, C3-C7 cycloalkyl, -(CR^ O TΦ where n 7 is 0 thru 4 and φ is optionally substituted widi 1, 2 or 3 R 3 _ 2 where R 3 . 2 is selected from the group consisting of -F, -Cl, -Br, -I, -CN, -NO 2 , -O-CO-R 3 .2a where R3.2,, is -H, C r C 4 alkyl or C3-C7 cycloalkyl, -(CH 2 ) n 3 0 -CF 3 where n 30 is 0 dim 3, -O-CF3, C r C 6 alkyl, C3-C7 cycloalkyl, -CH 2 -(C 3 -C 7 cycloalkyl), -CH 2 CH(CF 3 )CH 3 , -C(OH)(CH 2 OH)(CH 2 CH 3 ), -C(OH)(CH 2 OH)CH 3 , -C(CH 3 )(OH)(CH 2 OH), -CH(OH)(CH 2 OH), -CH(OH)(CH 3 ), -CH 2 CH 2 OH, -C(CH 3 ) 2 (CH 2 OH), -CH(CH 2 OH) 2 , -C(CH 2 -OH) 3 , -C(CH 3 ) 2 -OH, -C(CH 3 ) 2 -F, -NR3.2b-CO-R3.2c where R 3 . 2b is -H or C r C 4 alkyl, and where 3.2 C * s -H, C r C 6 alkyl, -Φ, -CH 2 -φ, -(CH2) n8 -OR3.2d where n 8 is 0 dim 3 and R3_2d is -H or C r C 4 alkyl, -(CH 2 ) n21 -OH where n 21 is 3 thru 4, -(CH2),ι22~ . where n 2 2 is 0 thm 3 and where -φ is optionally substituted with -F, -Cl, -Br, -I or C r C 4 alkyl, -(CH2) n 8-N(R 3 _2 C }.2 where n 8 and R 3 _2d are as defined above and where the two 3_2 ' s can De token togedier widi the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4- morpholinyl, l-(4-methyl)piperazinyl, "_ "I_3-2d where R3.2 C I * s ^ defined above, -SO 2 -N(R 3 . 2e ) 2 where R 3 _2e is -H or C r C 4 alkyl, -CO-N(R 3 .2 e )2 wnere -2e' s ^ defined aboveand where die two R3_2e's can be taken together with the attached nitrogen atom to from a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, l-(4- medιyl)piperazinyl, where R3_2f and R3_2 g are the same or different and are -H or C j - ^ alkyl and where R 3 . 2 f and R3_2 g can be taken together with the attached nitrogen atom to form a ring, which may contain an additional heteroatom, selected from die group consisting of piperazine, morpholine, pyrrolidine or piperidine, with the proviso tiiat when R 3 _g is -O-, -S- or -NR3.7-, n j and n 2 are 1 or 2, (6) aryl, where aryl is -φ optionally substituted widi one or two R 3 . 2 where (F-Aryl-I) R 3 _2 is as defined above, 1-naphtiιyl optionally substituted widi one or two (F-Aryl-H) R 3 _2 where R3.2 is as defined above, 2-naphtiιyl optionally substituted widi one or two (F-Aryl-IH) R 3 _2 where R3.2 is as defined above, 2-pyridyl optionally substituted with one or two (F-Aryl-IV) R 3 _ 2 where R3.2 is as defined above, 3-pyridyl optionally substituted with one or two (F-Aryl-V) R3.2 where R3.2 is as defined above, 4-pyridyl optionally substituted with one or two (F-Aryl-VI) R 3 _2 where R3.2 is as defined above, 2-pyrimidinyl optionally substituted with one or (F-Aryl-VII) two R3.2 where R3.2 is as defined above, 4-pyrimidinyl optionally substituted widi one or (F-Aryl-VIII) two R3.2 where R3.2 is as defined above, 5-pyrimidinyl optionally substituted with one or two (F-Aryl-D_) 3.2 where R3_2 is as defined above, 3-pyridazinyl optionally substituted with one or two (F-Aryl-X) R3.2 where R 3 . 2 is as defined above, 4-pryidazinyJ option _lly substituted with one or two (F-Aryl-XI) R 3 . 2 where R 3 . 2 is as defined above, 3-pyrazinyl optionally substituted widi one or two (F-Aryl-XII) R 3 . 2 where R 3 . 2 is as defined above, 2-quinolyl optionally substituted with one or two (F-Aryl-XIII) R3.2 where R 3 . 2 is as defined above, 3-quinolyl optionally substituted with one or two (F-Aryl-XIV) R 3 . 2 where R 3 . 2 is as defined above, 4-quinolyl optionally substituted widi one or two (F-Aryl-XV) R 3 . 2 where R 3 . 2 is as defined above, 1-isoquinolyl optionally substituted widi one or (F-Aryl-XVI) two R 3 . 2 where R 3 . 2 is as defined above, 3-isoquinolyl optionally substituted with one or (F-Aryl-XVII) .two R3.2 where R3.2 is as defined above, 4-isoquinolyl optionally substituted with one (F-Aryl-XVIII) or two R3.2 where R3.2 is as defined above, 2-quinazolinyl optionally substituted widi one (F-Aryl-XIX) or two R 3 . 2 where R 3 . 2 is as defined above, 4-quinazolinyl optionally substituted widi one or (F-Aryl-XX) two R3.2 where R 3 . 2 is as defined above, 2-quinoxalinyl optionally substituted widi one or (F-Aryl-XXI) two R3.2 where R3.2 is as defined above, 1-phdιalazinyl optionally substituted widi one (F-Aryl-XXII) or two R 3 . 2 where R3.2 is as defined above, 2-imidazolyl optionally substituted with one or (F-Aryl-XXIII) two R 3 . 2 and R 3 . 12 where R 3 . 2 and 3.12 ^ as defined above, 4-imidazolyl optionally substituted widi one (F-Aryl-XXIV) or two R3.2 where R 3 . 2 is as defined above and where R3.12 ιs -H, C j -C 4 alkyl or -CHO, 3-isoxazolyl optionally substituted with one or (F-Aryl-XXV) two R3.2 where R3.2 is as defined above, 4-isoxazolyl optionally substituted with one (F-Aryl-XXVI) or two R3.2 where R3.2 is as defined above, 5-isoxazolyl optionally substituted widi one or (F-Aryl-XXVII) two R3.2 where R3.2 is as defined above, 3-pyrazolyl optionally substituted widi one or (F-Aryl-XXVIII) two R3.2 where R3.12 aad R 3 . 2 are as defined above, 4-pyrazoIyl optionally substituted widi one (F-Aryl-XXIX) or two R 3 . 2 where R3.12 an R 3 . 2 are as defined above, 5-pyrazolyl optionally substituted widi one or (F-Aryl-XXX) two R3.2 where 3-12 an R3-2 re as defined above, 2-oxazolyl optionally substituted widi one or (F-Aryl-XXXI) two 3.2 where R 3 . 2 is as defined above, 4-oxazolyl optionally substituted with one (F-Aryl-XXXU) or two R3.2 where R 3 . 2 is as defined above, 2-thiazolyl optionally substituted widi one or (F-Aryl-XXXffl) two R3.2 where R 3 . 2 is as defined above, 4-dιiazolyl optionally substituted with one (F-Aryl-XXXIV) or two R3.2 where R 3 . 2 is as defined above, 2-indolyl optionally substituted with one or two (F-Aryl-XXXV) R 3 _2 where 3.12 and R 3 . 2 are as defined above, 3 -indolyl optionally substituted with one or (F-Aryl-XXXVI) two R3.2 where R3.12 and R 3 . 2 are as defined above, 3-indazolyl optionally substituted with one or (F-Aryl-XXXVII) twp R3.2 where 3.12 nd R3-2 are as defined above, 2-benzoxazolyl optionally substituted with (F-Aryl-XXXVHI) one or two R 3 . 2 where R3.2 is as defined above, 2-benzothiazolyl optionally substituted widi (F-Aryl-XXXK) one or two R 3 _ 2 where R 3 _ 2 is as defined above, 2-benzimidazolyl optionally substituted widi one (F-Aryl-XL) or two R3.2 where R3.12 and R 3 . 2 are as defined above, 2-benzofuranyl optionally substituted widi one or (F-Aryl-XLI) two R3.2 where R 3 . 2 is as defined above, 3 -benzofuranyl optionally substituted widi one (F-Aryl-XLϋ) or two R3.2 where R 3 _ 2 is as defined above, 2 -furanyl optionally substituted widi one or two (F-Aryl-XLIII) R 3 _2 where R3.2 is as defined above, 3-furanyI optionally substituted with one or two (F-Aryl-XLIV) R3.2 where R 3 . 2 is as defined above, 2-dιienyl optionally substituted widi one or two (F -Aryl-XLV) R 3 . 2 where R 3 . 2 is as defined above, 3-thienyl optionally substituted widi one or two (F-Aryl-XLVI) R3.2 where R 3 . 2 is as defined above, 2-pyrrolyl optionally substituted widi one or (F-Aryl-XLVII) two R 3 _2 where R3.22 and R 3 . 2 are as defined above, 3-pyrrolyl optionally substituted with one (F-Aryl-XLVIII) or two R3_ 2 where R3-12 and R 3 _ 2 are as defined above, l,2,4-oxadiazol-3-yl optionally substituted with (F-Aryl-XLIX) one R3.2 where R 3 . 2 is as defined above, l,2,4-oxadiazol-5-yl optionally substituted with one (F-Aryl-L) R3.2 where R3.2 is as defined above, l,2,4-tiιiadiazol-3-yl optionally substituted with one (F-Aryl-LI) R 3 . 2 where R 3 . 2 is as defined above, l,2,4-thiadiazol-5-yl optionally substituted (F-Aryl-LII) with one R 3 . 2 where R 3 . 2 is as defined above, l,2,4-triazol-3-yl optionally substituted with (F-Aryl-LIII) one or two R 3 _ 2 where R3.22 and R 3 . 2 are as defined above, l,2,4-triazol-5-yl optionally substituted with one (F-Aryl-LIV) R 3 . 2 where R 3 . 12 and R 3 . 2 are as defined above, l,2,3,4-tetrazol-5-yl substituted with R 3 . 12 where (F-Aryl-L V) R 3 . 12 is as defined above, 5-oxazolyl optionally substituted widi with one (F-Aryl-L VI) or two R3.2 where R3.2 is as defined above, 5-dιiazolyI optionally substituted widi with one (F-Aryl-LVII) or two R3.2 where R3.2 is as defined above, oxazolo[4,5-b]pyridin-2-yl optionally substituted (F-Aryl-LXXI) with one or two R 3 . 2 where R 3 . 2 is as defined above; imidazo[l,2-a]pyridin-2-yl optionally substituted (F-Aryl-LXXII) with one or two R 3 _ 2 where R 3 . 2 is as defined above; (C 3 - 2) -CO-NR3. j oR3.2 j where R3.20 and R 3 . n are the same or different and are C j -C 4 alkyl, C3-C7 cycloalkyl or -φ, (C 3 - 3) -CN, (C3 - 4) aryl, where aryl is as defined above, (C 3 - 5) -Cs_C-R3_2 where R3.2 is as defined above, (C 3 - 6) -CO-R3.2 where R3.2 is as defined above, (C 3 - 7) -CS-R3.2 where R3.2 is as defined above, (C 3 - 8) -CO-R3.23 where R3.23 is selected from the group consisting of 1-imidazolyl optionally substituted widi one (F-Aryl-L VIII) or two R3.2 where R 3 . 2 is as defined above, 1-pyrrolyl optionally substituted widi one (F-Aryl-LIX) or two R 3 . 2 where R 3 . 2 is as defined above, 1-pyrazolyl optionally substituted widi one (F-Aryl-LX) or two R3.2 where R 3 . 2 is as defined above, 1,2,3-triazoI-l-yl optionally substituted (F-Aryl-LXI) widi one or two R 3 . 2 where R 3 _ 2 is as defined above, 1,2,4-triazol-l-yl optionally substituted (F-Aryl-LXH) with one or two R3.2 where R3.2 is as defined above, 1-tetrazolyl optionally substituted widi one (F-Aryl-LXIII) or two R3.2 where R 3 . 2 is as defined above, 1-indolyl optionally substituted widi one (F-Aryl-LXIV) or two R3.2 where R 3 . 2 is as defined above, 1-indazolyl optionally substituted widi one (F-Aryl-LXV) or two R3.2 where R 3 . 2 is as defined above, 2 -isoindolyl optionally substituted with one (F-Aryl-LXVI) or two R3.2 where R 3 . 2 is as defined above, 1-purinyl optionally substituted widi one (F-Aryl-LXVH) or two R3.2 where R3.2 is as defined above, 2-furanyl optionally substituted widi one or two (F-Aryl-XLIH) R3.2 where R3.2 is as defined above, 3-furanyl optionally substituted with one or two (F-Aryl-XLIV) R3.2 where R 3 . 2 is as defined above, 2-dιienyI optionally substituted widi one or two (F-Aryl-XLV) or two R3.2 where R3.2 is as defined above, 3-thienyl optionally substituted with one or two (F-Aryl-XLVI) R3.2 where R3.2 is as defined above, 2-oxazolyl optionally substituted widi one or two (F-Aryl-XXXI) R 3 _2 where R3.2 is as defined above, 4-oxazolyl optionally substituted with one or two (F-Aryl-XXXU) R 3 _2 where R 3 . 2 is as defined above, 5-oxazolyl optionally substituted widi one or two (F-Aryl-LVI) R 3 _ 2 where R3.2 is as defined above, 3-isoxazolyl optionally substituted widi one or two (F-Aryl-XXV) R 3 _2 where R3.2 is as defined above, 4-isoxazolyl optionally substituted widi one or two (F-Aryl-XXVI) R3.2 where R3.2 is as defined above, 5-isoxazolyl optionally substituted with one or two (F-Aryl-XXVII) R 3 . 2 where R 3 . 2 is as defined above, 2-dιiazolyl optionally substituted widi one or two (F-Aryl-XXXIII) R 3 . 2 where R 3 . 2 is as defined above, 4-dιiazolyl optionally substituted widi one or two (F-Aryl-XXXIV) R3-2 where R3-2 is as defined above, 5-dιiazolyl optionally substituted widi one or two (F-Aryl-LVII) R 3 . 2 where R3.2 is as defined above, 3-isodιiazolyl optionally substituted widi one or F-Aryl-LVffl) two R3.2 where R3.2 is as defined above, 4-isodιiazolyl optionally substituted widi one or two (F-Aryl-LXIX) R 3 _2 where R 3 . 2 is as defined above, 5 -isotiiiazolyl optionally substituted with one or two (F-Aryl-LXX) R 3 . 2 where R 3 . 2 is as defined above; imidazo[ l,2-a]pyridin-2-yl optionally substituted (F-Aryl-LXXII) widi one or two R 3 _ 2 where R3.2 is as defined above; (C 3 - 9) -C*=N-C(R3_ 14 )2-[C(R 3 _ 1 5)2_ n 23-R*3_2 6 where the atoms marked with an asterisk (*) are bonded to each odier resulting in die formation of a ring, where the 3_ 4's are the same or different and are -H or C -C3 alkyl, where n 2 3 is 1 dim 3, where die Rs. j s's are the same or different and are -H or C2-C3 alkyl, where R3. 6 i "0"> "S . -C( -14)2"» " N -12 where R3.22 and R3.24 are as defined above, (C 3 - 10) -CH(OH)R 3 _2 where R3.2 is as defined above, (C3 - 11) -CH2-O-R3. where R3. is as defined above, (C 3 -12) -CH 2 -NR3_4R 3 _5 where R3.4 and R3.5 are as defined above; (R 4 /R 5 /R 6 - 1) where R is α-R^tf-R^ where one of R 4-1 and R . 2 is -H and die other of R 4 _2 and R . 2 is taken together widi R 5 to form a ring of the formula (R 5 (R 4 end) (R4/R5 R6 "I) where n 3 is 0 dim 3 and R45.2 is -O-, -CO-, -S-, -CH=CH-, -C(R3_j7 . 2- where die R3_27's are the same or different and are -H or C j -C 4 alkyl, -N .5-2 where R 45-2 i -H, C j -C 6 alkyl, -(CH 2 ) n 9-< . where r_g is 0 thru 4 and -φ is optionally substituted with -F, -Cl, -Br, -I or C r C 4 alkyl, -(CH 2 ) nl o- NR 45-3 R 45-4 where n 10 is 2 dim 6, where R 45 . 3 is -H, C r C 4 alkyl, -φ and where R45.4 is -H or C -C3 alkyl, and where is -H, -F, -Cl, -Br, -I, -CN, -NO 2 , -O-CO-R^ where ^6-1 is -H. c r c 4 altyl or C3-C7 cycloalkyl, -CF 3 , -O-CF3, C2-C 6 alkyl, C3-C7 cycloalkyl, -CH 2 CH 2 OH, -NRg^-CO-R β ^ where R^ is -H or C2-C 4 alkyl, and where R^ is -H, C r C 6 alkyl, -φ optionally substituted widi -F, -Cl, -Br, -I or C2-C 4 alkyl, -CΑ 2 -φ, -(CH 2 ) n 2 4 -OR 6 _4 where n 2 is 0 dim 3 and R^ is C2-C 4 alkyl, -(CH 2 )-25-OH where n25 is 2 dim 4, -(CH 2 ) n 26"Ψ where n 26 is 0 dim 3, -(CH 2 ) n 2 -N(R 6 _ ) 2 where n 24 and Rg^ are as defined above, -S-Re- where Rg^ is as defined above, -SO2- (R 6 .5) 2 where R 6 . 5 is -H or C r C 4 alkyl, -CO-NflR^^ where R 6 _5 is as defined above, -CO2-R6_4 where Rg_4 is as defined above, -NRg . g g^ where R^ and R^ are the same or different and are -H or C j -C alkyl and where R^ and Rg.7 can be taken together with die attached nitrogen atom to form a ring, which may contain an additional heteroatom, selected from the group consisting of piperazine, mo holine, pyrrolidine or piperidine; (R 4 /R 5 /R 6 - 2) where R5 and Rg are taken togedier to form a heterocyclic ring selected from the group consisting of (Rg end) -(CH 2 )_ 1 3-R5 6 . 1 -(CH2) n ι 4 -CO-(CH 2 ) 11 i5 (R 5 end) (R 4 /R 5 /Rg - 2a) where n j3 is 0 dim 3, n i4 is 0 dim 3, n 15 is 0 dim 2, R 56 .2 is -O-, -S-, -CH 2 -, -CH=CH-, -C(R56_3)_ where the Rsg^'s are die same or different and are C2-C3 alkyl, or -NR 56 . 2 where R 56 . 2 is -H, C j -Cg alkyl, C 3 -C 7 cycloalkyl, -(CH 2 ) nl 7-0 H h ere n 17 is 2 dim 4, -(CH 2 ) al6 -φ where n l6 is 0 dim 4 and -φ is optionally substituted widi -F, -Cl, -Br, -I, C j -C alkyl, (Rg end) -R j g. j -CO-CO- (R 5 end) (R 4 /R 5 /R 6 - 2b) where R 56 _2 is as defined above, where R is α-R . 3 :/S-R 4 ^ where R 4 . 3 and R 4- are die same or different and are -H, -OH or C2-C alkyl, with die proviso that only one of R 4 . 3 and R - can be -OH at any one time; (R 4 /R 5 /R 6 - 3) where R 4 is C3-C7 spirocycloalkyl or α-R 4 . 5 :/S-R 4 _g where R 4 . 5 and R 4 _g are the same or different and are -H or C -C alkyl, where R 5 is -(CH 2 ) n 29-CO-H where n 29 is 0 dim 4, -(CH 2 ) n 2 9 -CO-(C2-Cg alkyl) where n 29 is as defined above, -(CH 2 ) n29 -CO-(C 3 -C7 cycloalkyl) where n 29 is as defined above, -(CH 2 ) n29 -CS-(C 1 -C 6 alkyl) where n 29 is as defined above, -(CH 2 ) n 29-CO-(CH2) n2 8 where n 28 is 0 thm 3, where R5.2 is as defined for R3.2 with the proviso diat R3.2 and R5.2 may be die same or different, where R5. is -H, C j -Cg alkyl, -CH 2 -CH 2 -OH, -CH 2 -CH 2 -OCH 3 or -φ optionally substituted widi 1 or 2 R3_ 2 's where R 3 . 2 is as defined above, and where the n 29 's may be the same or different and are as defined above, -(CH 2 ) n 2 9 -CO-(CH 2 ) n28 -NR 5 _ i ((CH 2 ) n29 -NR5.ιR 5 . 5 )whereR5.5 is -H, -Cg alkyl, -CH 2 -CH 2 -OH, -CH 2 -CH 2 -OCH 3 , where n 28 , R 5 . and R 5 ^ are as defined above, where die n 29 's may be die same or different and are as defined above, and where R 5 ^ and R5.5 are taken together with die attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, l-(4-methyl)piperazinyl, -(CH 2 )- 29 -CS-(C 3 -C 7 cycloalkyl) where n 29 is as defined above, -(CH 2 ) n29 -CO-aryl where aryl and n 29 are as defined above, -(CH 2 ) n 2 9 -CS-aryl where aryl and n 29 are as defined above, "( CH 2)_29" C0 "°" R 5-1 where R5. and n 29 is as defined above, -(CH2) - J 2S . -CO-S-R5.J where R5.2 and n 2 are as defined above, -(CH2) n 2 9 -CO-(CH2) n 28-NR5^R5.5wheren 28 ,n 29 ,R 5 ^andR5.5 are as defined above and where R5. and R 5 . 5 are taken togedier widi die attached nitrogen atom to from a heterocyclic ring selected from die group consisting of -N*-(Cl^ 5 . s )^-(CH 2 ) nr R 5 ^-(CH^^-(C*HR 5 . 9 )^- (C 5 - la) -N*-(CH2) nl -(CHR5. 8 ) nA -R5^-(CHR5. 9 ) πB -(C*H 2 )π2- (C 5 - ») where R 3 . 8 is -H or C2-C 3 alkyl, n A is 1 or 2, n χ is 0 dim 2, n 2 is 0 dim 2, R 3 . 9 is -H or C2-C3 alkyl, n B is 1 or 2, where the atoms marked widi an asterisk (*) are bonded to each other resulting in the formation of a ring, with die proviso that the ring not contain more than 8 atoms, and where -O-, -S-, -CO-, -CR 5 . 8 R 5 . 9 where R 5 . 8 and R5_ 9 are die same or different and are -H or C j -C 4 alkyl, -NR5.7 where R5.7 is -H, C r Cg alkyl, -(CH2)nl%~Φ where n 18 is 0 dim 4 and where -φ is optionally substituted widi -F, -Cl, -Br, -I or C2-C3 alkyl, -(CH2) n 9 -OH where n 19 is 2 dim 4, widi the proviso that when R5_g is -O-, -S- or -NR5.7-, n j and 112 are 1 or 2, -(CH2) n 29-CO-CO-NR5. 4 R5_5 where R 5 _ 4 , R5.5 and n 29 are as defined above, -(CH 2 ) n 2 -CO-COOR5_ 8 where n 29 is as defined above and where R5.8 is -H, C r C 4 alkyl, -(CH2)-_>o"Φ where n 2 Q is 1 thru 4, -φ optionally substituted widi 1 or 2 -F, -Cl,-Br, -I or C - C 3 alkyl, -(CH2)u2 9 -CO-R5_23 where n 29 is as defined above and where R 5 _ 23 is defined as being selected from the same group as R3.23 -CCH 2 ) n 2 9 -C*=N-C(R 5 .ι 0 ) 2 -[C(R5. I ι) 2 ] n 2 7 -R*5. 12 where the atoms marked with an asterisk (*) are bonded to each odier resulting in the formation of a ring, where the RS.JO'S are the same or different and are -H or C2-C3 alkyl, where n 2 7 is 1 dim 3, where the Rs.n's are the same or different and are -H or C j -C 3 alkyl, where 5.22 is -° _ » _s -> "C(R5_i3.2-> " NR 5-14 where R 5 . 13 and R5.24 are -H or C2-C3 alkyl, and where Rg is as defined for (R 4 /R5/R - 1) above; where Wg is -N= or -CRg= where Rg is as defined above; where W 7 is -N= or -CR 7 = where R 7 is as defined for R 6 , the Rg R 7 , R 8 and R 9 may be the same or different. where W 8 is -N= or -CR 8 = where R 8 is as defined for R 6 , the Rg R 7 , R 8 and R 9 may be die same or different. where W 9 is -N= or -CR9= where g is as defined for Rg, the Rg R 7 , R 8 and R 9 may be the same or different. » with the proviso diat not more tiian two of Wg, W 7 , W 8 and W 9 can be -N= at any one time; and pharmaceutically acceptable salts thereof where such exist. 2. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R 3 is selected from die group consisting of -COOR 3 _ι, aryl or -CO-NR 3 ^R 3 . 5 . 3. An imidazo . l,5-a]quinoxaline (I) according to claim 2 where aryl is selected from die group consisting of l,2,4-oxadiazol-3-yl or l,2,4-oxadiazol-5-yl. 4. An imidazo[l,5-a]quinoxaline (I) according to claim 3 where the l,2,4-oxadiazol-3-yl or 1,2,4- oxadiazol-5-yl is substituted with C 2 -C 4 alkyl and C3-C5 cycloalkyl. 5. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R 4 is o_-R 4 _2:/--R 4 _ 2 where one of R 4 _2 and R 4 . 2 is -H and the odier of R 4-1 and R . 2 is taken together with R 5 to form a ring of the formula ( end) - O-R 45 _ι-(CH2) n 3- (R 4 end). ^^5^6 ' 6. An i___idazo[l,5-a]quinoxaline (I) according to claim 1 which is selected from d e group consisting of l-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazo[l,5-a]pyrrolo[2,l- c]quinoxalin-10(l lH)-one, (3bS)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-oxo-3b,4,5,6-tetrahydroimidazo[l,5- a]pyrrolo[5, 1-c] quinoxal ine, (3bR)-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-6-oxo-3b,4,5,6-tetrahydroimidazo[l ,5- a]pyrrolo[5, l-c]quinoxaline, (S)-l- en_oxazol-2-yl)-12,12a-dihydroimidazo[l,5-a]pyrrolo[2,l-a]quinoxalin-10(llH one, tert-butyl (S)-12,12a-dihydroimidazo[l,5-a]pyrrolo[2,l-c]quinoxaline-l-carboxylate, 12-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-l, 12b-dihydroimidazo[5,l-a]oxazolo[4,3- c]quinoxalin-3(3H)-one, (S)-I-[5-(l , l-dimethylethyl)-l ,2,4-oxadiazol-3-yl]-12, 12a-dihydroimidazo[l ,5-a]pyrrolo[2, 1- c]quinoxaline. 7. An imid___o[l,5-a]quinoxaline (I) according to claim 1 where R 5 and Rg are taken together to form a heterocyclic ring of die formula (Rg end) -(CH 2 )_ 1 3-R56. 1 -(CH2) n ι 4 -CO-(CH 2 ) n i5- (R 5 end) (R 4 /R 5 /Rg - 2a) 8. An imidazo[l,5-a]quinoxaline (I) according to claim 7 which is selected from the group consisting of 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b-hexahydro-7H-imidazo[5, l-f]-7-oxa- 4a,10b-diazaphenalen -5-one, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl) -3 a,4,4a,5,6, 10b-hexahydro-7H-imidazo[5, l-f]-6-oxa- 4a, 10b-diazaphenalen-5-one, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b-hexahydro-7H-6-(l- medιylethyl)imidazo[5, l-f]-4a,6, lOb-triazaphenalen-5-one, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-3a,4,4a,5,6, 10b-hexahydro-7H-6-methyIimidazo- [5, l-f]-4a,6, lOb-triazaphenalen-5-one. 9. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R5 is not cyclized. 10. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R is α-R 4 . 5 :/S-R 4 ^ where R 4 . 5 and R 4 _g are -H:-H. 11. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R 4 is c.-R 4 _ 5 : .-R 4 .g where R . 5 and R _g are C j alkykC j alkyl. 12. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where R 5 is selected from me group consisting of -(CH^-CO-.Ci-Cg alkyl), -(CR 2 ) Ώ29 -CO-(CH 2 ) Π2S -NR 5 R 5 . 5 , -(CH^^-CO-aryl, -(CH 2 ) n2 9-CO-O-(C 1 -C 6 alkyl), -(CH 2 ) n 2 9 -CO-(C 3 -C7 cycloalkyl), 13. An imidazo[l,5-a]quinoxaline (I) according to claim 12 where R5 is selected from the group consisting of -(CH2) n 2 9 -CO-(CH 2 ) n 2 8 -NR5_ t R5. 5 , -(CH 2 ) n29 -CO-aryl and -(O ^-CO-O-^- C 6 alkyl). 14. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where W 6 is -CRg=, W 7 is -CR 7 = , W 8 is -CR 8 = and W 9 is -C__ 9 = . 15. An imidazo[l,5-a]quinoxaline (I) according to claim 14 where Rg, R 7 , R 8 and R j) are all -H. 16. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where Wg is -CF=, -CC1= or -CCH 3 = . 17. An imidazo[l,5-a]quinoxaline (I) according to claim 1 where W 7 is -CF=, -CC1= or -CCH 3 = . 18. An imidazo[l,5-a]quinoxaline (I) according to claim 1 which is selected from me group consisting of tert-butyl 6-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, 6-fluoro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, 7-dluoro-4,5-dihydro-4,4-dimethyl-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, tert-butyl 7-fluoro-4,5-dihydro-4,4-dimethyl-5-[(pyrroIidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, 5-(tert-butyloxycarbonyl)-3-(5-cyclopropyI-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a] quinoxal ine, 5-benzoyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-(2-furoyl)4,5-dihydroimid___o[ 1 ,5-a]quinoxaline, 5-(tert-butyloxycarbonyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6- methylimidazo[l ,5-a] quinoxal ine, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazof 1 ,5-a]quinoxal ine, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline, 5-(tert-butyloxycarbonyl)-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[l,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-(2-furoyl)-4,5-dihydroimidazo[l,5- ajquinoxaline, 5-benzoyl-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline, 5-(tert-butyloxycarbonyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline, 5-acetyl-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-propionylimidazo[l,5- ajquinoxaline, tert-butyl 7-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, tert-butyl 7-Chloro-5-[(dimethylamino)carbonyl]^. ,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3- carboxylate, 7-chloro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline, 7-chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5- yl)imidazo[l,5-a]quinoxaline, 7-cUoro-3-(5-e_hyl-l,2,4-ox_di__x)l-3-yl)-4.5-dihydro-5-[φyrrolidino)carbonyI]imidazo[l,5- a]quinoxaline, 7-chloro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-I ,2,4-oxadiazol-3-yl)-4,5- dihydroimidazo[ 1 ,5-a]quinoxaline, tert-butyl 7-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, 7-fluoro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, 7-chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3- yl)imidazo[l ,5-a]quinoxaline, tert-butyl 6-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline-3- carboxylate, 6-chIoro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, tert-butyl 6-chloro-5-[(dimethylamino)carbonyI]-4,5-dihydroimidazo[l,5-a]quinoxaline-3- carboxylate, 6-chloro-3-(5-ethyl-1.2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaline, 6-chloro-5-[(dimethylamino)carbonyI]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3- yl)imidazo[l ,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-(3-isopropyI-l,2,4-oxadiazol-5-yl)-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, 6-chloro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-l ,2,4-oxadiazol-3-yl)-4,5- dihydroimidazof 1 ,5-a]quinoxaline, 6-chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5- yl)imidazo[l ,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yI)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimedιylamino)carbonyl]-4,5-dihydro- 4,4-dimedιylimidazo[l,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline, 7-chloro-5-[(dimemylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4»4- dimetiiylimidazofl ,5-a]quinoxaline, tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, tert-butyl 7-chloro-5-[(dimeti ylamino)carbonyl]-4,5-dihydro-4,4-dimedιylimidazo[l ,5- a]quinoxaline-3-carboxylate, 7-chloro-5-[(dimethyIamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4»4- dimetiiylimidazofl ,5-a]quinoxaline, 7-chloro-3-(5-ethy 1- 1 ,2, 4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 7-chloro-5-[(dimethylamino)carbonyl]-3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline, tert-butyl 6-chloro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, 6-chloro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 6-chloro-5-[(dimemylamino)carbonyI]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4»4- dimethylimidazoP ,5-a]quinoxaline, 6-chloro-3-(5-ethy 1- 1 ,2 , 4-ox ad iazol-3-yl)-4, 5-dihydro-4,4-d imethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, tert-butyl 6-chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-4,4-dimedιylimidazo[l,5- a]quinoxaline-3-carboxylate, 6-chloro-5-[(dimemylamino)carbonyl]-4,5-dmydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4,4- dimethylimidazo[l,5-a]quinoxaline, 6-chloro-5-[(dimedιylamino)carbonyl]-3-(5-edιyl-l,2,4-oxadia_ol-3-yl)-4,5-dihydro ,4- dimetiιylimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-propionylimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-(ethoxyoxalyl)-4,5-dihydroimidazo[l,5- a]quinoxaline, 5-[(2-chloro)benzoyl]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(morpholino)-carbonyl]imidazo[l,5- a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazoI-3-yl)-5-[(3,5-dimethylpyrazolo)carbonyl]-4,5- dihydroimidazo[l ,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4-dimedιylimidazo[l,5- a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(5-cycIopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyI]-6-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(pyrroIidino)carbonyl]- imidazo[l,5-a]quinoxaline, 5-acetyI-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[l,5- a]quinoxaline, 5-benzoyI-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydroimidazo[l,5-a]quin- oxaline, 5-acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydroimidazo[l,5- a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-7-fluoro-4,5- dihydroimidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazofl ,5-a]quinoxaline, 5-beπzoyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydroimidazo[l,5- a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazoI-3-yl)-7-fluoro-4,5-dihydro-5-[(l-imidazo)ca- rbonyl]imidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4 > 5-dihydro-5-[(morpholino)carbonyl]- imidazo[l,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethylimidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(methoxy)carbonyI]-4,4- dimethylimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(isopropyIoxy)carbonyl]-4,4- dimethylimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(ethoxy)oxalyl]-4,5-dihydro-4,4- dimedιylimidazo[ 1 ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimetiιyl-5-[(phenoxy)carbonyl]- imidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)oxalyl]- imidazo[l,5-a]quinoxaline, 6-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yI)-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[ 1 ,5-a] quinoxal ine, 6-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[ 1 ,5-a]quinoxaline, 6-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(methanedιio)carbonyl]- imidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(trifluoroacetyl)imidazo[l,5- a]quinoxaline, 3-(5-cy clopropyl-1 ,2,4-oxadiazol-3-yl)4,5-dihydro-5-[(l-imidazolyl)carbonyl]- imidazo[l ,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2-pyridylcarbonyl)imidazo[l,5- a] quinoxal ine, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2-pyrrolyl)carbonyl]imidazo[l,5- a]quinoxaIine, 5-[(anilino)carbonyl]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-ylH»5-dihydro-5-[(medιylamino)carbonyl]- imidazo[l,5- ajquinoxaline, 5-[(2-chlorophenylamino)carbonyl]-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yI)-4,5- dihydroimidazo [ 1 ,5-a] quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(isopropylamino)carbonyI]- imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiaz»l-3-yl)-5-[(diedιyl___ ino)c_xbonyl]-4,5-dihydroimida__o[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[φyrrolidino)carbonyl]_ι_idazo[l,5- ajquinoxaline, 5-[(benzenedιio)carbonyl]-3-(5-eyclopropyH,2,4-oxadiazol-3-yl)-4,5-dihydro_nidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(e_ιanedιio)carbonyl]-4,5-dihydroimidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(edιylamino)carbonyl]-4,5-dihydroimidazo[l,5- aj quinoxaline, 5-(carbamoyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyi-l,2,4-oxadiazol-3-yI)-4,5-dihydro-5-[(medιanedιio)carbonyl]- imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonylj-4,5-dihydro-4,4- dimedιylimidazo[l,5-ajquinoxaline, 5-[(benzenedιio)carbonyI]-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimedιylimidazo[l ,5-a]quinoxaline, 5-(carbamoyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-ylH > 5-dihydro-4,4-dimethylimidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(diediylamino)carbonyl]-4,5-dihydro-4,4- dimethylimidazofl ,5-ajquinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5- [(medιylamino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethylamino)carbonyl]-4,5-dihydro-4,4- dimethyliπ_idazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(methanethio)carbonyl]-4,4- dimedιylimidazo[l,5-alquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethanethio)carbonyl]-4,5-dihydro-4,4- dimedιylimida_o[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-formyl-4,5-dihydro-4,4-dimedιylimidazo[l,5- ajquinoxaline, 3-(5-cyclopentyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- ajquinoxaline, 4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4,4-dimethyl-5-[(pyrrolidino)carbonylj- imidazo[ 1 ,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-4,4-dimethyI-5- [(pyrrolidino)carbonyljimidazo[l,5-a]quinoxaline, tert-butyl 4,5-dihydro-4(S)-methyl-5-[(pyrrolidino)carbonyl]imidazo[ 1 ,5-ajquinoxaline-3- carboxylate, tert-butyl4,5-dihydro-4(RS)-methyl-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, tert-butyl 4,5-dihydro-4(S)-methyl-7-methyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, 4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4(S)-methyl-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline, 4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4(S)-methyl-5-[(pyrrolidino)- carbonyl]imidazo[l ,5-a]quinoxaline, tert-butyl 4,5-dihydro-5-[2-(morpholino)acetyl]imidazo[ 1 ,5-a]quinoxaline, tert-butyl 4,5-dihydro-7-medιyl-5-[2-(morpholino)acetyl]imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-5-[(pyrrolidino)carbonyl]-4- (spirocyclopentyl)imidazo[l ,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxa!ine, 7-fluoro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yI)-5-[(pyrrolidino)- carbonyl]imidazo[l,5-a]quinoxaline, tert-butyl 4,5-dihydro-5-[(pyrrolidino)carbonyl]-4-(spirocyclopentyl)imidazo[l,5- a]quinoxaline, tert-butyl 4,5-dihydro-5-[2-(pyrrolidino)acetyl]imidazo[l,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4(S)-methyl-N-pyrrolidino-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxamide, tert-butyl 4,5-dihydro-4,4-dimethyl-5-[2-(pyrrolidino)acetyl]imidazo[ 1 ,5-a]quinoxaline-3- carboxylate, 4,5-dihydro-3-(5-isoρropyl-l,2,4-oxadiazol-3-yl)-5-[(pyrrolidino)carbonyl]-4- (spirocyclopentyl)imidazo[ 1 ,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-4(S)-methyl-5- [(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-4(S)-methyl-5- [φyrrolidino)carbonyl]_nidazo[l,5-a]quinoxaline, tert-butyl 7-fluoro-4,5-dihydro-4(S)-methyl-5-[(pyrroIidino)carbonyl]imidazo[l,5- a] quinoxaline-3-carboxylate, tert-butyl 4,5-dihydro-4(S)-isobutyl-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, tert-butyl 4(S)-ediyl-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, 4(S)-ediyl-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5- [(pyrτoIidino)carbonyI]imid___o[l,5-a]quinoxaline, 4(S)-edιyl-4,5-dihydro-3-(3-isopropyl-l ,2,4-oxadiazol-5-yl)-5- [φyrτolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, N-tert-butylamino-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxamide, N-tert-butyl mino-6-fluoro-4,5-dihydro-5-[φyrtolidmo^ 3-carboxamide, N-tert-butyla_ ιino-6-chloro-4,5-dihydro-_^[φyrrolidino)car_ )nyl]imid__κ)[l,5-a]qui_ox 3-carboxamide, 7-cbloro-4,5-dihydro-N-moφholino-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxamide, N-tert-butyl_Jiιino-7-chloro-4,5-dihydro-_H[φyrrolidino)c_rbonyl]imidazo[l,5-a]Q^inoxalin^ 3-carboxamide, 7-chloro-N-cyclohexyIamino-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxamide, N-tert-butylamino-6-chloro-4,5-dihydro-5-(2-pyrrolidino-2-oxoethyl)imidazo[l,5- a]quinoxaline-3-carboxamide, N-tert-butylamino-7-chloro-4,5-dihydro-5-(2-pyrrolidino-2-oxoethyl)-imidazo[l,5- a]quinoxaline-3-carboxamide, 4,5- lihydro-3-(hydroxymediyl)-5-[(pyrrolidino)carbonyl]imidazo-[l,5-a]quinoxaline 4,5- dihydro-5-[(pyrroIidino)carbonyl]imidazo[l,5-a]quinoxaline-3-me_ianol, 3-(2-benzoxazolyl)-7-fluoro-4,5-dihydro-5-[φyrtolid^ tert-butyl 4,5-dihydro-5-[(morpholino)carbonyl]imidazo[l,5-a]quinoxalin-3-carboxylate, 4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-5-[(morpholino)carbonyl]imidazo[l,5- ajquinoxaline, tert-butyl 5-[(di-n-propylamino)carbonyl]-4,5-dihydroimidazo[l,5-a]quinoxaline-3- carboxylate, 5-[(di-n-propylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazoI-3- yl)imidazo[ 1 ,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-phenyl-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, tert-butyl 5-(tert-butyloxycarbonyl)-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, tert-butyl 5-acetyl-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, 3-(2-benzoxazolyl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, 3-(2-ben_»xazolyl)-7-fluoro-4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(moφholino)carbonyl]imidazo[l,5- a]quinoxaline, 3-(5-tert-butyI-l ,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4,4-dimethyl-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazofl ,5-a]quinoxaline, 5-[(dimedιylamino)carbonyl]-3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a]quinoxaline, 5-[(dimethylamino)carbonyl]-3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline, 3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-[(pyrroIidino)carbonyl]- imidazo[ 1 ,5-a]quinoxaline, 3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- ajquinoxaline, 4,5-dihydro-3-(5-isopropyl-l ,2,4-oxadiazol-3-yl)-5-[(piperidino)carbonyl]imidazo[ 1 ,5- a] quinoxaline, tert-butyl 4,5-dihydro-5-[(piperidino)carbonyI]imidazo[l,5-a]quinoxaline-3-carboxylate, 4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-5-[(piperidino)carbonyl]imidazo[l,5- a]quinoxaline, 3-(5-ethyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(piperidino)carbonyl]imidazo[l,5- a] quinoxal ine, tert-butyl 4,5-dihydro-4,4-dimediyl-5-[(piperidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, 4,5-d_hydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4,4-dimethyl-5-[(piperidino)carbonyI]- imidazo[l,5 -ajquinoxaline, tert-butyl 5-[(dimethylamino)carbonyl]-4,5-dihydro-7-methylimidazo[ 1 ,5-a]quinoxaline-3- carboxylate, 5-[(dimethyIamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-7- methylimidazo[l,5-ajquinoxaline, tert-butyl 4,5-dihydro-7-methyl-5-[(pyrroIidino)carbonyljimidazo[l,5-a]quinoxaline-3- carboxylate, 4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-7-mediyl-5-[(pyrrolidino)carbonyl]- imidazo[l,5-ajquinoxaline, 3-(5 -ert-butyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5-dihydroimidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyI]-4,5-dihydro-4,4- dimethylimidazo[l ,5-a] quinoxaline, tert-butyl 4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyI]imidazo[l,5-a]quinoxaline-3- carboxylate, tert-bu^-t(dim__hylamino)carbonyI]-4,5-dihydro-4,4-dime ylimidazo[l,5-a]quinox_line- 3-carboxylate, 4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4,4-dimedιyl-5-[φyrrolidino)carbonyI]- imidazo[l ,5-a]quinoxaline, 5-[(dimedιylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4,4- d_methyl_midazo[ 1 ,5-a]quinoxaIine, tert-butyl 4,5-dihydro-5-[ pyrroIidino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate, tert-butyl 5-[(dimethylamino)carbonyl]-4,5-dihydroimid___o[l ,5-a]quinoxaIine-3-carboxylate, 5-[(dimedιyIamino)(a-bonyl] ,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)imidazo[l,5- a]quinoxaline, 4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyl]-3-(p-tolyl)imidazo[l,5-a]quinoxaIine, 5-[(dimemylammo)carbonyl]-4,5-dihydro-4,4-dimedιyl-3-(p-tolyl)imidazo[l,5-a]quinox_^ 3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-[(pyrroIidino)carbonyI]imidazo[l,5- a] quinoxaline, 5-[(d_methylamino)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro-4,4-dimedιylimidazo[l,5- a]quinoxaline, 4,5-dihydro-3-phenyl-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazoI-3-yl)-5-[(pyrrolidino)carbonyl]imidazo[l,5- a] quinoxaline, 5-[(dimediylam_K))car_ _ ) nyl]-4,5-d_hydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)imidazo[l,5- a]quinoxaline, 5-[(dimediylamino)carbonyl]-4,5-dihydro-3-(3-isopropyl-l,2,4-oxadiazol-5-yl)-4.4- dimethylimidazotl ,5-a]quinoxaline, 5-[(dimedιylamino)carbonyl]-4,5-dihydro-4,4-dimethyl-3-phenylimidazo[l,5-a]quinoxaline, 6-chloro-5-[(dimethylamino)carbonyl]-4,5-dihydro-4,4-dimethyl-3-phenylimidazo[l,5- a] quinoxal ine, 7-chloro-4,5-dihydro-4,4-dimethyl-3-phenyl-5-[(pyrrolidino)carbonyI]imidazo[l,5- a]quinoxaline, 7-chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-4,4-dimethyl-3-phenylimidazo[l,5- a]quinoxaline, tert-butyl 4,5-dihydro-6-metiiyl-5-[(pyrrolidino)carbonyl]imidazotl,5-a]quinoxaline-3- carboxylate, 4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-6-methyl-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, tert-butyl 5-[(dimedιylamino)carbonyl]-4,5-dihydro-6-medιylimidazo[l,5-a]quinoxaline-3- carboxylate, 5-[(dimethylamino)carbonyl]-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-6- methylimidazo[l,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimediyl-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-7-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yl)-7-chloro-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-ox_diazol-3-yl)-7-chloro-5-[(dimedιylamino)carbonyl]-4,5-dihydro-4,4- dime _hylimidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,5-dihydro-4,4-dimedιyl-5-[(pyrrolidino)- carbonyI]imidazo[l ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-ox_dia_»l-3-yl)-6-chloro-5-[(dimetiιylamino)carbonyl]-4,5-dihydro-4,4- dimedιylimidazo[ 1 ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,5-dihydro-5-[(pyrrolidino)carbonyl]- imidazof 1 ,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-chloro-5-[(dimethylamino)carbonyl]-4,5- dihydroimidazofl ,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(pyπOlidino)carbonyl]imidazo[l,5-a]quinoxaline, 5-[(dimedιylamino)carbonyl]-3-(4-fluorophenyl)-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline, 5-[(dimethylamino)carbonyl]-4,5-dihydro-3-phenylimidazo[l,5-a]quinoxaline, 4,5-dihydro-3-phenyI-5-[(piperidino)carbonyl]imidazo[l,5-a]quinoxaline, 4,5-dihydro-5-[φyrrolidino)carbonyl]-3-φ-tolyI)imidazo[l,5-a]quinoxaline, 5-benzoyl-3-(3-cyclopropyI-l,2,4-oxadiazol-5-yl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-propionylimidazo[l,5-α]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl) ,5κlihydro-5-φhenoxycaroonyl)imidazo[l,5-a]quin- oxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(edιoxycarbonyl)imidazo[l,5- a]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-5-[(diethylamino)carbonyl]-4,5-dihydroimidazo[l,2- ajquinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(2-furoyl)imidazo[l,5-a]- quinoxaline, tert-butylamino 7-fluoro-4,5-dihydro-4,4-dimethyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaIine-3-carboxamide, 4,5-dihydro-3-[5-[l-(2-methylpropyI)]-l,2,4-oxadiazol-3-yl]-5-[(pyrrolidino)carbonyl]- imidazo[l,5-a]quinoxaline, tert-butyl__-iino 7-fluoro-4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5-a]- quinoxaline-3-carboxamide, 4,5-dihydro-5-[(pyrrolidino)carbonyl]-3-[5-(3,3,3-trifluoropropyl)-l,2,4-oxadiazol-3- yl]imidazo[l,5-a]quinoxaline, tert-butyl 6-fluoro-4,5-dihydro-5-φ-tolylsulfonyl)imidazo[l,5-a]quiπoxaline-3- carboxylate, 7-fluoro-4,5-dihydro-3-[5-(2-methylpropyl)-l ,2,4-oxadiazol-3-yl]-5- [φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[5-(2-methyl-3,3,3-trifluoropropyl)-l,2,4-oxadiazol-3-yl]-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-[5-(2-methyl-3,3,3-trifluoropropyl)-l,2,4-oxadiazol-3-yl]-5- [φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-[5-(2-methyl-3,3,3-trifluoropropyl)-l,2,4-oxadiazol-3-yl]-5- [(morpholino)carbonylmethyI]imidazo[l,5-a]quinoxaline, 3-[5-(cyclopentyl)-l,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-4(R)-methyI-5- [(moφholino)carbonylmethyl] imidazo[ 1 ,5-a] quinoxaline, 7-fluoro-4,5-dihydro-3-(5-isopropyl-l,2,4-oxadiazol-3-yl)-4(R)-methyI-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-methyl-5-[2- (moφholino)acetyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopentyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-methyl-5- [(piperidino)carbonylmedιyl]imidazo[l,5-a]quinoxaline, tert-butyl 7-fluoro-4,5-dihydro-4(R)-methyl-5-[(pyrrolidino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, 3-(5-cyclopentyl-l ,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-methyl-5-[2- (pyrrolidino)acetyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopentyl-l ,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-methyl-5- [(pyrrolidino)carbonylmediyl]imidazo[l,5-a]quinoxaline, 5-benzoyl-4,5-dihydro-3-[5-[(l,l-dimethyl)etiιyl]-l,2,4-oxadiazol-3-yl]imidazo[l,5- ajquinoxaline, 5-benzoyl-4,5-dihydro-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3-yl]-7-fluoroimidazo[l,5- ajquinoxaline, tert-butyl 5-benzoyl-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, tert-butyl 5-benzoyl-4,5-dihydro-7-fluoroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, tert-butyl 5-(2-chlorobenzoyl)-4,5-dihydro-7-fluoroimidazo[l ,5-a]quinoxaline-3- carboxylate, tert-butyl 4,5-d_hydro-6-fluoro-5-[(tert-butyloxy)carbonyl]imidazo[l,5-a]quinoxalin-3- carboxylate, 5-[(tert-butyloxy)carbonyl]-4,5-dihydro-3-[(l,l-dimethyI)ethyl-l,2,4-oxadiazol-3- yl]imidazo[l,5-a]quinoxaline, 5-[(tert-butyloxy)carbonyl]-4,5-dihydro-3-[(l,l-dimethyl)ethyl-l,2,4-oxadiazol-3-yl]-6- fluoroimidazo[l,5-a]quinoxaline, 4,5-dihydro-5-medιoxycarbonyl-3-(benzoxazol-2-yl)imidazo[l,5-a]quinoxaline, tert-butyl 4,5-dihydro-4,4-dimedιyl-7-fluoro-5-medιoxycarbonyIimidazo[ 1 ,5-a]- quinoxalin-3-carboxylate, tert-butyl 4,5-dihydro ,4-dimemyl-5-[(l-medιyl)e_ιoxyc_rbonyIimida∞[l,5-ajquinoxalin-3- carboxylate, tert-butyl 4,5-dihydro-6-fluoro-5-medioxycarbonylimidazo[l,5-a]quinoxalin-3- carboxylate, 4,5-dihydro-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazoI-3-yl]-5-[(moφholino)carbonylj- imidazo[l ,5-ajquinoxaline, 4,5-dihydro-4,4-dimethyI-3-[5-[(l,l-dimethyl)ethyl]-l,2,4-oxadiazol-3-yl]-7-fluoro-5- [(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 5-[[4-(tert-butyloxycarbonyl)piperazino]carbonyl]-4,5-dihydro-3-[5-[(l,l-_limedιyl)ethyl]- l,2,4-oxadiazol-3-yl]imidazo[l,5-a]quinoxaline, tert-butyl 5-[[4-(tert-butyloxycarbonyJ)piperazino]carbonyl]-4,5-dihydroimidazo[l,5- a]quinoxaline-3-carboxylate, tert-butyl4,5-dihydro-4,4-dimemyl-5-[(moφholino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate, 4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylicacid, phenyl 4,5-dihydro-5-[φyrrolidino)carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxyIate, N-(cyanomethyl)-4,5-dihydro-5-[(pyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxamide, 4,5-dihydro-3-(oxazoIin-2-yl)-5-[ pyrrolidino)carbonyl]imidazo[l,5-ajquinoxaline, 4,5-d ydro-3-(hydroxymeώyl)imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-(benzoylmedιyl)-5-(benzoyl)imidazo[l,5-a]quinoxaline, 4,5-dihydro-3-(benzoylmedιyl)-5-φyπOlidinyl)carbonyl]imidazo[l,5-ajquinoxal_ιe, 4,5-dihydro-3-(isopropyloxymethyl)-5-φyrroIidinyl)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4(R)-methyl-5- [(pyrrolidino)carbonyl]-imidazo[l ,5-ajquinoxaline, 7-fluoro-4,5-dihydro-4(R)-methyl-3-[5-(l-mediylcyclopropyl-l,2,4-oxadiazoI-3-yl)-5- tφy_τolidino)_arbonyl]imidazo[l,5-a]quinoxaline, 3-[3-cyclopropyl-l,2,4-oxadiazol-5-yl]-7-fluoro-4,5-dihydro-4-(moφholinylcarbonyl)- imidazo[l,5-a]quinoxal_ne, 3-(4-cycIopropylthiazol-2-yl)-4,5-dihydro-5-(morpholinylcarbonyl)imidazo[l,5- ajquinoxaline, 3- enzoxazol-2-yl)-4,5-dihydro-5-(moφholinylcarbonyl)imidazo[l,5-ajquinoxaline, 3-C5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-Cmoφholinylcarbonyl)- imidazo[l ,5-a]quinoxaline, 3-tert-butyl 5-methyl-7-fluoro-4,5-dihydroimidazo[l,5-a]quinoxaIine-3,5(4H)- dicarboxylate, 3-(5-CycIopropyl-l,2,4^xadia_Ol-3-yl 5-[(3,5-_lime_ιyl)moφhol ylcarbonyl]-7-fluoro-4,5- dihydroimidazo[l,5-a]quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-(pyrrolidinocarbonyl)- imidazo[l ,5-ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-φiperidinylcarbonyl)imidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-5-(3-fluorobenzoyl)-4,5-dihydroimidazo[l,5- ajquinoxaline, methyl 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5-a]quinoxaIine-5- carboxylate, mediyl 3-(5-tert-butyl-l,2,4-oxadϊa_»l-3-yl)-7-chloro-4,5-dihydroimidazo[l,5-a]- quinoxaline-5-carboxylate, 3-(5-tert-butyl-l ,2,4-oxadiazol-3-yl)-5-benzoyl-4,5-dihydroimidazo[ 1 ,5-ajquinoxaline, methyl 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-7-chloro-4,4-dimethylimidazo[l,5- a]quinoxaline-5-carboxylate, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-7-chloro-4,4-dimedιyl-5-(4-moφholinylcarbonyl)- imidazo[ 1 ,5-ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-6-chloro-4,4-dimedιyl-5-(4-moφholinylcarbonyl)- imidazo[ 1 ,5-ajquinoxaline, 3-(3-tert-butyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(pyrrolidinocarbonyl)imidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-nitrobenzoyl)imidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l, 2, 4-oxadiazol-3-yl)-5-(4-fluorobenzoyl)-4,5-dihydro imidazo . 1,5- a] quinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-5-(3-chlorobenzoyl)-4,5-dihydroimidazo[l,5- ajquinoxaline, 3-(5-tert-butyl-l,2,4-oxadiazol-3-yI)-5-(2-fluorobenzoyl)-4,5-dihydroimidazo[l,5- ajquinoxaline, 4,5-dihydro-5-dimemylamino-3-(4-methylphenyl)imidazo[l,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(4-moφholinocarbonyl)imidazo[ 1 ,5-ajquinoxaline, 3-(4-fluorophenyl)-5-(3-fluorobenzoyl)-4,5-dihydroimidazo[l,5-a]quinoxaline, methyl 3-(4-fluorophenyl)-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-5-carboxylate, 5-(tert-butylaminocarbonyI)-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(4-trifluoromethylbenzoyl)imidazo[l,5-a]quinoxaline, 5-(aminocarbonyl)-3-(4-fluorophenyl)-4,5-dihydroimidazo[ 1 ,5-ajquinoxaline, 5-(ediylaminocarbonyl)-3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxaline, isopropyl 3-(4-fluorophenyl)-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-5-carboxylate, 3-(4-fluorophenyl)-5-(4-fluorobenzoyl)-4,5-dihydroimidazo[l,5-a]quinoxaline. 3-(5-tert-butyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-[(pyrrolidino)carbonyI]- imidazo[l,5-a]quinoxaline, tert-butyl 7-chloro-4,5-dihydro-5-[(methoxy)carbonyl]-4,4-dimethylimidazo[ 1,5- a]quinoxaline-3-carboxylate, tert-butyl 5-benzoyl-7-chloro-4,5-dihydroimidazo[l,5-a]quinoxaline-3-carboxylate, tert-Butyl 7-chloro-4,5-dihydro-5-[(methoxy)carbonyl]imidazo[l,5-a]quinoxaline-3- carboxylate tert-butyl 4,5-dihydro-5-[(4-trifluoromethyl)benzoyl]imidazo[ 1 ,5-a]quinoxaline-3- carboxylate, tert-butyl 5-[(4-dimethylamino)benzoyl]-4,5-dihydroimidazo[l,5-a]quinoxaIine-3- carboxylate, tert-butyl 5-benzoyl-4,5-dihydro-4,4-dimetiιylimidazo[l,5-ajquinoxaline-3-carboxylate, tert-butyl 4,5-dihydro-5-[(isopropoxy)carbonyl]imidazo[l ,5-a]quinoxaline-3-carboxylate, tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(moφholino)carbonyl]imidazo[l,5- a]quinoxaline-3-carboxylate, tert-butyl 4,5-dihydro-5-[(medιoxy)carbonyl j-4,4-dimethylimidazo [ 1 ,5-a] quinoxaIine-3- carboxylate, tert-butyl 5-[(tert-butyloxy)carbonyl]-7-chloro-4,5-dihydro-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate, 3-(3-tert-butyl-5-isoxazolyl)-4,5-dmydro-5-[φy_rolidino)c_rbonyl]imidazo[l,5-a]quinox_line, tert-butyl 6-chloro-4,5-dihydro-5-[(methoxy)carbonyI]imidazo[l ,5-a] quinoxal ine-3- carboxylate, tert-butyl 5-benzoyl-7-chloro-4,5-dihydro-4,4-dimethylimidazo[l,5-a]quinoxaline-3- carboxylate, tert-butyl 5-[(3-fluoro)benzoylj-4,5-dihydro-4,4-dimediylimidazo[l,5-a]quinoxaline-3- carboxylate, tert-butyl 5-[(3-fluoro)benzoyl]-7-chloro-4,5-dihydro-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate, tert-butyl 6-chloro-4,5-dihydro-4,4-dimethyl-5-[(moφhoIino)carbonyl]imidazo[l,5- a] quinoxaline-3-carboxylate, tert-butyl 6-chloro-4,5-dihydro-5-[(methoxy)carbonyl]-4,4-dimethylimidazo[l,5- ajquinoxaline-3-carboxylate, tert-butyl 7-chloro-4,5-dihydro-5-[(isopropoxy)carbonyl]-4,4-dimediylimidazo[l ,5- a]quinoxaline-3-carboxylate, tert-butyl 7-chloro-5-[(4-dimedιylamino)benzoylj-4,5-dihydroimidazo[l,5-a]quinoxaIine- 3-carboxylate, tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(3,5-dimethylmoφholino)carbonylj- imidazo[l ,5-a]quinoxaline-3-carboxylate, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(moφholino)carbonylj- imidazofl ,5-a]quinoxaline, 7-chloro-3-(3-cycIopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(moφholino)carbonyl]- imidazo[l ,5-ajquinoxaline, 7-chloro-3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-(3,5- dimethyl)moφholino)carbonyl]imidazo[l ,5-ajquinoxaline, 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl] imidazo [ 1 ,5-a] quinoxal ine, 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(isopropoxy)carbonyl]- imidazo[l,5-ajquinoxaline, tert-butyl 5-[(ethylamino)carbonyl]-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, tert-butyl 5-[(tert-butylamino)carbonyl]-4,5-dihydroimidazo[ 1 ,5-a]quinoxaline-3-carboxylate, tert-butyl 5-carbamoyl-4,5-dihydro-4,4-dimethylimidazo[l,5-a]quinoxaline-3-carboxylate, tert-butyl 5-[(tert-butylamino)carbonyl]-4,5-dihydro-4,4-dimediylimidazo[l,5-aj- quinoxaline-3-carboxylate, tert-butyl 5-[(ethylamino)carbonyI]-4,5-dihydro-4,4-dimedιylimidazo[ 1 ,5-a]quinoxaline-3- carboxylate, tert-butyl 5-carbamoyl-7-chloro-4,5-dihydro-4,4-dimethylimidazo[ 1 ,5-a]quinoxaline-3- carboxylate, tert-butyl 7-chloro-5-[(ethylamino)carbonyI]-4,5-dihydro-4,4-dimethylimidazo_l,5- ajquinoxaline-3-carboxylate, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2-(4- moφholinyl)ethylamino)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(2-(diethylamino)ethylamino)carbonylj-4,5- dihydroimidazo[ 1 ,5-a]quinoxal ine, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2- (medιoxy)edιylamino)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyI]imidazo[ 1 ,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2- methoxyethoxy)carbonyl]imidazo[l,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethylamino)carbonyl]-4,5- dihydroimidazo[l ,5-a]quinoxaline, 5-(carbamoyl)-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- a] quinoxal ine, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(isopropoxy)carbonyl]-7- metiιylimidazo[l ,5-a]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5- [(moφholino)carbonyl]imidazo[l ,5-ajquinoxaline, 3-(3-cyclopropyl-l ,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- d_me_hyl)piperazino)carbonyl]-7-methylimidazo[l,5-a]quinoxaline, 5-(carbamoyl)-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-medιylimidazo[l,5- a] quinoxaline, 3-(5-cycIopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,4,5- trim__hyl)piper___ino)carbonyl]imidazo[l,5-a]quinoxaIine, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[((2- dimedιylamino)e_ιoxy)carbonyl]imidazo[l,5-a]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-5-[(ethylamino)carbonyl]-4,5-dihydro-7- mediylimidazo[l,5-a]quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(4- methyI)piperazino)carbonyljimidazo[l,5-a]quinoxaIine, 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- d_methyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline, 3 -(5-cyclopropyl- l,2,4-o xadiazo 1-3 -yl) -4,5 -dihydro-6-meth yl-5- [(moφholino)carbonyljimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-[(l-(4- medιyl)piperazino)carbonyl]imida_o[l,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyI]imidazo[ 1 ,5-a]quinoxaline, 5-[(2-fluoro)benzoyl]-3-(4-fluorophenyI)-4,5-dihydroimidazo[l,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-d_hydro-5-[(3-trifluoromethyl)benzoyl]imidazo[l,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihy__ro-5-[(moφholmo)c_rbonyl]imida__o[l,5-a]quinoxallne, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(morpholino)carbonyl]imidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[bis-(2- methoxyethyl)aminocarbonyl]imidazo[l,5-a]quinoxaline, tert-butyl 7-fluoro-4,4-dimethyl-5-(moφholino)carbonylimidazo[ 1 ,5-a]quinoxaIine-3- carboxylate, tert-butyl 7-fluoro-5-[bis(2-methoxyediyI)aminocarbonyl]-4,4-dimediylimidazo[l,5- a]quinoxaline-3-carboxylate, tert-butyl 7-fluoro-4,5-dihydro-5-(isopropyloxycarbonyl)imidazo[l,5-a]quinoxaline-3- carboxylate, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-(isopropyloxycarbonyl)- imidazofl ,5-ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-φiperazinylcarbonyl)- imidazo[l,5-a]quinoxalϊne, 3 - (5 - cy cl op rop y l - l , 2 , 4-oxad i azo l -3 -yl )-6-fl u o ro-4 , 5-d ih ydro -5 - φiperazinylcarbonyl)imidazo[ 1 ,5-ajquinoxaline, t-Butyl 7-fluoro-4,5-dihydro-5-(morpholinocarbonyl)inidazo[l ,5-a]quinoxaline-4- carboxylate. 19. An imidazo[l,5-a]quinoxaline (I) according to claim 18 which is selected from die group consisting of 5-(tert-butyloxycarbonyl)-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5- dihydroimidazof 1 ,5-ajquinoxaline, 3-(5-cyclopropyl-l,2,4- xadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(morpholino)carbonylj- imidazo[l ,5-a]quinoxaline, 3-(5-cyclopropyl- l ,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl]-4,5- •dihydroimidazofl ,5-ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(ethylamino)carbonyl]-4,5-dihydroimidazo[l,5- ajquinoxaline, 7-fluoro-4,5-dihydro-4(R)-methyl-3-[5-(l-methylcyclopropyl-l,2,4-oxadiazol-3-yl)- 5[φyrrolidino)carbonyl]imidazo[l,5-a]quinoxaline, 3-[3-cyclopropyl-l,2,4-oxadiazol-5-yl]-7-fluoro-4,5-dihydro-4-(moφholinylcarbonyI)- imidazo[l ,5-ajquinoxaline, 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-(morpholinylcarbonyI)imidazo[l ,5- a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(moφholinylcarbonyl)- imidazo[l ,5-ajquinoxaline, 3-(5-Cyclopropyl-l,2,4-oxadiazol-3-yl 5-[(3,5-dimethyl)moφholinylcarbonyl]-7-fIuoro ,5- dihydroimidazo[l,5-a]quinoxaline, isopropyl 3-(4-fluorophenyl)-4,5-dihydroimidazo[l,5-a]quinoxaline-5-carboxylate, 7 -chloro-3 -(3 -cyclopropyl- l , 2 ,4-oxad iazol-5-yl)-4 , 5-dihydro-5- [(isopropoxy)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5-[(2-(diethylamino)ethylamino)carbonyl]-4,5- dihydroimidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2-methoxyethoxy)carbonylj- imidazo[l ,5-ajquinoxaline, 5-(carbamoyl)-7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[l,5- ajquinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(moφholino)carbonylj- imidazo[ 1 ,5-a]quinoxaline, 5-(carbamoyl)-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-mediylimidazo[l,5- ajquinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,4,5-trimethyl)piperazino)- carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadi___oI-3-yl)-4,5-dihydro-5-[((2-dimethyIamino)ethoxy)- carbonyl]imϊdazo[ 1 ,5-ajquinoxaline, 7-fluoro-3-(4-fluorophenyl) ,5-dihydro-5-[(moφholmo)c__:bonyl]imid___o[l,5-ajquinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dϊhydro-5-[(morpholino)carbonyl]imidazo[l,5- ajquinoxaline, 3-(5-cyclopropy 1-1 ,2, 4-oxadiazol-3-y l)-7-fluoro-4, 5-dihydro-5-[bis-(2- medioxyediyl)aminocarbonyl]imidazo[l,5-a]quinoxaline, tert-butyl 7-fluoro-5-[bis(2-methoxyethyl)aminocarbonyl]-4,4-dimethylimidazo[l,5- a]quinoxaline-3-carboxylate. 20. An imidazo[l,5-a]quinoxaline (I) according to claim 1 which is selected from the group consisting of 3 - (3 -cycI opropyl - l , 2 ,4-oxadiazol -5-yl)-4, 5-dihydro-5-[( l -(4- methyI)piperaz_no) carbonyl] imidazo[ 1 ,5-a] quinoxaline, 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline, 3-(3-cyclopropyl-l ,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- medιyl)piperaziπo)carbonyl]imidazo[ 1 ,5-ajquinoxaline, 3-(3-cyclopropyl-l ,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(l-(4- medιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline, 3 -(5-cy cl o p rop yl - l , 2 , 4-oxad i azo l -3 -yl )-4 , 5-d ihydro-5-[ ( l -(4- medιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline, 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-medιyl-5-[(l-(4- methyI)piper___ino)carbonyI]imidazo[l,5-a]quinoxaline 3-(4-fIuorophenyl)-4,5-dihydro-5-[(l-(4-methyl)piperazino)carbonyl]imidazo[l,5- ajquinoxaline 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaIine 3-(4-fluorophenyl) ,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl jimidazof 1 ,5-ajquinoxaline 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl] imidazo[ 1 ,5-a] quinoxal ine 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(4- me_hyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(4- methyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,4,5- trimetiιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline • 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- tr_methyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l ,5-ajquinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl) ,5-dihydro-7-methyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyI-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,4,5-trimedιyl)piperazino)carbonyl]imidazo- [1,5-ajquinoxaline 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,4,5- trimediyI)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(l-(3,4,5- _rimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,4,5- trime_iyl)piperazino)carbonyljimidazo[l,5-a]quinoxaline 7-chloro-3-(4-cyclopropyldιiazol-2-yl)-4,5-dihydro-5-[(l-(3 ,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,4,5- trim ethyl)piperazino)carbonyl] imidazo [ 1 ,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yI)-6-fluoro-4,5-dihydro-5-[(l-(3,4,5- trimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(3,4,5- trim_thyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(3,5- dime_hyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazoI-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyI]imidazo[l,5-ajquinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadϊazol-5-yl)-4,5-dihydro-7-medιyl-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l ,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimethyI)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- d_me_hyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5-dimetiiyl)piperazino)carbonyl]imidazo- [l,5-a]quinoxaline 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[l ,5-ajquinoxaline 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-7-medιyl-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropyldιiazol-2-yl)-4,5-dihydro-5-[(l -(3 ,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyI]imidazo[ 1 ,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(3,5- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(3,5- dimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazoI-5-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trime_ιyl)piperazino)carbonyljimidazo[ 1 ,5-ajquinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trime_hyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-medιyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piper___ino)carbonyl]imidazo[l ,5-ajquinoxaline 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,4,6- trimediyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,4,6- trimedιyl)piperazino)carbonyl] imidazo[ 1 ,5-a] quinoxal ine 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-medιyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,4,6-trimethyl)piperazino)carbonyl]imidazo- [l,5-a]quinoxaline 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piper___ino)carbonyl]imidazo[l,5-a]quinoxaline 7-fluoro-3-(4-fIuorophenyl)-4,5-dihydro-5-[(l-(2,4,6- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(l -(2 ,4,6- trimediyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(4-cyclopropylthi___ol-2-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l ,5-ajquinoxaline 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,4,6- trimethyl)piperaz_no)carbonyljimidazo[l,5-ajquinoxaline 3-(4-cyclopropyl _hiazol-2-yl)-7-fluoro-4,5-d_hydro-5-[(l -(2,4,6- trimethyl)piper___ino)carbonyl j imidazo [ 1 ,5-a] quinoxaline 3-(4-cyclopropylthiazol-2-yl)-6-fluoro-4,5-dihydro-5-[(l -(2,4,6- trimedιyl)piperazino)carbonyljimidazo[l,5-ajquinoxaline 3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyI]imidazo[l ,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyljimidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazoI-5-yl)-7-fluoro ,5-dihydro-5-[(l-(2,6- d_methyl)piperazino)carbonyljimidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(3-cyclopropyl-l,2,4-oxadiazol-5-yl)-4,5-dihydro-7-medιyl-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaIine 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(l-(2,6- d_methyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,6- dimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimetiiyI)piperazino)carbonyl]imidazo[l ,5-ajquinoxaline 3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,6-dimethyl)piperazino)carbonyl]imidazo- [l,5-a]quinoxaline 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline 7-fluoro-3-(4-fluorophenyl) ,5-dihydro-5-[(l-(2,6- dimedιyI)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-fluorophenyl)-4,5-dihydro-7-medιyl-5-[(l-(2,6- dimedιyl)piperazino)carbonyljimidazo[l,5-a]quinoxaline 3-(4-cyclopropylthi___ol -2-yl)-4,5-dihydro-5-[(l-(2,6- dimemyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 7-chloro-3-(4-cyclopropylthiazol-2-yl)-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline 3-(4-cyclopropyldιiazol-2-yl)-7-fluoro-4,5-dihydro-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline 3-(4-cyclopropylthi___ol-2-yl)-6-fluoro-4,5-dihydro-5-[(l-(2,6- dimethyl)piperazino)carbonyl]imidazo[l,5-ajquinoxaline 3-(4-cyclopropyldιiazol-2-yl)-4,5-dihydro-7-methyl-5-[(l-(2,6- dimedιyl)piperazino)carbonyl]imidazo[ 1 ,5-ajquinoxaline tert-butyl 4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trimediyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 7-fluoro-4,5-dihydro-4,4-dimediyl-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 6-fluoro-4,5-dihydro-4,4-dimethyl-5-[(l-(3,4,5- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 4,5-dihydro-7-medιyl-4,4-dimethyl-5-[(l-(3,4,5- trimethyl)piperazino)carbonyl]imidazo[l,5-ajquinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-4,5-dihydro-4,4- dimethylimidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 7-chloro-5-[(l-(3,5-dimediyl)piperazino)carbonyl]-4,5-dihydro-4, 4-dimedιylimidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-7-fluoro-4,5-dihydro-4, 4-dimedιylimidazo[l,5-a]quinoxaIine-3-carboxylate tert-butyl 5-[( 1 -(3 ,5-dimedιyl)piperazino)carbonyl]-6-fluoro-4,5-dihydro-4, 4-dimethylimidazo[l ,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimedιyl)piperazino)carbonyl]-4,5-dihydro-7-medιyl-4, 4-dime ylimidazo[ 1 ,5-a]quinoxaline-3-carboxylate tert-butyl 4,5-dihydro-4,4-dimethyl-5-[(l-(2,4,6- trimethyl)piper___ino)carbonyl]imidazo[ 1 ,5-a]quinoxaI ine-3-carboxylate tert-butyl 7-chloro-4,5-dihydro-4,4-dimethyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[ 1 ,5-a]quinoxaline-3-carboxylate tert-butyl 7-fluoro-4,5-dihydro-4,4-dimediyl-5-[(l-(2,4,6- trimediyl)piperazino)carbonyl]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 6-fluoro-4,5-dihydro-4,4-dimedιyl-5-[(l-(2,4,6- trimethyl)piperazino)carbonyl]imidazo[l,5-ajquinoxaIine-3-carboxylate tert-butyl 4,5-d_hydro-7-methyl-4,4-dimetiιyI-5-[(l-(2,4,6- trimethyl)piperazino)carbonyI]imidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5-dihydro-4, 4-dimethylimidazo[l,5-a]quinoxaline-3-carboxyIate tert-butyl 7-chloro-5-[(l-(2,6-dimethyl)piperazino)carbonyl]-4,5-dihydro-4, 4-dimethylimidazo[l ,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-7-fluoro-4,5-dihydro-4, 4-dimethyIimidazo[l ,5-a]quinoxaIine-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-6-fluoro-4,5-dihydro-4, 4-d_methyIi_mdazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyI)piperazino)carbonyl]-4,5-dihydro-7-medιyl-4, 4-dimethylimidazo[l,5-a]quinoxaline-3-carboxylate tert-butyl 4,5-dihydro-5-[(l-(3,4,5-trimethyl)piperazino)carbonyl]imidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 7-chloro-4,5-dihydro-5-[(l-(3,4,5-trimedιyl)piperazino)carbonyl]imidazo- [l,5-ajquinoxaline-3-carboxylate tert-butyl 7-fluoro-4,5-dihydro-5-[(l-(3,4,5-trimethyl)piperazino)carbonyl]imidazo- [ 1 ,5-a]quinoxaline-3-carboxyIate tert-butyl 6-fluoro-4,5-dihydro-5-[(l-(3,4,5-trimethyl)piperazino)carbonyl]imidazo- [1 ,5-ajquinoxaline-3-carboxylate tert-butyl 4,5-dihydro-7-mediyl-5-[(l-(3,4,5-trimethyl)piperazino)carbonyl]_midazo- [l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimethyl)piperazino)carbonyl]-4,5-dihydroimidazo- [l,5-a]quinoxaline-3-carboxyIate tert-butyl 7-chloro-5-[(l-(3,5-dimethyl)piperazino)carbonyl]-4,5-dihydroimidazo- [l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimethyI)piperazino)carbonyl]-7-fluoro-4,5-dihydroimidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(3,5-dimediyl)piperazino)carbonylj-6-fluoro-4,5-dihydroimidazo- [1 ,5-a]quinoxaIine-3-carboxylate tert-butyl 5-[(l-(3,5-dime yl)piperazino)carbonyI]-4,5-dihydro-7-medιylimidazo- [1 ,5-a]qui_oxaline-3-carboxylate tert-butyl 4,5-dihydro-5-[(l-(2,4,6-trimethyl)piperazino)carbonyl]imidazo- [ 1 ,5-aj quinoxal ine-3-carboxyl ate tert-butyl 7-chloro4,5-dihydro-5-[(l-(2,4,6-trimethyl)piperazino)carbonyl]imidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 7-fluoro4,5-dihydro-5-[(l-(2,4,6-trimethyl)piperazino)carbonyl]imidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 6-fluoro4,5-dihydro-5-[(l-(2,4,6-trimediyl)piperazino)carbonyl]imidazo- [ 1 ,5-a]quinoxaline-3-carboxylate tert-butyl 4,5-dihydro-7-medιyl-5-[(l-(2,4,6-trimethyl)piperazino)carbonyl]imidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonylj4,5-dihydroimidazo- [l,5-a]quinoxaline-3-carboxylate tert-butyl 7-chloro-5-[(l-(2,6-dimethyl)piperazino)carbonyl]4,5-dihydroimidazo- [l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]-7-fluoro4,5-dihydroimidazo- [1 ,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimediyl)piperazino)carbonyl]-6-fluoro4,5-dihydroimid___o- [l,5-a]quinoxaline-3-carboxylate tert-butyl 5-[(l-(2,6-dimethyl)piperazino)carbonyl]4,5-dihydro-7-methylimidazo- [1 ,5-a]quinoxaline-3-carboxylate. 21. Imidazo[l,5-a]quinoxalines (LX) selected from die group consisting of tert-butyl 7-fluoro4,5-dihydro4(R)-me_ιyl-5-(2-pyridylme_ιyl)imidazo[ 1 ,5-a]quinoxaline-3- carboxylate, 7-fluoro-4,5-dihydro4(R)-medιyl-3-[5-(l-methylcyclopropyl)-l,2,4-oxadiazol-3-yl]-5-(2- pyridylmedιyl)imidazo[l,5-a]quinoxaline, cyclopropylmetiιylamin7>fluoro4,5-dihydro4(R)-methyl-5-(2-pyridylmethyl)imidazo[l,5- a]quinoxaline-3-carboxamide, 7-fluoro4,5-dihydro4(R)-medιyl-3-[5-(2-medιylcyclopropyl)-l,2,4-oxadiazol-3-yl]-5-(2- pyridylmethyl)imidazo[l ,5-ajquinoxaline.

Inventors: GAMMILL RONALD BRUCE, JACOBSEN ERIC JON, TENBRINK RUTH ELIZABETH, GAMMILL, RONALD, BRUCE, JACOBSEN, ERIC, JON, TENBRINK, RUTH, ELIZABETH
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1992
Main classification: A61K31
IPC codes: A61K31, A61P25, C07D471, C07D487, C07D498, C07D519